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O aumento de produção e aplicação de compostos orgânicos resultou na sua deteção no 
ambiente. Estes compostos incluem disruptores endócrinos (também chamados 
xenoestrógenios, que afetam a regulação do sistema hormonal), pesticidas e produtos 
farmacêuticos e de higiene pessoal.  
Tendo em conta, dados da União Europeia, existem mais de 3000 tipos de princípios 
ativos de origem farmacêutica aplicados na prática de medicina humana e veterinária. 
Os chamados ingredientes farmacêuticos ativos (do inglês, active pharmaceutical 
ingredients - APIs) são atualmente uma classe emergente de contaminantes ambientais 
com a capacidade de causar danos e efeitos inesperados em organismos aquáticos, 
nomeadamente em espécies de elevado interesse comercial (como peixes e moluscos).  
Um dos fatores que desencadeou a necessidade de conhecer melhor esta problemática 
foi o aparecimento de fenómenos de intersex (mudança de sexo) em algumas espécies 
aquáticas que não podiam estar diretamente associados aos efeitos dos chamados 
contaminantes clássicos (i.e. metais, derivados de petróleo, pesticidas). Isto fomentou o 
desenvolvimento de novas tecnologias para a deteção e quantificação de fármacos na 
água e à necessidade de avaliar o efeito da exposição em diversas espécies a várias 
concentrações de produtos farmacêuticos de todas as classes terapêuticas.  
Embora, o primeiro estudo que refere a incidência de fármacos no ambiente seja do 
final da década de 70, são ainda relativamente recentes os estudos nesta área. No 
entanto, uma enorme quantidade de APIs já foi detetada em afluentes e efluentes de 
estações de tratamento de águas residuais (ETARs), águas superficiais (fluviais e 
marinhas) e mais preocupantemente na água de abastecimento público de diversos 
países em concentrações na gama de ng a µg por Litro.  
O principal problema do impacte de fármacos no ambiente refere-se à combinação de 
dois aspetos: a aplicação continuada e persistente pelas populações (com uma esperança 
média vida cada vez mais elevada) e ao fato da maioria destes compostos ser excretada 
praticamente na sua forma nativa ou na forma de metabolitos (por vezes, 
potencialmente mais tóxicos) que entram indiretamente (através de efluentes de 
hospitais e domésticos que não são eliminados nas ETARs) para os sistemas aquáticos.  
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Em Portugal, as ETARs estão somente capacitadas para a remoção de matéria orgânica 
e nalguns casos de nutrientes (fosfatos e nitratos). Além disso, não existe qualquer 
controlo relativamente à presença e posterior remoção de produtos de origem 
farmacêutica e higiene pessoal, o que pode levar a médio-longo prazo a sérios 
problemas ambientais e num cenário pior a perigo para a saúde pública.  
Os mexilhões são mundialmente considerados excelentes instrumentos para avaliar os 
níveis de poluição marinha e estuarina, tendo sido selecionados como espécie sentinela 
em importantes programas internacionais de monitorização de contaminação aquática, 
nomeadamente o  programa “Mussel Watch”. 
Tendo por base estas premissas, a presente tese teve como objetivos a deteção de APIs 
na água do Rio Arade (Portugal), o impacte do período estival na alteração das suas 
concentrações utilizando amostradores passivos de compostos orgânicos, POCIS (do 
inglês: polar organic compounds integrative samplers) e a avaliação dos efeitos numa 
espécie não-alvo, o mexilhão Mytilus galloprovincialis causados pela exposição a anti-
inflamatórios não esteroides (AINEs) ibuprofeno (IBU) e diclofenac (DCF), bem como 
ao antidepressivo (inibidor seletivo da recaptação de serotonina - ISRS) fluoxetina 
(FLX) e suas misturas à qual também foi adicionado um contaminante clássico, o cobre 
(Cu). Para tal, foi efetuada uma análise de multibiomarcadores de stress oxidativo 
(atividade de enzimas antioxidantes como a: superóxido dismutase -SOD, catalase - 
CAT, glutationa redutase - GR e a enzima de fase II glutationa-S-transferase - GST), de 
dano - peroxidação lipídica (LPO), de efeito neurotóxico (através da atividade da 
enzima acetilcolinesterase - AChE) e de disrupção endócrina (pela medição de proteínas 
similares à vitelogenina através do método indireto de fosfatos-lábeis alcalinos - ALP)  
após a exposição desta espécie a concentrações ambientalmente relevantes.  
Os principais resultados permitiram detetar a presença de 19 APIs no Rio Arade de 
diversas classes terapêuticas, cujas principais concentrações foram o alcaloíde cafeina, o 
antiasmático teofilina, AISE ibuprofeno e analgésico paracetamol. O impacte do 
período estival foi, no entanto, inconclusivo devido a alterações bastante significativas 
das concentrações nos meses amostrados.   
Quanto à análise de biomarcadores, os resultados revelaram diferentes respostas para 
cada um dos APIs selecionados quer a nível de exposição individual ou na forma de 
misturas, sendo dependentes dos tecidos analisados e do tempo de exposição. São 
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também propostas diversas interações entre os diferentes componentes das misturas. Os 
resultados revelaram ainda o potencial de cada API para originar stress oxidativo, dano 
lipídico, efeito neurotóxico e disrupção endócrina, mesmo a concentrações 
extremamente baixas, numa espécie muito vulnerável à presença destes contaminantes 
emergentes dando enfoque à urgência da alteração e desenvolvimento de métodos 
preventivos à entrada destes compostos no ambiente aquático.    
Palavras-chave: Compostos farmacêuticos ativos; ibuprofeno; diclofenac; fluoxetina; 
Mytilus galloprovincialis.  
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More than 3000 types of active pharmaceutical ingredients (APIs) are applied in Human 
and veterinary medicine practice. These compounds are considered an emergent class of 
environmental contaminants with the ability to cause damage and unexpected effects to 
aquatic organisms, namely in species of high commercial value. APIs are ubiquitous in 
the environment being frequently detected in influents and effluents of waste water 
treatment plants (WWTPs), surface waters and more distressingly in the public tap 
water in concentrations ranging from ng to µg.L
-1
.  
Considering these premises, the present thesis focused on APIs detection in the Arade 
river water, the impact of summer period in APIs’ concentration alterations applying the 
passive sampler device, POCIS (polar organic compound integrative sampler), as well 
as, the assessment of the effects caused by non-steroidal anti-inflammatory drugs 
(NSAID) ibuprofen (IBU) and diclofenac (DCF) and antidepressant selective serotonin 
reuptake inhibitor (SSRI) fluoxetine as single and mixture exposures along with a 
classical contaminant copper (Cu) on a non-target species, mussel Mytilus 
galloprovincialis. For this purpose, a multibiomarker approach was applied namely 
including biomarkers of oxidative stress (antioxidant enzymes activities of superoxide 
dismutase – SOD, catalase – CAT, glutathione reductase – GR and Phase II glutathione-
S-transferase), damage - lipid peroxidation (LPO), neurotoxic effects (through the 
activity of acetylcholinesterase enzyme - AChE) and endocrine disruption (through 
vitellogenin-like proteins measurement applying the indirect method of alkali-labile 
phosphate - ALP) after exposure of mussel species’ to selected APIs at environmental 
relevant concentrations. 
The main results highlighted the occurrence of 19 APIs in the river Arade from several 
distinct therapeutic classes. Stimulant caffeine, antiasthmatic theophylline, NSAID 
ibuprofen and analgesic paracetamol presented the highest concentrations. Summer 
impact was inconclusive due to each API transient concentration in each month. 
The multibiomarker results revealed distinct responses towards each selected API (as 
single exposure or as mixtures) that were tissue and time dependent. Several 
multistressor interactions were proposed for each biomarker. The results also revealed 
General Abstract 
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APIs potential to induce oxidative stress, LPO, neurotoxicity and endocrine disruption 
even at extremely low concentrations on a species extremely vulnerable to APIs 
presence highlighting the urgency on the development of methodologies able to prevent 
its entrance in the aquatic environment.     
Keywords:  Active pharmaceutical ingredients (APIs); ibuprofen; diclofenac; 
fluoxetine; Mytilus galloprovincialis 
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1 General Introduction 
1.1 Historical Background 
The oldest pharmaceutical document known reports how, perhaps 4000 years ago, 
Sumerians prepared some curative drugs. Illness was thought as a divine punishment 
and healing as the purification. That same concept was parallel throughout centuries 
(Kremers et al., 1986). Only on the 5
th
 century B.C. Hippocrates and his theory of “The 
Four Humors” changed that generalized view; the main basis for health was owed to the 
correct balance between blood, phlegm, yellow and black bile. Following Hippocrates 
stepping stone in Medicine, Galen also known as “father of Pharmacy”, was the first to 
test the action of drugs associated to each specific humors’ imbalance. Galenic concepts 
prevailed until the 16
th
 century, when Paracelsus challenged them, announcing that 
illness actually resulted from outside body agents’ attacks. Since then, the internal use 
of chemical remedies was made a matter of principle and study (Kremers et al., 1986). 
1.1.1 Pharmacy as an Industry 
In the period between 1850 and 1914 as chemists enhanced the extent of their 
operations the retailing sector also expanded noticeably. By then, the use of the term 
“pharmaceutical” (from the Greek φάρμακον 'pharmakos' = drug) was widespread, and 
Pharmacy began to be seen as a prospective industry. Nowadays, the modern 
pharmaceutical industry has a high-technological image being one of the most 
prosperous economic sectors of the world (Tweendale, 2003). Pharmaceutical products 
regard a group of bioactive compounds with chemically complex molecular structures 
(which the key component is the active pharmaceutical ingredient - API) used for the 
diagnosis, treatment, mitigation or prevention of diseases or health conditions 
(Anderson et al., 2004; Kümmerer, 2004). These products are generally categorized 
according to their therapeutic purpose (e.g. analgesics, antiasthmatics, antibiotics, 
antidepressants, antidiabetics, antiepileptics, antihypertensives, antilipidemics, 
antipsychotics, anti-ulcerants, autoimmune agents, non- and narcotics oncologics, etc.) 
see examples in Tables 1.3., 1.4 and 1.6 and from then on classified as prescription only 
medicines (POM) [requiring physician’s instructions] or as “over the counter 
medicines” (OTC) being bought without any restriction (Anderson et al., 2004; 
Kümmerer, 2004). 
Chapter 1: General Introduction 
2 | C h a p t e r  1  
1.1.2 Worldwide Pharmaceutical Production and Consumption 
Most pharmaceutical production is concentrated in industrialized countries in which 
two-thirds of the value of all medicines produced is accounted for by few transnational 
corporations headquartered in USA, UK, Switzerland, Germany, France and Japan 
(WHO, 2004; IMS Health, 2011) (Table 1.1).  
 
These countries are simultaneously the biggest individual exporters and importers of 
pharmaceutical products (WHO, 2004). The pharmaceutical consumption is measured 
by the country’s pharmaceutical production value plus its import minus its export value 
(WHO, 2004). In terms of world pharmaceutical consumption from 2000 to 2010, USA 
clearly led global market sales (Table 1.2) (doubling from 150 to 300 billion US$ which 
worldwide corresponded from approximately 300 billion to over 800 billion US$ (10% 
of which were “over-the-counter” non-prescription drugs) (WHO, 2004; IMS Health, 
2011) yet the global pharmaceutical market growth in average from 9% in 2003 to 4.1% 
Table 1.1: World top pharmaceutical companies by value of sales in 2001 to 2010 
(adapted from WHO, 2004; IMS Health, 2011) 
Corporation ranking (2001)  Corporation ranking (2010) 
1. Pfizer (USA) = 1. Pfizer (USA) 
2. GlaxoSmithKline (UK/USA)  2. Novartis (Switzerland) 
3. Merck & Co. (USA) = 3. Merck & Co. (USA) 
4. AstraZeneca  (Sweden/UK) 
 
4. Sanofi-Aventis 
(France) 
5. Aventis (France/Germany) 
 
5. AstraZeneca 
(Sweden/UK) 
6. Bristol-Myers Squibb  (USA) 
 
6. GlaxoSmithKline 
(UK/USA) 
7. Johnson & Johnson (USA)  7. Roche (Switzerland) 
8. Novartis (Switzerland) 
 
8. Johnson & Johnson 
(USA) 
9. Upjohn/Pharmacia (USA)  9. Abbott (USA) 
10. Wyeth/American Home  Products (USA)  10. Eli Lilly (USA) 
11. Eli Lilly (USA)  11. Teva (Israel) 
12. Roche (Switzerland)  12. Bayer (Germany) 
13. Bayer (Germany)  13. Amgen (USA) 
14. Schering-Plough  (USA) 
 
14. Bristol-Myers Squibb  
(USA) 
15. Abbott (USA) 
 
15. Boehring Ingel 
(Germany) 
16. Takeda  (Japan) = 16. Takeda (Japan) 
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in 2010. This growth decrease tendency corresponded mostly to Japanese and North 
American market growth decline, which nevertheless was counter-balanced by the 
increment of Asian, African and South American countries markets (IMS Health, 2011). 
Table 1.2: Top 10 pharmaceutical markets in the world between 2000 and 2010 with 
projection for 2015 (adapted from WHO, 2004; IMS Health, 2011) 
2000 2005 2010 2015 
1. USA 1. USA 1. USA 1. USA 
2. Japan  2. Japan  2. Japan 2. Japan 
3. France 3. France 3. China 3. China 
4. Germany 4. Germany 4. Germany 4. Germany 
5. UK 5. Italy 5. France 5. France 
6. Italy 6. UK 6. Italy 6. Brazil 
7. Spain 7. Spain 7. Brazil 7. Italy 
8. Canada 8. Canada 8. Spain 8. India 
9. Brazil 9. China 9. Canada 9. Spain 
10. Mexico 10. Brazil 10. UK 10. Russia 
 
In terms of total sales revenue of global pharmaceutical products in 2010, over 50% of 
global sales were represented by the top 20 therapeutic classes led by oncologic 
products (total 56 billion US$) (Table 1.3), nevertheless Lipitor
®
 an anti-lipidemic 
(a.k.a. lipid-regulator) marketed by Pfizer was the world’s best-seller pharmaceutical 
product brand engrossing 13 billion US$ in that year alone (IMS Health, 2011) (Table 
1.4).  
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Table 1.3: Top-20 most sold therapeutic classes in 2010 in the world (adapted from IMS 
Health, 2011) 
Therapeutic class Billion US $ 
1. Oncologics 55972 
2. Lipid Regulators 36400 
3. Antiasthmatic/Respiratory Agents 35926 
4. Antidiabetics 34429 
5. Anti-ulcerants 27972 
6. Antihypertensive/Angiotensin II Antagonists 26630 
7. Antipsychotics 25412 
8. Autoimmune agents 20710 
9. Antidepressants 20216 
10. HIV antivirals 15432 
11. Platelet aggregation inhibitors 15244 
12. Vitamins and minerals 12971 
13. Antiepileptics 12553 
14. Narcotic analgesics 12011 
15. Antibiotics 11466 
16. Non-narcotic analgesics  10986 
17. Vaccines 10972 
18. Erythropoietins 10596 
19. Anti-rheumatics, non-steroidal 10152 
20. Multiple sclerosis 9844 
       Global Market 791449 
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Table 1.4: Top-20 most sold pharmaceutical product brands in the world (adapted from 
IMS Health, 2010) 
Pharmaceutical  Therapeutic class Corporation Billion US$ 
LIPITOR Lipid regulator  Pfizer 12.6 
PLAVIX Platelet aggregation inhibitor  Bristol-Myers Squibb   8.8 
SERETIDE Antiasthmatic/Respiratory agent  GlaxoSmithKline 8.5 
NEXIUM Antiulcerants AstraZeneca 8.4 
SEROQUEL Antipsychotic  AstraZeneca 6.8 
CRESTOR Lipid regulator  AstraZeneca  6.8 
ENBREL Autoimmune agent  Amgen and Pfizer 6.2 
REMICADE Autoimmune agent  Merck & Co. 6.0 
HUMIRA Autoimmune agent  Abbot 6.0 
ZYPREXA Antipsychotic  Eli Lilly & Co. 5.7 
AVASTIN Oncologics Roche 5.5 
SINGULAIR Antiasthmatic/Respiratory agent  Merck & Co. 5.5 
ABILIFY Antipsychotics/antidepressant  Bristol-Myers Squibb 5.4 
MABTHERA Oncologics Roche 5.0 
LANTUS Antidiabetic Sanofi-Aventis 4.7 
ARICEPT Acetylcholinesterase inhibitor  Pfizer 4.4 
ACTOS Antidiabetics  Takeda 4.3 
LOVENOX Anticoagulant/Blood thinner Sanofi 4.3 
HERCEPTIN Oncologics Roche 4.2 
DIOVAN Antihypertensive  Novartis 4.2 
  
 
   
  
Chapter 1: General Introduction 
6 | C h a p t e r  1  
1.1.3 Pharmacy and Pharmaceutical Products Consumption in Portugal 
In Portugal, the pharmaceutical industry began at the end 19
th
 century. Later on, the 
Great War recession required a higher effort of pharmaceutical production [since the 
majority of the pharmaceutical products came from Germany] forcing the emergence of 
subsidiary industries and new laboratories (Sousa Dias, 2008). Nowadays, the total 
market of pharmaceutical specialties sales reports an income of more than 3 billion € 
each year, corresponding to over 2 % of Portugal’s GDP (INFARMED, 2006; 2009). 
Portuguese available data in terms of production, trade, total sales and expenditure in 
pharmaceuticals in 2000 is represented in Table 1.5 (WHO, 2004), while the top 50 
active substances in Portugal are given in Table 1.6 comprising between 55 to 62 
million sold packages in 2006 and 2009 respectively (INFARMED, 2006; 2009). 
 
 
Table 1.5: Portugal in World medicine situation in 2000 (WHO, 2004)  
Production and trade  Million US$  
Production 2 459 635* 
Importations 699 953 
Exportations 171 707 
Total sales Number  
Licensed brands 236 131 
Original brands 679 797 
Other brands 515 540 
Patent brands 81 574 
Unbranded 9 547 
Expenditure US$  
Total expenditure on health (per capita at average exchange rate)  934 
Total expenditure on pharmaceuticals (% total expenditure on health)  23.1 
Total expenditure on pharmaceuticals (per capita at exchange rate) 216 
Government expenditure on pharmaceuticals (per capita at exchange rate)  151 
Private expenditure on pharmaceuticals (per capita at exchange rate)  65 
Private expenditure as % total health spending 32.9* 
* represents available 1997 data   
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Table 1.6:  Evolution of the top 50 APIs with highest number of packages in the Portuguese National Health Service from 2006 to 2009 
(adapted from INFARMED, 2007; 2010) 
 Ranking (2006) API Packages (2006) Position Ranking (2009) API 
Packages 
(2009) 
1 paracetamol/acetaminophen 3 485 502 = 1 paracetamol/acetaminophen 3 642 302 
2 alprazolam 2 777 192  2 simvastatin 2 941 467 
3 diclofenac 2 009 755  3 metformin 2 429 287 
4 trimetazidine 1 978 072  4 alprazolam 2 280 686 
5 simvastatin 1 961 484  5 amoxicillin + clavulanic acid 2 239 124 
6 nimesulide 1 929 370  6 trimetazidine 2 102 559 
7 amoxicillin + clavulanic acid 1 905 374  7 omeprazole  2 029 495  
8 metformin 1 829 256  8  ibuprofen 2 016 009  
9 lorazepam 1 774 078 = 9 lorazepam 1 909 169 
10 indapamide 1 753 628  10 diclofenac 1 817 520  
11 omeprazole 1 535 483  11 acetylsalicylic acid  1 778 370 
12 bromazepam 1 427 739  12 indapamide 1 743 762 
13 ibuprofen 1 416 708  13 nimesulide 1 510 441 
14 diazepam 1 334 654  14 gliclazide  1 355 017  
15 gliclazide 1 261 323  15 influenza vaccines 1 343 266  
16 ethinylestradiol + gestodene 1 119 474  16 furosemide 1 312 465 
17 furosemide 1 044 148  17 bromazepam  1 196 396  
18 zolpidem 1 020 976  18 flavonoids  1 170 030  
19 flavonoids 1 005 970  19 clopidogrel 1 153 693 
20 influenza vaccines 993 044  20 losartan + hydrochlorothiazide  1 139 107 
21 amlodipine 967 452  21 diazepam  1 130 220 
22 acarbose 922 185  22 bisoprolol 1 126 119 
23 alendronic acid 854 164  23 zolpidem 1 078 175 
24 losartan + hydrochlorothiazide 835 205  24 irbesartan + hydrochlorothiazide 1 021 011 
       
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 Table 1.6: (Continuation). 
25 atorvastatin 818 039  25 levothyroxine sodium  963 390 
26 bisoprolol 813 321  26 tamsulosin 951 188 
27 azithromycin 800 945  27 perindopril 941 067 
28 clopidogrel 799 096  28 betahistine 934 658  
29 irbesartan + hydrochlorothiazide 796 793  29 rosuvastatin 913 081 
30 nifedipine  777 566  30 azithromycin 912 055 
31 acetylsalicylic acid  774 849  31 lansoprazole 856 467 
32 perindopril 766 600  32 pantoprazole 851 273 
33 levothyroxine sodium 750 326  33 valsartan + hydrochlorothiazide  831 899 
34 glibenclamide 746 375 100 34 ethinylestradiol + gestodene  828 145 
35 domperidone 723 191  35 amlodipine  826 128 
36 glucosamine 722 271 = 36 glucosamine 811 444 
37 valsartan + hydrochlorothiazide 720 017  37 domperidone  775 022  
38 betahistine 695 494  38 allopurinol 771 752 
39 ciprofloxacin 681 745  39 nifedipine 769 754 
40 fluoxetine 675 111  40 acarbose 744 087 
41 tamsulosin 673 969  41 fluoxetine 708 266 
42 ambroxol 647 132 * 42 losartan 702 736 
43 amoxicillin 633 260 55 43 atorvastatin 694 185 
44 allopurinol 625 868  44 alendronic acid 693 515 
45 salbutamol 625 638 62 45 etoricoxib 680 552 
46 lansoprazole 622 581  46 desloratadine 669 753 
47 citicoline 608 787 58 47 ciprofloxacin 640 648 
48 sertraline 602 221 = 48 sertraline 630 785 
49 acetylcysteine 601 254 * 49 ramipril 623 243 
50 etoricoxib 583 958  50 alendronic acid** 618 178 
* out of the top-100 list; ** repetition of the same API;  APIs in bold were selected and detected in Arade River, Portugal (see Chapter 2). 
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1.2 Pharmaceutical Products Usage 
Common pharmaceutical dosage forms are: aerosols, capsules, creams, drops, 
emulsions, enema, gels, implants, inhalations, injections, irrigations, liniments, lotions, 
nebulizers, ointments, pastes, pills, powders, solutions, suppositories, suspensions, 
tablets, transdermal patches, etc. Besides the API, these compounds also include 
excipients, which comprise the product's delivery system, characterized for: a) 
transporting the API to the site in the body where the drug is intended to exert its action; 
b) restricting the drug from early release in the assimilation process; c) promoting the 
stability of the drug for maximum effectiveness at time of use; d) promoting the 
cleavage of the drug into small particles allowing a faster reach into the blood stream; or 
finally e) favoring the identification of a drug product. Pharmaceutical excipients are 
essential components of a modern drug product, even though technically "inactive" 
from a therapeutic sense (Weiner and Kotkoskie, 1999; International Pharmaceutical 
Excipients Council of the Americas, 2008). 
Considering that the main goal in pharmaceutical development is to discover molecules 
that are resistant to metabolic degradation processes and still, persist to exert the desired 
effect, results that inevitably, a part of the API is excreted unchanged, withstanding the 
wastewater treatment processes, and finally entering in most aquatic ecosystems 
(Anderson et al., 2004). 
1.3 Pharmaceuticals and Personal Care Products (PPCPs) and the Environment 
For many years, persistent organic pollutants (POPs) (such as synthetically 
manufactured organic chemicals and metals) were recognized as the most important 
contaminants with considerable potential hazards to environmental and human health 
(Bahe et al., 2005). 
Only in the last two decades, environment exposure to PPCPs (thought to be harmless) 
has been considered as a major concern. This misconception may be due to the fact that 
their development and application in healthcare has always been looked as one of the 
greatest benefits in modern society, improving substantially the health and lifestyle of 
individuals (Roberts and Bersuder, 2006). However, the exponential growth of 
industrial economies and human population demographics resulted in their ubiquity in 
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the environment. As Metcalfe et al. (2004a) states API’s potential to enter the 
environment concerns the amount sold, its pharmacokinetic behavior (API’s interaction 
in the body like its adsorption, distribution, metabolism and excretion) and degradation 
rates (chemical, microbial or photolytic) in the WWTP and in the environment itself.  
An emergent contaminant express certain features as: 1) occurrences and effects at very 
low concentrations, 2) undefined effects of chronic low level exposures on ecosystem 
and human health, 3) being unsuccessfully removed by typical waste treatment 
processes, and/or 4) being subjected to environmental dispersion and transportation 
after treatment at WWTP systems (Wall, 2004). APIs meet all the emergent pollutant 
requisites and therefore must be issued in environmental managing (Daughton, 2003; 
Khetan and Collins, 2007). In addition, WHO (2010; 2011) alerts to the importance of 
the rational use of medicines addressing to the correct, proper and appropriate use 
referring to two important factors which can ultimately be linked to API’s increased 
presence in the environment: “1) More than 50% of all medicines are prescribed, 
dispensed or sold inappropriately, and half of all patients fail to take medicines correctly 
and 2) the overuse, underuse or misuse of medicines harms people and wastes 
resources”. 
  
Chapter 1: General Introduction 
11 | C h a p t e r  1  
1.3.1 Drug Metabolism and Excretion 
APIs are usually ingested or absorbed orally, transported via the portal circulation to the 
liver, subjected to hepatic metabolism followed by elimination as bile or via the kidneys 
(Li, 2001). APIs are partially metabolized (biotransformed) by Phase I or Phase II 
reactions in the body, before finally being excreted via urine and faeces (Halling-
Sørensen et al., 1997; Daughton and Ternes, 1999; Kümmerer, 2004) (Figure 1.1).  
Elimination rates vary depending on the individual, drug and dosage (Bound and 
Voulvoulis, 2004; Bound et al., 2006). Both Phase I and Phase II reactions change the 
physical chemical behavior of the parent substance. Phase I reactions typically consist 
of oxidation (which key enzymes comprehend CYP P450 family isoforms, like 
CYP3A4 responsible for 50% of known APIs xenobiotic metabolism) (Li, 2001), 
reduction or hydrolysis (for esters and epoxides), adding a reactive functional groups to 
the molecule and often converting it into a more toxic compound. Phase II or 
conjugation reactions include: acetylation, methylation, sulfation, glucuronide and 
glutathione conjugation, which promote the binding of functional groups to the 
compound. The key Phase II enzymes are UDP-dependent glucuronosyl transferase 
(UGT), phenol sulfotransferase (PST), estrogen sulfotransferase (EST) and glutathione-
 
Figure 1.1: Scheme of API pathway in the body. Source of body figure: Google body 
Chapter 1: General Introduction 
12 | C h a p t e r  1  
S-transferase (GST) (Li, 2001). This metabolic strategy enhances excretion since it 
creates metabolites successively more polar and thereby more water-soluble than the 
parent compound (Halling-Sørensen et al., 1997; Daughton and Ternes, 1999; 
Kümmerer, 2004; Josephy and Mannervik, 2006) (Figure 1.2). 
 
 
 
 
 
 
 
 
 
APIs usage rely on its drug metabolism on different properties, namely 1) metabolic 
stability – a rapidly metabolized API implies multiple dosing to maintain therapeutic 
effect at plasma level; a slow metabolized API implies a slow elimination (prolonged 
half-life) and be unsafe to take; 2) drug-drug interactions – may occur due to the 
interference between each API metabolism when co-administrated and 3) drug toxicity - 
APIs may be transformed to non-toxic (detoxification) or more toxic (metabolic 
activation) by its metabolism (Li, 2001). Lastly, as Kümmerer (2004) refers an API 
parent compound may be excreted: unchanged, as a glucuronide or sulfate conjugate, as 
a metabolite or as a complex mixture of several metabolites.  
1.3.2 APIs Sources and Routes in the Environment 
The two major entering routes in the aquatic system are: (1) via domestic and hospital 
WWTP effluent discharges into receiving surface water and (2) via out-of-date or 
unwanted medicines disposal either flushed in the sink and/or toilet or as household 
waste which ends up in landfill sites leaking into surrounding water compartments 
(Figure 1.3). Other APIs pathways into the environment comprise: APIs applied in 
 
Metabolites – Phase  II 
 
Metabolites - Phase I API 
C 
API 
B 
API 
A 
API 
B 
API 
A 
API 
C 
Transferases 
 API 
B 
CYP 450 
 
 Oxidation, reduction, hydrolysis 
excretion 
excretion Conjugation 
Conjugation 
Figure 1.2: APIs metabolic biotransformation pathways to increase polarity and excretion 
(adapted from Daughton and Ternes, 1999) 
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aquacultures which are directly discharged in surrounding surface water; surface runoff 
after the application of biosolids/WWTP sludge and/or veterinary medicine treated 
animals manure as i.e. fertilizers; untreated sewage discharged into receiving waters 
(e.g., flood overload events); APIs application in food industry and disposal of APIs 
manufacturing wastes [usually low due to Good Manufacturing Practice regulations 
(GMPs)] (Christensen, 1998; Halling-Sørensen et al., 1997; Ternes, 1998; Jones et al., 
2001; Heberer et al., 2002; Andreozzi et al., 2003; Metcalfe et al., 2003a, b; Kümmerer, 
2004; Bendz et al., 2005; Castiglioni et al., 2005; Bound et al., 2006; Lishman et al., 
2006; Bound and Voulvoulis, 2007; Gagné et al., 2007; Kümmerer, 2009; Santos et al., 
2010). 
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Figure 1.3: Pathways of APIs from production to the aquatic environment (adapted from Heberer, 2002; Kümmerer, 2004; Bound and Voulvoulis, 2007) 
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1.3.3 Fate of APIs in Waste Water Treatment Plants (WWTPs) 
WWTPs are able to effectively control microbial pollution, eliminate organic matter and 
some nutrients (e.g., nitrogen and phosphorus). Generally the terms used to describe 
different degrees of treatment are:  
 preliminary: include mostly coarse screening, grit removal and sometimes 
comminution/reduction of large objects;  
 Primary: removal of organic and inorganic solids by sedimentation and the 
removal of materials that remain on surface by skimming - organic nitrogen, 
organic phosphorus, and metals associated with solids are also removed; 
 Secondary: involves the removal of biodegradable dissolved and colloidal 
organic matter using aerobic biological treatment processes by aerobic 
microorganisms (principally bacteria) and apply several processes such as 
activated sludge, biofilters, oxidation ditches and rotating biological contactors 
(RBC); 
 Tertiary and/or advanced wastewater treatment: is applied when further 
individual treatment processes are necessary to remove nitrogen, phosphorus, 
additional suspended solids, refractory organics, metals and dissolved solids. 
Advanced treatment processes are, in some cases, combined with primary or 
secondary treatment or used in place of secondary treatment;  
 Disinfection: involves the injection of a chlorine solution and less frequently 
ozone and/or ultra violet (UV) irradiation (FAO, 1992).  
These processes are nowadays usually based on complex biological treatment 
configurations by the combination of multiple reactors (anoxic, aerobic and anaerobic) 
and internal recycling between the different unit-processes (Rivas et al., 2008). Yet, 
urban WWTPs continuously receive streams that include several different trace 
polluting compounds (either synthetic and/or natural), for which conventional treatment 
technologies have not been specifically designed, namely for active pharmaceutical 
ingredients removal (Carballa et al., 2004; Reif et al., 2008). 
WWTPs play a critical role in the partitioning of APIs (largely depending on its degree 
of polarity and adsorption coefficients) into two exposure pathways associated with the 
liquid and the solid phase. Non-polar molecules and/or with high adsorption coefficient 
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(such as: musk and estrogens) are retained in sludge material, while the polar ones 
and/or with low adsorption coefficients (such as: anti-inflammatories and antibiotics) 
are likely to remain in the aqueous phase. The removal of APIs is affected by various 
factors such as: the chemical properties of the specific compounds, the age of the 
activated sludge, the dilution and temperature of the raw sewage, the treatment process 
employed, the environmental conditions (e.g. season), the characteristics of the influent, 
the hydraulic and solids retention time (HRT and SRT respectively) and the plant 
configuration (Kanda et al., 2003; Carballa et al., 2004; Clara et al., 2004; Kreuzinger 
et al., 2004; O'Brien and Dietrich, 2004; Clara et al., 2005a, b; Vieno et al., 2005; 
Tauxe-Wuersch et al., 2005; Castiglioni et al., 2006; Joss et al., 2006; Zuccato et al., 
2006; Gros et al., 2010). 
The majority of the APIs are characterized as being: polar, non-volatile, low solubility 
and biodegradability. These characteristics favor their mobility into the receiving 
environment by escaping sedimentation and biological treatment in the WWTP 
(Carballa et al., 2004; Bendz et al., 2005). Additionally, these substances can bypass 
WWTPs through colloid-facilitated transport during periods of high effluent turbidity, 
overflow due to technical problems, floods, or high influent loads (Daughton and 
Ternes, 1999; Paxéus et al., 2004). Although some APIs may have low persistence, the 
constant load may dominate over the transformation rate in the WWTPs (Bendz et al., 
2005). 
Even though generally reported removal rates (RE%) data intervals vary for each 
individual API. Most studies refer that individually APIs elimination from municipal 
WWTPs is often incomplete (ranging on average between 50% and 99% of efficiency) 
which ultimately enables them to reach the environment at continuous influx 
(Christensen, 1998; Halling-Sørensen et al., 1997; Ternes, 1998; Stumpf et al., 1999; 
Heberer et al., 2002; Andreozzi et al., 2003; Metcalfe et al., 2003b; Bendz et al., 2005; 
Lindqvist et al., 2005; Castiglioni et al., 2006; De Lange et al., 2006; Han et al., 2006; 
Lishman et al., 2006; Bound and Voulvoulis, 2007; Gagné et al., 2007; Gros et al., 
2010). Some APIs can be easily removed during wastewater treatment, mainly by 
adsorption and biodegradation like analgesics acetylsalicylic acid (ASA), fenofibrate, 
and paracetamol/acetaminophen; some antibiotics and estrogens such as estrone (E1), 
17-estradiol (E2), and 17-ethinylestradiol (EE2) also exhibit high removal rates when 
exposed to conventional activated sludge treatment. For instance, analgesic ibuprofen 
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exhibit high rates of oxic degradation, while iodinated X- ray contrast media remain 
unaffected by conventional activated sludge (Kümmerer, 2004). 
Additionally, Gros et al. (2010) verified three different behaviors linking RE% with 
therapeutic class in WWTPs: (a) an increase in APIs concentration through its passage 
in the WWTP - macrolide antibiotics, anti-epileptic carbamazepine, benzodiazepines 
and serotonin reuptake inhibitors presented poor or no elimination at WWTP therefore 
exhibiting higher concentrations in wastewater effluents; (b) no significant to medium 
removal - lipid regulators, fluoroquinolone, tetracycline antibiotics, anti-cholesterol, 
antihistaminics, β- blockers, β-agonists and anti-diabetic glibenclamide were partially 
degraded with either average removal efficiencies between 40 and 60–70% or in another 
situations were not eliminated at all and (c) high removal efficiency - NSAIDs and the 
antihypertensive enalapril shown consistently high removal rates, except diclofenac (0 
to 100%). 
Although the APIs more frequently detected in receiving river waters  generally match 
with those that are more ubiquitous in wastewater effluents, the highly consumed 
analgesics and anti-inflammatory drugs (like ibuprofen) are an exception since even 
after efficient removal by wastewater treatment this process is not enough to prevent 
their occurrence at considerable concentrations in river waters (Gros et al., 2010). 
1.3.4 APIs Transformation and Degradation in the Environmental 
As Kümmerer (2009) refers an API can undergo different structural changes such as 
biotic (biotransformation, biodegradation) and non-biotic (oxidation, hydrolysis and 
photolysis) transformation processes after its introduction in different environmental 
compartments such as surface water, soil or sewage which alter their physico-chemical 
and pharmaceutical properties (as described in Figure 1.4). 
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The transformation and/or degradation of the parent compound when complete involve 
mineralization to low molecular weight compounds (i.e. carbon dioxide, sulfate, nitrate) 
or when the degradation is partial the process stops before mineralization and the 
intermediates are formed i.e. stable product of biotransformation, can be more stable 
than the parent compound itself and often have comparatively a higher accumulation 
potential (Kümmerer, 2009; Santos et al., 2010). Bacteria and fungi are the organisms 
most capable to degrade organic compounds. Bacteria are particularly efficient in the 
aquatic environment biodegradation and fungi in soils biodegradation. For this reason, 
microbial degradation will be slower in surface water than in the sewage system due to 
its lower bacterial density and lower diversity (Kümmerer, 2009). Nevertheless, 
Sammartino et al. (2008) reports that APIs due to their specific action and stability are 
not subjected to microbial degradation, and on the contrary they can act reducing the 
bacterial flora present in the wasting site and therefore the non-biotic process of 
photodegradation can be considered the main way to eliminate APIs and their residues 
from the environment. Photodegradation comprises C-C bond break and in cases the 
break of the entire molecule by the action of the UV component of the solar radiation, 
this mechanism is dependent of e.g. UV radiation energy and intensity, latitude 
(seasonal and geographical variation), physical state of the APIs’ molecule, chemical 
parameters such as pH, presence of photosensitizes (e.g. nitrates, humic acids) 
(Andrezotti et al., 2003; Sammartino et al., 2008; Santos et al., 2010). Even if these 
Figure 1.4: APIs metabolites and transformation products (adapted from Kümmerer, 2009) 
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metabolic and transformation processes usually lead to decreases in APIs toxicity in the 
environment, the inverse can occur e.g. in the case of pro-drugs (Kümmerer, 2009). 
Finally, the inefficiency or insufficient action of the natural degradation processes is 
demonstrated by the presence of APIs in the aquatic system implicating potential 
toxicological and ecological problems (Sammartino et al., 2008). 
1.3.5 Occurrence in the Aquatic Environment 
The first report featuring the occurrence of pharmaceuticals in the environment was 
published by Garrison et al. (1976). Pharmaceuticals are ubiquitous in the environment. 
More than 160 from all therapeutic classes have been screened at a concentration range 
from ng.L
-1
 to μg.L-1, in surface, groundwater, raw and treated wastewater, soil, 
biosolids, sediment samples and even drinking water worldwide including the Arctic 
environment (Kümmerer, 2009; Daughton et al., 2010; Santos et al., 2010). In order to 
trace APIs in water, concentration and extraction are required analytical procedures, 
allowing both the concentration of the analyte to measurable concentrations and the 
sample cleanup which removes analytical interferences. Solid phase extraction (SPE) is 
the method most commonly used for the extraction/concentration of all classes of APIs 
from aqueous samples using different types of sorbents (e.g. hydrophilic-lipophilic 
balanced (HLB), C18, polystyrene-divinylbenzene (PS-DVB) or mixed-mode cationic 
exchange (MCX) depending on the polarity of the selected compounds but also solid 
phase microextraction (SPME) and liquid-liquid extraction (LLE). These processes of 
extraction may be followed either by derivatisation and instrumental analysis: gas 
chromatography (GC), gas-chromatography-mass spectrometry (GC-MS) (usually for 
acidic pharmaceuticals quantification), high performance liquid chromatography 
(HPLC) or followed directly by liquid chromatography-mass spectrometry (LC-MS-
MS) or liquid chromatography electrospray ionization tandem mass spectrometry (LC-
ESI-MS-MS) and ultra-performance liquid chromatography–quadrupole–time-of-flight 
mass spectrometry (LC-Q-TOF-MS) (Ternes, 2001; Weigel et al., 2004a; Alvarez et al., 
2005; Petrovic et al., 2006; 2007; Radjenovícet al., 2007; Togola and Budzinski, 2008; 
Gros et al., 2010; Buchberger, 2011; Munaron et al., 2012). 
Additionally, passive samplers such as Polar Organic Integrative Sampler (POCIS) may 
be used to overcome the process of  pre-concentration (Weigel et al., 2004a; Togola and 
Budzinski, 2008; Buchberger, 2011) (see further detail in Chapter 2). The top detected 
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APIs therapeutic classes in the environment are described thoroughly by Santos et al. 
(2010) (Figure 1.5) in which NSAIDs are the class more recurrent whereas 
antipsychotics are the least present in the aquatic systems. The following Chapters 2, 3, 
4 and 5 give a general idea of the maximum concentrations detected for some of these 
compounds in different aquatic matrices.  
 
   
Figure 1.5: Therapeutic classes present in the environment between 1997 and 2009 (Santos et 
al., 2010) 
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1.4 Current Legislation, Environmental Risk Assessment (ERA) of APIs 
There is, since 1993 an acknowledgement of the relevant impact of APIs on the 
ecosystem by the European Medicine Evaluation Agency (EMEA) and U.S. Food and 
Drug Administration (FDA) since their current guidelines implicate that in order to 
authorize any novel API commercialization it is mandatory to perform an ERA. 
Broadly, an ERA is defined “as the procedure by which the likely or actual adverse 
effects of pollutant and other anthropogenic activities on ecosystems and their 
components are estimated with a known degree of certainty using scientific 
methodologies” (Depledge and Fossi, 1994). The ERA of APIs involves a two phase 
process: Phase I - is limited on the estimation of parental API or its metabolites 
environmental exposure, if the predicted environmental concentration (PEC) exceeds a 
threshold value that poses environmental concern additional studies on environment fate 
and effects are necessary in a second phase (Phase 2). In Europe that happens when the 
API’s PEC exceeds 10 ng.L-1 in surface waters whereas in the U.S. is 1000 ng.L-1; 
Phase 2 - includes a hazard quotient approach, estimated by the ratio between PEC and 
predicted no effect concentration (PNEC) for various compartments that has to be < 1 
(FDA, 1998; EMEA, 2006; 2007; EEA, 2010; Santos et al., 2010; Buchberger, 2011). 
A good portrait of this process complexity is the one applied to the French situation, this 
prioritization methodology based itself on the APIs threshold values of PECs 
established by the EMEA ranking APIs from class IA – “highest risk compound” to IV 
– “very low risk for the environment” (Besse and Garric, 2008) (see Phase 1: Figure 1.6 
and Phase 2: Figure 1.7). Although there is the possibility to estimate the PEC for 
several APIs, it is very difficult to calculate PNEC for most APIs since their 
ecotoxicological data is still too scarce. Nonetheless as an example, NSAID diclofenac 
(DCF) (further characterized in Section 1.9.2. and Chapter 4) was recently the first API 
to be included in the new list of priority substances adopted by the European Union 
(European Commission, 2012a, b) and previously classified as a class IIA “potentially 
hazardous compound”.  
Still, based on the ERA process, an API applied in Human medicine may not be refused 
to be marketed, while a veterinary use one will be refused or need further risk mitigation 
measures (FDA, 1998; EMEA, 2006; 2007; EEA, 2010; Santos et al., 2010; 
Buchberger, 2011). Finally, concerning known ERA on APIs results, EEA (2010) refers 
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that 95 % of the applied APIs were not readily biodegradable according to OECD Test 
301 (OECD, 1992) and 15% of the human pharmaceuticals were persistent in water and 
50% in the sediment according to and 308 (OECD, 2002)
1
. 
1.4.1 “Green Chemistry” 
Following the same logical principles of “Green Chemistry” which intend to eliminate 
and/or minimize the usage and production of ecologically hazardous reagents and 
design of alternative synthesis pathways, “Green Pharmacy” involves, as proposed by 
Daughton (2003), the application of several strategies and measures to reduce the 
impact of APIs in the environment. For instance developments on: 1) drug design – i.e. 
increasing the specificity of API’ mode of action (MoA) at the target receptor would 
greatly favor the evaluation of potential effects on non-target species; 2) drug delivery – 
i.e. provide prescriptions at lower doses and/or promote individualization of therapy; 3) 
packaging – i.e. reduce packages size, offer unit doses alternative and finally 4) disposal 
– providing consumer-oriented guidance on the package for how to dispose unused 
medicines). Furthermore, “Green” APIs would have the advantage of while enhancing 
and/or maintaining therapeutic efficacy improve APIs susceptibility to biodegradation, 
photolysis, or other physicochemical alterations to convert them to harmless end 
products (Daughton, 2003). Green and sustainable pharmacy is an emerging topic and is 
at early stages of implementation being currently not a high priority for the 
pharmaceutical industry (EEA, 2010). Most of all, since very little is yet known 
concerning environmental effects, fate and behavior of APIs it is crucial to create 
awareness and inform the general population, health care practitioners and 
manufacturers on these matters (Daughton, 2003; EEA, 2010). 
                                                 
1
 Note: OECD Test 301 is based on the determination of parameters in aquatic environments under 
aerobic conditions such as dissolved organic carbon (DOC), CO2 production and oxygen uptake. The test 
is passed if in a 10 days window (within 28 day period) 70% removal of DOC and 60% of theoretical 
oxygen demand (ThOD) or carbon dioxide production (ThCO2) (OECD, 1992); OECD Test 308 is based 
on the determination of aerobic and anaerobic transformation in aquatic sediment systems parameters 
(OECD, 2002)]. 
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Figure 1.6: Phase I of the prioritization methodology proposal based on EMEA guidelines applied to French situation. PECa assumes the excretion of the API 
100% as parental compound and 0% removal rate at WWTP; PECb takes in consideration the real amount of parental compound excreted (from Besse and 
Garric, 2008). 
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Figure 1.7: Phase 2 of the prioritization methodology proposal based on ecotoxicological, 
pharmacological and physico-chemical data. The YES is chosen only in the case of agreement with 
two criteria (adapted from Besse and Garric, 2008). 
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1.5 Ecotoxicological Effects on Aquatic Organisms 
As mentioned previously, APIs are designed, for human and veterinary health practice, 
to exert a given therapeutic action targeting speciﬁc metabolic and molecular pathways 
(Fent et al., 2006a, b). Even though APIs are claimed to be the most well-studied 
chemicals (Van der Ven et al., 2006), their reactivity, MoA and associated side-effects 
are still not completely understood (Fent et al., 2006a). Potentially when present in the 
aquatic ecosystem APIs will affect the same pathways in non-target organism with 
identical or similar target organ tissues, cells or biomolecules with analogous MoA 
(Fent et al., 2006a). As referred by these authors, the MoA of NSAIDs (see Section 
1.10.1) inhibit cyclooxygenase isoforms (COX-1 and -2) and consequently 
prostaglandins biosynthesis. Invertebrates also possess prostaglandins and COX activity 
(Osada and Nomura, 1990; Gagné, 2007; 2011). Another example is the antidepressant 
fluoxetine (see Section 1.10.2) action as a serotonin re-uptake inhibitor (SSRI) and 
serotonin (5-hydroxytrypamine or 5-HT) being also present in bivalves (although 
mediating endocrine functions) (Fong, 1998; Gagné and Blaise, 2003; Gagné et al., 
2007; 2011). In order to support an ERA several ecotoxicological studies have to be 
performed on organisms (i.e. algae, zooplankton, invertebrates and fish) such as acute 
(short-time exposure) and chronic (long-time exposure) toxicity bioassays related either 
to survival rate (lethal concentrations) or to other specific parameters (such as 
reproductive, feeding, growth alterations rates) occurring through the exposure to single 
or mixture to one or more concentrations of pharmaceutical compounds. For this matter, 
it is highly recommended the consultation of WikiPharma, EPA ECOTOX and 
European Commission Joint Research Center databases which enable easy and open 
access to up-to-date data related to most APIs acute and chronic toxicity effects on 
many different species (search should be made, either by name or CAS number). 
Although present knowledge on APIs effects in non-target organisms is growing at a 
good pace as seen by the evident increase of peer-reviewed publications on the matter 
(Fent et al., 2006a; Kümmerer et al., 2009; Santos et al., 2010), very few studies have 
included the potential biochemical, metabolic and physiological response changes in 
aquatic organisms derived from chronic environmental realistic exposure concentrations 
to APIs using a multibiomarker analysis approach (see Section 1.6). As referred Van der 
Oost et al. (2003) the knowledge and understanding of the relationships between 
biomarker and bioassay responses is essential for a more reliable and holistic ERA.  
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1.5.1 Mixture Toxicity  
Although individual APIs concentrations can often be considered low to cause any 
environmental risk, in an ecotoxicological point of view, a realistic scenario should 
consider that APIs are often (depending on the therapeutic intention) applied jointly and 
the overall input in the surface waters refers to a rather complex mixture. Preliminary 
data reports the co-occurrence of fourteen APIs from eight different therapeutic classes 
in the Arade and Guadiana Rivers (Portugal) (Gonzalez-Rey et al., unpublished data). It 
is crucial to address this issue, because even if the components of a mixture are present 
below their individual ERA threshold concentrations, as a mixture they can eventually 
contribute to an increased toxicity through combined modes of action. In order to 
anticipate the effects of a chemical mixture often its calculation derives from known 
toxicities of the mixture of the individual components (Schnell et al., 2009). 
Concentration addition (CA) and independent action (IA) are the two concepts available 
for formulating the null hypothesis of additivity, this happens assuming that chemicals 
act exerting their effects without diminishing or enhancing each other’s toxicity 
(Cleuvers, 2003; 2004). In APIs studies, CA assumes that each mixture component 
possesses similar pharmacological MoAs and accordingly applicable for APIs targeting 
the same molecular site; IA conversely assumes that components have dissimilar MoAs 
and interaction at different target sites nevertheless reaching a common toxicological 
endpoint although through distinct mechanisms within an organism (Cleuvers, 2003; 
2004; Schnell et al., 2009). Phenomena of synergism or antagonism can also occur 
independently of a similar or dissimilar MoA (Cleuvers, 2003; 2004). Synergism and 
antagonism interactions are defined in relation to this additivity assumption as upwards 
(i.e. higher than expected mixture toxicities) or downwards deviations (i.e. lower than 
expected mixture toxicities) (Cleuvers, 2003; Maria and Bebianno, 2011). Very few 
studies have addressed APIs mixture effects in non-target organisms. 
1.6 Biomarkers  
Biomarkers have been successfully applied to test xenobiotic compounds effects 
particularly environmental contaminants such as: metals, polycyclic aromatic 
hydrocarbons (PAHs), pesticides, endocrine disruptors, etc. Essentially, the majority of 
the biomarkers refers to a quantitative biologic response (either at molecular, 
histological, immunological, physiological or behavioral levels) induced in a sentinel 
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species, like mussels (see Section 1.8) by the presence or exposure to contaminants 
(Cajaraville et al., 2000; Van der Oost et al., 2003). Furthermore biomarkers, 
particularly molecular ones, are defined as “short-term indicators of long-term 
biological effects” as they can be used on the early warning signaling of a contaminant 
derived deviation (comparatively to an unstressed situation) ultimately allowing 
bioremediation strategies to prevent an irreversible damage on the ecosystem 
(Cajaraville et al., 2000; Van der Oost et al., 2003). There are three classes of 
biomarkers: 1) biomarkers of susceptibility: indicating the organism’s inherent or 
acquired ability to respond to exposure to a specific xenobiotic substance (Van der Oost 
et al., 2003); 2) biomarkers of effect: measurable biochemical, physiological or other 
alterations within organism’s, for instance tissues, implying deleterious effect and 3) 
biomarkers of exposure: addressing the specific contaminant, its metabolite or product 
of interaction detection and quantification within the organism compartments (ex. 
tissues, cells). Although biomarkers indicative of exposure to contaminants are useful, 
biomarker of effects are more ecologically relevant (Cajaraville et al., 2000). 
1.7 Oxidative Stress 
The occurrence of oxidative stress in aquatic organisms has been frequently associated 
with both natural abiotic factors and the presence of contaminants (Winston and Di 
Giulio, 1991; Winston et al., 1996). Oxidative stress reflects an imbalance between the 
production and removal or scavenging of oxyradials or reactive oxygen species (ROS) 
[such as superoxide anion radical (O2
-
), hydrogen peroxide (H2O2), and hydroxyl 
radical (OH

)] (Figure 1.8). The latter is a potent oxidant which in elevated 
concentrations can be highly toxic to cell compartments (Winston and Di Giulio, 1991; 
Winston et al., 1996). Several contaminants have the ability to promote ROS, especially 
the ones that undergo univalent metabolism to form redox-cycling intermediates (like 
PAHs and metals) (Winston and Di Giulio, 1991; 1996; Valavanidis, 2006) this is also 
the case of APIs since “their specific redox reactivity is the basis for their biological 
(therapeutic) effects, metabolism, elimination and toxicity” (Martín-Díaz et al., 2009). 
Antioxidant systems are efficient protective mechanisms against ROS toxic action 
intercepting and inactivating their toxic action maintaining them at minimal intracellular 
levels. Therefore, due to their high sensitivity antioxidant systems assume an import 
role in environmental studies (Winston and Di Giulio, 1991; Winston et al., 1996: 
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Cajaraville et al., 2000; Livingstone, 2001; Regoli et al., 2002a, b; Valavanidis et al., 
2006) and may be non-enzymatic (through the action of ascorbic acid and β-carotene) or 
enzymatic, through the action of enzymes such as superoxide dismutase (SOD), catalase 
(CAT) and glutathiones peroxidase (GPx) which synthesis adjusts and adapts to stress 
levels fluctuations (Fridovich, 1998; Valavanidis et al., 2006). The assessment of these 
enzymes activities alterations is consequently considered an efficient oxidative stress 
biomarker (Cajaraville et al., 2000; Regoli et al., 2002a, b; Valavanidis et al., 2006; 
Martín-Díaz, 2009; Maria and Bebianno, 2011).  
1.7.1 Antioxidant Enzymes: Oxidative stress biomarkers 
SOD (EC 1.15.1.1) activity is one of the first defense mechanisms against oxidative 
stress, mostly acting on the catalytic conversion (dismutation) of the highly reactive O2
-
 
anion into the more stable and less reactive H2O2. From then, H2O2 can easily cross the 
cellular membranes to be breakdown into H2O and O2 in the cytosol by CAT and 
glutathione peroxidases (Fridovich, 1998). CAT (EC 1.11.1.6) is located in the 
peroxisomes occurring in almost all aerobic organisms. This enzyme can also act as 
peroxidase, where organic substances like ethanol may act as a hydrogen donor 
(Santovito et al., 2005). Glutathione is a water-soluble tripeptide constituted by the 
glutamine, cysteine and glycine amino acids present in abundance in most cells being 
both an important substrate for glutathione peroxidases and glutathione transferases but 
also as a ROS scavenger (Regoli and Principato, 2005; Fridovich, 1998; Townsend et 
al., 2003). Glutathione can exist intracellularly either as GSSG or GSH (oxidized or 
reduced form respectively) and its antioxidant ability is associated to its thiol group (as 
a reducing agent). Therefore, GSH plays a significant role in electrophilic compounds 
Figure 1.8: Diagram of reactive oxygen (ROS) formation. Adapted from Racila and Bickenbach 
(2009). 
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and peroxides detoxiﬁcation via catalysis by glutathione S-transferases (GST) and 
glutathione peroxidases (GPx). Low GSH levels are associated to a higher sensitivity to 
prooxidants and increase of cellular membrane damage (Townsend et al., 2003). 
Glutathione reductase (GR) (EC 1.6.4.2) is a flavoenzyme, which regenerates GSH 
from GSSG and plays a crucial role in GSH turnover and in cellular antioxidant 
protection maintaining GSH in high concentrations and GSSG at low concentrations 
(Bashir et al., 1995). As mentioned by Cossu et al., (1997) decreased in GR activity 
may lead to GSH depletion if not corrected by new glutathione molecules synthesis. On 
another hand, Phase II glutathione-S-transferase (GST) (EC 2.5.1.18) has an important 
function as catalyst in the conjugation reaction with tripeptide glutathione converting 
xenobiotic molecules into more hydrophilic conjugates (more polar) therefore 
enhancing their excretion and detoxification from cells. In addition, GST is also a 
catalyst of selenium-independent glutathione peroxidase activity possessing also a 
protective role against ROS deleterious effects (Manduzio et al., 2004). 
Despite the collective action of these enzymes there is always a percentage of ROS that 
can overcome oxidative stress detoxification mechanisms, namely the highly toxic OH

 
radical having an important oxidative potential with indiscriminate reactivity in cellular 
components that can cause severe alterations on several enzymatic activities and 
ultimately damage on biological membranes (lipid peroxidation - LPO) and DNA 
(Valavanidis et al., 2006) (Figure 1.9). 
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1.7.2 Lipid Peroxidation (LPO) 
LPO is characterized by phospholipid membrane permeability loss, rigidity onset and 
consequently as an assault to cell membrane integrity (Valavanidis et al., 2006). This 
phenomenon happen as a cascade of oxidative reactions set particularly in phospholipid 
membranes’ polyunsaturated lipids (LH) whose high sensitivity to ROS action is due to 
their double bond structure. The final product of these reactions is the lipid 
hydroperoxide (LOOH) which can be decomposed into several reactive species, 
including lipid alkoxyl radicals, aldehydes (e.g. malondialdehyde, HOC–CH-CHO), 
alkanes, lipid epoxides and alcohols (Valavanidis et al., 2006). The quantification of 
LPO enables the assessment of cell membrane damage, since it can induce deleterious 
effects in tissues and cells, and in extremis in DNA damage. Therefore, LPO is 
considered an efficient biomarker of damage cause by oxidative stress and extensively 
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Figure 1.9: Antioxidant enzymatic reactions cascade. Adapted from Winston and Di Giulio (1991) 
and from Sigma-Aldrich official site (http://www.sigmaaldrich.com/technical-
documents/articles/biofiles/cellular-derived-blood.html) 
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reported in mussels (Rilkans and Hornbrook, 1997; Girotti, 1998; Valavanidis et al., 
2006; Gagné et al., 2011). 
1.8 Neurotoxic Effects 
1.8.1 Acetylcholinesterase (AChE) 
AChE activity has a critical role in cholinergic nervous function (ex. for muscular 
contraction and heart beating in bivalves) as the promoter of neurotransmitter 
acetylcholine (ACh) hydrolysis to choline and acetic acid (Tsuchiya et al., 2004). AChE 
inhibition is considered as a biomarker of exposure to several contaminants such as 
organophosphorus pesticides, detergents and APIs (Ricciardi et al., 2006; Matozzo et 
al., 2005; Solé et al., 2010) and has been successfully applied in M. galloprovincialis to 
assess neurotoxic effect (Bodin et al., 2004; Banni et al., 2010; Dondero et al., 2010; 
Gorbi et al., 2011). 
1.9 Endocrine Disruption 
One of the very first effects associated to exposure to SSRIs in aquatic organisms was 
the induction and potentiation of parturition/spawning (Fong, 1998; Fong and Molnar, 
2008). Therefore, some APIs do have the ability to induce evidences of endocrine 
disruption in non-target organism. Endocrine disruption is often associated to a very 
diverse group of compounds including natural (17-estradiol - E2) and synthetic 
hormones (17α ethynylestradiol - EE2), polychlorinated biphenyls, organochlorine 
pesticides, plasticizers (like bisphenol A - BPA) and detergents (like nonylphenols -
NPs). Many known endocrine disruptor compounds (EDCs) are estrogenic, affecting in 
particular reproductive functions. Additionally, due to its persistent nature and 
lipophilicity most xenoestrogens (and their metabolites) are bioaccumulated and 
biomagnified in environmental compartments, including marine biota, nevertheless 
most data concerning biological effects and mechanisms of action of EDCs on marine 
organisms derive from studies made on vertebrates and data on invertebrates are 
evidently lacking  mainly due to the lack of knowledge of the invertebrates endocrine 
system (Porte et al., 2006; Gagnaire et al., 2009).  
Vitellogenins (Vtg) precede egg-yolk protein vitellin (Vn) in oviparous species being 
naturally synthesized in females and inactive in males (Matozzo and Marin, 2008; 
Matozzo et al., 2008). Whenever elevated levels are detected in males it is a sign of the 
Chapter 1: General Introduction 
32 | C h a p t e r  1  
occurrence of endocrine disruption (ED) (Blaise et al., 1999; Gagné et al., 2002; 
Matozzo and Marin, 2008; Matozzo et al., 2008). The measurement of alkali-labile 
phosphates (ALP) released by Vg after alkali hydrolysis is considered an effective and 
cost-effective method of indirectly assess xenoestrogenicity in bivalves and therefore 
ED biomarker in invertebrates (Blaise et al., 1999; Gagné et al., 2001; 2002; Porte et 
al., 2006; Ortiz-Zarragoitia and Cajaraville, 2006; Matozzo and Marin, 2008; Matozzo 
et al., 2008). 
1.10 Selected Species 
Mussels are economically valuable species, easy to cultivate or collect in coastal areas 
(Fuentes et al., 2009). The Genus Mytilus has been successfully applied as an 
environmental sentinel species in numerous ecotoxicological studies (like “Mussel 
Watch” Program) (Goldberg et al., 1978) due to its natural ability to accumulate 
contaminants from the surrounding water, wide distribution and long-life span 
(Cajaraville et al., 2000; Porte et al., 2006; Ricciardi et al., 2006; Gorbi et al., 2008; 
Cravo et al., 2009; Dondero et al., 2010; Ericson et al., 2010; Ortiz-Zarragoitia and 
Cajaraville, 2010; Sureda et al., 2010; Franzellitti et al., 2011; Gonzalez-Rey et al., 
2011; Maria and Bebianno, 2011). 
1.10.1 Mytilus galloprovincialis (Lamark, 1819) (Figure 1.8) 
M. galloprovincialis have a wide native range distribution being present in the Atlantic 
Ocean coast (from the shores of the Irish 
Sea, where it co-occurs and hybridizes with 
Mytilus edulis Linnaeus, to Southern Spain) 
and in Western Mediterranean, Tyrrhenian, 
Adriatic, Aegean and Black Seas (Daguin 
and Borsa, 1999; Branch and Stefani, 2004). 
This species has been introduced 
intentionally and/or accidentally via 
aquaculture, ballast waters or attachment to ships’ hulls, etc. in South Africa, Asia 
(Hong Kong, Japan and Korea), Southeast Australia and West Coast of North America 
(Branch and Stefani, 2004). This mussel lives attached by segregated byssus threads on 
hard substrates (rocks and piers) within sheltered harbors, estuaries and open coast 
Figure 1.10: Mussel Mytilus galloprovincialis. 
Source: http://eol.org/pages/449961/overview 
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rocky shores over the intertidal region to 40 m depth (FAO, 2012).  It is a filter-feeder 
species and its diet consists of phytoplankton and detritus present in the surrounding 
water. Lastly, M. galloprovincialis possess gonochoristic reproduction (males and 
females spawn simultaneously) and its high fecundity is controlled by water 
temperature and food availability (Bayne, 1976; FAO, 2012). 
1.11 Selected APIs for Exposure 
The APIs selected in the present thesis (ibuprofen, fluoxetine and diclofenac) were 
chosen since they are amongst the top selling pharmaceuticals worldwide being at the 
same time the most frequently detected in the aquatic environment. Its general chemical 
properties are in Table 1.7. This section describes each API major characteristics, such 
as therapeutic action, pathways in the human body, metabolism and fate in the 
environment.  
1.11.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
Antipyretic analgesics are a group of heterogeneous substances including acidic (like, 
NSAIDs) and nonacidic (like, paracetamol) drugs. NSAIDs are the most present 
therapeutic group in the aquatic system (Parolini et al., 2009; Santos et al., 2010) 
comprising top-selling non-prescription APIs such as: ibuprofen, naproxen and 
diclofenac. In the 70’s, it was shown that the anti-inflammatory action of NSAIDs rests 
in their ability to promote the non-selective inhibition of cyclooxygenase (COX)-1 and -
2 isoforms which mediate the biosynthesis of proinflammatory eicosanoid 
prostaglandins (PGs) from the phospholipid arachidonic acid (AA) (Vane et al., 1998; 
Table 1.7: Chemical properties of selected pharmaceuticals: IBU, DCF and FLX (adapted from 
Tixier et al., 2003 and retrieved online: DrugBank; ChemID plus Advanced) 
 Therapeutic class NSAIDs SSRI 
Properties IBUPROFEN 
(IBU) 
DICLOFENAC 
Sodium (DCF) 
FLUOXETINE 
Hydrochloride (FLX) 
CAS number 15687-27-1 15307-86-5 59333-67-4* 
Molecular formula C13H18O2 C14H10Cl2NNaO2 C17H19ClF3NO 
Molecular weight 206.29 318.13 345 
Water solubility 0.049 mg.ml-1 2.43 mg.ml-1 14 mg.ml-1 
pKa 4.91 13.4 10.06 (without HCl) 
Henry’s law constant 
(atm.m3.mol-1) 
1.5 x 10-7 4.75 x 10-12 8.90 x 10
-8 
(estimated) Log Kow 4.13-4.91 0.7 4.05 
* (R-(-) fluoxetine hydrochloride) CAS number: 114247-09-5 
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Fent et al., 2006a; Hinz and Brune, 2006; Praveen Rao and Knaus, 2008). PGs produced 
during inflammatory states may significantly increase the excitability of nociceptive 
(“pain-receptor”) nerve fibers contributing to the development of burning pain and 
therefore the action of NSAIDs arises from this peripheral sensitization prevention, 
diminishing pain perception (Hinz and Brune, 2006; DrugBank, 2012). Eicosanoids 
derived from AA three pathways metabolization (i.e. PG and thromboxane – from COX 
pathway; leukotrienes and lipoxins - from lipoxygenase (LOX) pathway and 
epoxyeicosatrienoic acids – from CYP P450 epoxygenase pathway) are involved in the 
regulation of inflammation, ion transport and neural and reproductive function 
(Heckmann et al., 2007; 2008). The metabolization pathway of NSAIDs in humans and 
mammals is represented in Figure 1.11. In invertebrates, like molluscs, PGs act as 
“local” hormones critical in physiological functions such as: reproduction (gonadal 
development, spawning - behavior and oocyte fertilization/production control), water 
transport, osmoregulation ion balance, control of cardiac function (in Octopus vulgaris) 
and chemical defense (Ruggeri and Thoroughgood, 1985; Osada and Nomura, 1990; 
Rowley et al., 2005).  
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Figure 1.11: NSAID pathway in humans. Adapted from Hinz and Brune, 2006 and DrugBank (http://www.drugbank.ca/drugs/DB00586) 
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Figure 1.12: IBU chemical 
structure. Source: ChemID plus 
Advanced. 
1.11.1.1 Ibuprofen (IBU) 
IBUPROFEN (IBU), (2-(4-isobutylphenyl) propanoic acid (Figure 1.12), is known as 
prototypical NSAID with analgesic and antipyretic 
properties used in the treatment of fever and pain. Is 
commercialized as a non-prescription drug and most 
known brand names are Advil
®
 and Brufen
®
 (Zwiener 
et al., 2002; DrugBank, 2012). After application IBU is 
rapidly metabolized and excreted in the urine, 
approximately 15% as the parent compound and in 
form of its metabolites: hydroxyibuprofen (OH-IBU), 
carboxyibuprofen (CA-IBU) and carboxyhydratropic 
acid (CA-HA) (Ternes, 1998; Zwiener et al., 2002). At 
WWTPs IBU shown removal rates averaging 91% (Tixier et al., 2003; Khetan and 
Collins, 2007; Quintana et al., 2005; Palmer et al., 2008; Gros et al., 2010). Direct 
phototransformation can be neglected because this compound does not absorb sunlight, 
though its elimination by sedimentation is relevant due to a high sorption coefficient to 
particles combined with particulate organic carbon (Tixier et al., 2003). IBU is defined 
as a class IA compound which defines it as posing a “high environmental risk” (Besse 
and Garric, 2008).  
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Figure 1.13: DCF chemical 
structure. Source: ChemID plus 
Advanced 
1.11.1.2 Diclofenac (Sodium Salt) 
Diclofenac sodium salt (DCF) or 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 
sodium salt (Figure 1.13) is the most highly consumed 
anti-inflammatory predominantly prescribed for the 
treatment of rheumatic (arthritic) pain. Its 
administration is usually oral or topical and common 
brand names are Voltaren
®
 and Cataflan
®
. DCF 
appears to be less active on COX-1 as compared to 
COX-2 (Hinz and Brune, 2006). DCF undergoes a 
considerable first-pass metabolism that causes its 
limited oral bioavailability (about 50%), the lack of 
therapeutic effect imply an adaptation of the dosage or 
change of the drug (Hinz and Brune, 2006). The DCF metabolism in humans and 
animals has been studied extensively, DCF undergoes bioactivation by cytochrome 
P450 oxidation to hydroxylated derivatives including 4-hydroxy (OH) and 5-OH 
metabolites and minor metabolites include 3-OH, 3-OH-4-methoxy and 4,5-dihydroxy 
diclofenac (Marco-Urrea et al., 2010). DCF is eliminated through metabolism and 
subsequent urinary and biliary excretion (DrugBank, 2012). Nevertheless, parental DCF 
is commonly found in water following a still contradictory removal rate at the WWTPs 
(averaging 58%) (Gros et al., 2010; Marco-Urrea et al., 2010). Direct 
phototransformation (by sunlight) is the main elimination process in surface waters 
nevertheless this process strongly time and site specific (Tixier et al., 2003; Bartels and 
Tümpling, 2007). In a ecotoxicology perspective, DCF was one of the first APIs raising 
“a red flag” on APIs potential as an environmental contaminant when it was directly 
associated as the cause of Indian vulture (Gyps sp.) population decline after scavenging 
DCF-treated livestock carcasses (Oaks et al., 2004). As mentioned previously according 
to Besse and Garric (2008) DCF is classified as a class IIA “potentially hazardous 
compound” and has been recently included in the list of priority substances in the field 
of water policy by the European Union (European Commission, 2012a, b).  
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1.11.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 
Selective serotonin reuptake inhibitors (SSRIs) have emerged as a major therapeutic 
advance in neuropsychopharmacology establishing the pathophysiological role of 
serotonin (5-HT) and confirming that neurotransmitter reuptake inhibition is an 
important therapeutic principle in affective and anxiety disorders treatment (Vaswani et 
al., 2003). SSRIs were developed to inhibit/block 5-HT neuronal uptake pump, without 
affecting the various other neuroreceptors (i.e., histamine, acetylcholine and adrenergic 
receptors) or fast sodium channels like tricyclic antidepressants (TCAs), therefore 
avoiding its associated safety problems (Vaswani et al., 2003). In humans, 5-HT 
modulates homeostasis between dopamine, noradrenaline and γ-aminobutyric acid 
(GABA) when this homeostasis gets disturbed, the onset of depression and anxiety 
occurs. Patients may respond differently to SSRI however that does not imply that one 
is more effective than another (Vaswani et al., 2003). First SSRI antidepressant 
marketed was zimelidine which was banned due to serious cases of central and/or 
peripheral neuropathy, namely suicide tendency. Nowadays common SSRIs are 
fluoxetine, fluvoxamine, citalopram, paroxetine and sertraline (Vaswani et al., 2003; 
DrugBank, 2012).  
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Figure 1.14: FLX chemical 
structure. Source: ChemID plus 
Advanced 
1.11.2.1 Fluoxetine  
Fluoxetine (FLX) [(R-(-) fluoxetine hydrochloride)] or methyl({3-phenyl-3-[4-
(trifluoromethyl)phenoxy]propyl})amine (Figure 1.14) 
is the most widely prescribed psychoactive agent in the 
market. Most common brand name is Prozac
®
 and it is 
used to treat depression, bulimia, premenstrual 
dysphoric disorder, panic disorder and post-traumatic 
stress (Hiemke and Hartler, 2000; Kwon and 
Armbrust, 2006; DrugBank, 2012). After oral 
administration, FLX is almost entirely absorbed, 
undergoing extensive metabolic conversion to its 
active metabolite norfluoxetine in the liver. FLX is 
mainly excreted in urine, with less than 10% excreted unchanged or as fluoxetine N-
glucuronide (Hiemke and Hartler, 2000; Vaswani et al., 2003). FLX has a half-life of 1 
- 4 days, whereas the half-life of norfluoxetine ranges between 7 and 15 days (Hiemke 
and Hartler, 2000). The pathway of FLX in humans and mammals is represented in 
Figure 1.15. Several studies reveal the occurrence of FLX in the environment, after a 
60% removal rate at WWTPs. Photodegradation has a low contribution of to the 
dissipation of FLX in the aquatic systems (Kwon and Armbrust, 2006). According to 
Besse and Garric (2008), FLX is classified as a class III “very low risk” compound, 
nevertheless several ecotoxicological effects including bioaccumulation in several fish 
muscles (Brooks et al., 2005) and induction of spawning in bivalves (Fong and Molnar, 
2008; Lazzara et al. 2012; Bringolf et al., 2010) have been attributed to FLX exposure.  
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Figure 1.15: Fluoxetine pathway in human and mammals. Adapted from DrugBank: 
www.drugbank.ca/drugs/DB00472 
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1.12 Copper (Cu) 
Briefly, copper (Cu) is considered one of the most important risk factors in the marine 
environment and a “classic” contaminant entering the aquatic environment through 
several pathways, including runoff resulting from mining activities, industrial activities, 
leaching from wood preservatives, and multi-application as antifouling agents in paints, 
fertilizers (Bonnard et al., 2010; Maria and Bebianno, 2011) and lately as copper oxide 
nanoparticles containing products (Gomes et al., 2011; 2012). Yet playing an essential 
role in living organisms as a micronutrient, when present at high concentrations Cu’s 
participation in Fenton reaction, which generates toxic ROS, is linked to cause several 
deleterious effects at different cellular levels (EPA, 2007; Maria and Bebianno, 2011). 
Cu concentrations in the aquatic system have been reported ranging from 0.03 to 0.23 
µg.L
-1
 in surface seawaters and from 0.20 to 30 µg.L
-1 
in freshwater systems, 
additionally in water loads subjected to direct anthropogenic inputs concentrations can 
vary greatly reaching more than 100 µg.L
-1 
(EPA, 2007). 
In mussel species, exposure to environmental realistic concentrations of Cu were 
reported to affect its physiological status, namely inducing the alteration of several 
oxidative stress related antioxidant enzymes, LPO, immunomodulation, byssogenesis 
inhibition and metallothionein transcription expression and induction (Pipe et al., 1999; 
Nicholson and Lam, 2005; Maria and Bebianno, 2011; Gomes et al., 2011; 2012). 
Moreover, the results of mussels M. galloprovincialis exposure to realistic 
concentrations of Cu and polycyclic aromatic hydrocarbon benzo[a]pyrene (B[a]P) 
mixture which showed an overall higher alterations of antioxidant enzymes (SOD, CAT 
and GR) activities by 5 µg.L
-1 
Cu
 
single exposure (with the exception of Phase II GST) 
in both gills and digestive glands and LPO levels (in gills) than as a mixture component 
(Maria and Bebianno, 2011) were particularly relevant for its concentration selection 
and inclusion in one of the mixtures exposure assays (Chapter 6). 
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1.13 Objectives 
Based on the several above mentioned introductory aspects, currently the knowledge 
regarding APIs occurrence and associated effects on non-target organisms is still very 
scarce, more so considering that the problematic is “emergent” by the scientific 
community. Nevertheless, in order to favor each API reliable associated ERA and 
subsequent associated regulatory measures, it is absolutely necessary to perform studies 
regarding validated methodologies of APIs quantification in all types of aquatic 
matrices and also provide data regarding the effects of each APIs, ideally through a 
multibiomarker assessment approach.  
The objectives of this thesis pertained firstly, to contribute to the assessment of APIs 
concentrations in surface waters through the application of passive sampler (POCIS) 
and secondly, to the relevance of a multibiomarker approach application on the 
assessment of oxidative stress, neurotoxic and endocrine disruption effects using mussel 
Mytilus galloprovincialis as sentinel species. Based on the therapeutic classes of the 
APIs mentioned above one of the main objectives was to assess the effects of the 
selected APIs in mussel tissues comprising single exposure to environmental relevant 
concentrations and multiple stressors. Therefore specimens of M. galloprovincialis were 
collect from a reference site situated in the Ria Formosa Lagoon, Southeast of Portugal 
(37°06'58.62"N, 7°37'43.93"W)  
This thesis is structured in seven Chapters organized as follows: 
Chapter 1 Provides an introductory description concerning the problematic of APIs 
occurrence in the aquatic environment and potential effects on non-target organisms;  
Which are the most important APIs occurring in Arade river? Is there any spatial and 
seasonal variability? These questions are addressed in Chapter 2 where several APIs of 
therapeutic classes (analgesic, anticonvulsant, antidepressant, anxiolytic, antiasthmatic, 
anti-lipidemic, NSAID and stimulant) were identified and detected in Arade river 
applying the passive sampler POCIS with emphasis on summer impact changes. 
Does non-steroidal anti-inflammatory (NSAID) ibuprofen affect oxidative stress 
responses and endocrine disruption in mussel Mytilus galloprovincialis tissues? 
Chapter 3 address this problematic comprising a multibiomarker approach on 
antioxidant enzyme activities (SOD, CAT, GR and GST) alterations, damage (LPO) in 
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mussels gills and digestive gland and vitellogenesis (by ALP levels) in sex-
differentiated gonads during the exposure to ibuprofen at an environmental relevant 
concentration (250 ng.L
-1
). 
Does selective serotonin reuptake inhibitor (SSRI) fluoxetine induce antioxidant system 
responses alteration, neurotoxic effect and/or endocrine disruption evidences in mussel 
Mytilus galloprovincialis tissues? This chapter (Chapter 4) focuses on the effects of an 
environmental relevant concentration of fluoxetine (75 ng.L
-1
) in mussel tissues 
applying a multibiomarker approach on alterations in antioxidant enzyme activities 
(SOD, CAT and GST) in mussels’ gills and digestive gland, AChE activity in gills and 
vitellogenesis (ALP) in sex-differentiated gonads. 
Does NSAID diclofenac have the ability to alter antioxidant enzyme activities and 
produce neurotoxic and endocrine disruption effects in mussel Mytilus galloprovincialis 
tissues? Chapter 5 focuses on the effects of anti-inflammatory diclofenac at an 
environmental relevant concentration (250 ng.L
-1
) applying a multibiomarker approach 
on antioxidant enzyme activities (SOD, CAT, GR and GST) alterations, damage (LPO), 
neurotoxicity (AChE) and endocrine disruption (ALP) effects in mussels’ gills, 
digestive gland, and sex-differentiated gonads.  
Do distinct APIs mixtures induce distinct oxidative stress responses, neurotoxic and 
endocrine disruption effects in Mytilus galloprovincialis? What is the impact of a 
classic contaminant, such as Cu, in an emergent compound mixture? Chapter 6 focuses 
on the effects of two mixtures of multiple stressors: one induced by a mixture of the 
APIs mentioned in the previous chapters and the other using the same mixture of 
emerging contaminants (APIs) with a classical contaminant (Cu). Effects on biomarkers 
of susceptibility (antioxidant enzymes SOD, CAT, GR and GST), damage (LPO), 
neurotoxicity (AChE) and endocrine disruption (ALP) were evaluated in mussels’ gills, 
digestive gland and in sex-differentiated gonads and effects compared with those of the 
individual exposure. 
Finally in Chapter 7, the overall conclusions were synthesized and future perspective 
studies proposed. 
  
Chapter 1: General Introduction 
44 | C h a p t e r  1  
1.14 References 
Alvarez, D.A., Stackelberg, P.E., Petty, J.D., Huckins, J.N., Furlong, E.T., Zaugg, S.D., Meyer, 
M.T., 2005. Comparison of a novel passive sampler to standard water-column sampling for 
organic contaminants associated with wastewater effluents entering a New Jersey stream. 
Chemosphere 61, 610–622. doi:10.1016/j.chemosphere.2005.03.023 
Amiard, J.-C., Bacheley, H., Barillé, A.-L., Barillé, L., Geffard, A., Himery, N., 2004. Temporal 
changes in nickel and vanadium concentrations and in condition index and metallothionein 
levels in three species of molluscs following the “Erika” oil spill. Aquatic Living Resources 17, 
281–288. doi:10.1051/alr:2004037 
Anderson, P.D., D´Aco, V.J., Shanahan, P., Chapra, S.C., Buzby, M.E., Cunningham, V.L., 
Duplessie B.M., Hayes, E.P., Mastrocco, F.J., Parke, N.J., Rader, J.C., Samuelian, J.H., 
Schwab, B.W., 2004. Screening Analysis of Human Pharmaceutical Compounds in U.S. 
Surface Waters. Environmental Science and Technology 38, 838-849. PMID:14968872 
Andreozzi, R., Raffaele, M., Nicklas, P., 2003. Pharmaceuticals in STP effluents and their solar 
photodegradation in aquatic environment. Chemosphere 50, 1319-1330. doi:10.1016/S0045-
6535(02)00769-5 
Bahe, A.R., Classen, J.J., Williams, R., Stavely, J., 2005. Emerging environmental contaminants 
and antibiotic resistance: science and policy concerns. Animal Waste Management Symposium, 
246-259 pp.  
Banni, M., Negri, A., Dagnino, A., Jebali, J., Ameur, S., Boussetta, H., 2010. Acute effects of 
benzo[a]pyrene on digestive gland enzymatic biomarkers and DNA damage on mussel Mytilus 
galloprovincialis. Ecotoxicology and Environmental Safety 73(5), 842–848. 
doi:10.1016/j.ecoenv.2009.12.032 
Bartels, P.,  Tümpling, W.Jr., 2007. Solar radiation influence on the decomposition process of 
diclofenac in surface waters. Science of the Total Environment 374 (2007) 143–155. 
doi:10.1016/j.scitotenv.2006.11.039 
Bashir, A., Perham, R.N., Scrutton, N.S., Berry, A., 1995. Altering kinetic mechanism and 
enzyme stability by mutagenesis of the dimer interface of glutathione reductase. The Journal of 
Biochemistry 312(2), 527-533. PMID:8526866. 
Bayne, B.L. ed., 1976. Marine mussels: their ecology and physiology. Cambridge University 
Press, New York. 506 pp. 
Bendz, D., Paxeus, N.A., Ginn, T.R., Loge, F.J., 2005. Occurrence and fate of pharmaceutically 
active compounds in the environment, a case study: Hoje River in Sweden. Journal of 
Hazardous Materials 122, 195-204. doi:10.1016/j.jhazmat.2005.03.012 
Besse, J.-P., Garric, J., 2008. Human pharmaceuticals in surface waters. Implementation of a 
prioritization methodology and application to the French situation. Toxicology Letters 176(2), 
104–123. doi:10.1016/j.toxlet.2007.10.012 
Blaise, C., Gagné, F., Pellerin, J., Hansen, P.D., 1999. Determination of vitellogenin-like 
properties in Mya arenaria hemolymph (Saguenay Fjord, Canada): a potential biomarker for 
endocrine disruption. Environmental Toxicology 14, 455–465. doi:10.1002/(SICI)1522-
7278(199912)14:5<455::AID-TOX2>3.0.CO;2-8 
Bodin, N., Burgeot, T., Stanisière, J. Y., Bocquené, G., Menard, D., Minier, C., Boutet, I., 
Amat, A., Cherel, Y., Budzinski, H., 2004. Seasonal variations of a battery of biomarkers and 
physiological indices for the mussel Mytilus galloprovincialis transplanted into the northwest 
Chapter 1: General Introduction 
45 | C h a p t e r  1  
Mediterranean Sea. Comparative Biochemistry and Physiology Part C 138(4), 411-427. 
doi:10.1016/j.cca.2004.04.009 
Bonnard, M., Romeo, M., Amiard-Triquet, C., 2009. Effects of copper on the burrowing 
behavior of estuarine and coastal invertebrates, the polychaete Nereis diversicolor and the 
bivalve Scrobicularia plana. Human and Ecological Risk Assessment 15(1), 11–26. 
doi:10.1080/10807030802614934 
Bound, J.P., Kitsou, K., Voulvoulis, N., 2006. Household disposal of pharmaceuticals and 
perception of risk to the environment. Environmental Toxicology and Pharmacology 21, 301–
307. doi:10.1016/j.etap.2005.09.006 
Bound, J.P., Voulvoulis, N., 2004. Pharmaceuticals in the aquatic environment - a comparison 
of risk assessment strategies. Chemosphere 56, 1143–1155. 
doi:10.1016/j.chemosphere.2004.05.010 
Bound, J.P., Voulvoulis, N., 2006. Predicted and measured concentrations for selected 
pharmaceuticals in UK rivers: Implications for risk assessment. Water Research 40, 2885 – 
2892. doi:10.1016/j.watres.2006.05.036 
Bound, J.P., Voulvoulis, N., 2007. Household disposal of pharmaceuticals as a pathway for 
aquatic contamination in the United Kingdom. Environmental Health Perspectives 113(12), 
1705- 1711. doi:10.1289/ehp.8315 
Branch, G.M., Steffani. C.N., 2004. Can we predict the effects of alien species? A case-history 
of the invasion of South Africa by Mytilus galloprovincialis (Lamarck). Journal of 
Experimental Marine Biology and Ecology 300, 189-215. doi:10.1016/j.jembe.2003.12.007 
Brooks, B. W., Chambliss, C. K., Stanley, J. K., Ramirez, A., Banks, K. E., Johnson, R. D., 
Lewis, R. J. 2005. Determination of select antidepressants in fish from an effluent-dominated 
stream Environmental Toxicology and Chemistry 24, 464-469. doi:10.1897/04-081R.1 
Buchberger, W.W., 2011. Current approaches to trace analysis of pharmaceuticals and personal 
care products in the environment. Journal of Chromatography A 1218(4), 603–618. 
doi:10.1016/j.chroma.2010.10.040 
Cajaraville, M.P., Bebianno, M.J., Porte, C., Sarasquete, C., Viarengo, A., 2000. The use of 
biomarkers to assess the impact of pollution in coastal environments of the Iberian Peninsula: a 
practical approach. Science of the Total Environment 247, 295–311. doi:10.1016/S0048-
9697(99)00499-4 
Carballa, M., Omil, F., Lema, J.M., Llompart, M., Garcia-Jares, C., Rodriguez, I., Gomez, M., 
Ternes, T., 2004. Behavior of pharmaceuticals, cosmetics and hormones in a sewage treatment 
plant. Water Research 38, 2918-2926. doi:10.1016/j.watres.2004.03.029 
Castiglioni, S., Bagnati, R., Calamari, D., Fanelli, R., Zuccato, E., 2005. A multiresidue 
analytical method using solid-phase extraction and high-pressure liquid chromatography tandem 
mass spectrometry to measure pharmaceuticals of different therapeutic classes in urban 
wastewaters. Journal of Chromatography A 1092, 206–215. doi:10.1016/j.chroma.2005.07.012 
Castiglioni, S., Bagnati, R., Fanelli, R., Pomati, F., Calamari, D., Zuccato, E., 2006. Removal of 
pharmaceuticals in sewage treatment plants in Italy. Environmental Science and Technology 40, 
357-363. doi:10.1021/es050991m 
ChemID plus Advanced, 2012. Retrived from http://chem.sis.nlm.nih.gov/chemidplus/ 
Christensen, F.M., 1998. Pharmaceuticals in the Environment - A Human Risk? Regulatory 
Toxicology and Pharmacology 28, 212–221. doi:10.1006/rtph.1998.1253 
Chapter 1: General Introduction 
46 | C h a p t e r  1  
Clara, M., Strenn, B., Ausserleitner, M., Kreuzinger N., 2004. Comparison of the behaviour of 
selected micropollutants in a membrane bioreactor and a conventional wastewater treatment 
plant. Water Science and Technology 50(5), 29-36. PMID:15497826 
Clara, M., Kreuzinger, N., Strenn, B., Gans, O., Kroiss, H., 2005a. The solids retention time - a 
suitable design parameter to evaluate the capacity of wastewater treatment plants to remove 
micropollutants. Water Research 39, 97-106. doi:10.1016/j.watres.2004.08.036 
Clara, M., Strenn, B., Gans, O., Martinez, E., Kreuzinger, N., Kroiss, H., 2005b. Removal of 
selected pharmaceuticals, fragrances and endocrine disrupting compounds in a membrane 
bioreactor and conventional wastewater treatment plants. Water Research 39, 4797-4807. 
doi:10.1016/j.watres.2005.09.015 
Cleuvers, M., 2003. Aquatic ecotoxicity of pharmaceuticals including the assessment of 
combination effects. Toxicology Letters 142, 185-194. doi:10.1016/S0378-4274(03)00068-7 
Cleuvers, M., 2004. Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, 
naproxen, and acetylsalicylic acid. Ecotoxicology and Environmental Safety 59, 309–315. 
doi:10.1016/S0147-6513(03)00141-6 
Cossu, C., Doyotte, A., Jacquin, M.C., Babut, M., Exinger, A., Vasseur, P., 1997. Glutathione 
reductase, selenium-dependent glutathione peroxidase, glutathione levels, and lipid peroxidation 
in freshwater bivalves, Unio tumidus, as biomarkers of aquatic contamination in field studies. 
Ecotoxicology and Environmental Safety 38(2), 122–131. doi:10.1006/eesa.1997.1582 
Cravo, A., Lopes, B., Serafim, A., Company, R., Barreira, L., Gomes, T., Bebianno, M.J., 2009. 
A multibiomarker approach in Mytilus galloprovincialis to assess environmental quality. 
Journal of Environmental Monitoring 11, 1673–1686. doi:10.1039/b909846a 
Daguin, C., Borsa, P., 1999. Genetic characterisation of Mytilus galloprovincialis Lmk. in North 
West Africa using nuclear DNA markers. Journal of Experimental Marine Biology and Ecology 
235, 55–65. doi:10.1016/S0022-0981(98)00163-4 
Daughton, C.G., 2003. Cradle-to-cradle stewardship of drugs for minimizing their 
environmental disposition while promoting human health: I. Rationale for and avenues toward a 
Green Pharmacy. Environmental Health Perspectives 111(10), 775-785. PMID:1241488 
Daughton, C.G., 2010. Pharmaceutical ingredients in drinking water: Overview of occurrence 
and significance of human exposure, In: Contaminants of emerging concern in the environment: 
Ecological and human health consideration, Rolf Halden (Ed.), ACS Symposium, Series 1048, 
American Chemical Society, Washington, D.C., Chapter 2, 9-68 pp. 
Daughton, C.G., Ternes, T.A., 1999. Pharmaceuticals and health care products in the 
environment: Agents of subtle change? Environmental Health Perspectives 107(6), 907-938. 
PMID:10592150 
De Lange, H.J., Noordoven, W., Murkc, A.J., Lürling, M., Peeters, E.T.H.M., 2006. 
Behavioural responses of Gammarus pulex (Crustacea, Amphipoda) to low concentrations of 
pharmaceuticals. Aquatic Toxicology 78, 209–216. doi:10.1016/j.aquatox.2006.03.002 
Depledge, M.H., Fossi, M.C., 1994. The role of biomarkers in environmental assessment (2). 
Invertebrates. Ecotoxicology 3, 161-172. doi:101007/BF00117081  
Dondero, F., Negri, A., Boatti, L., Marsano, F., Mignone, F.,  Viarengo, A., 2010. 
Transcriptomic and proteomic effects of a neonicotinoid insecticide mixture in the marine 
mussel (Mytilus galloprovincialis, Lam.). Science of the Total Environment 408(18), 3775–
3786. doi:10.1016/j.scitotenv.2010.03.040 
Chapter 1: General Introduction 
47 | C h a p t e r  1  
DrugBank, 2012. Retrived from http://www.drugbank.ca/ 
EMEA, 2006. Guideline on the environmental risk assessment of medicinal products for human 
use. European Medicines Evaluation Agency. Doc.Ref. EMEA/CHMP/SWP/4447/00 
EMEA, 2007. Guideline on environmental impact assessment for veterinary medicinal products 
in support of the VICH guidelines GL6 and GL38. European Medicines Agency. Committee for 
Medicinal Products for Veterinary Use (CVMP). EMEA/CVMP/ ERA/418282/2005-Corr 
EPA ECOTOX database: http://cfpub.epa.gov/ecotox/advanced_query.htm  
Ericson, H., Thorsén, G., Kumblad, L., 2010. Physiological effects of diclofenac, ibuprofen and 
propranolol on Baltic sea blue mussels. Aquatic Toxicology 99 (2), 223–231. 
doi:10.1016/j.aquatox.2010.04.017 
European Commission Joint Research Center: http://esis.jrc.ec.europa.eu/ 
European Commission, 2012a. Proposal for a directive of the European parliament and of the 
council amending Directives 2000/60/EC and 2008/105/EC as regards priority substances in the 
field of water policy, European Environment Agency, Brussels, 35 pp. 
http://ec.europa.eu/environment/water/water-dangersub/lib_pri_substances.htm 
European Commission, 2012b. Report from the commission to the European parliament and the 
council on the outcome of the review of Annex X to Directive 2000/60/EC of the European 
Parliament and of the Council on priority substances in the field of water policy. European 
Environment Agency, Brussels, 6 pp. http://ec.europa.eu/environment/water/water-
dangersub/lib_pri_substances.htm 
European Environment Agency, 2010. EEA Technical report No 1/2010 Pharmaceuticals in the 
environment: Results of an EEA workshop, ISSN 1725-2237. Retrieved: 
http://www.eea.europa.eu/publications/pharmaceuticals-in-the-environment-result-of-an-eea-
workshop 
FAO - Food and Agriculture Organization of the United Nations, 1992. Wastewater treatment 
and use in agriculture. Wastewater treatment and use in agriculture – FAO irrigation and 
drainage paper 47, Rome. Retrieved: http://www.fao.org/docrep/T0551E/T0551E00.htm 
FAO - Food and Agriculture Organization of the United Nations, 2012. Retrieved: 
http://www.fao.org/fishery/culturedspecies/Mytilus_galloprovincialis/en 
FDA - Food and Drug Administration, 1998. Guidance for Industry: Environmental Assessment 
of Human Drug and Biologics Applications, Food and Drug Administration (Center for Drug 
Evaluation and Research), CMC 6, Revision 1 
Fent, K., Weston, A.A., Caminada, D., 2006a. Ecotoxicology of human pharmaceuticals. 
Aquatic Toxicology 76(2), 122-159. doi:10.1016/j.aquatox.2005.09.009  
Fent, K., Escher, C., Caminada, D., 2006b. Estrogenic activity of pharmaceuticals and 
pharmaceutical mixtures in a yeast reporter gene system. Reproductive Toxicology 22(2), 175–
85. doi:10.1016/j.reprotox.2006.04.010 
Fong, P., 1998. Zebra mussel spawning is induced in low concentrations of putative serotonin 
reuptake inhibitors. Biology Bulletin 194, 143–148. 
Fong, P. P., Molnar, N., 2008. Norfluoxetine induces spawning and parturition in estuarine and 
freshwater bivalves. Bulletin of Environmental Contamination and Toxicology 81, 535–538. 
doi:10.1007/s00128-008-9558-7 
Chapter 1: General Introduction 
48 | C h a p t e r  1  
Franzellitti, S., Buratti, S., Valbonesi, P., Capuzzo, A., Fabbri, E., 2011. The β-blocker 
propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean 
mussels, Mytilus galloprovincialis. Aquatic Toxicology 101(2), 299–308. 
doi:10.1016/j.aquatox.2010.11.001 
Fridovich, I., 1998. Oxygen toxicity: a radical explanation. Journal of Experimental Biology 
201, 1203–1209. 
Fuentes, A. Fernández-Segovia, I., Escriche, I.,  Serra, J.A., 2009. Comparison of physico-
chemical parameters and composition of mussels (Mytilus galloprovincialis Lmk.) from 
different Spanish origins. Food Chemistry 112, 295–302. doi:10.1016/j.foodchem.2008.05.064 
Gagnaire, B., Gagné, F., André, C., Blaise, C., Abbaci, K., Budzinski, H., Dévier, M.-H., 
Garric, J., 2009. Development of biomarkers of stress related to endocrine disruption in 
gastropods: alkali-labile phosphates, protein-bound lipids and vitellogenin-like proteins. Aquatic 
Toxicology 92(3), 155–67. doi:10.1016/j.aquatox.2009.01.012 
Gagné, F., Blaise, C., Salazar, M., Salazar, S., Hansen, P.D., 2001. Evaluation of estrogenic 
effects of municipal effluents to the freshwater mussel Elliptio complanata. Comparative 
Biochemistry and Physiology Part C 128, 213–225. doi:10.1016/S1532-0456(00)00189-7 
Gagné, F., Blaise C., 2003. Effects of municipal effluents on serotonin and dopamine levels in 
the freshwater mussel Elliptio complanata. Comparative Biochemistry and Physiology Part C 
136, 117-125. doi:10.1016/S1532-0456(03)00171-6 
Gagné, F., Blaise, C., André, C., Gagnon, C., Salazar, M., 2007. Neuroendocrine disruption and 
health effects in Elliptio complanata mussels exposed to aeration lagoons for wastewater 
treatment. Chemosphere 68, 731–743. doi:10.1016/j.chemosphere.2006.12.101 
Gagné, F., Bouchard, B., André, C., Farcy, E., Fournier, M., 2011. Evidence of feminization in 
wild Elliptio complanata mussels in the receiving waters downstream of a municipal effluent 
outfall. Comparative Biochemistry and Physiology Part C  153(1), 99–106. 
doi:10.1016/j.cbpc.2010.09.002 
Garrison, A.W., Pope, J.D., Allen, F.R., 1976. GC/MS analysis of organic compounds in 
domestic wastewaters. In: Keith CH (Ed) Identification and analysis of organic pollutants in 
water Ann Arbor Science Publishers, Ann Arbor, MI, 517–556 pp. 
Goldberg, E.D., Bowen, V.T., Farrington, J.W., Harvey, G., Martin, J.H., Parker, P.L., 
Risebrough, R.W., Robertson, W., Schneider, W., Gamble, E., 1978. The mussel watch. 
Environmental Conservation 5, 101-125. 
Gomes, T., Pereira, C.G., Cardoso, C., Pinheiro, J.P., Cancio, I., Bebianno, M.J., 2012. 
Accumulation and toxicity of copper oxide nanoparticles in the digestive gland of Mytilus 
galloprovincialis. Aquatic Toxicology 118-119, 72-79. doi:10.1016/j.aquatox.2012.03.017 
Gomes, T., Pinheiro, J.P., Cancio, I., Pereira, C.G., Cardoso, C., Bebianno, M.J., 2011. Effects 
of copper nanoparticles exposure in the mussel Mytilus galloprovincialis. Environmental 
Science and Technology 45(21), 9356-9262. PMID:21950553 
Gonzalez-Rey, M., Lau T.C., Gomes T., Maria V.L, Bebianno M.J., Wu R., 2011. Comparison 
of metal accumulation between ‘Artificial Mussel’ and natural mussels (Mytilus 
galloprovincialis) in marine environments. Marine Pollution Bulletin 63(5-12), 149-153. 
doi:10.1016/j.marpolbul.2010.12.007 
Gorbi, S., Virno, C., Notti, A., Benedetti, M., Fattorini, D., Moltedo, G., Regoli, F., 2008. An 
ecotoxicological protocol with caged mussels, Mytilus galloprovincialis, for monitoring the 
Chapter 1: General Introduction 
49 | C h a p t e r  1  
impact of an offshore platform in the Adriatic sea. Marine Environmental Research 65, 34–49. 
doi:10.1016/j.marenvres.2007.07.006 
Gros, M., Petrovic, M., Ginebreda, A., Barceló, D., 2010. Removal of pharmaceuticals during 
wastewater treatment and environmental risk assessment using hazard indexes. Environment 
International 36, 15–26. doi:10.1016/j.envint.2009.09.002 
Halling-Sørensen, B., Nielsen, S.N., Lanzky, P.F., Ingerslev, F., Lutzhoft, H.C.H., Jorgensen, 
S.E., 1997. Occurrence, fate and effects of pharmaceutical substances in the environment - A 
review. Chemosphere 36, 357-394. doi:10.1016/S0045-6535(97)00354-8 
Han, G.H., Hur, H.G., Kim, S.D., 2006. Ecotoxicological risk of pharmaceuticals from 
wastewater treatment plants in Korea: occurrence and toxicity to Daphnia magna. 
Environmental Toxicology and Chemistry 25(1), 265–271. PMID:16494251 
Heberer, T., 2002. Occurrence, fate, and removal of pharmaceutical residues in the aquatic 
environment: a review of recent research data. Toxicology Letters 131, 5-17. 
doi:10.1016/S0378-4274(02)00041-3 
Hiemke, C., Härtter, S., 2000. Pharmacokinetics of selective serotonin reuptake inhibitors. 
Pharmacology and Therapeutics 85(1), 11–28. PMDI: 20122921 
Hinz, B., Brune, K., 2006. Antipyretic analgesics: nonsteroidal antiinflammatory drugs, 
selective COX-2 inhibitors, paracetamol and pyrazolinones. Handbook of Experimental 
Pharmacology 2(177), 65–93. PMDI:17087120 
IMS Institute for Healthcare informatics, 2011. The global use of medicines: Outlook through 
2015. 27 pp. http://www.imshealth.com/ 
INFARMED Autoridade nacional do medicamento e produtos de saúde/National authority for 
pharmaceutical and health products, 2007. Estatística do Medicamento 2006 – Medicines 
Statistic. INFARMED - Instituto Nacional da Farmácia e do Medicamento Direcção de 
Economia do Medicamento e Produtos de Saúde, Ministério da Saúde, Portugal. 
INFARMED Autoridade nacional do medicamento e produtos de saúde/National authority for 
pharmaceutical and health products, 2010. Estatística do Medicamento 2009 – Medicines 
Statistic. INFARMED - Instituto Nacional da Farmácia e do Medicamento Direcção de 
Economia do Medicamento e Produtos de Saúde, Ministério da Saúde, Portugal. 
International Pharmaceutical Excipients Council of the Americas, 2008. Retrieved: 
http://ipecamericas.org.  
Jones, O.A.H., Voulvoulis, N., Lester, J.N., 2001. Human pharmaceuticals in the aquatic 
environment: a review. Environmental Technology 22, 1383–1395. PMID:11873874 
Josephy, P.D., Mannervik, B., 2006. Molecular toxicology. Second edition. Oxford University 
Press, New York, U.S.A., 589 pp. 
Joss, A., Zabczynski, S., Gobel, A., Hoffmann, B., Loffler, D., McArdell, C.S., 2006. Biological 
degradation of pharmaceuticals in municipal wastewater treatment: Proposing a classification 
scheme. Water Research 40(8), 1686-1696. doi:10.1016/j.watres.2006.02.014 
Kanda, R., Griffin P., James, H.A., Fothergill, J., 2003. Pharmaceutical and personal care 
products in sewage treatment works. Journal of Environmental Monitoring 5(5), 823-830. 
PMID:14587856 
Khetan, S.K., Collins, T.J., 2007. Human pharmaceuticals in the aquatic environment: a 
challenge to green chemistry, Chemical Reviews 107, 2319-2364. doi:10.1021/cr020441w 
Chapter 1: General Introduction 
50 | C h a p t e r  1  
Kremers, E., Sonnedecker, G., Urdang, G. 1986. Kremers and Urdang's History of Pharmacy, 
American Institute of the History of Pharmacy, 571 pp.  
Kreuzinger, N., Clara, M., Strenn, B., Vogel, B., 2004. Investigation on the behaviour of 
selected pharmaceuticals in the groundwater after infiltration of treated wastewater. Water 
Science and Technology 50(2), 221-228. PMID:15344795 
Kümmerer, K., 2004. Pharmaceuticals in the environment - scope of the book and introduction. 
In Pharmaceuticals in the environment - Sources, fate, effects and risks, 2
nd
 Ed.; Kümmerer K, 
Ed., Springer; Berlin, Germany, Chapter 1, 3-11 pp.  
Kümmerer, K., 2009. The presence of pharmaceuticals in the environment due to human use - 
present knowledge and future challenges. Journal of Environmental Management 90, 2354–
2366. doi:10.1016/j.jenvman.2009.01.023 
Kwon, J.-W., Armbrust, K.L., 2006. Laboratory persistence and fate of fluoxetine in aquatic 
environments. Environmental Toxicology and Chemistry 25(10), 2561–8. PMID:17022394 
Lazzara, R., Blázquez, M., Porte, C., Barata, C., 2012. Low environmental levels of fluoxetine 
induce spawning and changes in endogenous estradiol levels in the zebra mussel Dreissena 
polymorpha, Aquatic Toxicology 106-107, 123-130. doi:10.1016/j.aquatox.2011.11.03. 
Li, A.P., 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug 
Discovery Today 6(7), 357-366. doi:10.1016/S1359-6446(01)01712-3 
Lindqvist, N., Tuhkanen, T., Kronberg, L., 2005. Occurrence of acidic pharmaceuticals in raw 
and treated sewages and in receiving waters. Water Research 39, 2219–2228. 
doi:10.1016/j.watres.2005.04.003 
Lishman, L., Smyth, S.A., Sarafin, K., Kleywegt, S., Toito, J., Peart, T., Lee, B., Servos, M., 
Beland, M., Seto, P., 2006. Occurrence and reductions of pharmaceuticals and personal care 
products and estrogens by municipal wastewater treatment plants in Ontario. Science of the 
Total Environment 367, 544-558. doi:10.1016/j.scitotenv.2006.03.021 
Livingstone, D.R., 2001. Contaminant-stimulated reactive oxygen species production and 
oxidative damage in aquatic organisms. Marine Pollution Bulletin 42(8), 656-666. 
doi:10.1016/S0025-326X(01)00060-1  
Manduzio, H., Monsinjon, T., Galap, C., Leboulenger, F., Rocher, B., 2004. Seasonal variations 
in antioxidant defences in blue mussels Mytilus edulis collected from a polluted area: major 
contributions in gills of an inducible isoform of Cu/Zn-superoxide dismutase and of glutathione 
S-transferase. Aquatic Toxicology 70, 83–93. doi:10.1016/j.aquatox.2004.07.003 
Marco-Urrea, E., Pérez-Trujillo, M., Cruz-Morató, C., Caminal, G., Vicent, T., 2010. 
Degradation of the drug sodium diclofenac by Trametes versicolor pellets and identification of 
some intermediates by NMR. Journal of Hazardous Materials 176(1-3), 836–42. 
doi:10.1016/j.jhazmat.2009.11.112 
Maria, V. L., Bebianno, M. J., 2011. Antioxidant and lipid peroxidation responses in Mytilus 
galloprovincialis exposed to mixtures of benzo(a)pyrene and copper. Comparative Biochemistry 
and Physiology Part C 154(1), 56–63. doi:10.1016/j.cbpc.2011.02.004 
Martín-Díaz, M. L., Gagné, F., Blaise, C., 2009. The use of biochemical responses to assess 
ecotoxicological effects of Pharmaceutical and Personal Care Products (PPCPs) after injection 
in the mussel Elliptio complanata. Environmental Toxicology and Pharmacology 28(2), 237–
242. doi:10.1016/j.etap.2009.04.009 
Chapter 1: General Introduction 
51 | C h a p t e r  1  
Matozzo, V., Tomei, A., Marin, M.G., 2005. Acetylcholinesterase as a biomarker of exposure to 
neurotoxic compounds in the clam Tapes philippinarum from the Lagoon of Venice. Marine 
Environmental Research 50, 1686–1693. doi:10.1016/j.marpolbul.2005.07.011 
Matozzo, V., Gagné, F., Marin, M.G., Ricciardi, F., Blaise, C., 2008. Vitellogenin as a 
biomarker of exposure to estrogenic compounds in aquatic invertebrates: a review. Environment 
International 34, 531–545. doi:10.1016/j.envint.2007.09.008 
Matozzo, V., Marin, M.G., 2008. Can 17-ß estradiol induce vitellogenin-like proteins in the 
clam Tapes philippinarum? Environmental Toxicology and Pharmacology 26, 38–44. 
doi:10.1016/j.etap.2008.01.001 
Metcalfe, C.D., Koenig, B.G., Bennie, D.T., Servos, M., Ternes, T.A., Hirsch, R., 2003a. 
Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. 
Environmental Toxicology and Chemistry 22(12), 2872-2880. PMID: 14713026 
Metcalfe, C.D., Miao, X-S., Koenig, B.G., Struger, J., 2003b. Distribution of acidic and neutral 
drugs in surface waters near sewage treatment plants in the lower great lakes, Canada. 
Environmental Toxicology and Chemistry 22(12), 2881-2889. PMID: 14713027 
Munaron, D., Tapie, N., Budzinski, H., Andral, B., Gonzalez, J., 2012. Pharmaceuticals, 
alkylphenols and pesticides in Mediterranean coastal waters : Results from a pilot survey using 
passive samplers. Estuarine, Coastal and Shelf Science 114, 82–92 
doi:10.1016/j.ecss.2011.09.009 
Nicholson, S., Lam, P. K. S., 2005. Pollution monitoring in Southeast Asia using biomarkers in 
the mytilid mussel Perna viridis (Mytilidae : Bivalvia). Environment International 31, 121 - 
132. doi:10.1016/j.envint.2004.05.007 
Oaks, J.L., Gilbert, M., Virani, M.Z., Watson, R.T., Meteyer, C.U., Rideout, B.A., Shivaprasad, 
H.L., Ahmed, S., Chaudhry, M.J.I., Arshad, M., Mahmood, S., Ali, A., Khan, A.A., 2004. 
Diclofenac residues as the cause of vulture decline in Pakistan. Nature 427, 630–633. 
doi:10.1038/nature02317 
O'Brien, E., Dietrich, D.R., 2004. Hindsight rather than foresight: reality versus the EU draft 
guideline on pharmaceuticals in the environment. Trends in Biotechnology 22(7), 326-330. 
doi:10.1016/j.tibtech.2004.05.003 
OECD, 1992.  OECD Guidelines for the testing of chemicals, Test 301: Ready biodegradability. 
OECD/OCDE, 62 pp. 
OECD, 2002. OECD Guidelines for the testing of chemicals, Test 308: Aerobic and anaerobic 
transformation in aquatic sediment systems. OECD/OCDE, 19 pp. 
Ortiz-Zarragoitia, M., Cajaraville, M.P., 2010. Intersex and oocyte atresia in a mussel 
population from the Biosphere’s Reserve of Urdaibai (Bay of Biscay). Ecotoxicology and 
Environmental Safety 73, 693–701.doi:10.1016/j.ecoenv.2010.04.002 
Osada, M., Nomura, T., 1990. The levels of reproductive cycle prostaglandins associated with 
the reproductive cycle of the scallop, Patinopecten yessoensis. Prostaglandins 40 (3), 229–239. 
doi:10.1016/0090-6980(90)90011-J 
Palmer, P.M., Wilson, L.R., O'Keefe, P., Sheridan, R., King, T., Chen, C.-Y., 2008. Sources of 
pharmaceutical pollution in the New York City Watershed. Science of the Total Environment 
394, 90 -102. doi:10.1016/j.scitotenv.2008.01.011 
Chapter 1: General Introduction 
52 | C h a p t e r  1  
Parolini, M., Binelli, A., Cogni, D., Riva, C., Provini, A., 2009. An in vitro biomarker approach 
for the evaluation of the ecotoxicity of non-steroidal anti-inflammatory drugs (NSAIDs). 
Toxicology in Vitro 23 (5), 935–942. doi:10.1016/j.tiv.2009.04.014 
Petrovic, M., Barceló, D., 2007. LC-MS for identifying photodegradation products of 
pharmaceuticals in the environment. Trends in Analytical Chemistry 26(6), 486-493. 
doi:10.1016/j.trac.2007.02.010 
Petrovic, M., Gros, M., Barceló, D., 2006. Multi-residue analysis of pharmaceuticals in 
wastewater by ultra-performance liquid chromatography–quadrupole–time-of-flight mass 
spectrometry. Journal of Chromatography A 1124, 68–81. doi:10.1016/j.chroma.2006.05.024 
Porte, C., Janer, G., Lorusso, L.C., Ortiz-Zarragoitia, M., Cajaraville, M.P., Fossi, M.C., Canesi, 
L., 2006. Endocrine disruptors in marine organisms: approaches and perspectives. Comparative 
Biochemistry and Physiology Part C 143(3), 303-315. doi:10.1016/j.cbpc.2006.03.004 
Praveen Rao, P.N., Knaus, E.E., 2008. Evolution of nonsteroidal anti-inflammatory 
cyclooxygenase (COX) inhibition and beyond drugs (NSAIDs). North 11 (2), 81–110. 
PMID:1920347 
Quintana, J.B., Weiss, S., Reemtsma, T., 2005. Pathways and metabolites of microbial 
degradation of selected acidic pharmaceuticals and their occurrence in municipal wastewater 
treated by a membrane bioreactor. Water Research 39, 2564-2664. 
doi:10.1016/j.watres.2005.04.068 
Racila, D., Bickenbach, J.R. 2009. Are epidermal stem cells unique with respect to aging? 
Aging 1(8), 746 -750. 
Radjenovíc, J., Petrovíc, M., Barceló, D., 2007. Advanced mass spectrometric methods applied 
to the study of fate and removal of pharmaceuticals in wastewater treatment. Trends in 
Analytical Chemistry 26(11), 1132-1144. doi:10.1016/j.trac.2007.10.002, 
Regoli, F., Gorbi, S., Frenzilli, G., Nigro, M., Corsi, I., Focardi, S., Winston, G.W., 2002a. 
Oxidative stress in ecotoxicology: from analysis of individual antioxidants to a more integrated 
approach. Marine Environmental Research 54, 419–423. doi:10.1016/S0141-1136(02)00146-0 
Regoli, F., Pellegrini, D., Winston, G.W., Gorbi, S., Giuliani, S., Virno-Lamberti, C., 
Bompadre, S., 2002b. Application of biomarkers for assessing the biological impact of dredged 
materials in the Mediterranean: the relationship between antioxidant responses and 
susceptibility to oxidative stress in the red mullet (Mullus barbatus). Marine Pollution Bulletin 
44, 912–922. doi:10.1016/S0025-326X(02)00120-0 
Regoli F., Principato, G., 1995. Glutathione, glutathione-dependent and antioxidant enzymes in 
mussel, Mytilus galloprovincialis, exposed to metals under field and laboratory conditions: 
implications for the use of biochemical biomarkers. Aquatic Toxicology 31, 143-164. doi: 
10.1016/0166-445X(94)00064-W 
Reif, R., Suárez, S., Omil, F., Lema, J.M., 2008. Fate of pharmaceuticals and cosmetic 
ingredients during the operation of a MBR treating sewage. Desalination 221, 511–517. 
doi:10.1016/j.desal.2007.01.111 
Ricciardi, F., Binelli, A., Provini, A., 2006. Use of two biomarkers (CYP450 and 
acetylcholinesterase) in zebra mussel for the biomonitoring of Lake Maggiore (northern Italy). 
Ecotoxicology and Environmental Safety 63, 406-412. doi:10.1016/j.ecoenv.2005.02.007 
Rivas, A., Irizar, I., Ayesa, E., 2008. Model-based optimisation of Wastewater Treatment Plants 
design. Environmental Modelling and Software 23(4), 435–450. 
doi:10.1016/j.envsoft.2007.06.009 
Chapter 1: General Introduction 
53 | C h a p t e r  1  
Roberts, P.H., Bersuder, P., 2006. Analysis of OSPAR priority pharmaceuticals using high-
performance liquid chromatography-electrospray ionization tandem mass spectrometry. Journal 
of Chromatography A 1134, 143–150. doi:10.1016/j.chroma.2006.08.093 
Rowley, A.F., Vogan, C.L., Taylor, G.W., Clare, A.S., 2005. Prostaglandins in non insectan 
invertebrates: recent insights and unsolved problems. Journal of Experimental Biology 208, 3–
14. doi:10.1242/jeb.01275 
Ruggeri, B., Thoroughgood, C.A., 1985. Prostaglandins in aquatic fauna: a comprehensive 
review. Marine Ecology Progress Series 23, 301–306. doi:10.3354/meps023301 
Sammartino, M.P., Bellanti, F., Castrucci, M., Ruiu, D., Visco, G., Zoccarato, T., 2008. 
Ecopharmacology: Deliberated or casual dispersion of pharmaceutical principles, phytosanitary, 
personal health care and veterinary products in environment needs a multivariate analysis or an 
expert systems for the control, the measure and the remediation. Microchemical Journal 88, 
201–209. doi:10.1016/j.microc.2007.11.021 
Santos, L.H.M.L.M., Araújo, A.N., Fachini, A., Pena, A., Delerue-Matos, C., Montenegro, 
M.C.B.S.M., 2010. Ecotoxicological aspects related to the presence of pharmaceuticals in the 
aquatic environment. Journal of Hazardous Materials 175(1-3), 45–95. 
doi:10.1016/j.jhazmat.2009.10.100 
Santovito, G., Piccinni, E., Cassini, A., Irato, P., Albergoni, V., 2005. Antioxidant responses of 
the Mediterranean mussel, Mytilus galloprovincialis, to environmental variability of dissolved 
oxygen. Comparative Biochemistry and Physiology Part C 140(3-4), 321–329. 
doi:10.1016/j.cca.2005.02.015 
Schnell, S., Bols, N. C., Barata, C., Porte, C., 2009. Single and combined toxicity of 
pharmaceuticals and personal care products (PPCPs) on the rainbow trout liver cell line RTL-
W1. Aquatic Toxicology 93(4), 244–52. doi:10.1016/j.aquatox.2009.05.007 
Solé, M., Shaw, J.P., Frickers, P.E., Readman, J.W., Hutchinson, T.H., 2010. Effects on feeding 
rate and biomarker responses of marine mussels experimentally exposed to propranolol and 
acetaminophen. Analytical and Bioanalytical Chemistry 396(2), 649–656. doi:10.1007/s00216-
009-3182-1 
Sousa Dias, J.P., 2008. Retrived from http://www.ff.ul.pt/paginas/jpsdias/Historia.html 
Stumpf, M., Ternes, T.A., Wilken, R.-D., Rodrigues, S.V., Baumann, W., 1999. Polar drug 
residues in sewage and natural waters in the state of Rio de Janeiro, Brazil. Science of the Total 
Environment 225, 135 -141. doi:10.1016/S0048-9697(98)00339-8 
Sureda, A., Box, A., Tejada, S., Blanco, A., Caixach, J., Deudero, S., 2010. Biochemical 
responses of Mytilus galloprovincialis as biomarkers of acute environmental pollution caused 
by the Don Pedro oil spill (Eivissa Island; Spain). Aquatic Toxicology 101(3-4), 540–549. 
doi:10.1016/j.aquatox.2010.12.011 
Tauxe-Wuersch, A., De Alencastro, L.F., Grandjean, D., Tarradellas, J., 2005. Occurrence of 
several acidic drugs in sewage treatment plants in Switzerland and risk assessment. Water 
Research 39, 1761-1772. doi:10.1016/j.watres.2005.03.003 
Ternes, T.A., 1998. Occurrence of drugs in German sewage treatment plants and rivers. Water 
Research 32(11), 3245-3260. doi:10.1016/S0043-1354(98)00099-2 
Ternes, T.A., 2001. Analytical methods for the determination of pharmaceuticals in aqueous 
environmental samples. Trends in Analytical Chemistry 20(8), 419-434. doi:10.1016/S0165-
9936(01)00078-4 
Chapter 1: General Introduction 
54 | C h a p t e r  1  
Tixier, C., Singer, H.P., Foellers, S., Müller, S.R., 2003. Occurrence and fate of carbamazepine, 
clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. Environmental 
Science and Technology 37(6), 1061-1068. doi:10.1021/es025834r 
Togola, A., Budzinski, H., 2008. Multi-residue analysis of pharmaceutical compounds in 
aqueous samples. Journal of Chromatography A 1177, 150–158. 
doi:10.1016/j.chroma.2007.10.105 
Tweendale, G., 2003. Archives of the pharmacy industry: their scope and use. In: Richmond, L., 
Stevenson, J. , Turton, A., 2003. The Pharmaceutical Industry: A Guide to Historical Records, 
Ashgate Publishing Ltd., 561 pp. 
Townsend, D.M., Tew, K.D., Tapiero, H., 2003. The importance of glutathione in human 
disease Dossier : Oxidative stress pathologies and antioxidants. Biomedicine and 
Pharmacotherapy  57, 145–155. doi:10.1016/S0753-3322(03)00043-X 
Van der Oost, R., Beyer, J., Vermeulen, N.P.E., 2003. Review article fish bioaccumulation and 
biomarkers in environmental risk assessment: a review. Environmental Toxicology and 
Pharmacology 13, 57-149. doi:10.1016/S1382-6689(02)00126-6 
Van Der Ven, K., Keil, D., Moens, L.N., Van Leemput, K., Van Remortel, P. , De Coen, W.M., 
2006. Environmental Toxicology: Neuropharmaceuticals in the environment: mianserin-
induced neuroendocrine disruption in zebrafish (Danio rerio) using cDNA microarrays. 
Environmental Toxicology and Chemistry 25(10), 2645–2652. PMID:17022405 
Vane, J.R., Bakhle, Y.S., Botting, R.M., 1998. Cyclooxygenases 1 and 2. Annual Review of 
Pharmacology and Toxicology 38, 97–120. doi:10.1146/annurev.pharmtox.38.1.97 
Vaswani, M., Linda, F. K., Ramesh, S., 2003. Role of selective serotonin reuptake inhibitors in 
psychiatric disorders: a comprehensive review. Progress in Neuro-Psychopharmacology and 
Biological Psychiatry27(1), 85–102. PMID:12551730 
Vieno, N.M., Tuhkanen, T., Kronberg, L., 2005. Seasonal variation in the occurrence of 
pharmaceuticals in effluents from a sewage treatment plant and in the recipient water. 
Environmental Science and Technology 39 (21), 8220–8226. PMID:16294858 
Wall, R., 2004. “Emerging” contaminants in U.S. water supplies Part 1 – A new kind of 
pollution? [Online] http://www.acnatsci.org/education/kye/hi/kye5152004.html. In: Bahe, A.R., 
Classen, J.J., Williams, R., Stavely,J., 2005. Emerging environmental contaminants and 
antibiotic resistance: science and policy concerns. Animal Waste Management Symposium, 
246-259 pp.  
Weigel, S., Kallenborn, R., Hühnerfuss, H., 2004. Simultaneous solid-phase extraction of 
acidic, neutral and basic pharmaceuticals from aqueous samples at ambient (neutral) pH and 
their determination by gas chromatography–mass spectrometry. Journal of Chromatography A 
1023, 183–195. PMID:14753684 
Weiner, M.L., Kotkoskie, L.A., 1999. Excipient Toxicity and Safety. Drug and Pharmaceutical 
Sciences 103, 370 pp. 
WHO - World Health Organization, 2004. The world medicine situation 2004, 
WHO/EDM/PAR/2004.5, 149 pp.   
WHO - World Health Organization, 2010. Medicines: rational use of medicines, Fact sheet 
N°338, May 2010. Retrieved:  http://www.who.int/mediacentre/factsheets/fs338/en/index.html 
Chapter 1: General Introduction 
55 | C h a p t e r  1  
WHO - World Health Organization, 2011. The world medicines situation 2011, rational use of 
medicines. WHO/EMP/MIE/2011.2.2, 3
rd
 edition, 22 pp. 
WikiPharma: http://www.wikipharma.org/ 
Winston, G. W., Moore, M. N., Kirchin, M. A., Soverchia, C., 1996. Production of reactive 
oxygen species by hemocytes from the marine mussel, Mytilus edulis: lysosomal localization 
and effect of xenobiotics. Comparative Biochemistry and Physiology Part C 113(2), 221–229. 
PMID:8646615 
Winston, G.W., Di Giulio, R.T., 1991. Prooxidant and antioxidant mechanisms in aquatic 
organisms. Aquatic Toxicology 19, 137–161. doi:10.1016/0166-445X(91)90033-6 
Zuccato, E., Castiglioni, S., Fanelli, R., Reitano, G., Bagnati, R., Chiabrando, C., Pomati, F., 
Rossetti, C., Calamari, D., 2006. Pharmaceuticals in the environment in Italy: causes, 
occurrence, effects and control-Environmental Science and Pollution Research 13(1), 15 - 21. 
doi:10.1065/espr2006.01.004 
Zwiener, C., Seeger, S., Glauner, T., Frimmel, F.H., 2002. Metabolites from the biodegradation 
of pharmaceutical residues of ibuprofen in biofilm reactors and batch experiments. Analytical 
and Bioanalytical Chemistry 372, 569–575. doi:10.1007/s00216-001-1210-x 
 
  
 
 
 
 
  
Occurrence of APIs in the aquatic 
system  
Chapter 2 
Chapter 2: Occurrence of APIs in the Aquatic System 
57 | C h a p t e r  2  
2 Occurrence of APIs in the Aquatic System 
Abstract 
The development analytical techniques able to detect and quantify APIs in aquatic 
environment matrices is still recent and in constant evolution. Most techniques are very 
expensive, with complex technical challenges which depending on the circumstances 
only provide incomplete (“snap-shot”) data concerning the concentration of APIs in a 
given time at a given site. There is  almost no information concerning the actual APIs 
concentrations in Portuguese surface waters, this Chapter deals with the problematic 
around the detection of these emergent compounds and gives information about the 
usefulness of the application of passive samplers – like Polar Organic Compound 
Integrative Sampler (POCIS), which enable the assessment of time-weighted average 
(TWA) concentration of each bioavailable target analytes. Moreover, it constitutes the 
first study reporting the occurrence and quantification of APIs in Arade River (Portugal) 
encompassing a preliminary study made in 2009 to infer obtained data validity and a 
following study regarding the impact of Summer on the alteration of APIs 
concentrations in the same riverine water in 2010. The results reveal that out of the 21 
APIs used as target analytes 14 were present in 2009 whereas in 2010 from the 19 target 
analytes 13 occurrent in Arade river although at different concentrations. In both cases, 
caffeine (CAF) was the active compound found at highest concentrations at both sites 
followed by the antiasthmatic theophylline (THEO). Although the summer impact is 
unclear, the results highlighted POCIS suitability for the quantification and profile of 
APIs concentrations in surface water following Water Frame Directive (WFD) 
recommendations. 
 
2.1 Introduction 
As mentioned in the previous chapter, pharmaceutical products have been used for 
centuries however, from an ecotoxicological viewpoint, APIs are considered emerging 
environmental contaminants since only recently the development of novel analytical and 
sampling techniques enabled their quantification in environmental samples (Söderström 
et al., 2009; Munaron et al., 2012). As APIs are designed to preserve their chemical 
structure to be therapeutically active, a serious concern about the environmental fate and 
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related impacts in water quality status and potential effects on non-target organisms has 
led to new EU and US legislative frameworks and directives (Roberts and Bersuder, 
2006; Santos et al., 2010). However APIs monitoring in natural waters is very complex 
due to APIs multiplicity in terms of e.g. physico-chemical properties, chemical 
structures and persistence in the environment (Castiglioni et al., 2004; Togola and 
Budzinski, 2007a). 
2.1.1 Active and Biological Sampling in Water Quality Monitoring 
The often called conventional aqueous matrices active screening methods (like, grab 
and pump sampling) present two major limitations on an overall contaminant exposure 
assessment: 1) the ability to provide an accurate time integrative estimation only giving 
a snap-shot of contaminants concentrations at the exact sampling time often neglecting 
episodic environmental changes (such as accidental spills and seasonal variations) and 
2) the ability to quantify target analytes at ultra-trace and/or trace levels in discrete 
water samples (Petty et al., 2004; Alvarez et al., 2005; Togola and Budzinski, 2007a; 
Arditsoglou and Voutsa, 2008; Söderström et al., 2009). Even though these limitations 
can be respectively tackled by 1) the combination of multiple and repetitive time 
sampling and 2) large water sample volumes; these methodologies are extremely costly 
and time consuming involving large scale water samples clean-up, pre-treatment and 
pre-concentration processes (Arditsoglou and Voutsa, 2008; Söderström et al., 2009; 
Togola and Budzinski, 2007a). 
The estimation of water contaminants concentration applying biological samples 
through the analysis of contaminants in bivalve and fish tissues is based on species 
inherent contaminant bioconcentration processes and even though providing a much 
better understanding in terms of ecotoxicological risk assessment than discrete water 
sampling, this methodology is limited by several factors such as: 1) intra- and 
interspecific metabolism (e.g. detoxification mechanisms) and tested-organisms survival 
rate, 2) complex biological matrices chemical analysis and 3) relatively low uptake of 
polar organic compounds (POCs) compared to non-polar compounds in species tissues 
(Petty et al., 2004; Söderström et al., 2009). 
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2.1.2 Passive Sampling in Water Quality Monitoring 
Passive samplers were conceived to tackle the difficulty of biological sampling data 
interpretation although mimicking biological uptake and concomitantly provide a time-
weighted average (TWA) concentration of bioavailable target analytes reducing 
efficiently active sampling costs, maintenance and handling in water quality screening 
(Petty et al., 2004; Alvarez et al., 2005; Söderström et al., 2009). For further knowledge 
the thoroughly reviews by Vrana et al. (2005) and Dévier et al. (2011) describing the 
broadly use, applications and current state of the art of passive sampling technology for 
waterborne organic and inorganic contaminants in environmental monitoring are 
recommended. In these studies two passive integrative samplers for the sequestering of 
ultra- to trace levels of organic contaminants mixtures in natural waters developed by 
US Geological Survey’s Columbia Environmental Research Center (CERC) are 
referred: 1) the semipermeable membrane device (SPMD) (US Patent, 5,098,573, 
Huckins et al., 1992; 5,395,426, Huckins et al., 1995) for hydrophobic organic 
compounds and 2) the polar organic chemical integrative sampler (POCIS) (US Patent 
6,478,961, Petty et al., 2002) for hydrophilic organic compounds. Both passive 
samplers are based on the exchange flow kinetics of organic compounds from the 
surrounding water to the device receiving solid-phase by 1) partitioning for non-polar 
compounds trapped in SPMD and 2) by adsorption for polar compounds sequestered in 
POCIS, until the equilibrium is reached (Vrana et al., 2005; Arditsoglou and Voutsa, 
2008). 
2.1.3 POCIS Concept and Modeling 
POCIS devices are generally used for sampling polar 
organic molecules (0 < logKow < 4) with no limitation of 
the type of natural waters being constituted by a solid 
receiving/sequestration phase (sorbent) enclosed between 
two hydrophilic microporous polyethersulfone (PES) 
membranes and attached by two stainless still rings (Petty 
et al., 2002; 2004;  Alvarez et al., 2004; 2007; Vrana et 
al., 2005) (Figure 2.1). The type of membranes used is 
optimal due to high analytes uptake rate and interfering 
macromolecules exclusion, minimal biofouling and durability compared to others like 
Figure 2.1: Polar Organic 
Integrative Sampler (POCIS). 
Source: www.est-lab.com. 
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polysulfone having an average effective sampling surface of 41 cm
2
 (Alvarez et al., 
2004; 2005). Furthermore, solely depending on the type of sorbent used POCIS can 
present two commercially available configurations: pesticide or more generic 
hydrophilic compounds-POCIS using a triphasic sorbent admixture of Isolute ENV+ 
polystyrene divinylbenzene (Argonaut Technologies, Redwood City, CA, USA) or 
pharmaceutical-POCIS applying Oasis hydrophilic-lipophilic balanced (HLB) (i.e. 
neutral) sorbent (Alvarez et al., 2004; 2005). Since their development POCIS have been 
successfully applied in surface waters (lagoon, riverine and marine) and sewage 
effluents for the detection and quantification of  numerous organic compounds like 
pharmaceuticals, polar pesticides, steroids, alkyphenols and hormones (Alvarez et al., 
2004; 2005; Jones-Lepp et al., 2004; Petty et al., 2004; MacLeod et al., 2007; Mazzella 
et al., 2007; 2010; Togola and Budzinski, 2007a; Arditsoglou and Voutsa, 2008; Zhang 
et al., 2008; Harman et al., 2008a, b; 2009; Martínez Bueno et al., 2009; Li et al., 2010; 
Pesce et al., 2011; Munaron et al., 2012). 
The major drawback associated to the application of passive samplers particularly 
POCIS is the necessity of calculating accurate concentrations and availability of each 
target-compound sampling rate Rs (L.day
-1
) pre-calibration data prior to its deployment 
in order to enable environmental water concentrations to be expressed as ng analyte per 
L (Togola and Budzinski, 2007a; Li et al., 2010b; 2011). For this each polar analyte RS 
has to be determined through laboratory experiments using flow-through or static 
renewal microcosm exposure systems describing the exchange kinetics between water 
and the passive samplers (Togola and Budzinski, 2007a; Söderström et al., 2009). 
Nevertheless Rs depends on each compound physicochemical properties and 
environmental conditioning (e.g. water flow rate, temperature, pH, salinity, dissolved 
organic matter (DOM) and biofouling) (Roberts and Bersuder, 2006; Togola and 
Budzinski, 2007a; Söderström et al., 2009; Li et al., 2011). This limitation can be 
suppressed through the application of performance reference compounds (PRCs) like 
the ones added to receiving phase of SPMDs prior to deployment. PRCs release is 
afterwards measured and this difference enables in situ Rs appraisal (Huckins et al., 
2002). Although under investigation for application in POCIS this approach is still very 
costly (Togola and Budzinski, 2007a) and as argued by Munaron et al. (2012) POCIS 
exposed up to one month are unlikely to endure environmental parameter changes 
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(temperature, salinity and flow conditions) that would question the validity of Rs 
obtained by laboratory testing.   
Contrarily with what was proposed by Alvarez et al. (2004) relating Rs value to the 
remaining analyte concentration in water after each exposure, Togola and Budzinski 
(2007a) refute that compound global loss in water is not exclusively due to analyte 
trapping in sorbent but also related to degradation kinetics phenomena. 
Considering the above, the objective of this chapter pertains the detection and 
quantification of APIs concentrations in two different sites in Arade river, Portimão 
(Portugal) using passive sampler devices: POCIS. After the first screening of 
pharmaceutical compounds in the area in May/June 2009 representing one month 
POCIS deployment in both up and downriver sites, another survey on the same sites 
was carried out to assess the impact of tourism increase in the summer months (August 
to October) in 2010 on APIs concentration change due to the expected higher WWTPs 
discharges caused by the three-fold population density increase in the area during this 
period. 
2.2 Materials and Methods 
2.2.1 Sites Characterization 
Located in Southern Portugal, Arade estuary comprises an area of 987 km
2 
and is an 
important ecological and economic system in this region. Surrounded by saltmarsh 
riverbanks, Arade river cross several urban areas such as Ferragudo, Parchal, 
Mexilhoeira da Carregação and Portimão with an approximate total of 66,000 
inhabitants (INE, 2010) and supports a marina and a large harbor. The major 
contamination sources derive mostly from municipal, industrial and agriculture 
(orcharding and rice culture) effluent discharges and runoff, but also from activities 
associated with tourism, marine traffic and aquaculture (DGPA, 2004; Fernandes et al., 
2007).  
The two sites selected for POCIS deployment were (see Figures 2.2 and 2.3): Site 1 
(also referred as downriver site) located inside Portimão commercial harbor (mostly 
dedicated to large cruises docking) on the west margin of Arade river and in the vicinity 
of two marinas and a shipyard, about 2 Km from the river mouth, (37º07’42.9”N, 
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Site 2  
Site 1  
WWTP 1  
WWTP 2  
Figure 2.2: POCIS deployment sites and WWTPs in Arade river. Source: ArcGIS 9 ArcMap 
version. 
8º31’50.8”W). Additionally, this site is under the influence to the North of 
Companheira WWTP discharges (WWTP1). This WWTP1serves Portimão city (55,614 
inhabitants), Alvor (> 6000 inhabitants) and Mexilhoeira Grande (> 4000 inhabitants) 
(INE, 2011) to the west of Arade river and has been operating applying secondary 
treatment since 1982. Site 2 (also referred as upriver site) is about 2 Km upriver from 
site 1 and is located in the east margin of Arade river near a small recreational marina 
about 4 km from the river mouth (37º 08’54.1”N, 8º30’21.9”W). Additionally, this site 
is in very close vicinity of small Mexilhoeira da Carregação WWTP discharges 
(WWTP2, Figure 2.3). 
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2.2.2 POCIS Field Deployment 
POCIS devices containing 200 mg Oasis HLB sorbent (exposure diameter of 54 mm 
and a sampling surface area of 45.8 cm
2
) were from Exposmeter (Tavelsjö, Sweden) 
and provided by the Laboratoire de Physico- et Toxico-Chimie de l'Environnement 
(LPTC), Université de Bordeaux-1, Bordeaux (France), sent to the University of 
Algarve (Portugal) and immediately relocated at -20ºC.  
First POCIS deployment took place for around a month from (25
th
 May - 26
th
  June 
2009) under the project “PESSOA”; the second POCIS deployment took place from the 
1
st
 of August to the 1
st
 of November 2010 under the project “PORTONOVO” in which 
by the end of each month POCIS were immediately collected and replaced by a new 
batch of POCIS. The devices were placed in triplicate inside a protective steel canister 
in the two sites as shown in Figure 2.4. The POCIS canister was tied with a rope and 
connected to the nearby structure at half-depth in the water column being stabilized with 
weight over the seabed. Temperature, salinity, pH and dissolved oxygen were measured 
with a multi-probe system (YSI 556MPS) (Table 2.1). By end of the exposure time (on 
average 30 days), each device was carefully rinsed with Milli-Q
® 
ultrapure water and 
wrapped individually in aluminum foil and transported inside a cooler to the laboratory. 
Once in the laboratory POCIS were stored at -20ºC prior to analysis. 
 
Figure 2.3: POCIS deployment in site 1 (up) and in site 2 (down). 
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Table 2.1: Abiotic parameters measurement per site per year 
Year Day/Month Site  Temperature (°C) Salinity DO (%) pH depth 
2009 25th May 1 18.1 33.7 122.0 7.9 2.5 
  26th June   19.3 33.7 120.0 7.5 2.5 
  25th May 2 20.3 30.7 149.0 7.6 1.5 
  26th June   20.0 31.4 115.0 7.5 1.5 
2010 6th August 1 23.8 34.5 105.4 7.9 2.5 
  6th Setember   22.9 35.2 104.4 7.8 2.5 
  6th October   16.3 37.1 104.0 7.9 2.5 
  6th November   16.6 33.8 120.0 7.8 2.5 
  6th August 2 24.6 34.1 88.5 7.9 1.5 
  6th Setember   23.5 34.8 95.0 7.8 1.5 
  6th October   16.4 33.9 98.8 7.8 1.5 
  6th November   17.3 33.6 105.7 7.7 1.5 
Figure 2.4: POCIS deployment in triplicate and protective cage. 
Chapter 2: Occurrence of APIs in the Aquatic System 
65 | C h a p t e r  2  
2.3 POCIS Content Analysis 
2.3.1 Materials and Chemicals 
Acetone, dichloromethane, acetonitrile and methanol (HPLC reagent grade, Scharlau) 
were purchased from ICS (Belin-Beliet, France). Glass SPE cartridges (6 mL) with 
Teflon frits (20 µm porosity) filled with Oasis HLB bulk sorbent (60 µm) were 
purchased from Supelco (Saint Quentin-Fallavier, France). Ultrapure deionized water 
was prepared using Milli-Q system (Millipore, Molsheim, France). All internal 
standards were purchased from Sigma Aldrich (St. Quentin Fallavier, France, purity > 
98%). 
2.3.2 POCIS Extraction 
The extraction procedures for POCIS was adapted 
from Togola and Budzinski (2007a) and Tapie et al. 
(2011) with the intended target APIs (Table 2.2) 
time-integrated concentration assessment. Prior to 
analysis POCIS were removed from storage at -20ºC 
and allowed to reach room temperature. POCIS 
stainless still rings were then carefully disassembled 
(preventing the membrane perforation) and the two 
membranes detached and rinsed with ultrapure water 
to clean them in the best way possible of detritus 
avoiding any sorbent (solid-phase) loss (Figure 2.5). 
The sorbent was then directly transferred into 
previously weighted glass SPE cartridge with 5 ml 
of ultrapure water and dried by vacuum for 1 hour 
(until the frit inside the SPE cartridge was completely dried). A solution containing the 
internal standards (Table 2.3) was gravimetrically added to each sample and to the 
blanks and eluted using 10 ml methanol, 10ml 50:50 methanol/dichloromethane and 10 
ml dichloromethane.  
  
Figure 2.5: POCIS disassembling 
(up) and transferal of sorbent to SPE 
cartridge (down). 
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Table 2.2: Targeted-APIs 
Therapeutic class API/Common registred brand  CAS number 
analgesic aspirin (ASP or ASA)* 50-78-2 
  paracetamol Panadol (PAR) 103-90-2 
anticonvulsant carbamazepine Tegretol (CAR) 298-46-4 
antidepressant amitriptyline ADT (AMI) 50-48-6 
  doxepin (DOX) 1668-19-5 
  imipramine (IMI) 50-49-7 
  fluoxetine Prozac (FLX)  54910-89-3 
anxiolytic alprazolam Xanax (ALP) 28981-97-7 
  bromazepam Bromalex
 (BRO) 1812-30-2 
  diazepam Valium (DIA) 439-14-15 
  nordiazepam Sopax
 (NOR) 1088-11-5 
NSAID diclofenac Voltaren (DCF) 15307-86-5 
  ibuprofen Brufen(IBU) 15687-27-1 
  ketoprofen Profenid (KET) 22071-15-4 
  naproxen Naprosyn (NAP) 22204-53-1 
antiasthmatic clenbuterol Mucopax (CLE) 37148-27-9 
  salbutamol Ventilan (SAL) 18559-94-9 
  terbutaline Bricanyl (TER) * 23031-25-6 
  theophylline Eufilina (THEO) 58-55-9 
anti-lipidemic gemfibrozil Lopid (GEM) 25812-30-0 
stimulant caffeine (CAF) 58-08-2 
APIs signaled by an * only screened in 2009   
 
The cartridges were weighted again to assess sorbent mass. The flasks containing the 
resulting extract were then concentrated in a RapidVap vacuum evaporation system at 
70% speed, 51ºC, vacuum 900 mbar for 25 minutes (this step of the procedure was not 
used on the 2009 samples) and finally evaporated to dryness applying a gentle nitrogen 
flux. Depending on the type electrospray ionization (ESI) required for each 
pharmaceutical, 150 µl of solvent was added and transferred into vials: acetonitrile for 
ESI- and a mixture of acetonitrile/water (v/v: 80/20) for ESI + and finally analyzed by 
liquid chromatography electrospray ionization tandem mass spectrometry (LC-MS-MS-
ESI) using internal standard calibration (See Table 2.3). Also samples were blanks-
corrected (n = 3) to detect potential contamination and recovery rates were assessed by 
the spiked samples.  The recovery for the majority of the APIs was higher than 86%. 
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Table 2.3: Type of ESI ionization and respective internal standard used. 
  API Internal standard 
ESI - ASP or ASA* ibuprofen d3 
  DCF diclofenac d3 
  IBU ibuprofen d3 
  GEM gemfibrozil d6 
  KET ketoprofen d3 
  NAP naproxene d3 
ESI + AMI amitriptyline d6 
  ALP diazepam d5 
  BRO diazepam d5 
  CAF caffeine c13 
  CAR diazepam d5 
  CLE diazepam d5 
  DIA diazepam d5 
  DOX amitriptyline d6 
  FLX amitriptyline d6 
  IMI amitriptyline d6 
  NOR nordiazepam d5 
  PAR paracetamol d4 
  SAL salbutamol d3 
  TER* diazepam d5 
  THEO diazepam d5 
API signaled by * only analyzed in 2009 
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Rs - sampling rate 
Qo - initial analytes quantity in water 
Qs - analyte quantity in sorbent at the end of exposure 
V - volume of water (L)  
t - exposure time in days 
2.3.3 Calculation of APIs Concentration 
According to Togola and Budzinski (2007a) the Rs should be calculating by the 
following equation (1):  
  =     
 
  
 
 
 
Applied Rs (L. day
-1
) for concentration assessment followed the ones obtained by 
Togola (2006), Togola and Budzinski (2007a), Budzinski et al. (2009) and MacLeod et 
al. (2009). 
The concentration of each analyte in natural water samples was calculated applying the 
following the equation (2):  
  = 
    
    
 
 
 
 
  
Cw - concentration in water 
Cs - concentration in sorbent 
Ms - mass of sorbent 
Rs – sampling rate 
t – exposure time in days 
 
(1) 
(2) 
Chapter 2: Occurrence of APIs in the Aquatic System 
69 | C h a p t e r  2  
2.3.4 Statistical Analysis 
Two-way ANOVA was performed using SIGMAPLOT
®
 to test differences between 
each API concentration per site per month. When needed ad-hoc Holm-Sidak was used 
on single API differences discrimination over time within and between sites.  
Principal component analysis (PCA) was performed using XLSTAT
® 
2012
 
to assess 
each targeted-analyte and abiotic parameters responsibility on the variability at each set 
of time (by month) in both sites within 2010. Statistical significance was defined at p < 
0.05. 
Chapter 2: Occurrence of APIs in the Aquatic System 
70 | C h a p t e r  2  
0
10
20
30
40
50
60
CAF (1/2) THEO IBU GEM PAR
TW
A
 c
o
n
ce
n
tr
at
io
n
s 
(n
g.
L-
1 )
 
Site 1 Site 2
2.4 Results 
Neither DOX, CLE, IMI, KET or SAL were not detected between years,  while AMI 
and BRO were only not detected in 2009
2
 and 2010 respectively. 
2.4.1 First Screen 
In the POCIS deployed in 2009, from the 21 targeted analytes, 14 were detected 
between sub- and ng.L
-1
 range (Figures 2.6 and 2.7).  
 
The highest APIs concentrations (Figure 2.6) decreased in the following pattern: for site 
1 (downriver) - CAF > THEO > IBU > GEM > PAR and for site 2 (upriver) - CAF > 
THEO > IBU > PAR > GEM. For the lowest concentrations (Figure 2.7) decrease 
pattern were: for site 1 – NAP > CAR > NOR > DCF > BRO > ALP > DIA3; for site 2 
– NAP > CAR > DCF > FLX > NOR > ALP > DIA and only BRO was below detection 
limit. For the top detected analytes CAF and THEO concentrations were 1.7- and 2.2-
fold higher at site 2 although only significantly for THEO, while inversely 
                                                 
2
 ASP and TER were not considered in the results since the recovery rate was below 35% and therefore 
not included in 2010 assessment. 
3
 FLX was below detection limit 
Figure 2.6: TWA concentrations (ng.L
-1
) in two sites of the Arade river in 2009. CAF concentration 
scale was divided by a factor of 2. * highlights differences between sites (p < 0.05). 
 
* 
* 
* 
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concentrations of IBU, GEM and PAR were 2.0-, 2.7- and 1.5-fold higher in site 1 only 
not significantly for PAR. Concerning the APIs detected at lower concentrations, NAP, 
CAR, DCF were similar at both sites while NOR, BRO and DIA were higher at site 1 
and ALP and FLX t site 2.  
 
 
 
 
 
 
 
 
Comparing the percentage of therapeutic classes between both sites (Figures 2.8A and 
B), the overall pattern is similar. Nevertheless, there were no antidepressants at site 1 
(concentrations below detection limit) (Figure 2.8A) and the percentage of anti-
lipidemics (a.k.a. lipid-regulators) (gemfibrozil), analgesics (paracetamol), NSAIDs, 
anticonvulsants and anxiolytics was higher than at site 2 (Figure 2.8B). Conversely, the 
percentage of stimulants (CAF) and antiasthmatics (theophylline) was higher at site 2. 
Regarding therapeutic classes without stimulants (CAF) (Figures 2.8C and D) it is 
evident the prevalence of antiasthmatics at site 2 (32% higher than at site 1), which in 
turn has approximately twice the percentage of NSAIDs. This is followed by a switch of 
anti-lipidemics and analgesics between sites, 10 and 6% higher respectively at site 1. 
Moreover the distribution of therapeutic classes’ was more homogeneous at site 1 which 
apart from antiasthmatics was always consistently higher at site 2. 
bdl bdl 
Figure 2.7: TWA concentrations (ng.L
-1
) in two sites of the Arade river in 2009. bdl = below 
detection limit. * highlights differences between sites (p < 0.05). 
* 
* 
* 
* 
* 
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Figure 2.8: Percentage of APIs in Arade river in 2009 according to therapeutic classes + stimulant 
(CAF) (A - site 1 downriver, B - site 2 upriver) and therapeutic classes without CAF (C - site 1 
downriver, D – site 2 upriver). 
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2.4.2 Evolution of APIs Concentrations 
In the POCIS deployed in 2010, from the 19 targeted analytes, 13 were detected at sub- 
and ng.L
-1
 range whose variation was site and time-dependent. The highest 
concentration detected was that of CAF (Figure 2.9) with an overall average 804 ± 209 
ng.L
-1
, showing no significant differences between sites or months, although at site 2 
there was a tendency for a concentration increase with time (p > 0.05). The 
antiasthmatic THEO followed and in site 1 THEO concentrations significantly 
decreased after the first month increasing again in October while on site 2 there was an  
increase until September showing similar concentrations over the following months 
(maximum concentration of 186 ± 44 ng.L
-1
). Moreover, THEO concentrations although 
similar at both sites in the beginning, became significantly higher at site 2 in September 
and October (p < 0.05).      
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Figure 2.9: TWA concentrations (ng.L
-1
) (average ± SD) of CAT and THEO in Arade river sites 
between August to October 2010 (n = 3). CAF concentration was divided by a factor of 4. Different 
letters indicate significant differences within each API, * highlights differences between sites (p < 
0.05). 
* * 
* 
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Figure 2.10: TWA concentrations (ng.L
-1
) (average ± SD) of PAR, CAR, IBU, DCF, NAP and GEM 
in Arade river sites between August to October 2010 (n = 3). Different letters indicate significant 
differences within each API, * highlights differences between sites (p < 0.05). 
* 
* 
The following APIs detected were analgesic (PAR), anticonvulsant (CAR), NSAIDs 
(IBU, DCF and NAP) and anti-lipidemic (GEM) ranging from 3 to 88 ng.L
-1 
(Figure 
2.10). 
 
 
 
 
 
 
 
 
PAR concentration varied similarly in both sites showing an enhancement tendency 
over time, although similar between August and September. Both sites showed a clear 
increase during October but 1.8-fold higher at site 2 reaching a maximum of 88 ± 8 
ng.L
-1 
(p < 0.05). CAR concentration was quite similar in both sites. Even though CAR 
at site 1 showed a decrease in September (significantly lower than October) no 
significant differences were found between sites (maximum of 31 ± 5 ng.L
-1 
in site 1). 
IBU concentration increased progressively over time at site 1 although only 
significantly by the end of October, while at site 2 the highest concentration was in 
September  and decreased in October to levels similar to the beginning (p < 0.05). 
Comparing both sites, IBU was significantly higher in August and September in site 2.  
DCF concentrations followed the same pattern at both sites, showing a steep increase 
from August to September followed by a significant decrease in October with 
significantly higher DCF concentration in September at site 1. The comparison between 
sites showed a transient pattern while higher concentrations at site 2 in August, but over 
the following months, site 1 showed significantly higher DCF concentrations. NAP 
concentrations only increased significantly in October in site 1 being significantly 
* 
* 
* * 
* * 
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Figure 2.11: TWA concentrations (ng.L
-1
) (average ± SD) of NOR, FLX, AMI, DIA, ALP in 
Arade river sites between August to October 2010 (n = 3). Different letters indicate significant 
differences within each API, bdl = below detection limit. * highlights differences between sites (p 
< 0.05). 
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higher than in site 2. At site 2, NAP concentrations in the beginning were similar to site 
1 and increased in September reaching levels similar to August in October (p < 0.05). 
Finally, GEM concentrations varied significantly over time in site 1, decreasing 
between August and September reaching a maximum in October that was similar to 
levels detected in August and September at site 2. In site 2 the only significant 
difference was a GEM decrease over October.  
 
 
 
 
 
 
The lowest APIs concentrations detected included anxiolytics and antidepressants 
(NOR, FLX, AMI, DIA and ALP) with concentrations below 3 ng.L
-1
 (Figure 2.11). 
NOR concentrations did not vary significantly between sites or time, although levels at 
site 2 were slightly higher than at site 1 and showed a decrease tendency with time (p > 
0.05). The pattern variation of FLX concentrations was similar between sites. However, 
levels were only significantly higher in August at site 1. AMI concentrations were also 
not site or time dependent. Moreover, DIA concentration was significantly different in 
site 1; the highest concentration was in August followed by an abrupt decrease in 
September increasing again by October. In site 2, DIA concentration showed a 
progressive decrease reaching a concentration below detection limit in October. 
Furthermore, DIA was significantly higher at site 1 than at site 2 in August and October. 
Finally, ALP concentrations showed like NOR and AMI, to be not site nor time 
dependent.  
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In terms of therapeutic classes with stimulants (Figures 2.12A and B), CAF has in both 
sites a similar percentage 77% (site 2) to 80% (site 1) of overall targeted analytes 
detected. Compared to the first screen in 2009 (Figures 2.8A and B) CAF in 2010 is 
more prevalent in site 1 rather than site 2. Antiasthmatics are again the API more 
prevalent in site 2 (12%) than in site 1 (8%) as observed in 2009, although with lower 
percentage. Inversely to the homogeneity found in 2009 in terms of NSAIDs 
distribution (also in higher percentages than 2010), site 2 has a higher percentage of 
analgesics than NSAIDs which in this case is opposite of what was found in 2009. 
Furthermore, in 2010 anticonvulsants had higher prevalence in both sites than anti-
lipidemics, contrarily of what was observed in the first screen. Finally the overall 
percentage of anxiolytics and antidepressants, in both sites in 2010 was very similar, 
whether in 2009 no antidepressants were found in site 1. In terms of APIs percentages 
reported without CAF (Figures 2.12C and D), the percentage of antiasthmatics in site 1 
was similar with the one in 2009, being again lower than at site 2. The same can be said 
for NSAIDs in site 1 between years. However in site 2 analgesics were 2-fold higher in 
2010 than 2009, being lower than NSAIDs. For the following therapeutic classes, while 
in site 1 in 2010 anti-lipidemics are 10% lower than in 2009 and site 2 exhibits a similar 
percentage between years, anticonvulsants are 10% and 7% higher in site 1 and 2 over 
2010 than in 2009.   
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Figure 2.12: Percentage of APIs in Arade river in 2010 according to therapeutic classes + stimulant 
(CAF) (A– site 1 downstream, B – site 2 upstream) and therapeutic classes without stimulant (CAF) 
(C – site 1 downstream, D – site 2 upstream). 
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2.4.3 Principal Component Analysis (PCA) 
PCA was applied to the average of all target-analytes concentrations present at both 
sites in 2010 (Figure 2.13). PCA expresses 61% of Total Variance (Tvar) highlighting a 
separation within site 1 in which August distribution is further related to temperature 
and DIA, FLX while September is associated to salinity, pH and DCF which ultimately 
contrast with October dispersal further associated to NOR, GEM, CAR and AMI.  
At site 2, overall month dispersal is less noticeable than at site 1. Nevertheless August is 
further associated with NOR, GEM, CAR and AMI while the higher proximity among 
September and October is affected by the dispersal of NSAIDs (NAP, IBU) and CAF 
distribution with ALP, PAR and THEO respectively.  Overall, site 2 seems to be more 
affected by APIs distribution, than unlike site 1 further dependent of abiotic parameters 
distribution and antidepressants and anxiolytics presence.  
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Figure 2.13: PCA representing 61% of total variance of targeted-analytes concentration 
integration between sites and time from Arade river 2010 (● – site 1 and ♦ – site 2, color 
scheme is in agreement with the one previous applied in Figures above). 
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2.5 Discussion 
The assessment of average concentrations of contaminants in water bodies is one of the 
pivotal goals covered by the WFD for this reason the application of passive samplers 
that enable TWA concentrations determination provide a more holistic approach of 
water quality status compared to spot sampling (Dévier et al., 2011; Morin et al., 2012). 
The present results identify for the first time the presence of APIs screening by POCIS 
devices in Portugal and in the Arade river. Being one of the very few studies focusing 
on this subject in Portuguese water bodies apart from the ones made in Douro river 
analyzed by liquid chromatography–ion trap tandem mass spectrometry after off-line 
solid-phase extraction (SPE) (Madureira et al. 2009; 2010) analogous to POCIS solid-
phase medium which targeted 7 APIs analytes (antibiotics - trimethoprim and 
sulfamethoxazole, beta-blocker - propranolol, lipid regulating agent -  fenofibric acid 
and FLX, CAR, DIA common with the present study). 
In overall, 2009 TWA APIs concentrations were lower than 2010 except for BRO 
(which was not detected in the following year), IBU and GEM that presented both 
concentrations similar between both years in site 1. Nevertheless this scenario may have 
been influenced by the different extraction methodology applied between years rather 
than environmental conditioning (abiotic parameters) variation, thus not justifying Rs 
selection alteration. In 2010 results revealed good reproducibility amongst POCIS 
triplicate, with an analyte accumulation variability averaging approximately 30% in 
each site. APIs recovery rates were also in the range from 84 to 110 % . 
2.5.1 Summer Impact in APIs Concentrations in Arade River 
Regarding the impact of summer months in APIs concentrations assessment in the 
Arade river the results were quite inconclusive and transient between months in both 
sites. Nevertheless, at site 1 August presented higher concentrations of antidepressants 
(FLX and AMI) and anxiolytic (DIA), September higher concentrations of stimulant 
(CAF) and NSAID (DCF) and finally October presented the highest concentrations of 
several therapeutic classes such as antiasthmatic (THEO), analgesic (PAR), 
anticonvulsant (CAR), NSAIDs (IBU and NAP), anti-lipidemic (GEM) and anxiolytic 
(ALP). In general at this site, September was the month exhibiting lower concentrations 
of APIs whereas October exhibited the highest. Moreover, PAR, IBU and ALP were the 
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only APIs which nominal concentrations progressively increased over time, whereas the 
inverse was never observed.  
At site 2 the dissimilarity of APIs concentration distribution between months was less 
pronounced than at site 1. Nevertheless anticonvulsant CAR and anxiolytics NOR and 
DIA concentrations were slightly highest in August (p > 0.05). September showed 
significantly higher concentrations of NSAIDs IBU, DCF (alike site 1) and NAP and 
anti-lipidemic GEM. Finally alike site 1, October was globally the month showing 
higher APIs concentrations such as stimulant (CAF), antiasthmatic (THEO), analgesic 
(PAR), antidepressants (FLX and AMI) and anxiolytic (ALP) of which THEO, PAR 
and ALP concentrations were concomitantly higher at both sites at this month. 
Moreover CAF, THEO and PAR which were the APIs with overall highest 
concentrations in Arade river in both sites, showed a progressive enhancement with 
time at site 2, while anxiolytics NOR and DIA showed the opposite, decreasing over 
time. Finally, the three months average revealed that site 2 had consistently the highest 
APIs concentrations (with the exception of DCF, FLX and DIA) which can be 
explained by the closer proximity of WWTP2 discharge, higher site confinement and 
thus longer water renewal time than site 1 which is at greater distance of WWTP1. 
Moreover, the overall presence of APIs concentrations throughout summer (dry-season) 
particularly by October also attests to uncontrolled WWTPs discharges since as stated 
by Vystavna et al. (2012) water run-off volume at this period is usually low. 
2.5.2 Comparison with other TWA Concentrations in Surface Waters 
Very few studies have yet applied POCIS devices on the TWA concentration 
determination of APIs target-analytes. Table 2.4 presents the up to date TWA maximum 
concentrations reported of the selected APIs with the present study. In comparison with 
the maximum TWA concentrations found between different up and downstream of 
WWTPs sites in Lopan river (Ukraine) and Jalle river (France) targeting exactly the 
same analytes (Vystavna et al., 2012), Arade river presented similar concentrations of 
NOR, FLX and AMI than Jalle river all APIs occurring at a maximum concentration 
below 2 ng.L
-1
, while Lopan river did not present any concentration of NOR and 5-fold 
higher concentrations of FLX and AMI. Alike Arade river ASP, BRO, CLE, DOX, IMI, 
SAL and TER were also not detected in both Ukrainian and French rivers. Furthermore 
and only concerning the maximum concentration reported, Arade river presented 1.7 
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and 8-fold higher concentrations of PAR and CAF than Lopan river and 1.9 and 5-fold 
higher concentrations of IBU and GEM than Jalle river, while CAR concentration was 
9-fold lower than Lopan river and DCF and NAP were more than 2-fold lower than 
Jalle river. Unlike Arade river THEO, DIA and ALP concentrations were not present in 
neither Lopan nor Jalle rivers, while KET concentration which was not detected in 
Arade river was present in both rivers (60 and 130 ng.L
-1
 respectively).   
In a coastal lagoon and semi-enclosed bay in French Mediterranean coast (Munaron et 
al., 2012) lower CAF concentrations in all sites (up to 32 ng.L
-1
), also CAR (up to 12 
ng.L
-1
) and GEM (up to 5 ng.L
-1
) which was only present in the semi-enclosed lagoon 
site, than the ones found in both sites in Arade river. Like reported by Vystavna et al. 
(2012), KET was also found up to 3.5 ng.L
-1
 unlike for Arade river while all the 
remaining targeted APIs such as DIA and DCF were only found at ultra-trace levels (< 
1 ng.L
-1
). The presence of higher concentrations of APIs in more confined waters at 
lagoon and bay sites when compared to coastal water sites was justified due to longer 
water renewal time associated with higher urbanized watersheds (Munaron et al., 2012), 
as observed for Arade river site 2 compared to site 1. 
Lastly, Arade river presented approximately 5 and 14-fold lower concentrations of DCF 
and CAR than Ouse river in the United Kingdom (Zhang et al., 2008) and 7-fold lower 
FLX than Crabtree Creek in USA (Bringolf et al., 2010). 
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Table 2.4: TWA concentrations of commonly detected APIs in surface waters using POCIS 
Therapeutic class API Analytical Method Maximum concentration  (ng.L
-1
) Location Reference 
stimulant CAF POCIS Oasis HLB/ LS-MS-MS-ESI 32 Mediterranean French coast (France) Munaron et al., 2012 
      80 Jalle river (France) Vystavna et al., 2012 
      150 Lopan river (Ukraine)    
      1150 Arade River (Portugal) present study 
anticonvulsant CAR POCIS Oasis HLB/ LS-MS-MS-ESI 12 semi-enclosed lagoon (France) Munaron et al., 2012 
      25 Jalle river (France) Vystavna et al., 2012 
      31 Arade River (Portugal) present study 
      275 Lopan river (Ukraine)  Vystavna et al., 2012 
    POCIS Oasis HLB/ LS-MS-MS 427 Ouse river (United Kingdom) Zhang et al., 2008 
analgesic PAR POCIS Oasis HLB/ LS-MS-MS-ESI 45 Jalle river (France) Vystavna et al., 2012 
      50 Lopan river (Ukraine)    
      88 Arade River (Portugal) present study 
NSAIDs IBU POCIS Oasis HLB/ LS-MS-MS-ESI 15 Jalle river (France) Vystavna et al., 2012 
      28 Arade River (Portugal) present study 
  DCF POCIS Oasis HLB/ LS-MS-MS-ESI <10 Lopan river (Ukraine)  Vystavna et al., 2012 
      31 Arade River (Portugal) present study 
      70 Jalle river (France) Vystavna et al., 2012 
    POCIS Oasis HLB/ LS-MS-MS 165 Ouse river (United Kingdom) Zhang et al., 2008 
  NAP POCIS Oasis HLB/ LS-MS-MS-ESI < 10 Lopan river (Ukraine)  Vystavna et al., 2012 
      17 Arade River (Portugal) present study 
      40 Jalle river (France) Vystavna et al., 2012 
anti-lipidemic GEM POCIS Oasis HLB/ LS-MS-MS-ESI < 2 Jalle river (France) Vystavna et al., 2012 
      5 semi-enclosed lagoon (France) Munaron et al., 2012 
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Table 2.4: (Continuation). 
anti-lipidemic GEM POCIS Oasis HLB/ LS-MS-MS-ESI 10 Arade River (Portugal) present study 
antidepressant FLX POCIS Oasis HLB/ LS-MS-MS-ESI < 2 Arade River (Portugal) present study 
      < 2 Jalle river (France) Vystavna et al., 2012 
      < 10 Lopan river (Ukraine)    
      14 Crabtree Creek (USA) Bringolf et al., 2010 
  AMI POCIS Oasis HLB/ LS-MS-MS-ESI <2 Arade River (Portugal) present study 
      <2 Jalle river (France) Vystavna et al., 2012 
      <10 Lopan river (Ukraine)    
anxiolytic NOR POCIS Oasis HLB/ LS-MS-MS-ESI < 2 Jalle river (France) Vystavna et al., 2012 
      3 Arade River (Portugal) present study 
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2.5.3 Arade River API Concentrations in Comparison with other Studies 
Applying Spot Sampling in Surface Waters 
An overview of the commonly selected and detected APIs concentrations in surface 
waters obtained using spot sampling is in Table 2.5. Douro river (Madureira et al., 
2009; 2010) (downstream of WWTP discharge) presented concentrations of CAR (178 
ng.L
-1
) and DIA (3.7 ng.L
-1
) in June 2008 higher than the ones found in Arade river in 
2009 and 2010: 1 and 31 ng.L
-1 
of CAR (site 1 in June 2009 and October 2010 
respectively) and 0.1 and 2 ng.L
-1 
of DIA (site 1 in June 2009 and August 2010 
respectively), whereas FLX was only detected in the Arade river 0.5 and 2 ng.L
-1 
(site 2 
June 2009 and site 1 in August 2010 respectively while in Douro river was not 
quantified due to lack of accuracy upon validation process. In this particular case, even 
though the urban areas adjacent to Arade river comprise only an approximate average of 
65,000 inhabitants having 8-fold lower population density than Douro River estuary in 
the vicinity of Oporto (237,584 inhabitants) and Vila Nova de Gaia (302,296 
inhabitants) cities (INE, 2011) it is clear that this riverine water is as vulnerable to APIs 
occurrence, although is expected that the different sampling techniques used may induce 
proportionally higher values at Arade river due to TWA concentrations given by 
POCIS.  
Furthermore, in an overall comparison of the results with spot sampling (Table 2.5), 
Arade river presented high concentrations of CAF (max. of 1150 ng.L
-1
) and PAR (max. 
of 88 ng.L
-1
) being in agreement with the ones found in Halifax watershed (Comeu et 
al., 2008) and Ebro river basin (Gros et al., 2010) respectively which in turn comprise 
highly populated areas of approximately 390,000 and 3 million inhabitants (Canada 
Statistics, 2012; Deltanet Project, 2012). Concomitantly presented similar 
concentrations of CAR (max. of 31 ng.L
-1
 in Arade river) with Tamis river in Serbia 
(Vasiljevi et al., 2009); IBU (max. of 28 ng.L
-1
 in Arade river) with Zhujiang river 
(China) (Zhao et al., 2010) and Elbe river (Germany) (Weiger et al., 2004); DCF (max. 
of 31 ng.L
-1 
in Arade river) with Lake Alster (Germany) (Weiger et al., 2004) and 
Zhujiang river (China) (Zhao et al., 2010); NAP (max. of 17 ng.L
-1
 in Arade river) with 
Lake Greifensee (Switzerland) (Öllers et al., 2001) and Llobregat river (Spain) (Farré et 
al., 2001); GEM (max. of 9 ng.L
-1 
in Arade river) with Zhujiang river (China) (Zhao et 
al., 2010) and Halifax watershed (Canada) (Comeau et al., 2008). 
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It is obvious that APIs presence in water is dependent of social-economic-demographic 
factors and prescription practices of each region yet and foremost these emergent 
compounds entrance in the environment is due to inefficient WWTP treatments. Our 
results highlight the necessity of WWTPs treatments improvement in order to avoid 
further Arade river contamination by these compounds. The high presence of CAF, 
which is known to have a non-conservative behavior and be easily degradable during 
WWTP treatments and in aquatic systems (Togola and Budzinski, 2007a, Vystavna et 
al. 2012) and PAR concentrations compared to the above mentioned studies are 
particularly concerning since as remarked by Madureira et al. (2010) even though the 
presently detected APIs concentrations are not individually pertained to cause acute 
effects, it should not be excluded the potential chronic risks/effects of exposure to a 
continuous discharge of APIs mixtures in the ecosystem especially on commercial and 
economically relevant non-target species like bivalves (see following Chapters). 
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Table 2.5: Maximum concentrations of the commonly detected APIs in surface waters collected by spot sampling 
Therapeutic class API Country Location Analytical Method Maximum 
concentration (ng.L
-1
) 
Reference 
stimulant CAF France Lergue river  Oasis MCX, C18, HLB/ GC-MS 107 Togola and Budzinski, 2008 
     Seine estuary  Oasis HLB/ GC-MS 138 Togola and Budzinski, 2007b 
     Cortiou rocky inlet  Oasis MCX, C18, HLB/ GC-MS 8000 Togola and Budzinski, 2008 
   Germany Elbe river  Oasis HLB/ GC-MS 148 Weigel et al., 2004a 
     Lake Alster  Oasis HLB/ GC-MS 176   
   Romania Somes river  Oasis HLB/ GC-MS 9700 Moldovan, 2006 
   Spain Henares-Jarama-Tajo river  Oasis HLB/ HPLC-MS-ESI 416 Fernández et al., 2010 
   Canada Detroit river  Oasis HLB/ HPLC-MS 40 Hua et al., 2006 
     Halifax watershed  Oasis HLB/ GC-MS 1100 Comeau et al., 2008 
   USA Salt Creek  Oasis HLB/ GC-MS 18 Bartelt-Hunt et al., 2009 
     Tennessee river  Oasis HLB/ UPLC 32 Conley et al., 2008 
     Wood River  Oasis HLB/ GC-MS 321 Bartelt-Hunt et al., 2009 
     Big Blue river  Oasis HLB/ GC-MS 980   
anticonvulsant CAR China Liuxi river  Oasis HLB/ GC-MS 18 Zhao et al., 2010 
     Zhujiang river  Oasis HLB/ GC-MS 26   
     Shijing river  Oasis HLB/ GC-MS 43   
   France Lergue river  Oasis MCX, C18, HLB/ GC-MS 56 Togola and Budzinski, 2008 
     Seine estuary  Oasis HLB/ GC-MS 83 Togola and Budzinski, 2007b 
   Italy Po river  Oasis MCX/ HLPC-MS-MS 34 Zuccato et al., 2006 
     Lambro river  Oasis MCX/ HLPC-MS-MS 175   
   Portugal Douro river  Oasis HLB/ LC-MS-MS-ESI 178 Madureira et al., 2009; 2010 
   Romania Somes river  Oasis HLB/ GC-MS 75 Moldovan, 2006 
   Serbia Tamis river  Oasis HLB/ LC-MS-MS 30 Vasiljevi et al., 2009 
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Table 2.5: (Continuation). 
anticonvulsant CAR  Serbia  Sava river Oasis HLB/ LC-MS-MS 50  Vasiljevi et al., 2009 
   Danube river  Oasis HLB/ LC-MS-MS 130  
   Spain Ebro river basin  Oasis HLB/ LC-MS < 60 Gros et al., 2010 
     Henares-Jarama-Tajo river  Oasis HLB/ HPLC-MS-ESI 104 Fernández et al., 2010 
     Ebro river basin  Oasis HLB/ LC-MS 110 Gros et al., 2006 
     Llobregat river  Oasis HLB/ LC-MS-MS 3090 Ginebreda et al., 2010 
   Switzerland Lake Greifensee  Oasis HLB/ GC-MS < 60 Tixier et al., 2003 
     Lake Greifen  Oasis HLB/ GC-MS 60 Öllers et al., 2001 
     Aa and Aabach river  Oasis HLB/ GC-MS 250   
   United Kingdom Ouse river   Oasis HLB/ LC-MS-MS 539 Zhang et al., 2008 
   Canada Ottawa river  Oasis HLB/ LC-ESI-MS-MS <0.2 Segura et al., 2010 
     St. Lawrence river  Oasis HLB/ LC-MS-MS-ESI 2   
     Yamaska river  Oasis HLB/ LC-ESI-MS-MS 4   
     Detroit river  Oasis HLB/ HPLC-MS 40 Hua et al., 2006 
   USA Tennessee river  Oasis HLB/ UPLC 6 Conley et al., 2008 
     Loup River  Oasis HLB/ GC-MS 21 Bartelt-Hunt et al., 2009 
     Wood River  Oasis HLB/ GC-MS 51   
     Big Blue river  Oasis HLB/ GC-MS 132   
     Salt Creek  Oasis HLB/ GC-MS 296   
analgesic PAR France Lergue river  Oasis MCX, C18, HLB/ GC-MS 72 Togola and Budzinski, 2008 
   Serbia Danube river  Oasis HLB/ LC-MS-MS 78 Vasiljevi et al., 2009 
     Tamis river  Oasis HLB/ LC-MS-MS 310   
     Sava river   Oasis HLB/ LC-MS-MS 610   
   Spain Henares-Jarama-Tajo river  Oasis HLB/ HPLC-MS-ESI 43 Fernández et al., 2010 
     Ebro river basin  Oasis HLB/ SPE-LC-MS 80 Gros et al., 2010 
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Table 2.5: (Continuation). 
analgesic PAR Spain Ebro river basin Oasis HLB/ SPE-LC-MS 250 Gros et al., 2006 
   Llobregat river  Oasis HLB/ LC-MS-MS 2420 Ginebreda et al., 2010 
   USA Wood River  Oasis HLB/ GC-MS 35 Bartelt-Hunt et al., 2009 
     Salt Creek  Oasis HLB/ GC-MS 39   
     Big Blue river  Oasis HLB/ GC-MS 63   
NSAIDs IBU China Liuxi river  Oasis HLB/ GC-MS 11 Zhao et al., 2010 
     Zhujiang river  Oasis HLB/ GC-MS 31   
     Hai river  Oasis HLB/ GC-MS 127 Wang et al., 2010 
     Liao river Oasis HLB/ GC-MS 246   
     Yellow river  Oasis HLB/ GC-MS 416   
     Shijing river  Oasis HLB/ GC-MS 685 Zhao et al., 2010 
   Finland Kokemäenjoki river  Oasis MCX/ HPLC-MS-MS-ESI 64 Lindqvist et al., 2005 
   France Lergue river  Oasis MCX, C18, HLB/ GC-MS 5 Togola and Budzinski, 2008 
     Seine estuary  Oasis HLB/ GC-MS 611 Togola and Budzinski, 2007b 
     Cortiou rocky inlet  Oasis MCX, C18, HLB/ GC-MS <1000 Togola and Budzinski, 2008 
   Germany Lake Alster  Oasis HLB/ GC-MS 5 Weigel et al., 2004 
     Elbe river  Oasis HLB/ GC-MS 32   
   Italy Po river  Oasis MCX/ HLPC-MS-MS 17 Zuccato et al., 2006 
     Lambro river  Oasis MCX/ HLPC-MS-MS 20   
   Luxembourg Alzette river Oasis HLB/ LC-MS-MS 295 Pailler et al., 2009 
     Mess river  Oasis HLB/ LC-MS-MS 2383   
   Romania Somes river  Oasis HLB/ GC-MS 115 Moldovan, 2006 
   Spain Ebro river basin  Oasis HLB/ LC-MS < 100 Gros et al., 2010 
     Cardener river  Oasis HLB/ LC-MS 130 Farré et al., 2001 
    Ebro river basin  Oasis HLB/ LC-MS 150 Gros et al., 2006 
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Table 2.5: (Continuation). 
NSAIDs IBU  Spain Llobregat river  Oasis HLB/ LC-MS 153 Farré et al., 2001 
     Riera Rubi river  Oasis HLB/ LC-MS 1650   
   Anoia river  Oasis HLB/ LC-MS 2700  
     Henares-Jarama-Tajo river  Oasis HLB/ HPLC-MS-ESI 2784 Fernández et al., 2010 
     Llobregat river  Oasis HLB/ LC-MS-MS 10000 Ginebreda et al., 2010 
   Switzerland Lake Greifensee  Oasis HLB/ GC-MS <15 Tixier et al., 2003 
     Lake Greifen  Oasis HLB/ GC-MS 15 Öllers et al., 2001 
     Aa and Aabach river  Oasis HLB/ GC-MS 80   
   Canada Detroit river  Oasis HLB/ HPLC-MS 10 Hua et al., 2006 
     Halifax watershed  Oasis HLB/ LC-MS 160 Comeau et al., 2008 
  DCF China Liuxi river  Oasis HLB/ GC-MS 11 Zhao et al., 2010 
     Zhujiang river  Oasis HLB/ GC-MS 33   
     Hai river  Oasis HLB/ GC-MS 46 Wang et al., 2010 
     Liao river  Oasis HLB/ GC-MS 105   
     Yellow river  Oasis HLB/ GC-MS 136   
     Shijing river Oasis HLB/ GC-MS 150 Zhao et al., 2010 
   Finland Kokemäenjoki river  Oasis MCX/ HPLC-MS-MS-ESI 35 Lindqvist et al., 2005 
   France Lergue river  Oasis MCX, C18, HLB/ GC-MS 33 Togola and Budzinski, 2008 
     Seine estuary  Oasis HLB/ GC-MS 173 Togola and Budzinski, 2007b 
     Cortiou rocky inlet  Oasis MCX, C18, HLB/ GC-MS <1000 Togola and Budzinski, 2008 
   Germany Lake Alster  Oasis HLB/ GC-MS 26 Weigel et al., 2004 
     Elbe river  Oasis HLB/ GC-MS 67   
   Luxembourg Mess river  Oasis HLB/ LC-MS-MS 19 Pailler et al., 2009 
     Alzette river  Oasis HLB/ LC-MS-MS 55   
       
       
Chapter 2: Occurrence of APIs in the Aquatic System 
90 | C h a p t e r  2  
Table 2.5: (Continuation). 
 NSAIDs DCF Spain Cardener river  Oasis HLB/ LC-MS 51 Farré et al., 2001 
   Ebro river basin  Oasis HLB/ LC-MS < 60 Gros et al., 2010 
     Ebro river basin  Oasis HLB/ LC-MS 60 Gros et al., 2006 
     Llobregat river  Oasis HLB/ LC-MS 120 Farré et al., 2001 
     Henares-Jarama-Tajo river  Oasis HLB/ HPLC-MS-ESI 156 Fernández et al., 2010 
     Riera Rubi river Oasis HLB/ LC-MS 484 Farré et al., 2001 
     Anoia river  Oasis HLB/ LC-MS 610   
     Llobregat river  Oasis HLB/ LC-MS-MS 18740 Ginebreda et al., 2010 
   Switzerland Lake Greifensee Oasis HLB/ GC-MS <10 Tixier et al., 2003 
     Lake Greifen  Oasis HLB/ GC-MS 10 Öllers et al., 2001 
     Aa and Aabach river  Oasis HLB/ GC-MS 150   
   United Kingdom Ouse river Oasis HLB/ LC-MS-MS 65 Zhang et al., 2008 
   Canada Detroit river  Oasis HLB/ HPLC-MS 15 Hua et al., 2006 
  NAP China Zhujiang river  Oasis HLB/ GC-MS 5 Zhao et al., 2010 
     Yellow river  Oasis HLB/ GC-MS 18 Wang et al., 2010 
     Liao river Oasis HLB/ GC-MS 41   
     Shijing river  Oasis HLB/ GC-MS 125 Zhao et al., 2010 
   Finland Kokemäenjoki river   Oasis MCX/ HPLC-MS-MS-ESI 45 Lindqvist et al., 2005 
   France Lergue river  Oasis MCX, C18, HLB/ GC-MS 9 Togola and Budzinski, 2008 
   France Seine estuary  Oasis HLB/ GC-MS 275 Togola and Budzinski, 2007b 
   France Cortiou rocky inlet  Oasis MCX, C18, HLB/ GC-MS 2000 Togola and Budzinski, 2008 
   Spain Lloregat river  Oasis HLB/ LC-MS 17 Farré et al., 2001 
     Ebro river basin Oasis HLB/ LC-MS 50 Gros et al., 2006 
  Spain  Ebro river basin  Oasis HLB/ LC-MS < 110 Gros et al., 2010 
   Anoia river  Oasis HLB/ LC-MS 120 Farré et al., 2001 
       
Chapter 2: Occurrence of APIs in the Aquatic System 
91 | C h a p t e r  2  
Table 2.5: (Continuation). 
     Cardener river  Oasis HLB/ LC-MS 234 Farré et al., 2001 
     Henares-Jarama-Tajo river Oasis HLB/ HPLC-MS-ESI 640 Fernández et al., 2010 
     Riera Rubi river  Oasis HLB/ LC-MS 2000 Farré et al., 2001 
     Llobregat river  Oasis HLB/ LC-MS-MS 2060 Ginebreda et al., 2010 
   Switzerland Lake Greifen  Oasis HLB/ GC-MS 10 Öllers et al., 2001 
     Lake Greifensee  Oasis HLB/ GC-MS <15 Tixier et al., 2003 
     Aa and Aabach river  Oasis HLB/ GC-MS 400 Öllers et al., 2001 
   Canada Halifax watershed  Oasis HLB/ GC-MS 110 Comeau et al., 2008 
anti-lipidemics/ 
lipid-regulators 
GEM China Zhujiang river  Oasis HLB/ GC-MS 8 Zhao et al., 2010 
     Yellow river  Oasis HLB/ GC-MS 14 Wang et al., 2010 
     Shijing river  Oasis HLB/ GC-MS 20 Zhao et al., 2010 
     Hai river  Oasis HLB/ GC-MS 87 Wang et al., 2010 
   France Lergue river  Oasis MCX, C18, HLB/ GC-MS 2 Togola and Budzinski, 2008 
     Seine estuary  Oasis HLB/ GC-MS 86 Togola and Budzinski, 2007b 
   Spain Ebro river basin Oasis HLB/ LC-MS 40 Gros et al., 2010 
     Ebro river basin  Oasis HLB/ LC-MS 60 Gros et al., 2006 
     Cardener river  Oasis HLB/ LC-MS 75 Farré et al., 2001 
     Llobregat river  Oasis HLB/ LC-MS 236   
     Anoia river  Oasis HLB/ LC-MS 255   
     Riera Rubi river  Oasis HLB/ LC-MS 457   
     Llobregat river  Oasis HLB/ LC-MS-MS 7780 Ginebreda et al., 2010 
anti-lipidemics/ 
lipid-regulators 
GEM Canada Halifax watershed  Oasis HLB/ GC-MS 8 Comeau et al., 2008 
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Table 2.5: (Continuation). 
antidepressant FLX Spain Henares-Jarama-Tajo river  Oasis HLB/ HPLC-MS-ESI 66 Fernández et al., 2010 
     Ebro river basin  Oasis HLB/ LC-MS < 110 Gros et al., 2010 
     Rubi river  Oasis HLB/ LC-MS 1550 Farré et al., 2001 
   USA Crabtree Creek  C18 Empore disks/ LC-ESI-
MS-MS 
10 Bringolf et al., 2010 
anxiolytic DIA Portugal Douro river  Oasis HLB/ LC-ESI-MS-MS 4 Madureira et al., 2009; 2010 
   Romania Somes river  Oasis HLB/ GC-MS 34 Moldovan, 2006 
   Spain Ebro river basin  Oasis HLB/ LC-MS < 10 Gros et al., 2010 
Chapter 2: Occurrence of APIs in the Aquatic System 
93 | C h a p t e r  2  
 
2.6 Conclusions 
Overall, the present study highlights that the use of POCIS devices clearly enabled a 
suitable quantification and characterization of APIs concentrations in Arade river sites, 
in which although no clear indication of the summer impact was shown most of the 
selected APIs were present at relevant concentrations. Nevertheless, for POCIs 
application potential optimization it is necessary to further define deployment protocol 
and experimental calibration uniformity in order to enhance the validation and 
comparability of obtained data. Finally, the high versatility of POCIS on polar and 
semipolar contaminants quantification in all types of water environments can 
significantly improve the APIs’ ERA in the aquatic system and non-target species going 
in agreement with WFD implementation intents. 
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3 A. Non-steroidal Anti-Inflammatory Drug (NSAID) 
Ibuprofen Distresses Antioxidant Defense System in 
Mussel Mytilus galloprovincialis gills 
Abstract 
Active pharmaceutical ingredients (APIs) are presently considered an emergent class of 
environmental contaminants. Ibuprofen (IBU) is one of the most applied non-steroidal 
anti-inflammatory drugs (NSAIDs) in the world. Several authors report the occurrence 
of IBU in influents and effluents of waste water treatment plants (WWTPs), surface, 
river and public tap water in numerous countries. However, very little is known about 
the risks and chronic effects of IBU exposure in non-target organisms. This approach 
undertakes the assessment of several oxidative stress biomarkers responses through the 
analysis of antioxidant enzyme activities (superoxide dismutase – SOD, catalase – CAT, 
glutathione S-transferase – GST, glutathione reductase – GR) and lipid peroxidation 
(LPO) levels in sentinel species mussel M. galloprovincialis gills exposed for 2 weeks 
to an environmental realistic concentration of IBU. Results clearly show the significant 
induction and positive correlation between SOD activity and LPO in exposed gills, 
concomitant to an antioxidant defense depletion of CAT, GR and GST compared to 
controls. The integration of all biomarkers in mussels’ gills separates non- and exposed 
groups supporting the breakdown of the redox defense system and IBU’s pro-oxidant 
action. Further studies are needed to test possible endocrine disruption effects in 
mussels’ reproduction fitness as IBU is involved on prostaglandins biosynthesis 
inhibition. 
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3.1 Introduction 
One of the highest lifestyle altering improvements in modern societies is unquestionably 
owed to the application of active pharmaceutical ingredients (APIs) in healthcare 
practice. The various therapeutic actions attributed to APIs are critical to the treatment 
and/or prevention of numerous human diseases. However, its high consumption by an 
exponential worldwide growing population results in its ubiquity in the environment 
(Togola and Budzinski, 2008). APIs meet all of the emergent pollutant criteria since 
they (1) occur and induce effects at low concentrations, (2) potential chronic effects at 
low level exposures are still undefined on ecosystem and human health and/or (3) are 
after subjected to environmental dispersal after incomplete treatment at WWTP 
systems. Therefore APIs must be issued on environmental impact studies as stated by 
EU and US legislation guidelines (Besse and Garric, 2008; Santos et al., 2010). The 
first report featuring this problematic was published in the late 1970s (Garrison et al., 
1976). Since then, the development of new highly sensitive analytic techniques allowed 
to assess the occurrence, fate and sources of APIs on water bodies (such as waste water 
treatment plant – WWTPs, tap, surface, ground and marine waters) at concentrations 
from ng.L
−1
 to µg.L
−1
 (see reviews, Kümmerer, 2009; Santos et al., 2010). IBU is a 
propanoic acid derivative and as most widely used non-steroidal anti-inflammatory 
drugs (NSAIDs) is a nonselective inhibitor of both cyclooxygenase (COX)-1 and -2 
isozymes (Praveen Rao and Knaus, 2008). Pain and/or inflammation triggered by 
reactive oxygen species (ROS) (e.g. nitric oxide and hydrogen peroxide) promotes COX 
activities reduction, which in turn results in a decreased of prostaglandins synthesis. 
This feature confers to IBU its analgesic, antirheumatic and antipyretic therapeutic 
actions (Praveen Rao and Knaus, 2008). Since, most of the studies concerning exposure 
to IBU focus on acute (lethal concentration – LC50 or maximal effective concentration – 
EC50) and chronic tests (e.g. reproductive, behavior, growth alterations) (De Lange et 
al., 2006; Flippin et al., 2007) it is important to address IBU impact on antioxidant 
system of bivalves as most pharmaceuticals therapeutic action is related to specific 
redox reactivity (Martín-Díaz et al., 2009). Mussels, as filter-feeders and sessile 
organisms, are excellent tools on marine and estuarine pollution evaluation being 
frequently selected to integrate numerous international monitoring programs such as 
“Global Mussel Watch” (Goldberg et al., 1978).  
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It is well accepted that aerobic organisms possess regulatory mechanisms which 
intercept and inactivate toxic ROS induced by contaminants, leveling them to a 
minimum intracellular stage (Valavanidis et al., 2006). These mechanisms are mediated 
by antioxidant enzymes (such as: SOD, CAT and glutathione peroxidases (GPx) which 
increase the synthesis and adapt themselves to stress level fluctuations. If the 
antioxidant system is overwhelmed, damage in macromolecules occurs, namely LPO 
which can be translated in phospholipids membrane loss of rigidity and permeably 
(Valavanidis et al., 2006). Considering the above, this approach undertakes the 
assessment of several oxidative stress biomarker responses through the analysis of 
antioxidant enzyme activities (SOD, CAT, GST, GR) and LPO levels in mussel’s M. 
galloprovincialis gills exposed for 2 weeks to an environmental realistic concentration 
of non-steroid anti-inflammatory drug (NSAID) IBU i.e. similar to the ones found in 
WWTP effluents and surface waters (Thomas and Hilton, 2004; Palmer et al., 2008; 
Chapter 2). 
3.2 Materials and Methods 
3.2.1 Chemicals 
All the applied chemicals were obtained as described: ibuprofen (2-(4-isobutylphenyl) 
propanoic acid) (I4883, ≥ 98% GC, CAS: 15687-27-1); 5,5 -dithiobis(2-nitrobenzoic 
acid) (DTNB) (D8130, ≥ 98% TLC, CAS: 69-78-3); butylated hydroxytoluene (BHT) 
(B1378, ≥ 99.0% GC, CAS: 128-37-0); cytochrome c from equine heart (C7752, > 
95%, CAS: 9007-43-6); diethylenetriaminepentaacetic acid dianhydride (DTPA) 
(D6148, CAS: 23911-26-4); ethylenediaminetetraacetic acid (EDTA) (ED, ≥ 99%, 
CAS: 60-00- 4); glutathione reductase (G3664, CAS: 9001-48-3); hydrogen peroxide 
solution (H1009, 30% w/w, CAS: 7722-84-1); hypoxanthine (H9377, > 99%, CAS: 68-
94-0); l-glutathione oxidized (GSSG) (G4501, > 98%, CAS: 27025-41-8); l-glutathione 
reduced (GSH) (G4251, > 98%, CAS: 70-18-8); xanthine oxidase from bovine milk 
(X1875, CAS: 9002-17-9);  β-nicotinamide adenine dinucleotide reduced disodium salt 
hydrate (NADPH) (N8129, ≥ 97%, CAS: 606-68-8); bovine albumin serum (BSA) 
(A9418, > 98%, CAS: 9048-46-8); 1-methyl-2-phenylindone (99%, CAS: 3558-24- 5); 
1.1.3.3. tetramethoxypropane (MDA) (108383, CAS: 102-52-3) were obtained from 
Sigma–Aldrich (Steinheim, Germany). Bio-Rad protein assay dye reagent concentrate 
(phosphoric acid CAS: 7664-38-2 + methanol CAS: 67-56-1) was obtained from Bio-
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Rad Laboratories, Inc. (USA). Natriumazide (sodium azide) (106688, ≥ 99%, CAS: 
26628-22-8); potassium chloride (104936, 99.5%, CAS: 7447-40-7); trichloroacetic 
acid (TCA) (100807, CAS: 76-03- 9); TRIS (≥ 99%, CAS: 77-86-1); 1,4-dithiothreitol 
(DTT) (≥ 99%, CAS: 3483-12-3) obtained from Merck (Germany). 1-chloro-2,4,- 
dinitrobenzene (CDNB) (24440, ≥ 98% GC, CAS: 97-00-7) obtained from Fluka. D(+) 
saccharose extra pure (16104, 99%, CAS: 57-50-1) obtained from Riedel-de-Haën.  
3.2.2 IBU Exposure Assay (250 ng.L-1) 
Mussels M. galloprovincialis (n = 245, overall average shell length size: 69 ± 5 mm, 
width: 38 ± 3 mm) were collected from a reference site in Ria Formosa Lagoon, 
Southeast of Portugal, placed in 7 separated aquaria (n = 35, 1 mussel L−1) and 
acclimated in aerated seawater for 7 days prior to IBU exposure. A 250 ng.L
−1
 
concentration of IBU was added on three of these aquaria; the remaining four were used 
as control. Water was changed every 48-h and IBU concentration re-established. Each 
aquarium was kept at constant temperature (18 ◦C ± 1), salinity (32.5 ppm ± 1), pH 
(7.83 ± 0.5) and oxygen saturation (>94%). The treatment took place for 2 weeks; 
sampling times were set up: 0, 3, 7 and 15 days for control and 3, 7 and 15 days for 
exposure treatment. Over each selected set of time, mussels (n = 35) were collected 
from both control and exposure aquaria and subjected to biometric data measurement 
(shell: length, width). For condition index, mussels’ whole body tissue was considered, 
while for antioxidant enzyme activities and LPO analysis only gills were considered. 
After dissection, gills were immediately frozen with liquid nitrogen and stored at −80 
◦C until further analysis. Furthermore, the mortality observed was insignificant and no 
different between treatments (n = 4). 
3.2.3 Condition Index 
The condition index (CI) was calculated in both non- and exposed mussels (n = 20) over 
each set of time, by the ratio:  
  =  
 hole so t tissue   et ei ht  
 hole bod  tissue  shell   et ei ht 
 x     
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3.2.4 Tissue Preparation for Antioxidant Enzyme Activities Analysis 
Previously dissected gills were individually homogenized with 20 mM TRIS buffer 
(1mM of EDTA, 0.5 M of saccharose, 0.15 M of KCl and 1 mM of DTT), pH 7.6. The 
homogenates were then, centrifuged at 500 × g for 15 minutes at 4ºC to precipitate 
cytosolic fraction. The supernatants were recentrifuged for 45 minutes at 12,000 × g at 
4ºC; the volumes measured and purified applying Sephadex
®
 G-25 gel columns in order 
to remove low molecular weight proteins. A 100 µl aliquot was saved for total protein 
quantification according to Bradford’s method (Bradford, 1976) using bovine serum 
albumin (BSA) as a standard. 
3.2.5 Antioxidant Enzyme Analysis 
Aliquots of the resulting gills eluted fraction were used for the determination of enzyme 
activities by spectrophotometry.  
SOD activity in mussel gills (n = 5) was evaluated by measuring the reduction of 
cytochrome c absorbance generated by xanthine oxidase/hypoxanthine system at 550 
nm (McCord and Fridovich, 1969). The arbitrary units of SOD (U) are expressed as the 
quantity of enzyme that inhibits cytochrome c reduction by 50% per minute of mg
−1
 of 
total protein. 
CAT activity in mussel gills (n = 5) was determined by measuring at 240 nm the 
absorbance decrease due to hydrogen peroxide (H2O2) consumption according to 
Greenwald (1985). The CAT activity is expressed as µmol.mg
−1
 of total 
protein.min
−1
concentrations.  
GR activity in mussel gills (n = 5) was assessed using oxidized glutathione (GSSG) as 
substrate following Cribb et al. (1989) method. The GR activity was measured at 340 
nm subsequent to co-factor NADPH oxidation increase and expressed as µmol NADPH 
oxidized mg protein
−1
.min
−1
.  
GST activity (n = 5) was evaluated with 1-chloro-2,4- dinitrobenzene (CDNB) as a 
substrate following a modified method of Habig et al. (1974). The absorbance values 
were recorded at 340 nm considering as enzyme activity the µmol CDNB conjugate 
formed.mg 
−1
 of total protein.min
−1
.  
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3.2.6 LPO Analysis 
Dissected gills (n = 10) were homogenized separately with 20 mM TRIS-HCl buffer 
and butylated hydroxytoluene (BHT) (100:1µl respectively), pH 8.6. The homogenates 
were then, centrifuged at 30,000 × g for 45 minutes at 4ºC to precipitate cytosolic 
fraction. An aliquot was saved for total protein quantification according to Bradford’s 
method (Bradford, 1976). An aliquot of the previous cytosolic fraction was also used to 
determine LPO levels through the quantification of the absorbance of malondialdehyde 
(MDA) and (2E)-4-hydroxy-2-nonenal (HNE) at 586 nm following an adapted method 
of Erdelmeier et al. (1997). LPO levels are expressed as µmol MDA.g
−1 
protein. 
3.3 Statistical Analysis 
 Two-way ANOVA was performed using STATISTICA
®
 to test treatments (non- and 
exposure to IBU) and time effect over 2 weeks of conditioning. Duncan’s test was 
applied to discriminate the differences and interactions over time within each biomarker 
and CI. Pearson correlation was also used to measure the dependency between each 
biomarker. Principal component analysis (PCA) was used to compare the biomarkers 
levels responsible for the variance between exposed and non-exposed mussels at each 
sampling time. PCA was per-formed using XLSTAT
®
 2010. Statistical significance was 
defined at p < 0.05 level.  
3.4 Results 
3.4.1 Condition Index 
The condition index of mussels is in Table 3.1. Both non-and exposed mussels showed 
no significant detrimental effects between them on their physiological condition after 2 
weeks.  
Table 3.1: Condition Index (%) (mean ± standard deviation) of M. galloprovincialis non- 
and exposed to IBU for 2 weeks. Different letters express significant differences (p < 0.05). 
Time (days) 
CI (%)   
Control IBU exposure 
0 23.7 ± 4.7b   
3 32.0 ± 6.4a 34.7 ± 42a 
7 29.6 ± 7.6a 35.1 ± 6.7a 
15 22.9 ± 5.7b 23.2 ± 3.8b 
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3.4.2 Antioxidant Enzymes  
The results obtained for SOD activity are in Figure 3.1A. SOD activity was significantly 
different between treatments being higher in exposed mussels than control on the 3
rd
 
(1.4-fold) and 7
th
 (2.7-fold) days. Additionally, considering the variation within 
treatments, SOD activities in non-exposed mussels did not vary over time (p > 0.05) 
whereas in exposed mussels SOD activity linearly increased (SOD (U.mg
−1
 
protein.min
−1
) = 3.6 t (days) + 14.9, r = 0.998) over the first week, decreasing to 2.4-
fold lower activity by the end of the experiment to an activity not different from the one 
at the beginning of the experiment. CAT activity (Figure 3.1B) exhibited a totally 
different behavior from SOD activity. Results show that in both treatments CAT activity 
decreased over time although more markedly in exposed mussels. The difference 
between treatments was only significant after day 15, in which CAT activity in exposed 
mussels’ gills was 1.8-fold lower than controls (p < 0.05). 
Although there was a slight increase in GR activity (Figure 3.1C) in the gills of 
unexposed mussels this increment was not significant (p > 0.05). Remarkably, GR 
activity is the only antioxidant enzyme consistently inhibited by IBU, since in IBU 
exposed gills’ this enzyme activity significantly decreased after 3 (3.3-fold), 7 (4.4- 
fold) and 15 (2.8-fold) days compared to each controls (p < 0.05). 
GST activity (Figure 3.1D) significantly decreased in both non- and IBU exposed 
organisms, being similar after the first week. How-ever, on the 3
rd
 day of exposure, 
exposed mussels showed a significant GST activity decrease (about 1.7-fold lower) 
when compared to controls which in turn presented the highest GST activity (65.2 ± 0.9 
µmol CDNB conjugate formed.min
−1
.mg protein
−1
). GST activity was positively 
correlated with CAT activity (r = 0.992, p < 0.05), no other correlations were found 
within antioxidant enzyme activities. 
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Figure 3.1: Antioxidant enzyme activities (mean ± standard deviation): (A) superoxide dismutase (SOD), (B) catalase (CAT), (C) glutathione reductase (GR) and 
(D) glutathione S-transferase (GST) in two-week IBU exposed and controls M. galloprovincialis gills. Different letters express significant differences (p < 0.05). 
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3.4.3 LPO 
Despite LPO levels (Figure 3.2) varied significantly in controls at the beginning and end 
of the experiment, after 1 week LPO levels were significantly higher (3-fold) in exposed 
mussels compared to controls (p < 0.05), exhibiting a similar linear trend [LPO (µmol 
MDA.g
−1
 protein) = 2.34 t (days) + 1.27, r = 0.98) and direct correlation with SOD 
activity (r = 0.971, p < 0.05). Furthermore, from day 7 to 15 LPO significantly 
decreased (7-fold) in exposed mussels.   
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Figure 3.2: Lipid peroxidation (mean ± standard deviation) in two-week IBU exposed and controls M. 
galloprovincialis gills. Different letters express significant differences (p < 0.05). 
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3.4.4 Principal Component Analysis (PCA) 
Principal component analysis (PCA) (Figure 3.3) showed that 84.5% of total variance 
was explained by the two principal components. PC1 expresses 60.4% of total variance, 
the most significant response refers to the separation between controls, particularly of 
day 0 and day 7 IBU exposed gills, where the high induction of SOD activity associated 
to the decrease of the other antioxidant enzyme leads to higher LPO levels. Thereby, 
mussels’ gills exhibit a mirror image response between treatments.PC2 representing 
24.2% of total variance, clearly separates day 3 control with day 15 exposed mussels 
gills, on the later ones all biomarkers and CI significantly decrease. Furthermore within 
PC2, both day 15 non- and exposed mussels express similar responses, pointing to an 
antioxidant system recovery. 
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Figure 3.3: PCA corresponding to the integration of antioxidant enzymes SOD, CAT, GR, GST, lipid 
peroxidation (LPO) and condition index (CI) on total variance (84.5%) between treatments (○– 
control, ● – IBU exposed mussels) over exposure time (days: 0, 3, 7 and 15). 
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3.5 Discussion 
Our results confirm the alteration of antioxidant enzyme activities in mussels’ gills 
during a short-term exposure to 250 ng.L
−1
 of NSAID IBU, particularly evident by the 
enhancement of SOD activities over the first week and GR activity overall inhibition in 
exposed mussels. In order to better interpret an alteration of the antioxidant defense 
system caused by biologically active contaminants, two aspects have to be taken into 
account, (1) APIs therapeutic properties are based on redox reactivity and oxidative 
stability (Harmon et al., 2006; Martín-Díaz et al., 2009) and (2) NSAIDs (such as IBU) 
are known to disrupt eicosanoid biosynthesis (through the inhibition of COX pathway 
and prostaglandins) in both invertebrates and vertebrates (Heckmann et al., 2008). The 
blockage of one of the three membrane-phospholipid arachidonic acid (AA) metabolic 
pathways (beside, lipoxygenase (LOX) pathway and cytochrome P450 epoxygenase 
pathway) may distress several physiological functions (such as immune system, 
reproduction and ion transport) (Gagné et al., 2005; Rowley et al., 2005; Heckmann et 
al., 2008; Ericson et al., 2010). Furthermore, an increase of ROS is associated to an AA 
conversion via LOX pathway while the inverse effect can be found when transformed 
into prostaglandins via COX pathway (Ardaillou et al., 1987). Several studies refer the 
association of AA accumulation to an enhancement of basal ROS production, 
hemocytes concentration, phagocytosis and mitochondrial dysfunction either in 
mammals (Cocco et al., 1999) or in invertebrates (i.e. oysters fed by an AA 
supplemented diet) (Delaporte et al., 2006). For these reasons, we hypothesize that a 
possible accumulation of AA in the cells due to COX metabolic pathway obstruction 
may promote the increment of H2O2 production and consequently be other factor 
contributing for cell oxidative status alteration. 
Gagné et al. (2006) reports that the exposure to APIs can exhibit detrimental effects on 
aquatic biota since unlike mammals they are not as efficient eliminating lipophilic drugs 
and oxygen radicals. Nonetheless, they do possess a detoxification defense system that 
modulates the increment of intracellular generation of ROS through the alterations of 
antioxidant enzymatic activities (Viarengo et al., 1995). SOD, CAT and glutathiones are 
ROS naturally occurring scavengers (Santovito et al., 2005). SOD converts the highly 
reactive superoxide anion (O2
·−
) into H2O2; which is later degraded to water and oxygen 
by CAT (Regoli, 1998). In this study, the induction of the detoxifying action of SOD 
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activity (Figure 3.1A) was triggered over the first week of exposure to IBU followed by 
a systematic recovery by the end of the experiment. This transitory SOD activity pattern 
and values were very similar to those found for zebra mussel Dreissena polymorpha 
whole body exposed to 150 ng.L
−1
 of NSAID paracetamol by Parolini et al. (2010) even 
though the timeline refers to the first 24-h, probably associated to the faster size-
dependent metabolism of zebra mussel. The consequent elevated generation of H2O2 
seems not to be counteracted by CAT, GR or GST since these enzymes activities 
progressively decrease over time; this is further supported by the PCA analysis (Figures 
3.1 and 3.3). Relatively to CAT activity (Figure 3.1B) inhibition tendency overtime 
(significant by the end of the experiment) may be due to an overwhelming excess of 
H2O2 originated as a SOD activity conversion product and the increment of arachidonic 
acid metabolites (affected by COX pathway blockage). Nonetheless, the concomitant 
lower activities found in controls suggest other factors affecting mussels’ antioxidant 
system, such as laboratory conditions and absence of food. Martín-Díaz et al. (2009) 
reports no significant alterations on CAT activity in the same mussel species gills when 
exposed to 100 ng.L
−1
 of anticonvulsant carbamazepine after 7 days. Not directly 
implicated on the removal of oxygen radicals GR acts as a redox buffer on the 
maintenance of oxidized glutathione (GSSG)/reduced glutathione (GSH) ratio essential 
for cell homeostatic status (Vernouillet et al., 2010). In this study GR activity (Figure 
3.1C) was the most affected by IBU exposure, being clearly inhibited throughout the 
duration of the exposure. These results indicate that the presence of IBU alters the gills 
ability to form reduced glutathione, potentiating the risk of LPO. Consequently, the 
participation of Phase II detoxifying enzyme GST as a catalyst on the conjugation of 
GSH to electrophilic centers of several xenobiotics molecules (Regoli, 1998) is 
compromised, as GST has less substrate to act on hence the significant inhibition after 3 
days exposure (Figure 3.1D). As above mentioned it should be taken in account that as 
CAT, GST activity and mussels’ physiologic status given by CI showed similar 
variation patterns in both treatments highlighting other factors contributing to oxidative 
status alterations beside the presence of IBU. Nevertheless, LPO levels pattern (Figure 
3.2) indicates significant damage in gills membrane structural integrity after 1 week 
exposure followed by a recovery by the end of the experiment. Moreover, CAT, GST 
and particularly GR activities inhibition tendency may favor a higher formation of lipid 
peroxides in the gills. The enhancement of LPO levels after one week are in line with 
those obtained by Martín-Díaz et al. (2009) after exposure to carbamazepine being at 
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the same time, positively correlated with outlined SOD activity evolution. The 
integration of all biomarkers in mussels’ gills supports the breakdown of the redox 
defense system and IBU’s pro-oxidant action. As shown by PCA (Figure 3.3) after 7 
days, there is a clear mirror response between treatments, where the increment of both 
SOD detoxification response and LPO levels and inverse depletion of CAT, GR and 
GST activity levels place exposed mussels’ gills separately from controls. 
3.6 Conclusions 
Finally, even considering the contribution of other factors subjacent to the experimental 
design that should be taken account in the results interpretation, this study reveals that a 
seemingly low and environmental realistic concentration of NSAID IBU does exert 
significant fluctuations of several oxidative stress biomarkers in M. galloprovincialis 
gills. The study of other tissues response and the measurement of the uptake of IBU in 
mussels’ tissues would largely complement the obtained data. Overall the application of 
a multibiomarker approach to assess and highlight short-time effects associated to the 
presence of these emergent contaminants in sentinel species is further legitimized when 
considering the plethora of APIs continuously discharged into the aquatic systems and 
all possible interactions with other pollutants.  
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3B. Does non-steroidal anti-inflammatory (NSAID) 
ibuprofen induce antioxidant stress and endocrine 
disruption in mussel Mytilus galloprovincialis? 
 
Abstract 
Ibuprofen (IBU) is one of the most sold over-the-counter non-steroidal anti-
inflammatory drugs (NSAID) and widely detected in the aquatic ecosystems. 
Nevertheless, the information regarding IBU effects in biota is still sparse. The goal of 
this study was to assess IBU potential effect as oxidative stress and endocrine disruption 
inducer in mussel M. galloprovincialis applying a battery of biomarkers. Over two 
weeks of exposure to IBU (250 ng.L
−1
), superoxide dismutase (SOD), catalase (CAT), 
glutathione reductase (GR), Phase II glutathione S-transferase (GST) activities and lipid 
peroxidation (LPO) levels were determined in the digestive gland and alkali-labile 
phosphates (ALP) were carried out in sex-differentiated mussels’ gonads. The results 
confirm a transitory induction of antioxidant activities responses concomitant to lipid 
peroxide formation outline and an increase of ALP levels over time, particularly in 
exposed males which may lead to mussels’ reproductive fitness impairment highlighting 
a higher impact of IBU as an endocrine disruptor than as a short-term reactive oxygen 
species (ROS)-generator. 
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3.8 Introduction 
Active pharmaceutical ingredients (APIs) are complex bioactive molecules developed to 
produce an intended therapeutic effect being simultaneous capable to overcome body’s 
natural metabolic degradation (Anderson et al., 2004). These compounds are applied 
massively both in human and veterinary medicine, reaching the aquatic environment 
after excretion primarily via waste water treatment plants (WWTPs) effluents, where 
they are often subjected to an inefficient removal procedure (Ternes, 1998; Metcalfe et 
al., 2003). Even though APIs are claimed to be the most well-studied chemicals (Van 
der Ven et al., 2006), their reactivity and associated collateral effects of their usage is 
still far to be fully understood particularly when considering: (1) the innumerous APIs 
withdrawn from the markets after years of application and (2) the potential risks for the 
environment, particularly to non-target organisms. In this context, the U.S. Food and 
Drug Administration (FDA) and the European Medicines Agency (EMEA) have 
established guidelines for the mandatory elaboration of an environmental risk 
assessment (ERA) in order to authorize any API commercialization (EMEA, 2006; 
FDA, 1998). Furthermore, based on APIs threshold values of predicted environmental 
concentrations (PECs) proposed by these agencies, Besse and Garric (2008) developed 
an APIs exposure priority ranking list from class IA – “highest risk compound” to IV – 
“very low risk for the environment”. 
Ibuprofen (IBU) was selected for this study since it is one of the most detected non-
steroidal anti-inflammatory drug (NSAID) in the environment worldwide (Table 3.2) 
and simultaneously defined as a class IA compound by Besse and Garric (2008). In 
Portugal, IBU was the NSAID most sold over-the-counterdrug in terms of price 
(∼600,000 €), and second after paracetamol in terms of packages number (>168,000) 
(INFARMED, 2008). NSAIDs are known to promote the non-selective inhibition of 
cyclooxigenase (COX)-1 and -2 isoforms decreasing the catalysis of prostaglandin (PG) 
biosynthesis from phospholipid arachidonic acid (AA) (Vane et al., 1998; Fent et al., 
2006; Praveen Rao and Knaus, 2008). PGs are responsible for critical physiological 
functions acting as “local” hormones (Rowley et al., 2005) namely in reproduction, 
water transport and osmoregulation (Ruggeri and Thoroughgood, 1985; Osada and 
Nomura, 1990). Accordingly, Fent et al. (2006) relate NSAIDs long-term effects as 
derivative from the alteration of these functions. In humans, prostaglandins inhibition 
associated to NSAIDs is linked to the reduction of female fertility, miscarriages and 
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fetal malformations (INFARMED, 2008). In invertebrates, prostaglandins are 
implicated in the spawning mechanism (Osada and Nomura, 1990). Gagné et al.(2005) 
demonstrated that prostaglandins synthesis and COX activity were inhibited in mussels 
Elliptio complanata after injected with IBU. 
Table 3.2: Occurrence of NSAID IBU (ng.L
-1
) in worldwide surface and river water 
Country Environment IBU (ng.L-
1) 
Notes References 
Canada Detroit river 141 (mean) Metcalfe et al., 2003 
  Hamilton harbour 64 (mean)   
agricultural surface 
water 
30   Lissemore et al., 2006 
China Yellow river 41 (May 2008) Wang et al., 2010 
    11 (December 
2008) 
  
  Hai river 75 (July 2008)   
    54 (November 
2008) 
  
  Liao river 7 (July 2008)   
    62 (November 
2008) 
  
  Pear river 78   Huang et al., 2011 
France surface water 5   Togola and Budzinski, 
2008 Germany river 139   Halling-Sørensen et al., 
1998   Rhine river 41   
  surface water 70   Ternes, 1998 
 Elbe river 70 (max) Wiegel et al., 2004 
   300 (mean) Moeder et al., 2000 
  32  Weigel et al., 2004b 
 Lake Alster 5   
Italy Po river 4 (1997-2001) Castiglioni et al., 2004 
    7     
    13   Zuccato et al., 2005 
  Lambro River 20     
    79   Calamari et al., 2003 
Luxembourg Alzette river  295 (max) Pailler et al., 2009 
 Mess river 2383   
Norway seawater 8 sum Weigel et al., 2004b 
Poland surface waters 50 (mean) Debska et al., 2005 
Romania river 87 (mean) Moldovan, 2006 
South Korea surface waters 28   Kim et al., 2007 
  creek river 100   Yoon et al., 2010 
  Han river 23     
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Bivalves, like mussels, have been successfully applied as bioindicators species, since 
beside sessile filter-feeders and widely distributed, these organisms have the ability to 
accumulate the contaminants present in the water throughout their lifespan. This enables 
the appraisal of biological effects induced by contaminants through the use of 
biomarkers (Cajaraville et al., 2000; Ortiz-Zarragoitia and Cajaraville, 2006; Porte et 
al., 2006; Cravo et al., 2009). Several ecotoxicological effects of different APIs have 
already been evaluated in mussels through the direct and indirect exposure to single 
and/or mixtures of pharmaceutical ingredients (Table 3.3). However at the present, there 
is still a lot to unveil concerning the effects of IBU in these organisms: (1) as a potential 
Table 3.2: (Continuation). 
Spain rivers 816 (mean of 7 
rivers) 
Farré et al., 2001 
  surface waters 25 (mean) Gros et al., 2006 
Switzerland river 80   Öllers et al., 2001 
  rivers 6   Tixier et al., 2003 
UK Belfast estuary 124   Thomas and Hilton, 
2004 
  Mersey estuary 250 (average of 6 
values) 
  
  Taff river 20   Kasprzyk-Hordern et al., 
2008 
  Tees estuary 88   Thomas and Hilton, 
2004 
  Thames estuary 928     
  Thames river 504 (mean) Bound and Voulvoulis, 
2006 
  Tyne estuary 727 (average of 2 
values) 
Thomas and Hilton, 
2004 
  Tyne river 597 (average of 18) Roberts and Thomas, 
2006 
  stream 1105   Ashton et al., 2004 
  small river 1955 (mean) Bound and Voulvoulis, 
2006 
USA streams 200 (mean from 139 
streams) 
Kolpin et al., 2002 
  surface water 180   Cahill et al., 2004 
  Mississippi river 34   Zhang et al., 2007 
various 
countries 
rivers 152 (max) Hernando et al., 2006 
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oxidative stress inducer since most APIs pharmacodynamics relies on specific redox 
reactivity (Gagné et al., 2006; Martín-Díaz et al., 2009a) and (2) as a possible endocrine 
disruptor considering that NSAIDs may alter reproductive functions (Fent et al., 2006). 
In this perspective, this study comprises a two weeks exposure of mussels M. 
galloprovincialis to an environmental realistic concentration of 250 ng.L−
1
 of IBU in 
order to better understand the above points: (1) through changes in important mediators 
of toxic reactive oxygen species (ROS) neutralization in cells like antioxidant enzyme 
activities: superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR), 
Phase II glutathione S-transferase (GST), and the measurement of lipid peroxides 
formation by-products (LPO) in digestive gland and (2) through the indirect assessment 
of vitellogenin-like proteins by alkali-labile phosphates (ALP) method, since their levels 
are positively correlated (Ortiz-Zarragoitia and Cajaraville, 2006). Vitellogenins 
precede egg-yolk protein vitellin (Vn) in oviparous species being naturally synthesized 
in females and inactive in males (Matozzo and Marin, 2008; Matozzo et al., 2008). 
Whenever elevated levels are detected in males it is a sign of the occurrence of 
endocrine disruption (ED) (Blaise et al., 1999; Gagné et al., 2002; Matozzo and Marin, 
2008; Matozzo et al., 2008). The measurement of ALP released by Vg after alkali 
hydrolysis is considered a cost-effective ED biomarker in invertebrates (Porte et al., 
2006). 
Chapter 3: Effects of NSAID ibuprofen in mussel M. galloprovincialis 
 
121 | C h a p t e r  3 B  
 
Table 3.3: Ecotoxicological effects of APIs in mussel species 
Mussel species Tissue API concentration Time Biological end-points Reference 
zebra mussel 
Dreissena 
polymorpha 
gonads fluoxetine (>100nM) 
and norfluoxetine (> 5 
µM) 
4h   ↑ spawning induction Fong and Molnar, 
2008 
  hemocytes diclofenac (0.2, 0.5 and 
0.8 µM) + ibuprofen 
(0.2, 2 and 4 µM) + 
paracetamol (0.2, 1 and 
3 µM) 
1h  high cytogenotoxic potential (paracetamol < diclofenac < 
ibuprofen) 
Parolini et al., 2009 
  hemocytes and 
whole body 
paracetamol (1, 5, 10 
nM) 
96 hours  significant destabilization of the lysosomal membrane (LMS) Parolini et al., 2010 
         ↑ GST ↑ CAT   
         ↑ SOD (on the first 24 hours at low concentration)   
mussel Mytilus 
galloprovincialis 
digestive gland, 
gill, 
mantle/gonad, 
hemocytes 
carbamazepine (0.1, 
and 10 µg.L
-1
) 
7 days  ↑ neutral lipid and lipofuscin accumulation in digestive gland;  Martin-Diaz et al., 
2009a 
         ↑ LPO gill and mantle/gonad   
         ↑ GST and CAT activities in digestive gland and mantle   
          60% and 80% of haemocyte LMS   
          cAMP levels and protein kinase A (PKA) activities in all 
tissues 
  
  digestive gland 
and hemocytes 
bezafibrate and 
gemfibrozil (injection 
0.01, 0.1 and 1 
nmol/animal) 
24 hours  concentration-dependent lysosomal destabilization and 
extracellular lysozyme release 
Canesi et al., 2007 
         ↑ phagocytosis at highest concentration   
         ↑ glycolytic enzymes phosphofructokinase (PFK),  pyruvate 
kinase (PK), CAT GST, GR and total glutathione  
  
          Palmytoyl CoA oxidase by bezafibrate   
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Table 3.3: (Continuation).    
mussel Mytilus 
galloprovincialis 
digestive 
glands and gill 
propanolol (11 and 147 
µg.L
-1
) 
10 days   feeding rates, ↑ Phase I carboxylesterase (Cbe) in gill,  
GST at low concentration,  ↑ GST at high concentration,↑ 
LPO and acetylcholinesterase (AChE)  at high concentration; 
no observed alterations in digestive glands 
Solé et al., 2010 
    paracetamol (23 and 
403 µg.L
-1
) 
   ↑ feeding rates, ↑ LPO, ↑ Cbe; CAT and GST not affected 
digestive glands;  AChE; GST and LPO not affected in gills 
  
  digestive 
glands, gills, 
mantle/gonad 
propanolol (0.3, 3, 30, 
300, 30,000 ng.L
-1
) 
7 days   cAMP and PKA, ↑ CAT and ↑GST in digestive glands, ↑ 
cAMP and PKA ↓ CAT at 3 ng.L
-1
 and  CAT > 30 ng.L
-1
 and  
GST in the mantle/gonads  
Franzellitti et al., 
2011 
         unchanged cAMP and PKA in gills concentration-dependent 
LMS 
  
freshwater mussel 
Elliptio 
complanata 
digestive 
gland and 
gonad 
carbamazepine (0–
10mM) 
7 days  ↑Phase I dibenzylflourescein dealkylase (DBF), ↑ lipid 
peroxidation (LPO)  
Martin-Diaz et al., 
2009b 
    caffeine (0–10mM)    ↑DBF, ↑ LPO    
    methotrezate (0–10mM)    ↑EROD, ↑ DNA damage   
  hemolymph WWTP effluent 30 days  ↑ nitric oxide and COX activity Bouchard et al., 
2009 
         ↑ phagocytosis activity    
         ↑ ALP [vitellogenin (Vtg-like)]   
  gill and 
gonads 
ibuprofen (injection 0, 
10, 50 and 100 µmol) 
24h   COX in both tissues and ↑ serotonin transport Gagné et al., 2005 
    WWTP primary-treated 
effluent 
   ↑ COX and state of inflammation   
  visceral mass diazepam (4, 20 and 100 
nmol per mussel) 
48 hours   serotonin and AChE, ↑ dopamine and γ-aminobutyric acid 
(GABA) 
Gagné et al., 2010 
    morphine (4, 20 and 100 
nmol per mussel) 
    serotonin, ↑ glutamate and dopamine and serotonin-
dependent adenylyl cyclase (ADC) 
  
Baltic Sea blue 
mussels Mytilus 
edulis 
byssus diclofenac, ibuprofen, 
propranolol (1, 100, 
1000, 5000, 10
5
 mg.l
−1
) 
19 days    scope for growth,  byssus strength,  abundance of byssus 
threads.  
 bioaccumulation of diclofenac and propanolol 
Ericson et al., 2010 
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3.9 Materials and Methods 
3.9.1 Chemicals 
All the applied chemicals were obtained as described: IBU (2-(4-isobutylphenyl) 
propanoic acid) (I4883, ≥ 98% GC, CAS: 15687-27-1); 1.1.3.3. tetramethoxypropane 
(MDA) (108383, CAS: 102-52-3); 1-methyl-2-phenylindole (99%, CAS: 3558-24-5); 
5,5-dithiobis(2-nitrobenzoic acid) (DTNB) (D8130, ≥ 98% TLC, CAS: 69-78-3); bovine 
albumin serum (BSA) (A9418 > 98%, CAS: 9048-46-8); butylated hydroxytoluene 
(BHT) (B1378, ≥ 99.0% GC, CAS: 128-37-0); cytochrome c from equine heart (C7752, 
> 95%, CAS: 9007-43-6); diethylenetriaminepentaacetic acid dianhydride (DTPA) 
(D6148, CAS: 23911-26-4); ethylenediaminetetraacetic acid (EDTA) (ED, ≥ 99%, 
CAS: 60-00-4); Fiske and Subbarow Reducer (F5428); glutathione reductase (G3664, 
CAS: 9001-48-3); HEPES (H3375, >99.5%, CAS: 7365-43-9); hydrogen peroxide 
solution (H1009, 30%, w/w, CAS: 7722-84-1); hypoxanthine (H9377, >99%, CAS: 68-
94-0); L-glutathione oxidized (GSSG) (G4501, > 98%, CAS: 27025-41-8); L-
glutathione reduced (GSH) (G4251, > 98%, CAS: 70-18-8); methanesulfonic acid 
(>99.5%, CAS: 75-75-2); xanthine oxidase from bovine milk (X1875, CAS: 9002-17-
9); β-nicotinamide adenine dinucleotide reduced disodium salt hydrate (NADPH) 
(N8129, ≥ 97%, CAS: 606-68-8) were acquired from Sigma–Aldrich (Steinheim, 
Germany). Protein-assay dye reagent concentrate (phosphoric acid CAS: 7664-38-2 + 
methanol CAS: 67-56-1) was acquired from Bio-Rad Laboratories, Inc. (USA). 1,4-
dithiothreitol (DTT) (≥ 99%, CAS: 3483-12-3); acetonitrile (99.8%, CAS: 75-05-8); 
methanol (99.9%, CAS: 67-56-1); natriumazide (sodium azide) (106688, ≥ 99%, CAS: 
26628-22-8); potassium chloride (104936, 99.5%, CAS: 7447-40-7); trichloroacetic 
acid (TCA) (100807, CAS: 76-03-9); TRIS-(hydroxymethyl)-aminomethane (≥ 99%, 
CAS:77-86-1) were acquired from Merck (Germany). 1-chloro-2,4,-dinitrobenzene 
(CDNB) (24440, ≥ 98.0% GC, CAS: 97-00-7); molybdate reagent solution (puriss p.a.) 
and potassium dihydrogenphosphate (60218, 99.5%, CAS: 7778-77-0) acquired from 
Fluka. D(+) saccharose extra pure (16104, 99%, CAS: 57-50-1); sodium chloride 
(NaCl) (puriss p.a., CAS: 7647-14-5); sodium hydroxide (NaOH) (purified, CAS: 1310-
73-2) obtained from Riedel-de-Haën.  
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3.9.2 IBU Exposure Assay (250 ng.L-1) 
Specimens of mussels M. galloprovincialis (n = 150, length size: 69 ± 5 mm, width: 38 
± 3 mm) were collected from Ria Formosa Lagoon, Southeast of Portugal and 
transported alive to the laboratory in freezing boxes. After shell cleansing, the mussels 
were acclimated in aerated seawater for one week in 7 separated aquaria. Each aquarium 
(n = 35, 1 mussel.L−
1
) was maintained at constant temperature (18º C ± 1), salinity 
(32.5 ± 1), pH (7.8 ± 0.5) and oxygen saturation (> 94%). A solution of 250 ng.L−1 of 
IBU was prepared in distilled water and added to three of the aquaria; remaining four 
aquaria used as control. Every two days, seawater was changed and the concentration of 
IBU restored. The exposure had the duration of two weeks; at days 0, 3, 7 and 15 
mussels were sampled from both control and exposure groups and subjected to 
biometric measurement (shell: length, width). After dissection, digestive glands and sex 
differentiated gonads were immediately frozen with liquid nitrogen and stored at -80ºC 
until further analysis. 
3.9.3 Tissue Preparation for Antioxidant Enzyme Activities Analysis 
Dissected digestive glands were separately homogenized on ice with 20 mM TRIS 
buffer (1 mM of EDTA, 0.5 M of saccharose, 0.15 M of KCl and 1 mM of DTT) at pH 
7.6. The homogenates were centrifuged for 15 minutes at 500×g at 4◦C. The obtained 
supernatants were collected and centrifuged again for 45 minutes at 12,000×g at 4◦C. 
The volume of the supernatants (cytosolic fractions) was measured and 100 µl aliquot 
collected for the quantification of total proteins. A 2.5 mL aliquot of each cytosolic 
fraction was purified applying Sephadex
®
 G-25 gel columns to eliminate low molecular 
weight proteins. 
3.9.4 Antioxidant Enzymes Analysis 
Aliquots of individual digestive glands purified supernatant were used as triplicates in 
the quantification of enzyme activities by spectrophotometry. 
SOD activity in mussel digestive gland (n = 5) was assessed quantifying 50% of 
cytochrome c absorbance reduction promoted by xanthine oxidase/hypoxanthine system 
at 550 nm (McCord and Fridovich, 1969). 
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CAT in mussel digestive gland (n = 5) was evaluated through the decrease of 
absorbance originated by hydrogen peroxide (H2O2) consumption at 240 nm according 
to Greenwald (1985). The CAT activity is expressed as µmol.mg−
1
total protein.min−
1
. 
GR activity in mussel digestive gland (n = 5) was assessed according to Cribb et al. 
(1989) method.GR activity was measured at 340 nm through the increase of co-factor 
NADPH oxidation using as substrate, oxidized glutathione (GSSG), this activity is 
expressed as µmol NADPH oxidized.mg−
1
 total protein.min−
1
. 
GST activity (n = 5) was estimated according to an adaptation of Habig et al. (1974) 
method.1-chloro-2,4-dinitrobenzene (CDNB) was used as substrate. GST activity was 
measured at 340 nm and expressed µmol of formed CDNB conjugate.mg−
1
 total 
protein.min−
1
. 
Total protein concentrations were assessed using bovine serum albumin (BSA) as 
standard, according to Bradford’s method (Bradford, 1976). 
3.9.5 LPO Analysis  
Digestive glands (n = 10) were individually homogenized on ice with 20 mM TRIS–
HCl buffer and butylated hydroxytoluene (BHT) (100:1µL respectively) at pH 8.6. The 
resulting homogenates were centrifuged for 45 minutes at 30,000 ×g at 4º C in order to 
obtain the cytosolic fraction. An aliquot was used for the quantification of LPO levels 
according to Erdelmeier et al. (1998) method by the absorbance of malondialdehyde 
(MDA) and (2E)-4-hydroxy-2-nonenal (4-HNE) at 586 nm and expressed in the total 
protein content according to Bradford’s method (Bradford, 1976) as µmol MDA.g−1 
total protein. 
3.9.6 ALP Analysis 
The ALP method was adapted from Gagné and Blaise (1998) and Blaise et al. (1999). 
Sex-differentiated gonads (n = 20) were homogenized in ice with 25 mM Hepes–NaOH 
buffer (125 mM NaCl, 1 mM dithiothreitol (DTT) and 1 mM EDTA) at pH 7.4. The 
homogenates were centrifuged at 12,000×g at 2ºC for 30 minutes; the resulting 
supernatant (cytosolic fraction) was separated from the pellet. A supernatant aliquot was 
reserved for total protein content, another adjusted with 35% acetone and re-centrifuged 
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at 10,000×g for 5 min. The resulting liquid phase was discarded and the pellet 
dissolved with 1 M NaOH in a heating bath at 60ºC for 30 minutes. The concentration 
of inorganic phosphate (KH2PO4) was assessed by phosphomolybdenum method 
according to Stanton (1968) at 660 nm. Total ALP concentrations are expressed as µg 
[PO4].mg
−1
 total protein. 
3.9.7 Statistical Analysis 
All results are presented as mean ± standard deviation according to each selected 
sample time (0, 3, 7 and 15 days). In order to verify significant differences in the 
biomarker responses between and within non- and exposed individuals, parametric one-
way analysis of variance (ANOVA) was applied. If the parametric assumptions 
(normality and homogeneity) were not met non-parametric Kruskal–Wallis test was 
used. When necessary, Tukey’s, Dunn’s or Duncan’s tests were used to discriminate 
significant mean differences. Pearson correlation was applied to test significant 
correlations dependency between each biomarker (Zar, 1999). These analyses were 
performed using SigmaPlot 11.0
®
. 
Principal Component Analysis (PCA) was used to evaluate variable accountability for 
the variance between exposed and non-exposed mussels at each sampling time. PCA 
was performed using XLSTAT
® 
2010. Statistical significance was set at p < 0.05. 
3.10 Results 
3.10.1 Antioxidant Enzymes  
SOD activity in the digestive gland (Figure 3.4A) showed no significant differences 
between unexposed mussels (p > 0.05). In contrast, SOD activity in exposed digestive 
gland increased over the course of the first week reaching on day 7 an activity 1.7-fold 
higher than in controls. This was followed by a steep decrease (about 1.5-fold lower 
than in the previous week) by the end of the exposure reaching a value similar to 
controls. CAT activity in the digestive gland (Figure 3.4B) like SOD activity showed no 
significant differences between controls (p > 0.05). In exposed individuals, digestive 
gland CAT activity was about 2-fold higher on the 3
rd
 and 7
th
 day when compared to 
controls (p < 0.05), decreasing to control levels after two weeks (p > 0.05). 
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GR activity (Figure 3.4C) exhibited a very akin pattern to SOD activity, showing also 
no significant differences between controls (p > 0.05). Over the first week of exposure, 
GR activity increased linearly (GR (µmol oxidized NADPH.mg−
1
 protein.min−
1
) = 1.5t 
(days) + 6.7, r = 0.99), reaching 2.8-fold higher activity than controls (p < 0.05). After 
two weeks of exposure GR activity decreased (about 2.4-fold), reaching a value not 
different from controls. 
GST activity (Figure 3.4D) unlike any other antioxidant enzymes exhibited no 
significant differences between either controls or IBU-exposed mussels’ digestive 
gland. Although there was a slight increase (p > 0.05) in GST activity in the digestive 
gland of exposed mussels over time this increase was not significantly different from 
unexposed mussels at each set of time. Furthermore, GR and CAT activities were 
positively related (r = 0.966, p < 0.05). 
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Figure 3.4: Antioxidant enzyme activities (mean ± standard deviation): (A) superoxide dismutase (SOD), (B) catalase (CAT), (C) glutathione reductase (GR) and (D) 
glutathione S-transferase (GST) in M. galloprovincialis digestive gland non- and exposed to IBU for 15 days. Different letters bars are significantly different (p < 
0.05). 
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3.10.2 LPO 
In unexposed mussels, lipid peroxidation levels (Figure 3.5) was 1.6-fold higher from 
days 0 to 3 followed by a 1.9-fold decrease from days 7 to 15 reaching levels similar to 
the beginning of the experiment (p < 0.05). Exposed mussels exhibited a similar 
induction pattern to SOD and GR activities on the first week, where LPO levels 
increased linearly (LPO (µmol MDA. g−
1 
protein) = 0.5t (days) + 1.5, r = 0.93) reaching 
2.4-fold higher levels than controls (p < 0.05). This was followed by a significant 
decrease (about 3.8-fold lower) by the end of the two weeks. Additionally, LPO levels 
were directly related with GR activity (r = 0.975, p < 0.05). 
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 Figure 3.5: Lipid peroxidation (LPO) (mean ± standard deviation) in control and IBU exposed 
digestive gland of mussel M. galloprovincialis over 15 days. Different letters bars are significantly 
different (p < 0.05). 
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3.10.3 PCA – Oxidative Stress Biomarkers 
The PCA (Figure 3.6) integrating the results of antioxidant enzymatic activities and 
LPO between treatments expressed 94.3% of total variance in digestive gland. PC1 
contributes with 72% of total variance, separating clearly Phase II enzyme GST 
detoxifying activity from other antioxidant enzyme activities and LPO levels. In this 
sense, all controls and exposed digestive gland from day 15 show very similar 
responses, although controls at the beginning of the experiment exhibit further influence 
of GST activity. Oppositely, both exposed digestive glands from days 3 and 7 express 
their dependency on all the other biomarkers, with responses markedly divergent to the 
ones of controls. PC2 represents 22% of the total variance, revealing that GST activity 
is responsible for the difference between early days and controls at the end of the 
experiment. Simultaneously, day 3 exposed digestive gland variance is due to the 
increase of CAT activity and LPO levels, while digestive gland exposed for a week is 
more affected by SOD and GR activities. On the overall, it is evident that particularly 
after one week of exposure, all antioxidant biomarkers with the exception of GST were 
significantly induced by IBU. These pro-oxidant responses were also followed by a 
clear recovery of the antioxidant enzymatic system with reduction of lipid damage at the 
end of the experiment not different from controls further corroborated by day 15 
treatments overlapping response. 
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Figure 3.6: Principal component analysis (PCA) integrating antioxidant enzymes (SOD, CAT, GR, and GST) and LPO on total 
variance (94.3%) between treatments (◊– control, ♦ – IBU exposed mussels) over exposure time (days: 0, 3, 7 and 15). 
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3.10.4 ALP 
ALP levels (Table 3.4) in female and male mussels’ gonads controls were very similar 
over the first week (p > 0.05), after which males exhibited a significant lower value than 
females, and inversely by the end of the second week females showed a significantly 
lower value than males. On the 3
rd
 day of IBU exposure there was a significantly 
different gender specific response, in fact exposed males showed higher levels of ALP 
than exposed females (p < 0.05), this tendency continued until the end of the experiment 
only not significant by day 7 (p > 0.05). Furthermore, exposed female gonad showed a 
linear increase of ALP ((µg [PO4].mg
−1
 total protein) = 5.3t (days) + 46, r = 0.98) 
through the first week, followed by a slight but not significant concentration decrease. 
Overall, both IBU exposed males and females (except for day 3) exhibit significantly 
higher levels of ALP than the respective-day control, ranging from ♂34–117 and ♀39–
85 µg [PO4].mg
−1 total protein. 
 
 
Table 3.4: ALP concentrations in sex-differentiated M. galloprovincialis gonads exposed to 
250 ng.L
-1
 of IBU for two weeks 
Treatment  day ALP concentration (μg PO4.mg 
-1 total protein)   
  Females  Males 
  0 48.3 ± 8cde 46.3 ± 13cde 
control 3 41.7 ± 11cde 47.1 ± 14cde 
  7 54.5 ± 5cd 34.1 ± 10e 
  15 38.6 ± 7de 48.2 ± 8cde 
     
IBU exposure 3 59.5 ± 8c 88.9 ± 23 b 
  7 85.3 ± 11b 89.6 ± 6b 
  15 78.4 ± 19b 116.9 ± 35a 
Note: Different letters signal  significant differences between and within non- and exposed gonads (p < 
0.05) 
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3.11 Discussion 
WWTPs continuously receive urban and hospital effluents that include several 
concentrations of APIs, for which conventional removal treatment technologies have 
not been specifically designed (Carballa et al., 2004; Reif et al., 2008). Although some 
APIs may have low persistence, the constant load may dominate over the transformation 
rate in the WWTPs (Bendz et al., 2005), furthermore polar molecules with low 
adsorption coefficients like anti-inflammatory drugs tend to remain in the aqueous 
phase favoring their mobility and reaching the aquatic environment (Carballa et al., 
2004). Before being excreted via urine and faeces, APIs like IBU are partially 
metabolized to Phase I or Phase II metabolites in the human body (Halling-Sørensen et 
al., 1998; Daughton and Ternes,1999). The elimination rates vary depending on the 
individual, drug and dosage (Bound and Voulvoulis, 2004). Phase I reactions result in 
the addition of a reactive functional group to the molecule and often converting it into a 
more toxic compound either by parental compound oxidation, reduction or hydrolysis. 
Whereas Phase II or conjugation reactions promote the binding of functional groups to 
the parental compound through i.e. glutathione conjugation, enhancing excretion by its 
transformation to more hydrophilic metabolites (Halling-Sørensen et al., 1998; 
Daughton and Ternes, 1999). 
3.11.1 Oxidative Stress 
Even though mussels are able to use Phase I or Phase II enzymes to biotransform 
xenobiotic organic chemicals, they are not as efficient as vertebrates (Gagné et al., 
2007). In this sense, the antioxidant defense system is crucial in the neutralization of 
generated ROS by APIs redox reactivity (Viarengo et al., 1995; Regoli et al., 2002a, b). 
This system is mediated by a cascade of antioxidant enzymes which scavenge ROS to 
less toxic compounds. SOD leads this mechanism converting the highly reactive 
superoxide anion (O2
•−) into H2O2 (Viarengo et al., 1995). In IBU-exposed mussels’ 
digestive gland SOD activity is enhanced significantly over the first week (Figure 
3.4A), the activation of this antioxidant enzyme favors the evidence of a pro-oxidant 
action of IBU which at the 3
rd
 day is firstly offset by the induction of CAT activity 
action (Figure 3.4B). As a catalyst of SOD activity by-product H2O2 to form water and 
oxygen, CAT action is enabled by the slight enhancement of SOD activity over the first 
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days (p > 0.05) and/or by the possible increment of H2O2 formation in the cells due to 
the increase of ROS linked to arachidonic acid metabolism via lipoxygenase (LOX) 
pathway instead of COX pathway blockage by NSAIDs (Ardaillou et al., 1987). There 
are few studies concerning SOD activity alterations related to APIs exposure, however 
similar values were reported for zebra mussel D. polymorpha whole body exposed to 
150 ng.L
-1
 of NSAID paracetamol after 24 hours of exposure which progressively 
decrease to control levels over 96 hours, whereas CAT activity induction is slower and 
less pronounced (Parolini et al., 2010). Moreover, the CAT activity induction was also 
observed for M. galloprovincialis digestive gland 24 hours after injection with 0.1 
nmol/animal of blood lipid lowering pharmaceuticals (bezafibrate and gemfibrozil) 
(Canesi et al., 2007) and after one week of exposure to 100 ng.L−
1
 of anticonvulsant 
carbamazepine and 3 ng.L
−1 
DL-propranolol (Martín-Díaz et al., 2009a; Franzellitti et 
al., 2011). As shown by PCA (Figure 3.6), exposed digestive gland show a primarily 
induction of CAT activity at day 3, whereas SOD activity is more preponderant after 
one week of IBU exposure. The same occurred for GR (p < 0.05) (Figures 1C and 3), 
which indicates the necessity of oxidized glutathione (GSSG) conversion to reduced 
glutathione (GSH). This resulting GSH can act both as a direct ROS scavenger and/or as 
a cofactor of several antioxidant enzymes (Regoli et al., 2002b). In these terms, since 
GST activity outline (Figure 3.4D) is directly related to CAT activity pattern there are 
evidences that part of the GSH may have been used (1) as substrate by Phase II GST in 
exposed digestive gland promoting the conjugation reaction with either parental IBU or 
its metabolites, and/or (2) used to directly neutralize ROS action. Other authors also 
verified a simultaneous enhancement of CAT and GST activity in M. galloprovincialis 
exposed to bezafibrate (Canesi et al., 2007), carbamazepine (Martín-Díaz et al., 2009a) 
and DL-propranolol (Franzellitti et al., 2011). 
In mussels M. galloprovincialis gills exposed to the same IBU concentration, except for 
the 2-fold higher SOD activity, all antioxidant enzymes were significantly inhibited 
over time (Gonzalez-Rey and Bebianno, 2011). In fact, this may be linked to specific 
tissue functions in mussels. Gills are the first organ capable for a strong initial 
antioxidant response, however unable to counteract further ROS induction. While in 
digestive gland tissues, the concomitant increment of all antioxidant enzymes justifies 
its role as the organ primarily responsible for the detoxification of IBU-induced ROS 
and homeostasis status recovery. 
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Moreover, lipid peroxidation levels (LPO) were significantly enhanced by IBU presence 
over the first week (p < 0.05) (Figure 3.5), indicating damage derived from oxidative 
stress. The induction of LPO levels was also reported for digestive gland of M. 
galloprovincialis exposed to 23 µg.L−
1
 of paracetamol (Solé et al., 2010) and of E. 
complanata exposed to 0.4, 2 and 10 mM carbamazepine (Martín-Díaz et al., 2009b) 
(Table 3.2). Interestingly, the direct relationship between LPO levels and GR activity 
suggests that the induced formation of GSH was not enough to neutralize the presence 
of oxyradicals throughout the first week of exposure. However, as it can be further 
corroborated by the overlap between non- and exposed digestive glands on day 15 
(Figure 3.6), after IBU pro-oxidant action, the concomitant antioxidant enzyme 
activities increment favors the recovery to homeostatic baseline levels. 
3.11.2 Endocrine Disruption 
To our knowledge this is the first study using ALP method in gonads to test a potential 
effect of endocrine disruption caused by the exposure to an environmental realistic IBU 
concentration in mussels. The quantification of ALP levels is an effective indirect 
assessment of xenoestrogenicity in bivalves (Blaise et al., 1999; Gagné et al., 2001; 
2002; Matozzo and Marin, 2008). As referred above, inhibition in COX activity in 
freshwater mussels’ E. complanata was observed after injection with 100 µM of IBU. 
However when E. complanata were exposed for 30 days to a primary-treated municipal 
extract containing IBU and other NSAIDs in the range of µg.L−
1
, this was not sufficient 
to inhibit COX activity mussels and rather shown increased spawning and Vg-like 
proteins content (Gagné et al., 2005). In fact in the present study, ALP levels were 
significantly enhanced in both exposed males and females’ gonads at every selected 
time of exposure comparing to controls (p < 0.05) (Table 3.4), particularly in exposed 
males where after one week ALP levels were 2-fold higher than controls. Gagné et al. 
(2011) associated the induction of Vtg-like proteins as a biomarker of feminization in 
mussel E. complanata, through the assessment of female/male ratio and the expression 
of a female-specific protein in males. Even though, the present results are strictly related 
to ALP level alterations, evidences of serious interferences in male gonads were clearly 
elicited by IBU. This can potentially lead to the impairment of their reproductive fitness 
or ultimately its feminization. 
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3.12 Conclusions 
In conclusion, the exposure to an environmental realistic concentration of IBU (250 
ng.L
−1
) induces significant transitory antioxidant defense responses and membrane 
damage in the digestive gland of mussel M. galloprovincialis. In addition, IBU exposure 
results give evidence to endocrine disruption effects in mussels’ gonads which may 
debilitate particularly males’ reproductive health. The present study highlights the 
higher and more progressive impact of IBU as an endocrine disruptor than as a short-
term ROS-generator. Further studies are needed to assess and underline chronic and 
short-term effects in mussels associated to the multiplicity of therapeutic classes of 
APIs present in the aquatic environment. 
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4 Does Selective Serotonin Reuptake Inhibitor (SSRI) 
Fluoxetine Affect Mussel Mytilus galloprovincialis? 
Abstract 
Fluoxetine (FLX) the active pharmaceutical ingredient (API) in Prozac
® 
is a widely 
prescribed psychoactive drug which ubiquitous occurrence in the aquatic environment is 
associated to a poor removal rate in waste-water treatment plant (WWTP) systems. This 
API acts as a selective serotonin reuptake inhibitor (SSRI) frequently reported to cause 
disrupting effects in non-target species. The objective of this study includes a 
multibiomarker response evaluation on mussel M. galloprovincialis during two weeks 
exposure to 75 ng.L
-1
 FLX assessing antioxidant enzyme activities - superoxide 
dismutase (SOD), catalase (CAT) and glutathione-S-transferase (GST); lipid 
peroxidation (LPO), acetylcholinesterase (AChE) neurotoxic response and endocrine 
disruption through alkali-labile phosphates (ALP) indirect measurement of vitellogenin-
like proteins. Results show transient tissue-specific enzymatic responses and damage 
affecting mostly mussel gills. However, the clear ALP levels inhibition throughout time 
in both sex-differentiated gonads gives evidence to FLX reinforced action as an 
endocrine disruptor rather than an oxidative or neurotoxic inducer.  
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4.1 Introduction 
Ecotoxicological risks associated to the ubiquitous occurrence of active pharmaceutical 
ingredients (APIs) in aquatic ecosystems are far from known. As the detection 
technology improves, a larger variety of APIs are being detected in the aquatic 
environment (see reviews: Calisto and Esteves, 2009; Kümmerer, 2009; Li and Randak, 
2009; Alonso et al., 2010; Pal et al., 2010; Kümmerer, 2010; Santos et al., 2010, 
Brausch and Rand, 2011). Waste water treatment plants (WWTPs) are still ill-equipped 
for the constant APIs discharge load removal, consequently these bioactive compounds 
end up entering surface waters (rivers, estuaries and lakes) particularly via household 
and hospital treated effluents, and from there often recycled to drinking water (Ternes, 
2001; Ternes et al., 2002; Stackelberg et al., 2004; Jones et al., 2005; Gibs et al., 2007; 
Kim et al., 2007; Daughton, 2010) posing potential risks to non-target aquatic life 
(Fong, 2001; Brooks et al., 2005; Fent et al., 2006).  
Fluoxetine (FLX) present in antidepressant Prozac
®
 the most widely prescribed 
psychoactive drug in the market and like others (e.g. citalopram, fluvoxamine, 
paroxetine, and sertraline) act as selective serotonin reuptake inhibitor (SSRI) in the 
treatment of depression, and other mood disorders by increasing the serotonin (5-HT) 
levels in neuron synaptic space (Brosen, 1993; DeVane, 1999; Hiemke and Härtter, 
2000; Fent et al., 2006). Even though, FLX is excreted via urine approximately 10-30% 
as unchanged parent compound or metabolized to norfluoxetine (DeVane, 1999; 
Hiemke and Härtter, 2000; Fong and Molnar, 2008) is resilient to hydrolysis, photolysis 
and microbial degradation processes (Kwon and Armbrust, 2006) occurring in the 
aquatic environment at ng.L
-1 
(Table 4.1). 
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Table 4.1: Concentrations of FLX in the aquatic environment 
Country Concentration 
(ng.L-1) 
Environment Reference 
Canada 46 surface water Metcalfe et al., 2003 
  99 WWTP effluent   
  509 WWTP effluent Chen et al., 2006 
Croatia 66 surface water Gros et al., 2006 
South Korea 2 – 7 river water and creek 
water 
Yoon et al., 2010 
  2 WWTP effluent Trenholm et al., 2006; Kim et 
al., 2007 
Spain 18-66 river water Fernández et al., 2010 
  100 river water Gros et al., 2010 
        
   8-44 WWTP downstream Alonso et al., 2010 
  19-299 WWTP effluent Martínez et al., 2007 
  70 WWTP effluent Gros et al., 2006 
Sweden 225 WWTP effluent Zorita et al., 2007 
USA 5 reclaimed water facility 
effluent 
Kinney et al., 2006 
  12-20 stream Schultz and Furlong, 2008 
  3 surface water Vanderford and Snyder, 2006 
  12 surface water Kolpin et al., 2002 
  111 surface water Bringolf et al., 2010 
  14 water Stackelberg et al., 2007 
  17-25 WWTP effluent Vanderford and Snyder, 2006 
  18 WWTP effluent Stackelberg et al., 2004 
  21 WWTP effluent Glassmeyer et al., 2005 
  58 WWTP effluent Schultz and Furlong, 2008 
  540 WWTP effluent Weston et al., 2001  
  560 WWTP effluent Benotti and Brownawell, 2007 
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Since SSRIs alter neurotransmitter 5-HT regulation, which has been associated to the 
modulation of important functions in hormonal and neuronal mechanisms in both 
vertebrates and invertebrates (Fong, 2001; Fent et al., 2006; Stanley, 2007; Painter et 
al., 2009; Styrishave et al., 2011) most peer reviews on FLX exposure ecotoxicological 
effects focus on acute FLX toxicity and/or physiological, behavioral (mobility, feeding 
habits and aggression) and reproductive fitness alterations (Table 5.2). Nevertheless, 
FLX has also been related to affect antioxidant system in mice (Djordjevic et al., 2011). 
Oxidative stress is characterized by the imbalance when xenobiotic-mediated 
enhancement of reactive oxygen species (ROS) (e.g. superoxide anion (O2
·−
), hydrogen 
peroxide (H2O2) and hydroxyl radical (OH
·−)) exceed exposed aerobic organism’s 
antioxidant defense mechanisms. One of these mechanisms involves the counteracting 
response of antioxidant enzyme activities such as, superoxide dismutase (SOD) and 
catalase (CAT) and glutathiones (peroxidase - GPx and reductase - GR) (Livingstone, 
2001; Regoli et al., 2002a, b; Valavanidis et al., 2006). Additionally, Phase II 
glutathione S-transferase enzyme also enables detoxification, acting as a catalyst in 
conjugation reactions between glutathione with xenobiotic compounds electrophilic 
centers (Regoli and Principato, 1995). When the antioxidant system response is 
compromised by an ROS excess, lipid peroxidation (LPO) occurs, resulting in the 
damage of phospholipids membrane (Valavanidis et al., 2006). The fluctuation of 
antioxidant enzymes parallels to lipid peroxidation generation due to contaminant 
exposure have been used successfully as oxidative stress and damage biomarkers in 
mussel species (Regoli and Principato, 1995; Regoli et al., 2002a; Santovito et al., 
2005; Bebianno et al., 2005).  
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Table 4.2: FLX effects in aquatic molluscs and fish  
Species Name Exposure concentration Exposure time Test Biological end-points Reference 
Mytilus edulis (common 
mussel) 
0.15 mg.L
-1
   reproduction  Induction of spawning Hazardous Substances 
Databank (HSDB), 2005 
Sphaerium striatum 
(fingernail clam) 
5 µM FLX + 5 – 500 µM 5-
HT 
3 hours reproduction  Induction of parturition Fong et al., 1998 
Dreissena polymorpha 
(zebra mussel) 
5 x 10
-7
 from 5 x10
-4
 M 1 hours reproduction  Induction of spawning in males Fong, 1998 
5 x 10
-6
 from 5 x10
-5 
M 2 hours    Induction of spawning in females   
>100nM 4 hours    Induction of spawning and parturition Fong and Molnar, 2008 
  20 – 200 ng.L
-1
 6 days    Induction of spawining Lazzara et al., 2012  
         Dose dependent decrease oocytes (40-70%) and 
spertatozoan (21-25%) 
  
Elliptio complanata 
(freshwater mussel) 
300 µg.L
-1
 96 hours reproduction  Induction of parturition of nonviable larvae from 
female 
Bringolf et al., 2010 
3000 µg.L
-1
 48 hours    Induction of spermatozeugmata release   
caged freshwater mussels 
at stream sites near a 
municipal WWTP 
  bioaccumulation  79.1 ng.g
-1
 ww (bioaccumulation)   
injection 2.5 µg    metabolism  Increase of 5-HT response factor Gagné and Blaise, 2003 
Anodonta cygnea 
(freshwater mussel) 
1×10
–6
 M + presence of 
light 
24 hours reproduction  Induction of parturition Cunha and Machado, 2001 
Potamopyrgus antipodarum 
(NewZealand mudsnail) 
3.7, 11.1 and 100 µg.L
-1
 42 days reproduction  Decrease of  neonates number per living adult at 
100 µg.L
-1
 FLX 
Gust et al., 2009 
       Increase of shelled embryos and  embryos total 
number at 3.7 and 11.1 µg.L
-1
 FLX 
  
         Increase of unshelled embryos number at 3.7  µg.L
-1 
and decrease at 100 µg.L
-1
) 
  
         Thinner gonad tissues at 100 µg.L
-1
   
69 µg.L
-1
   reproduction  Decrease of reproduction (number of newborns per 
individual) 
Péry et al., 2008 
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Table 4.2: (Continuation).  
Potamopyrgus antipodarum 
(NewZealand mudsnail) 
0.64, 3.2, 16, 80, and 400 
µg.L
-1
 
14-56 days behavior and 
reproduction 
 Reduction of the mean embryo number at 80 and 
400 µg.L
-1
 
Nentwig, 2007 
400 µg.L
-1
   LC50    
Oncorhynchus mykiss 
(rainbow trout) 
1545 mg.L
-1
 24 hours EC50  Induction of hepatocyte cytotoxicity Laville et al., 2004 
0 -140  µg.L
-1
 4 hours    Induction of ROS production in  fish hepatocytes 
PLHC-1 
  
2 mg.L
-1
 48 hours LC50  Ferrari et al., 2004 
Pimephales promelas 
(fathead minnow) 
705 mg.L
-1
 48 hours LC50  Brooks et al., 2003 
212 µg/L R- FLX 48 hours LC50  Stanley et al., 2007 
16.1 (±20.2) µg.L
-1
 R- FLX 15 minutes after 
7 days exposure 
EC10  Decrease of  feeding rate   
132.9 (±21.2)  µg.L
-1
 R- 
FLX 
7 days    Decrease of growth rate   
125 ng.L
-1
 12d post-hatched behavior  Slower predator avoidance behaviors in larvae Painter et al., 2009 
Oryzias latipes (Japanese 
medaka) 
0, 0.1, 0.5, 1.0 and 5.0 
µg.L
-1
 
4 weeks    Abnormalities in embryo development (edema, 
curved spine, no pectoral fins, reduced eyes) 
Brooks et al., 2003; Foran et 
al., 2004 
       Increase of female circulating estradiol levels 0.1 
and 0.5 µg.L
-1
 FLX 
  
  0.2 (pH 9), 1.3 (pH 8), 5.5 
(pH 7) µg.L
-1
 
96 hours LC50  Nakamura et al., 2008 
Danio rerio (zebrafish) 0.32, 3.2, 32  µg.L
-1
 7 days reproduction  Ovarian levels of 17 β-estradiol (E2) decrease Lister et al., 2009 
       Average eggs spawning reduction   
         Reduction of ovarian aromatase, follicle stimulating 
hormone receptor (FSHr), and luteinizing hormone 
receptor (LHr) gene expression 
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Table 4.2: (Continuation). 
Thalassoma bifasciatum 
(bluehead wrasse) 
injection 6µg.g
-1
.day
-1
 2 weeks behavior  Decrease of territorial aggression Perreault et al., 2003; Semsar 
et al., 2004 
Ictalurus punctatus (channel 
catfish); Pomoxis 
nigromaculatus (black 
crappie); Lepomis 
macrochirus (bluegill) 
collected from 100 m 
downstream from the 
effluent discharge  (Pecan 
Creek, USA) 
  bioaccumulation  in brain (1.58 ± 0.74 ng.g
-1
);  liver (1.34 ± 0.65 ng.g
-1
) 
and muscle (0.11 ± 0.0365 ng.g
-1
) 
Brooks et al., 2005 
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To our knowledge, this is the first study focused on the potential antioxidant alteration 
status of an environmental realistic concentration of FLX (75 ng.L
-1
) exposure in 
mussels M. galloprovincialis through the assessment of antioxidant enzyme activities: 
SOD, CAT; Phase II GST activity, and LPO in mussels’ gills and digestive gland. In 
parallel, SSRI FLX potential to cause neurotoxic effects response was tested by 
assessing the activity of an essential neurotransmission modulator, enzyme 
acetylcholinesterase (AChE) in mussel gills. AChE activity has been reported to be 
inhibited in the presence of several organic contaminants (such as pesticides, detergents 
and pharmaceuticals) (Almeida et al., 2010; Solé et al., 2010). Finally, alkali-labile 
phosphate (ALP) method was applied on sex-differentiated mussel gonads to assess 
FLX as an endocrine disruption inducer, since ALP levels are positively correlated with 
those from vitellogenin-like proteins which are naturally synthesized in females and 
inactive in males (Blaise et al., 1999; Gagné et al., 2002; Matozzo et al., 2008). 
4.2 Materials and Methods 
4.2.1 Chemicals 
R-(-) fluoxetine hydrochloride (F1678, > 98%, CAS: 114247-09-5); 1.1.3.3. 
tetramethoxypropane (MDA) (108383, CAS: 102-52-3); 1-methyl-2-phenylindole 
(99%, CAS: 3558-24-5); 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) (D8130, ≥ 98% 
TLC, CAS: 69-78-3); acetyl thiocholine iodide (ATC) (A5751, ≥ 98% TLC, CAS: 
1866-15-5); bovine albumin serum (BSA) (A9418 > 98%, CAS: 9048-46-8); butylated 
hydroxytoluene (BHT) (B1378, ≥ 99.0% GC, CAS: 128-37-0); cytochrome c from 
equine heart (C7752, > 95%, CAS: 9007-43-6); diethylenetriaminepentaacetic acid 
dianhydride (DTPA) (D6148, CAS: 23911-26-4); ethylenediaminetetraacetic acid 
(EDTA) (ED, ≥ 99%, CAS: 60-00-4); Fiske and Subbarow Reducer (F5428); 
glutathione reductase (G3664, CAS: 9001-48-3); HEPES (H3375, >99.5%, CAS: 7365-
43-9); hydrogen peroxide solution (H1009, 30% w/w, CAS: 7722-84-1); hypoxanthine 
(H9377, >99%, CAS: 68-94-0); L-glutathione oxidized (GSSG) (G4501, > 98%, CAS: 
27025-41-8); L-glutathione reduced (GSH) (G4251, > 98%, CAS: 70-18-8); 
methanesulfonic acid (>99.5%, CAS: 75-75-2); triton x-100 (X6878, CAS: 9002-93-1) 
xanthine oxidase from bovine milk (X1875, CAS: 9002-17-9); β-nicotinamide adenine 
dinucleotide reduced disodium salt hydrate (NADPH) (N8129, ≥ 97%, CAS: 606-68-8) 
were purchased from Sigma-Aldrich (Germany). Protein-assay dye reagent concentrate 
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(phosphoric acid CAS: 7664-38-2 + methanol CAS: 67-56-1) was obtained from Bio-
Rad Laboratories, Inc. (USA). 1,4-dithiothreitol (DTT) (≥ 99%, CAS: 3483-12-3); 
acetonitrile (99.8%, CAS 75-05-8); methanol (99.9%, CAS 67-56-1); natriumazide 
(sodium azide) (106688, ≥ 99%, CAS: 26628-22-8); potassium chloride (KCl) (104936, 
99.5%, CAS: 7447-40-7); trichloroacetic acid (TCA) (100807, CAS: 76-03-9); TRIS-
(hydroxymethyl)-aminomethane (≥ 99%, CAS: 77-86-1) were acquired from Merck 
(Germany). 1-chloro-2,4,-dinitrobenzene (CDNB) (24440, ≥ 98.0% GC, CAS: 97-00-7), 
molybdate reagent solution (puriss p.a.) and potassium dihydrogen phosphate (60218, 
99.5%, CAS: 7778-77-0) acquired from Fluka.  D(+) saccharose extra pure (16104, 
99%,  CAS: 57-50-1); sodium chloride (NaCl) (puriss p.a., CAS: 7647-14-5); sodium 
hydroxide (NaOH) (purified, CAS: 1310-73-2) obtained from Riedel-de-Haën 
(Germany). 
4.2.2 Fluoxetine Exposure Assay (75 ng.L-1) 
Mussels M. galloprovincialis (n = 245, average shell length size: 67 ± 2 mm, width: 37 
± 1 mm) were collected in 2010 from Ria Formosa Lagoon in Portugal. These 
specimens were transported alive to the laboratory, subjected to shell cleaning and 
finally placed in separate aquaria (n = 35, 1 mussel.L
-1
) concerning control and 
exposure treatment to 75 ng.L
-1
 of FLX. Previously to the 75 ng.L
-1
 of FLX exposure all 
mussels were kept for 7 days acclimatizing in aerated natural seawater. The aquaria 
were kept at constant temperature (18.6 ºC ± 1), salinity (33 ± 0.4), pH (8.1 ± 0.2) and 
oxygen saturation (> 98% ± 2). Mussels were not fed until the end of the experiment. 
Water was changed and FLX concentration was re-established at every 48 hours.  
At each set up time (0, 3, 7, and 15 days), mussels (n = 20) were removed from control 
and exposure aquaria, individual shell biometric data was measured (length, width) and 
dissection performed, separating gills, digestive gland and gonads. Each tissue sample 
was immediately frozen in liquid nitrogen and stored individually at -80ºC prior to 
analysis. For condition index (CI) estimation, 15 mussels of each aquarium, where 
individual weighted regarding the ratio:  
  =  
 hole so t tissue   et ei ht  
 hole bod  tissue  shell   et ei ht 
 x     
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4.2.3 Antioxidant Enzymes Analysis 
Antioxidant enzyme analysis was performed using previously dissected gills (n = 5) and 
digestive glands (n = 5) separately. Each tissue sample was homogenized on ice 
individually with 20 mM TRIS buffer (containing 1 mM of EDTA + 0.5 M of 
saccharose + 0.15 M of KCl + 1 mM of DTT) at pH 7.6. Homogenates were centrifuged 
for 15 minutes at 500 × g at 4ºC and resulting supernatants recentrifuged for 45 
minutes at 12,000 ×g at 4ºC. After cytosolic fraction volume measurement, Sephadex® 
G-25 gel columns were applied to further purify the sample removing low molecular 
weight proteins. Prior to the purification a 100 µl aliquot was collected for total protein 
quantification using bovine serum albumin (BSA) as a standard according to Bradford’s 
method (Bradford, 1976).  
Purified aliquots of gills and digestive glands were individually analyzed in triplicate 
for the quantification of several antioxidant enzymes by spectrophotometric analysis 
applying the following methodology. In order to determine SOD activity in mussel 
tissues, 100 µl of each purified aliquot was evaluated measuring the cytochrome c 
absorbance reduction by 50% at 550 nm wavelength generated by xanthine 
oxidase/hypoxanthine system according to McCord and Fridovich (1969) method. SOD 
activity is expressed by arbitrary units (U) per minute of mg
-1
 of total protein. For CAT 
activity assessment 100µl of each purified tissue aliquot was used to measure the 
absorbance decrease related to hydrogen peroxide (H2O2) consumption at 240 nm 
(Greenwald, 1985) and expressed as µmoles.mg
-1
 of total protein concentration.min
-1
. 
GST activity analysis was performed quantifying the reaction of 50 µl of each purified 
sample with CDNB at 340 nm, following an adaptation of Habig et al. (1974) method 
and expressed as µmol of resulting CDNB conjugate formed.mg 
-1
 of total protein.min
-1
.  
4.2.4 LPO Analysis 
Dissected gills (n = 10) and digestive glands (n = 10) were homogenized on ice 
individually with 20 mM TRIS-HCl buffer and butylated hydroxytoluene (BHT) in a 
100:1 µl ratio at pH 8.6. In order to precipitate the cytosolic fraction, the homogenates 
were centrifuged at 30,000 × g for 45 minutes at 4ºC. An aliquot was set aside for total 
protein quantification according to Bradford’s method (Bradford, 1976). Resulting 
cytosolic fraction was used for the measurement of LPO levels by the quantification of 
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by-products malondialdehyde (MDA) and (2E)-4-hydroxy-2-nonenal (HNE) formation 
absorbance at 586 nm following an adaptation of Erdelmeier et al. (1998) method. LPO 
levels are expressed as µmol MDA.g
-1 
total protein. 
4.2.5 AChE Analysis 
Dissected gills (n = 5) were homogenized in 100 mM Tris-HCl buffer and 100:1 µl of 
Triton at pH 8.0 on ice. The homogenates were centrifuged at 12,000 × g for 30 minutes at 
4ºC. Resulting supernants were separated in aliquots, one for total protein determination 
(Bradford, 1976) and the other for AChE activity analysis according to an adaptation of 
Ellman et al. (1961) method. AChE activity was measured through the increase of yellow 
color resulting from the production of 5-mercapto-2-nitrobenzoate at 405 nm ( = 13.6 
mM
-1
.cm
-1
) by the reaction of substrate thiocholine with DTNB. AChE activity is 
expressed nmol.mg
-1
 total protein.min
-1
. 
4.2.6 ALP Analysis 
Sex-differentiated gonads (n = 10) were homogenized in 25 mM Hepes–NaOH buffer 
(containing 125 mM NaCl + 1 mM DTT + 1 mM EDTA) at pH 7.4 in ice following an 
adaptation of Blaise et al. (1999) method. Homogenates were centrifuged at 12,000 × g at 
2ºC for 30 minutes, resulting pellets were discarded. An aliquot of each supernant was 
reserved to determine total protein content (Bradford, 1976). The remaining cytosolic 
fractions were adjusted with 35% acetone and centrifuged at 10,000 × g for 5 minutes. 
Resulting pellets were dissolved with 1 M NaOH and placed for 30 minutes in a 60ºC 
heating bath. Phosphomolybdenum method (Stanton, 1968) was used to calculate inorganic 
phosphate (KH2PO4) concentration at 660 nm wavelength. ALP concentrations are 
expressed as μg [PO4].mg
-1
 total protein. 
4.2.7 Statistical Analysis  
All biomarkers results are presented as mean ± standard deviation corresponding to each 
set of time. Two-way ANOVA was performed using SIGMAPLOT
®
 to test differences 
between non- and mussels treated with FLX on each tissue at each set of time. Ad-hoc 
Holm-Sidak was used on single biomarker difference discrimination over time, within 
and when applicable between tissues. Pearson correlation was used to verify the 
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dependency between biomarkers. PCA were performed with XLSTAT
®
 2011 to assess 
each biomarker responsibility on the variability at each set of time in non- and FLX 
exposed 1) gills, 2) digestive glands and 3) gills vs. digestive glands. AChE activity was 
only considered in gills’ PCA, and ALP was not considered as it was analyzed in 
gonads. Statistical significance was defined at p < 0.05 level. 
4.3 Results 
4.3.1 CI 
A significant decrease was observed in control mussels from the beginning (26.0 ± 
2.6%) to the 3
rd
 day (22.2 ± 3.3%), remaining unchanged until the end of the experiment 
(min. 19.5 ± 4.4%). Additionally, FLX exposed mussels’ condition index was not 
affected throughout the exposure (day 3: 21.9 ± 4.0; day 7: 22.0 ± 3.3; day 15: 20.0 ± 
3.8%) being not significantly different from respective controls. 
 
4.3.2 Antioxidant Enzymes 
SOD activity is significantly higher in gills than in digestive glands for both non- and 
FLX exposed mussels throughout the experiment. Exposed gills showed a SOD activity 
inhibition trend over time only significant after two weeks (Figure 4.1A) (p < 0.05), 
whereas in the exposed mussels’ digestive glands no significant differences with 
controls exist (Figure 4.1B) (p > 0.05).  
Contrarily to SOD, CAT activity was higher in mussels’ digestive glands than in gills. 
Even though, no significant differences between control and FLX exposed gills were 
established, it was noticeable a slight CAT activity increase in exposed gills, which was 
related to the SOD activity inhibition over time in this tissue (r = -0.921, p < 0.05) 
(Figures 4.1 C and D). This was further related with an inverse relationship between 
these antioxidant enzymes. In digestive gland, controls mussels showed a slight, but 
significant CAT decrease over the experiment duration, while exposed mussels showed 
a transient pattern, in which CAT activity fluctuates to significantly higher activity 
levels than controls after 3 and 15 days of FLX exposure (p < 0.05).   
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Regarding Phase II enzyme GST (Figures 4.1E and F), both tissues exhibit similar 
activities, although with irregular patterns. In controls, GST activities in both tissues 
decreased; after the first week in gills and immediately after the 3
rd
 day in digestive 
gland. In exposed mussels, GST activity remained unaltered in gills (Figure 4.1E), 
whereas in digestive gland (Figure 4.1F) it fluctuates decreasing to control levels after 
the first week of exposure (p < 0.05) and varying to significantly higher activities than 
controls after the 3
rd
 and 15
th
 day of exposure. Furthermore, GST and CAT activities are 
directly related in this tissue (r = 0.791, p < 0.05). 
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Figure 4.1: Antioxidant enzymes activity (mean ± standard deviation) in control and FLX exposed M. galloprovincialis tissues. SOD activity in gills 
(A) and in digestive gland (B); CAT activity in gills (C) and in digestive gland (D). Different letters express significant differences (p < 0.05). Note: 
Figure continues in the next page. 
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Figure 4.1 (Continuation).: Antioxidant enzyme activity (mean ± standard deviation) in control and FLX exposed M. galloprovincialis tissues. GST 
activity in gills (E) and digestive gland (F). Different letters express significant differences (p < 0.05). 
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4.3.3 LPO  
LPO levels (Figures 4.2A and B) were higher in gills than in digestive glands in both 
mussels groups. In gills (Figure 4.2A), while controls showed no differences over time 
(p > 0.05), exposed mussels exhibit a significantly higher LPO levels than controls after 
one week (p < 0.05), recovering to control levels by the end of the experiment (p > 
0.05). In the digestive gland (Figure 4.2B), controls remained unaltered after a 
significantly decrease at the 3
rd
 day, whilst exposed mussels LPO levels increased but 
only significantly after two weeks of exposure (4-fold higher than controls) (p < 0.05).
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Figure 4.2: LPO (mean ± standard deviation) in control and FLX exposed M. galloprovincialis tissues, in gills (A) and digestive gland (B). Different letters express 
significant differences (p < 0.05). 
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4.3.4 AChE  
AChE (Figure 4.3) activity remained consistent in control individuals throughout the 
experiment (p > 0.05). Conversely AChE activity was significantly incremented in 
mussels’ gills after the 3rd day of FLX exposure comparing to controls, followed by a 
progressive inhibition, reaching a significantly lower activity than controls by the end of 
the experiment (p < 0.05).   
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Figure 4.3: AChE activity (mean ± standard deviation) in non- and exposed mussels’ M. 
galloprovincialis gills to 75 ng.L
-1
 of FLX along 15 days. Different letters express significant 
differences (p < 0.05). 
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4.3.5 ALP  
ALP levels (Figure 4.4) decreased significantly in control females after the first week (p 
< 0.05), while in males’ remained unchanged throughout the experiment duration (p > 
0.05). Nevertheless in exposed gonads, after 3 days of exposure, ALP levels decreased 
significantly in both females and males though more markedly in males comparing to 
controls. After this, ALP levels were significantly incremented after one week of 
exposure in both genders, decreasing again to levels significantly lower than controls by 
the end of the experiment (p < 0.05).   
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Figure 4.4: ALP level (mean ± standard deviation) in non- and exposed mussel’s gonads M. 
galloprovincialis to 75 ng.L
-1
 of FLX throughout 15 days. Different letters express significant 
differences (p < 0.05). 
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4.3.6 PCA in Gills and Digestive Gland 
PCA was applied to all parameters measured in the gills (Figure 4.5A) revealing 72 % 
of total variance (TVar). PC1 represents 52% of variance, highlighting the separation 
between non- and FLX exposed gills by the opposition in the factorial weight 
distribution of SOD activity with the remaining enzymes activities and LPO levels. The 
second component (explaining only 19% of the variance) shows the further influence of 
CI in the separation of day 0 (control) from the remaining controls, and day 15 FLX 
exposed gills from the other exposure-day groups in opposition to LPO levels and 
AChE activities. Furthermore, PCA reveals that SOD and CAT activities exhibit 
opposing factorial distribution, corroborating with the above mentioned inverse 
relationship.    
Digestive gland PCA (Figure 4.5B) represents almost 84% of TVar, in which both 
components had similar influence on the overall groups’ distribution (PC1, 46% and 
PC2, 38%). AChE activity was not considered since it was performed only in gills. PC1 
shows the cluster of controls (exception for day 0) particularly associated to the 
opposition of SOD activities with the remaining variables; and the separation of day 7 
FLX exposed digestive glands from the other exposure days. As observed in gills PC2, 
CI is the highest factor explaining the variability of day 0 control group from remaining 
groups and in this case, day 15 FLX exposed digestive glands were further influenced 
by the LPO levels. The digestive gland PCA also corroborates with the direct 
relationship between CAT and GST activities in this tissue.     
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Figure 4.5: PCA equivalent to the integration (A) of  SOD, CAT and GST, LPO, AChE and CI on 
77% of total variance in gills;  - (B) of  SOD, CAT and GST, LPO and CI on 83% of total variance 
in digestive gland of mussel M. galloprovincialis between treatments (●, ♦ – control, ○, ◊ – FLX 
exposed mussels) over exposure time (days: 0, 3, 7 and 15). 
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PCA (Figure 4.6) is related with tissue-specific integration of oxidative stress 
biomarkers (SOD, CAT, GST and LPO), explaining approximately 85% of TVar (PC1, 
51% and PC2, 34%). The first component clearly separates non- and FLX exposed gills 
from digestive glands treatment groups, particularly regarding gills to LPO levels and 
GST and SOD activities, while digestive glands are more related to the activity of CAT. 
The second component highlights the separation of both exposed gills and digestive 
glands from controls groups, with the exception of day 0 control and day 7 exposed 
digestive glands and day 15 gills control regarding to levels of CAT, LPO and GST in 
opposition to SOD. In overall PCA shows the aggregation of: 1) gills controls relating 
to higher SOD activities; 2) FLX exposed gills with the increment of LPO levels; 3) 
FLX exposed digestive glands with higher CAT activities; and finally 4) digestive 
glands controls in opposition to all integrated biomarkers.    
  
Figure 4.6: PCA related to the integration of SOD, CAT and GST, LPO on 85% of total variance in 
mussels´ M. galloprovincialis tissues between treatments (● – gills controls,  ○ – FLX exposed gills, ♦ 
– digestive gland controls, ◊ – FLX exposed digestive gland) over exposure time (days: 0, 3, 7 and 
15). 
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4.4 Discussion 
4.4.1 Oxidative Stress 
To our knowledge this is the first study concerning the effect of FLX as a potential 
oxidative stress inducer applying antioxidant enzymes response activities in mussels. 
The results reveal a transient antioxidant status alteration in both mussels’ tissues. As 
the first organ in direct contact with the contaminant, the significant SOD activity down 
regulation was inversely related only in the gills, the concomitant inhibition tendency of 
SOD activity in digestive glands resulted in a significant enhancement of CAT after 3 
days and two weeks of FLX exposure (Figures 4.1). The exposure of rainbow trout 
(Oncorhynchus mykiss) hepatocytes to FLX has shown to induce an enhancement of 
ROS production (Laville et al., 2004). Considering SOD primarily role in the 
dismutation of OH
·−
 into H2O2, its inhibition in presence of FLX is associated to a 
higher presence of ROS particularly in the gills and since digestive gland has a higher 
participation on general redox-cycling and biotransformation processes (Livingstone et 
al., 1992) CAT’s catalytic action is later triggered in this tissue (Regoli and Principato, 
1995). An inhibition of SOD activity was also found by Djordjevic et al. (2011) in mice 
exposed to 5 mg.kg
-1
 FLX body mass, although no enhancement of CAT activities was 
observed. Additionally, higher CAT activities were reported in digestive glands than in 
gills in the same mussel species exposed to carbamazepine (Martín-Díaz et al., 2009). 
Overall PCA clustering (Figure 4.6) provides a further validation for the discrepancy 
between the activity levels of SOD in gills and CAT in digestive gland.  
Phase II GST promotes reduced glutathione (GSH) conjugation with parental 
electrophilic compounds enabling its transformation to more extractable hydrophilic 
metabolites (Halling-Sørensen et al., 1998). Although, GST activity was generally 
transitory between treatments in both tissues (Figures 4.1E and F) giving evidence to 
the actuation of other affecting variables rather than exposure itself, this enzyme was 
more responsive in FLX-exposed digestive gland showing simultaneously higher 
activity than controls (except after one week) and was directly related with CAT 
activity. A positive relationship between the enhancement of GST and CAT was also 
observed in M. galloprovincialis digestive glands exposed to 250 ng.L
-1
 ibuprofen for 
the same time (Gonzalez-Rey and Bebianno, 2012 – Chapter 3B) alike for bezafibrate 
(Canesi et al., 2007), carbamazepine (Martín-Díaz et al., 2009) and propanolol exposure 
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(Franzellitti et al., 2011). Finally, GST enhancement confirms, as stated by Canesi et al. 
(2007) after 38.2 ng.g
-1
 bezafibrate injection in same species mussel, that FLX  is 
partially metabolized in mussels’ digestive glands.  
The alteration of antioxidant enzymes was unable to prevent and counteract FLX-
exposure as there was a clear tissue-specific response of membrane damage in which 
gills showed higher vulnerably at the beginning of FLX-exposure until the end of the 
first week while LPO enhancement in exposed digestive glands (7-fold higher) 
continued until the end of the experiment (Figures 4.2A and B). Even though, exposed 
gills seemed to recover to control levels after 2 weeks, PCA (Figure 4.6) suggests that 
FLX has a higher impact in this tissue than in digestive gland over time. Higher levels 
of LPO were also observed after 250 ng.L
-1
 ibuprofen exposure in the same mussels’ 
tissues particularly in gills (max: 19 µmol MDA mg
-1 
protein) than the ones induced by 
FLX (Chapter 3A-B - Gonzalez-Rey and Bebianno, 2011; 2012). 
4.4.2 Neurotoxic Effect 
AChE is responsible for the hydrolysis of neurotransmitter acetylcholine (ACh) to 
choline and acetic acid and has an important role in cholinergic nervous function 
(Tsuchiya et al., 2004), as the neurotransmitter 5-HT has in serotonergic 
neurotransmission. These neurotransmitters are critical in the control of many 
physiological processes like e.g. cardiac regulation in bivalves, though their roles may 
be inverted regarding excitation and inhibition in different species (Kuwasawa and Hill, 
1997). Since SSRI FLX induces an increase in extracellular 5-HT by the serotonin 
transport protein inhibition at nerve synapses (Lister et al., 2009) is not illicit to think 
that AChE may also be affected by FLX presence, further considering the evidences of 
5-HT increase in mussel E. complanata after injection with FLX (Gagné and Blaise, 
2003). 
Even though AChE activity has been reported to be inhibited in mussels by APIs 
namely by paracetamol (23 and 403 μg.L-1) in M. galloprovincialis gills (Solé et al., 
2010) and by diazepam (4, 20 and 100 nmol per mussel) in E. complanata visceral mass 
(Gagné et al., 2011) in FLX-exposed M. galloprovincialis gills the significant down 
regulation of AChE activity was only observed at the end of the 15
th
 day, being firstly 
preceded by a clear up regulation of AChE after 3 days of FLX exposure. Few other 
studies have shown the induction of AChE namely, in mussels placed in the final 
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aeration lagoon (Gagné et al., 2010) and in crabs in an impacted stream (Nieto et al., 
2010) with no noticeable explanation for this fact rather than antagonistic effects 
between contaminants. The enhancement of AChE activity implies the depletion of 
ACh, we hypothesize several possible explanations for the AChE activity temporary 
enhancement at the beginning of the experiment: 1) the enhancement of 
neurotransmitter 5-HT concentration by FLX action at nerve endings may have been 
competing with ACh and therefore causing its depletion, even though the receptor 
activation mechanism of 5-HT in mussels is still unknown as stated by Gagné and 
Blaise (2003); 2) AChE increase is associated to cell apoptosis (Zhang et al., 2002), 
FLX presence may promote gills’ cell apoptosis at the beginning of the experiment 
followed by the mussels’ recovery to controls’ AChE activity; 3) A relationship 
between estradiol levels and AChE activity regulation in mice brain cortex cells was 
reported noting that with high levels of 17β –estradiol (E2) AChE activity was 
suppressed whereas without E2, it increased (Tsuchiya et al., 2004). The alteration of 
endogenous levels of E2 may explain these AChE activity alterations in FLX exposed 
mussels at the beginning of the exposure, even though AChE activity was not measured 
in sex-separated gills the results indicate by the concomitant ALP down regulation over 
the 3
rd
 day of exposure that FLX has the ability to interfere with estrogen receptors. 
4.4.3 Endocrine Disruption 
ALP levels are released by vitellogenins (Vtg) after alkali hydrolysis (Porte et al., 
2006), which precede egg-yolk protein vitellin (Vn) in oviparous species (Matozzo et 
al., 2008). In bivalves, vitellogenesis is induced by estradiol (E2) and a neuropeptide 
(Matozzo et al., 2008). ALP levels enhancement is a sign of endocrine disruption (ED) 
in males (Blaise et al., 1999; Gagné et al., 2002; Matozzo et al., 2008). In FLX 
exposure, ALP levels were generally high (max. observed in females 1600 μg [PO4].mg
-
1
 total protein) and similar to the ones in M. edulis in anthropogenic influenced sites 
(Gagné et al., 2008). However FLX exposure did not induce an enhancement of males 
ALP levels, but rather a down regulation in both sex-differentiated gonads particularly 
in females over the 3
rd
 day. A similar experimental design with the same species 
exposed to 250 ng.L
-1
 of ibuprofen showed both: lower basal ALP values (max. in 
exposed males: 117 μg [PO4].mg
-1
 total protein) and significant induction in exposed 
mussels (Chapter 3B - Gonzalez-Rey and Bebianno, 2012).  
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ALP down regulation was also observed in females exposed to North Sea crude oil 
(NSO) which in turn was accompanied by the decreased of gonads development 
suggesting ALP levels influence on gonad development in adult blue mussels M. edulis 
through an antiestrogenic effect of polycyclic aromatic hydrocarbon (PAHs) and oils 
(Ortiz-Zarragoitia and Cajaraville, 2006). As also stated by these authors it is important 
to consider 5-HT function in bivalves on gonad development and reproduction, for this 
reason a histological study of FLX-exposed gonads would greatly complement the data 
on mussels’ reproduction fitness alteration.  
Furthermore, the ALP down regulation in both FLX-exposed female and male gonads 
may be associated to E2 inverse relationship with 5-HT levels as reported in freshwater 
mussels E. complanata and gonad 5-HT concentration increase during spawning (Gagné 
and Blaise, 2003) since by opposition Vtg synthesis induction is related to gonad 5-HT 
levels decrease (Matozzo et al., 2008). Also, recently Lazzara et al. (2012) reported the 
increase of 1.5-fold of E2 after 6 days of exposure to 200 ng.L
-1 
of FLX in mussel D. 
polymorpha. Nevertheless, along with the decrease of oocytes and spermatozoan, 
esterified E2 levels decreased approximately 3 to 8-fold in this species between 
spawning and after-spawning phases after 20 and 200 ng.L
-1 
of FLX exposure thus 
confirming this SSRI to be an endocrine disruptor.  
4.5 Conclusions 
FLX exposure to mussels for two weeks induced a transient antioxidant enzyme 
activities alteration particularly in gills. However these alterations were not as severe as 
overall ALP sex-differentiated down regulation in gonadal tissues, highlighting a higher 
endocrine disruption effect of FLX rather than an oxidative stress inducer. Furthermore, 
resulting from the influence of FLX as a SSRI, on 5-HT levels increase as mentioned 
before, AChE activity was clearly altered throughout the experiment and possibly 
results on cholinergic neurotransmission functions breakdown. The measurement of 
FLX concentration in tissues, as well as, serotonin and estradiol level alteration in both 
non- and exposed mussels’ tissues should clearly complement these findings. Finally, 
FLX presence, even at a relevant environmental concentration, clearly has potential to 
induce ecotoxicological effects in mussel M. galloprovincialis particularly affecting its 
reproduction fitness, although the mechanisms of 5-HT receptor activation in mussels 
are still unknown.  
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5 Effects of Non-Steroidal Anti-Inflammatory drug 
(NSAID) Diclofenac Exposure in Mussel Mytilus 
galloprovincialis 
Abstract 
An increasing research effort has been made focused on the assessment of active 
pharmaceutical ingredients (APIs) occurrence in the aquatic system. Yet a lot is still to 
unveil concerning its potential effects in non-target organisms due to the complexity of 
each specific drug mode of action, reactivity and bioconcentration potential. Non-
steroidal anti-inflammatory drug (NSAID) diclofenac (DCF) is one of the most 
frequently detected in surface waters worldwide and has been recently included in the 
list of priority substances under the European Commission. In this study mussels M. 
galloprovincialis were exposed to an environmental relevant concentration of DCF (250 
ng.L
-1
) during two weeks. Several biomarkers responses were assessed in mussel 
tissues: condition index (CI); superoxide dismutase (SOD), catalase (CAT), glutathione 
reductase (GR) and Phase II glutathione-S-transferase (GST) activities and lipid 
peroxidation levels (LPO) associated to oxidative stress; acetylcholinesterase (AChE) 
activity related to neurotoxic effect and finally vitellogenin-like proteins linked to 
endocrine disruption. The results reveal significant induction of SOD and GR activities 
in gills and CAT activity and LPO levels in digestive glands. Phase II GST remained 
unaltered in both tissues while AChE activity up regulation was directly related to 
vitellogenin-like protein levels in exposed-females which point to an estrogenic activity 
alteration rather than a cholinergic neurotransmission functions breakdown. This study 
confirms that DCF at a concentration often found in surface water induces tissue-
specific biomarker responses. Finally this study also reveals the importance of a multi 
biomarker approach on the potential deleterious assessment in a species extremely 
vulnerable to the continuously discharge of APIs into the aquatic systems providing 
crucial new information on the still unknown effects of DCF as a priority substance. 
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5.1 Introduction 
Diclofenac (DCF) (known as Voltaren
®
) is amongst the most applied non-steroidal anti-
inflammatory drugs (NSAIDs) in human and veterinary health practice due to its 
properties in the relieve of acute pain and osteo- and/or rheumatoid arthritis symptoms 
(Boesterli, 2003; Praveen Rao and Knaus, 2008; Ng et al., 2008). Nevertheless, DCF is 
also related to cause chronic gastric and renal toxicity in humans and Indian vulture 
(Gyps sp.) population decline after scavenging DCF-treated livestock carcasses 
(Boesterli, 2003; Oaks et al., 2004; Hinz and Brune, 2006; Taggart et al., 2007a, b; 
Praveen Rao and Knaus, 2008; Saini et al., 2012).  
After intake, DCF is partially biotransformed to hydroxilated metabolites (e.g. 4'-
hydroxy (OH) and 5-OH) through cytochrome P450 (CYP450) oxidation and is 
excreted via urine and faeces reaching wastewater treatment plants (WWTP) and 
ultimately the aquatic systems (Schwaiger et al., 2004; Marco-Urrea et al., 2010). 
Several authors report the presence of this API in superficial waters (river, ponds, lake 
and streams) with the maximum value of 15 µg.L
-1
 found in Erft river, Germany (Jux et 
al., 2002) (Table 5.1). Accordingly, DCF is considered as a class IIA - “potentially 
hazardous” compound with relevant adverse effects (Besse and Garric, 2008) and 
included in the list of priority substances by the European Union (European Comission, 
2012a, b). 
The ability of NSAIDs to promote the decrease of prostaglandins (PGs) biosynthesis 
from phospholipid arachidonic acid (AA) by the nonselective inhibition of 
cyclooxygenase (COX)-1 and -2 isoforms (Vane et al., 1998; Fent et al., 2006; Praveen 
Rao and Knaus, 2008) may interfere in critical physiological functions, like 
reproduction, water transport, osmoregulation and immune defense in non-target 
organisms (Ruggeri and Thoroughgood, 1985; Osada and Nomura, 1990; Vane et al., 
1998; Rowley et al., 2005; Fent et al., 2006). DCF-exposure in aquatic species and 
particularly in bivalves induces acute and/or chronic toxicity on survival, swimming and 
feeding behavior, growth, embryonic development, reproduction (see Nassef et al., 
2010a, b; Lee et al., 2011; Quinn et al., 2011; Schmidt et al., 2011) and 
bioconcentration factor (BCF) (Hoeger et al., 2008) at concentrations higher than the 
ones found in the environment. Nonetheless, in order to predict waterborne DCF-impact 
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at an ecotoxicological endpoint there are still limited information concerning medium-
/long term chronic exposure effects and BCF at environmental realistic concentrations 
(Table 5.2). 
Biomarkers enable an early assessment of potential contaminant-derived chronic effects 
in marine life through the swift alterations of several biochemical responses in a given 
sentinel organism (Van der Oost et al., 2003). Bivalve species, such as mussels, are 
considered useful bioindicators species, combining both a wide distribution and long-
life cycle to a natural ability to accumulate contaminants present in the surrounding 
water (Cajaraville et al., 2000; Ortiz-Zarragoitia et al., 2010; Porte et al., 2006; 
Ricciardi et al., 2006; Cravo et al., 2009; Ericson et al., 2010). Considering the above 
this study undertook a multi-biomarker approach related to: general physiology - 
condition index (CI), antioxidant defense system - antioxidant enzyme activities: 
superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GR)  and Phase II 
glutathione S-transferase (GST); damage - lipid peroxidation (LPO); neurotoxic effect - 
acetylcholinesterase activity (AChE) and vitellogenesis/endocrine disruption - alkali-
labile phosphate level (ALP) exposing mussel M. galloprovincialis to an environmental 
relevant concentration of DCF (250 ng.L
-1
) for two weeks.  
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Table 5.1: DCF concentrations (ng.L
-1
) in the aquatic system 
Country Environment Concentration (ng.L
-1
) Reference 
Austria river 23 Ahrer et al., 2001 
    166   
Brazil river 40 Stumpf et al., 1999  
Canada harbor 194 Metcalfe et al., 2003 
  river 420   
    15 Hua et al., 2006  
China river 11 – 150 Hao et al., 2007 
    1-52 Wang et al., 2010 
Croatia surface water 60 Gros et al., 2006 
Finland river 3-35 Lindqvist et al., 2005 
France river 2 Rabiet et al., 2006 
  surface water 5 Vulliet and Cren-Olivé, 2011 
    1-33 Togola et al., 2008 
Germany groundwater well 380 Heberer et al., 1997 
  groundwater 590 Sacher et al., 2001 
  pond and river 11 – 15033 Jux et al., 2002  
  river 1200 Ternes, 1998 
  50 Wiegel et al., 2004 
    16 -  36 Ahrer et al., 2001  
  surface water 1000 Heberer, 2002 
    23 - 140 Letzel et al., 2009 
  6 Weigel et al., 2002 
    31 - 67 Weigel et al., 2004 
    1000 DeLorenzo et al., 2008 
Italy river 489 Zuccato et al., 2001  
Korea river 1-7 Kim et al., 2007 
Luxembourg river 19 - 55 Pailler et al., 2009  
Pakistan harbor  lagoon 100 Scheurell et al., 2009 
  river 700 - 4400   
Slovenia river 9 - 282 Kosjek et al., 2005 
    89 Antonic and Heath, 2007 
Spain river 49 - 332 Farré et al., 2001 
    1 - 156 Fernández et al., 2010 
    2200 Ginebreda et al., 2010  
Sweden river 120 - 10 Bendz et al., 2005 
Switzerland lake n.d. - 10 Öllers et al., 2001 
  river 20 – 150 
    5-10 Tixier et al., 2003  
UK estuary 8 - 195 Thomas and Hilton, 2004  
  river 20 - 568 Ashton et al., 2004 
    91 Hilton and Thomas, 2003  
USA lake 17 - 42 Wu et al., 2009  
  stream 32 Spongberg et al., 2008  
various  river 26 - 72 Hernando et al., 2006 
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Table 5.2: DCF effects in aquatic species 
Species Exposure 
concentration 
Exposure time 
(days) 
Biological end-points   Effects Reference 
Dreissena polymorpha 0.3, 1, 2 nM 4 cyto and genotoxicity - no effects on apoptosis frequency, micronucleous 
test and lysosomal stability 
Parolini et al., 2010 
      oxidative stress 
status 
- no effects on SOD, CAT, GPx or GST   
  1  µg.L
-1
 4 cytotoxicology - cell viability decrease in gills and hemocytes Parolini et al., 2011 
      physiology - no alteration on CI Quinn et al., 2011 
      oxidative stress and 
DNA damage 
- GST, LPO and metallothionein (MT) increase, no DNA 
damage (visceral mass) 
  
      endocrine disruption - no alteration on ALP levels (visceral mass)   
Mytilus edulis trossulus 1  µg.L
-1
 14 – 19 physiology - scope for growth decrease tendency (SFG) Ericson et al., 2010 
    8 – 21   - byssus strength decrease tendency   
    8 BCF - 0.18 ± 0.02 µg.gww
-1
 (whole body)   
Mytilus spp.   4 oxidative stress and 
DNA damage 
- GST, LPO increase, no alteration of MT and DNA 
damage (digestive gland) 
Schmidt et al., 2011 
      endocrine disruption - no alteration on ALP levels (gonads)   
Hyalella azteca 48.7 µg.kg
-1
 
(DCF-enriched 
sediment) 
1/2 – 3 oxidative stress - SOD, CAT, GPx activities increase Oviedo-Gómez et al., 
2010 
        - LPO level increase   
Carcinus maenas 10 – 100 ng.L
-1
 7 physiology - impairment of osmo- and iono regulatory ability  Eades and Waring, 2010 
Oryzias latipes 1  µg.L
-1
 4 gene expression - CYP P450 1A, P53 and vitellogenin in males up 
regulation 
Hong et al., 2007 
Oncorhynchus mykiss 1.6 µg.L
-1
 15 gene expression - inflammation and immune response down regulation Cuklev et al., 2011 
      BCF - 4.02 ± 0.75 (blood plasma); 2.54 ± 0.36 (liver)   
  1  µg.L
-1
 28 BCF - 2732 (liver), 971 (kidney), 763 (gills) higher than at  ≥ 
5  µg.L
-1
 
Schwaiger et al., 2004 
 (LOEC)   hystopathological  
alterations 
- no  organ  (gills and kidney) lesions only at ≥ 5  µg.L
-1
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Table 5.2: (Continuation).    
Oncorhynchus mykiss     cytopathology 
alterations 
- in liver, kidneys and gills, no alteration in the 
intestine 
 Schwaiger et al., 2004 
Salmo trutta f. fario 0.5  µg.L
-1 
(LOEC) 
7 – 21 immunohistological 
alterations 
- erythrocyte volume in % of total blood volume  and  
leucocrit values decrease  
Hoeger et al., 2008 
      histopathological 
alterations 
- in gills, kidneys and liver   
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5.2 Materials and Methods 
5.2.1 Chemicals 
Diclofenac sodium salt (D68990, CAS: 15307-79-6); tetramethoxypropane (MDA) 
(108383, CAS: 102-52-3); 1-methyl-2-phenylindole (99%, CAS: 3558-24-5); 5,5′-
dithiobis(2-nitrobenzoic acid) (DTNB) (D8130, ≥ 98% TLC, CAS: 69-78-3); acetyl 
thiocholine iodide (ATC) (A5751, ≥ 98% TLC, CAS: 1866-15-5); bovine albumin 
serum (BSA) (A9418 > 98%, CAS: 9048-46-8); butylated hydroxytoluene (BHT) 
(B1378, ≥ 99.0% GC, CAS: 128-37-0); cytochrome c from equine heart (C7752, > 
95%, CAS: 9007-43-6); diethylenetriaminepentaacetic acid dianhydride (DTPA) 
(D6148, CAS: 23911-26-4); ethylenediaminetetraacetic acid (EDTA) (ED, ≥ 99%, 
CAS: 60-00-4); Fiske and Subbarow Reducer (F5428); glutathione reductase (G3664, 
CAS: 9001-48-3); HEPES (H3375, >99.5%, CAS: 7365-43-9); hydrogen peroxide 
solution (H1009, 30% w/w, CAS: 7722-84-1); hypoxanthine (H9377, >99%, CAS: 68-
94-0); L-glutathione oxidized (GSSG) (G4501, > 98%, CAS: 27025-41-8); L-
glutathione reduced (GSH) (G4251, > 98%, CAS: 70-18-8); methanesulfonic acid 
(>99.5%, CAS: 75-75-2); triton x-100 (X6878, CAS: 9002-93-1) xanthine oxidase from 
bovine milk (X1875, CAS: 9002-17-9); β-nicotinamide adenine dinucleotide reduced 
disodium salt hydrate (NADPH) (N8129, ≥ 97%, CAS: 606-68-8) were purchased from 
Sigma-Aldrich (Germany). Protein-assay dye reagent concentrate (phosphoric acid 
CAS: 7664-38-2 + methanol CAS: 67-56-1) was obtained from Bio-Rad Laboratories, 
Inc. (USA). 1,4-dithiothreitol (DTT) (≥ 99%, CAS: 3483-12-3); acetonitrile (99.8%, 
CAS 75-05-8); methanol (99.9%, CAS 67-56-1); natriumazide (sodium azide) (106688, 
≥ 99%, CAS: 26628-22-8); potassium chloride (KCl) (104936, 99.5%, CAS: 7447-40-
7); trichloroacetic acid (TCA) (100807, CAS: 76-03-9); TRIS-(hydroxymethyl)-
aminomethane (≥ 99%, CAS: 77-86-1) were acquired from Merck (Germany). 1-chloro-
2,4,-dinitrobenzene (CDNB) (24440, ≥ 98.0% GC, CAS: 97-00-7), molybdate reagent 
solution (puriss p.a.) and potassium dihydrogen phosphate (60218, 99.5%, CAS: 7778-
77-0) acquired from Fluka.  D(+) saccharose extra pure (16104, 99%,  CAS: 57-50-1); 
sodium chloride (NaCl) (puriss p.a., CAS: 7647-14-5); sodium hydroxide (NaOH) 
(purified, CAS: 1310-73-2) obtained from Riedel-de-Haën (Germany). 
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5.2.2 Diclofenac Exposure Assay (250 ng.L-1) 
Mussels M. galloprovincialis (n = 245, average shell length size: 60 ± 3 mm, width: 34 
± 2 mm) were collected from Ria Formosa Lagoon (Portugal) and transported alive to 
the laboratory. After shell-cleaning mussels were placed in separate aquaria 
acclimatizing during 7 days (n = 35, 1 mussel.L
-1
). Four aquaria were set as controls and 
three aquaria set for two-week exposure to 250 ng.L
-1
 DCF where at every 48 hours 
seawater was changed and DCF concentration re-established. Throughout the full 
duration of the experiment, all aquaria were kept at temperature (19.8ºC ± 1.6), salinity 
(34.8 ± 0.2), pH (7.8 ± 0.1) and oxygen saturation (97% ± 4.8). 
At each set up time (0, 3, 7, and 15 days), mussels (n = 20) were collected from control 
and exposure aquaria and subjected to individual shell biometric data measurement 
(length, width) and tissue dissection (gills, digestive gland and gonads). Single tissue 
samples were immediately frozen in liquid nitrogen and stored at -80ºC prior to 
biomarker analysis. For condition index (CI) assay, 15 mussels of each aquarium were 
individually weighted regarding the ratio:  
  =  
 hole so t tissue   et ei ht  
 hole bod  tissue  shell   et ei ht 
 x     
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5.2.3 Antioxidant Enzymes Analysis 
Each gills (n = 5) and digestive gland (n = 5) tissue sample was individually 
homogenized on ice with 20 mM TRIS buffer pH 7.6 (1 mM of EDTA + 0.5 M of 
saccharose + 0.15 M of KCl + 1 mM of DTT). Homogenates were centrifuged at 500 × 
g for 15 minutes (4ºC) and supernatants recentrifuged at 12,000 × g for 45 minutes 
(4ºC). Resulting cytosolic fraction volumes were measured and a 100 µl aliquot of each 
sample was collected for total protein quantification (Bradford, 1976). Samples were 
later purified applying Sephadex
®
 G-25 gel columns for the removal of low molecular 
weight proteins.  
Individual purified aliquots were analyzed (in triplicate) for each antioxidant enzyme 
activity spectrophometric assay, as following: 
SOD activity was determined by the 50%-reduction of cytochrome c absorbance 
generated by xanthine oxidase/hypoxanthine system at 550 nm (McCord and Fridovich, 
1969). SOD activity is expressed as arbitrary units (U).mg
-1
total protein.min
-1
.  
CAT activity was assessed by the absorbance decrease due to hydrogen peroxide (H2O2) 
consumption at 240 nm (Greenwald, 1985). CAT activity is expressed as µmol.mg
-1
 
total protein.min
-1
.  
GR activity was determined by the increase of co-factor NADPH oxidation using 
oxidized glutathione (GSSG) as substrate at 340 nm (adaptation from Cribb et al., 
1989). GR activity is expressed as µmol NADPH oxidized.mg
-1
 total protein.min
-1
. 
GST activity was performed following the conjugation of reduced glutathione (GSH) 
with 1-chloro-2,4- dinitrobenzene (CDNB) at 340 nm (adaptation from Habig et al., 
1974). GST activity is expressed as µmol of CDNB conjugate formed.mg 
-1
 total 
protein.min
-1
.  
5.2.4 LPO Analysis 
Gills (n = 10) and digestive gland (n = 10) tissue samples were individually 
homogenized with 20 mM TRIS-HCl buffer (pH 8.6) and butylated hydroxytoluene 
(BHT) in a 100:1 µl ratio on ice. Homogenates were centrifuged at 30,000 × g for 45 
minutes (4ºC) to precipitate cytosolic fraction. An aliquot was saved for total protein 
quantification (Bradford, 1976) and remaining cytosolic fraction was used to quantify 
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the formation of LPO by-products malondialdehyde (MDA) and (2E)-4-hydroxy-2-
nonenal (HNE) at 586 nm (adaptation from Erdelmeier et al., 1998). LPO levels are 
expressed as µmol MDA.g
-1
total protein. 
5.2.5 AChE Analysis 
Gills (n = 5) were homogenized individually in 100 mM Tris-HCl buffer (pH 8.0) and 
100:1 µl of Triton on ice. Homogenates were centrifuged at 12,000 ×g for 30 minutes 
(4ºC). Resulting supernants were separated in aliquots for total protein determination 
(Bradford, 1976) and AChE activity analysis following Ellman et al. (1961). AChE activity 
was determined measuring the increase of 5-mercapto-2-nitrobenzoate formation (yellow 
color) resultant from the reaction of thiocholine (substrate) with DTNB at 405 nm ( = 13.6 
mM
-1
.cm
-1
). AChE activity is expressed nmol.mg
-1
 total protein.min
-1
. 
5.2.6 ALP Analysis 
Sex-differentiated gonads (n = 10) were individually homogenized in 25 mM Hepes–NaOH 
buffer (pH 7.4) (125 mM NaCl + 1 mM DTT + 1 mM EDTA) on ice (adaptation from 
Blaise et al. (1999)). Homogenates were centrifuged at 12,000 × g for 30 minutes (2ºC) 
and pellets discarded. A supernant aliquot was reserved to determine total protein content 
(Bradford, 1976). Remaining cytosolic fractions were adjusted with 35% acetone and 
centrifuged at 10,000 ×g for 5 minutes. Pellets were later dissolved with 1 M NaOH and 
subjected to a 60ºC heating bath for 30 minutes. Phosphomolybdenum method was applied 
to quantify inorganic phosphate (KH2PO4) concentration at 660 nm (Stanton, 1968). ALP 
concentration is expressed as μg [PO4].mg
-1
 total protein. 
5.2.7 Statistical Analysis 
Results are presented as mean ± standard deviation at each set of time. Two-way 
ANOVA was performed using SIGMAPLOT
®
 to test differences between control and 
DCF exposed mussels in each tissue at each set of time. Holm-Sidak test was applied on 
biomarker difference discrimination within and when applicable between tissues 
through time. Pearson correlations between biomarkers were performed using 
XLSTAT
®
 2010 to verify each biomarker dependency. PCA were accomplished using 
XLSTAT
®
 2010 to assess the variability associated to each biomarker factorial weight 
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at each set of time and treatment group, for gills and digestive gland individually as well 
for gills vs. digestive glands. ALP levels in gonads were not considered in PCAs and 
AChE activities were only applied in gills PCA. Statistical significance was defined at p 
< 0.05 level. 
5.3 Results 
5.3.1 Condition index 
No significant differences were found regarding CI (%) between controls and DCF-
exposed mussels throughout the duration of the experiment (min: 13.8% ± 2.1, max: 
15.8% ± 3.0) (p > 0.05). 
5.3.2 Antioxidant Enzymes 
Generally, antioxidant enzyme basal activities were higher in gills than in digestive 
glands, with the exception of CAT activity which were similar in both tissues.  
SOD activity was stable in controls throughout the experiment (Figures 5.1A and B). 
DCF-exposed gills showed a significant 2.5-fold higher SOD activity on the 3
rd
 day (p < 
0.05) while for DCF-exposed digestive gland the increment was less pronounced and 
only significant after the first week (2.1-fold higher than control). Furthermore, both 
tissues exhibited a progressive SOD activity inhibition by the end of the experiment, 
being only significantly lower than controls in gills (p < 0.05). In gills, CAT activity 
showed no significant differences within controls and between exposed gills, although 
average values were lower in the later ones (p > 0.05). In digestive gland, even though 
controls exhibited a slight but not significant fluctuation (p > 0.05) exposed mussels 
clearly showed an increase in CAT activity after the 3
rd 
day (1.5-fold higher than 
controls), progressively declining to lower levels than controls by the end of exposure. 
This enzyme is positive related with SOD activity in gills (r = 0.90, p < 0.05 in Table 
5.3). Likewise, GR activity fluctuation in gills showed no differences in the controls (p 
> 0.05) and in DCF exposed mussels being positively related with both SOD in gills and 
also CAT in digestive gland (r = 0.984 and r = 0.902, p < 0.05 respectively; Table 5.3). 
These relationships are due to the concomitant 3.1-fold increase of GR activity in 
exposed gills on the 3
rd
 day and following decrease to control activities after two weeks. 
Furthermore in digestive gland, even though GR activities varied within controls, the 
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equally progressive increase of GR activity from the beginning of the exposure until the 
first week followed by a decrease to lower values than controls after two weeks (p < 
0.05) explains the direct relationship between GR and SOD activities in this tissue (r = 
0.817, p < 0.05; Table 5.3). Phase II GST activities decreased overtime in control’ gills, 
and after the first week in digestive glands (p < 0.05). In exposed-tissues GST activity 
was generally higher but not different from controls, except for day 7. Nevertheless, 
unlike any other enzymes, GST activities was directly related between tissues (r = 
0.925, p < 0.05; Table 5.3) and with SOD activity in digestive gland (r = 0.793 with 
gills and r = 0.843 with digestive glands, Table 5.3).  
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Figure  5.1: Antioxidant enzyme activities (mean ± standard deviation) in controls and DCF exposed M. galloprovincialis tissues. SOD activity in gills (A) and digestive 
gland (B); CAT activity in gills (C) and digestive gland (D); GR activity in gills (E) and digestive gland (F); GST activity in gills (G) and digestive gland (H). 
Different letters express significant differences (p < 0.05). 
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Figure 5.1 (Continuation): Antioxidant enzyme activities (mean ± standard deviation) in controls and DCF exposed M. galloprovincialis tissues. GR activity in gills 
(E) and digestive gland (F); GST activity in gills (G) and digestive gland (H). Different letters express significant differences (p < 0.05). 
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Table 5.3: Pearson correlations between biomarkers in gills (G), digestive gland (DG) and sex-differentiated gonads (F or M) 
Variables SOD  G SOD GD CAT G CAT DG GR G GR DG GST G GST DG LPO G LPO DG AChE ALP F ALP M 
SOD  G -             
SOD GD 0.495 -            
CAT G -0.733 -0.447 -           
CAT DG 0.902 0.415 -0.410 -          
GR G 0.984 0.421 -0.697 0.903 -         
GR DG 0.450 0.817 -0.420 0.296 0.318 -        
GST G 0.657 0.793 -0.689 0.577 0.569 0.656 -       
GST DG 0.534 0.843 -0.505 0.539 0.489 0.527 0.925 -      
LPO G 0.711 0.166 -0.801 0.553 0.738 0.073 0.577 0.475 -     
LPO DG 0.831 0.005 -0.572 0.731 0.889 0.024 0.201 0.091 0.738 -    
AChE 0.278 0.871 -0.457 0.071 0.244 0.656 0.524 0.617 0.079 -0.070 -   
ALP F 0.027 0.507 -0.222 -0.143 0.089 0.173 0.083 0.304 0.012 -0.038 0.827 - 
 ALP M -0.007 -0.445 -0.204 -0.286 0.060 -0.231 -0.546 -0.655 0.093 0.401 -0.073 0.216 - 
Bold values are different from zero at p < 0.05. 
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5.3.3 LPO  
LPO levels were generally higher in gills than in digestive gland (Figures 5.2A and B). 
In gills, controls showed a significant decrease from the first week to the second, 
although not different from the remaining controls. In exposed gills, LPO levels were 
quite transient, with higher levels found on the 3
rd
 and 15
th
 day (not different from 
respective controls) interposed by a significant 2.3-fold decrease after the first week. 
Additionally, LPO levels in gills are inversely related to CAT activities (r = -0.801, p < 
0.05; Table 5.3). In digestive glands, LPO levels progressively increased in controls 
even if only significantly at the beginning of the experiment (p < 0.05), while in DCF-
exposed ones alike for gills, the pattern oscillated from a significant 2.4-fold increase on 
the 3
rd 
day to a 2.9-fold decrease after the first week (p < 0.05), followed by a later 
increase to levels not different from controls by the end of the exposure treatment. 
Finally, LPO levels in digestive glands are directly related with both SOD and GR 
activities in gills (r = 0.831 and r = 0.889 respectively, p < 0.05; Table 5.3).
Chapter 5: Effects of NSAID diclofenac in mussel M. galloprovincialis 
 
196 | C h a p t e r  5  
 
 
0.0
0.2
0.4
0.6
0.8
1.0
0 3 7 15
LP
O
 (
µ
m
o
l M
D
A
.g
-1
 p
ro
te
in
) 
0.0
0.2
0.4
0.6
0.8
1.0
0 3 7 15
LP
O
 (
µ
m
o
l M
D
A
.g
-1
 p
ro
te
in
) 
 
B A 
ab 
ab a a 
b 
b 
ab 
c 
b 
a 
b 
d 
ab 
b 
Figure 5.2: LPO (mean ± standard deviation) in mussels M. galloprovincialis control and DCF-exposed gills (A) and digestive glands (B) over 15 days. Different 
letters express significant differences (p < 0.05). 
Exposure time (days)  
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5.3.4 AChE  
AChE activity in gills (Figure 5.3) did not vary within controls overtime (p > 0.05), 
while in exposed gills AChE activity gradually increased, reaching a significant higher 
levels after the first week (2.1-fold higher than control), and falling again to control 
levels by the end of the experiment. Furthermore, AChE activity was directly related 
with SOD activity in digestive gland and ALP levels in females-gonads (r = 0.871 and r 
= 0.827 respectively, p < 0.05; Table 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
ab 
b b 
b b 
ab 
Figure 5.3: AChE activity (mean ± standard deviation) in control and exposed mussels M. 
galloprovincialis gills to 250 ng.L
-1
 of DCF during 15 days. Different letters express significant 
differences (p < 0.05). 
Exposure time (days)  
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5.3.5 ALP  
ALP levels (Figure 5.4) varied significantly mostly in female gonads compared to 
males’. In female-controls ALP levels significantly decreased over the first week 
(overall min: 390 ± 116 μg PO4.mg
-1
 protein) followed by a significant increase at the 
end of the experiment whereas exposed-female gonads exhibited an inverse evolution 
pattern in which ALP levels progressively increased over the 3
rd 
day (1.9-fold higher 
than control) and first week reaching the maximum: 1284 ± 212 μg PO4.mg
-1
protein 
approximately 3.3-fold higher than controls (p < 0.05). In exposed-males ALP levels 
were more consistent throughout time than in females, being 1.5-fold higher than 
control on the 3
rd
 day (p < 0.05) which in turn was lower than remaining controls (p < 
0.05). Finally, except for the first week, no other differences were observed between 
exposed males and females which increased significantly over time.  
 
 
 
 
 
 
 
 
  
Exposure time (days)  
 Figure 5.4: ALP levels (mean ± standard deviation) in control and exposed mussels M. 
galloprovincialis sex-differentiated gonads to 250 ng.L
-1
 of DCF during 15 days. Different letters 
express significant differences (p < 0.05). 
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5.3.6 PCA in Gills and Digestive Gland 
In the gills (Figure 5.5A) PCA represents 81% of total variance (TVar). The first 
component (PC1) explains approximately 52% of the TVar, giving evidence to the 
separation between controls and DCF-exposed gills by the antagonist distribution of 
CAT activity in relation to the remaining enzymes activities and particularly negatively 
related to LPO levels (see Table 5.3). Two aspects are underlined in PC1: day 3 DCF-
exposed gills are more distant from controls due to significant higher and positively 
related SOD and GR activities (see Table 5.3) and LPO levels, while the opposing 
lower CAT activity explain day 15-exposed gills clustering behavior with controls. The 
second component explains 29% of the TVar showing CI, CAT, GR and SOD activities 
and LPO divergent distribution compared to AChE and GST activities. AChE activity 
induction is the major influencing variable on day 7 DCF-exposed gills dispersal. 
In digestive gland, PCA (Figure 5.5B) represents almost 85% of TVar, showing a more 
balanced influence of both components: PC1 (48%) and PC2 (37%) of TVar. AChE 
activity was not included as it was only measured in gills. PC1 clearly clusters most 
controls and particularly day 15-exposed digestive gland opposing CI to overall 
biomarkers responses. Moreover and particularly highlighted by the PC2, while day 3 
DCF-exposed digestive gland was further influenced by higher levels of LPO and CAT 
activity, day 7 DCF-exposed digestive gland dispersal was associated by the positive 
relationship between SOD, GST and GR activities combined to a significantly lower 
LPO level. 
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Figure 5.5: PCA concerning (A) SOD, CAT, GR,  GST, AChE activities, LPO levels and CI on 81% of total 
variance in M. galloprovincialis gills (○– gills controls,  ● – DCF exposed gills)  - (B) SOD, CAT, GR, GST 
activities, LPO levels and CI on 85% of total variance in digestive gland (♦ – digestive gland controls, ◊ – DCF 
exposed digestive gland) between groups over exposure time (days: 0, 3, 7 and 15) 
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PCA (Figure 5.6) (82% of TVar) represents a tissue-specific integration between 
antioxidant enzyme activities and LPO levels in which most variance is represented by 
PC1 (61% of Tvar) and PC2 only explains 22%. This PCA gives evidence 1) to the 
separation between tissues, as gills (non and DCF-exposed) exhibit higher activities of 
antioxidant enzymes and LPO than digestive glands (except CAT on day 3 DCF-
exposure), 2) to an overall clustering of both tissues controls in relation to most exposed 
treatment groups with the exception of 15 DCF-exposed gills which in turn give 
evidence to an antioxidant system recovery in this tissue, 3) the higher effect of DCF 
exposure over the antioxidant system in both tissues on the 3
rd 
day due to higher SOD 
and GR activities (in gills) and the simultaneous enhancement of CAT activity and LPO 
levels (in digestive glands).  
 
 
 
 
 
 
 
Figure 5.6: PCA representing 82% of total variance of tissue-specific integration of antioxidant 
enzyme activities (SOD, CAT, GR and GST) and LPO levels between controls and DCF exposed 
mussels M. galloprovincialis (● – gills control,  ○ – DCF exposed-gills, – digestive gland controls 
and ◊ – DCF exposed-digestive gland) between groups  over exposure time (days: 0, 3, 7 and 15) 
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5.4 Discussion 
This study confirms that even not significantly affected on its general physiological 
condition, mussels’ exhibit significant biomarker responses when continuously exposed 
to an environmental realistic concentration of DCF (250 ng.L
-1
) during two weeks. 
5.4.1 Oxidative Stress 
Invertebrates, like mammals, possess an inherent antioxidant defense system which 
prevents reactive oxygen radicals (ROS) derived-effects such as oxidative stress, LPO 
and apoptosis through the action of either non-enzymatic scavengers (e.g. glutathione-
GSH), specific antioxidant enzymes (like, SOD, CAT and GR) and Phase II 
biotransformation enzyme GST which enables detoxification converting parental 
compounds into more extractable hydrophilic metabolites through its conjugation with 
reduced GSH (Viarengo et al., 1995; Halling-Sorensen et al., 1998; Van der Oost et al., 
2003). 
Although DCF biotransformation after entering the body in aquatic organisms is yet 
unknown (Oviedo-Gómez et al., 2010), several studies report the ability of NSAIDs to 
cause oxidative stress in aquatic species (Oviedo-Gómez et al., 2010; Quinn et al., 
2011; Schmidt et al., 2011; Gonzalez-Rey and Bebianno, 2011; 2012 - Chapters 3A -B). 
In mammals oxidative stress production by DFC is both linked to CYP-mediated DCF-
bioactivation as well as p-quinone imines (derived from hydroxylated metabolites) 
involvement in redox cycling (Boesterli, 2003). Furthermore, NSAIDs inhibits COX 
pathway and consequently prostaglandins synthesis which is also associated to enhance 
basal ROS production via AA accumulation (Ardaillou et al., 1987; Cocco et al., 1999; 
Delaporte et al., 2006). 
Nevertheless, in this study antioxidant responses toward DCF exposure were quite time-
specific and transient, in which the results showed a clearer enhancement of antioxidant 
activities in gills than in digestive glands (Figures 5.1 and 5.6) except for CAT activity. 
Only over the 3
rd
 day a positive induction was shown regarding SOD and GR activities 
in gills and CAT activity in digestive glands (Table 5.3, Figure 5.6). These results 
indicate that antioxidant system is readily triggered in gills by the enhancement of SOD 
activity which is called to convert short-term DCF-derived ROS (such as super anion 
radical - O2
-
) into to less toxic molecules (like H2O2), which potentiates concomitant 
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CAT activity up regulation in digestive glands conversion of excess H2O2 into H2O and 
O2 (Viarengo et al., 1995; Van der Oost et al., 2003). At the same time the increase of 
gills-GR activity reveals the need of an increased conversion of oxidized glutathione 
(GSSG) into reduced GSH which in higher concentrations will act as a direct ROS 
scavenger and cofactor in this tissue cytosol (Viarengo et al., 1995). Moreover, NSAID 
radicals in mammals can oxidize GSH and NADPH based on peroxidase-catalyzed 
production (Boelsterli, 2003). Even so, in this study the activity of GST was not altered 
significantly in exposed tissues (Figure 5.1G and H) and showed to be directly related 
with digestive gland-SOD rather than with GR or CAT activity (Table 5.3). GST and 
CAT activities were reported to be directly related to M. galloprovincialis digestive 
glands exposed to antilipidemic bezafibrate, anticonvulsant carbamazepine, β-blocker 
propranolol and NSAID ibuprofen (Gonzalez-Rey and Bebianno, 2012 - Chapter 3B; 
Canesi et al., 2007; Martín-Díaz et al., 2009; Franzellitti et al., 2011). However, in 
bivalves D. polymorpha and Mytilus spp. exposed to a higher concentration of DCF (1 
µg.L
-1
) GST was inducted along with LPO increase in visceral mass and digestive gland 
(Quinn et al., 2011; Schmidt et al., 2011) which confirms that at this concentration DCF 
does not promote detoxification derived from Phase II conjugation with available 
reduced GSH. 
In addition, DFC exposure only induced clear LPO levels in mussels’ digestive gland 
over the 3
rd
 day which upturn was positively related with SOD and GR activities in gills 
highlighting evidences of transport between tissues related to its specific metabolic 
functionality. The significant LPO decrease afterwards attests those enzyme activities 
parallel effectiveness on the counteraction of ROS favoring the recovery of antioxidant 
system in this tissue. Whereas in exposed gills, LPO levels were generally not different 
from controls, showing an effective LPO decrease on the 7
th 
day which was further 
associated to its negative relationship with the overall inhibitory tendency of CAT 
activity (p > 0.05). NSAID ibuprofen exposed mussels also exhibited higher LPO in 
digestive gland directly related with GR activity, while in gills a much higher LPO level 
was directly associated to SOD activity enhancement with concomitant inhibition of 
CAT, GR and GST activities. Even though, the mussel exposure to NSAIDs ibuprofen 
and DCF promoted a different set of tissue-specific antioxidant responses over the first 
days, both experiments showed an overall recovery of tissues by the end of the 
experiment (Gonzalez-Rey and Bebianno, 2011; 2012 - Chapter 3). 
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5.4.2 Neurotoxic Effect and Endocrine Disruption 
AChE activity is critical in neuromuscular system functions (such as muscular 
contraction) as the promoter of neurotransmitter acetylcholine (ACh) hydrolysis to 
choline and acetic acid. AChE-inhibition is considered as a biomarker of exposure to 
several contaminants such as organophosphorus pesticides, detergents and APIs 
(Ricciardi et al., 2006; Matozzo and Marin, 2005; Solé et al., 2010). However, in this 
study DCF clearly induced AChE activity in gills during the first week, which is only in 
agreement with the results of an exposure of the same species to FLX (75 ng.L
-1
) 
(Gonzalez-Rey and Bebianno, in press - Chapter 4) whereas AChE activity was 
inhibited by other APIs paracetamol (23 and 403 μg.L-1) in M. galloprovincialis gills 
(Solé et al., 2010) and diazepam (4, 20 and 100 nmol per mussel) in E. complanata 
visceral mass (Gagné et al., 2011). AChE induction has been associated to cell 
apoptosis in various types of human and mammals cells being hypothesized that AChE 
is released after cell membrane disruption (Zhang et al., 2002). Also a link between 
estrogenic and AChE activity was reported in mice brain cells, in which an 
enhancement of AChE was observed when isoflavones (phytoestrogens) bind to the 
estrogen receptor (Isoda et al., 2002; Mun’im et al., 2004) and in the presence of low 
levels of estradiol (Tsuchiya et al., 2004).  
Vitellogenins (Vtg) are naturally synthesized in females and inactive in males, the 
increase of ALP concentration as result of Vtg alkali hydrolysis is considered a sign of 
endocrine disruption (ED) by estrogenic compounds (like pesticides, detergents, 
pharmaceuticals, industrial chemicals, etc.) particularly in males (Blaise et al., 1999; 
Gagné et al., 2002; Porte et al., 2006; Matozzo et al., 2008). In this study, the induction 
of ALP levels was more evident in DCF-exposed females than males (Figure 5.4). Even 
though, the concomitant increase of ALP levels in controls, particularly in males may 
have overshadowed the significance of DFC exposure in sex-differentiated gonads. In 
M. galloprovincialis exposed to 250 ng.L
-1 
NSAID IBU and 75 ng.L
-1 
antidepressant 
FLX shown respectively much stronger ALP levels enhancement and general ALP 
levels depletion in exposed-gonads (Gonzalez-Rey and Bebianno, 2012; 2013 – Chapter 
3 and 4).  
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In this sense, the direct relationship between ALP levels in females and AChE (Table 
5.3) give evidence to an unknown DFC-derived interference with mussels’ estrogen 
receptors rather than inducing neurotoxic effects just due to ACh accumulation. 
However this outcome can only be complimented by verifying the estradiol and 
prostaglandins levels in mussels’ tissues. 
Additionally, unlike the unalterated ALP levels observed after the exposure of mussels 
D. polymorpha and Mytilus spp to a higher concentration of DCF (1 µg.L
-1
)
 
(Quinn et 
al., 2011; Schmidt et al., 2011) the present results showed some evidences of endocrine 
disruption at a more environmentally relevant concentration especially in females. 
5.5 Conclusions 
In conclusion, mussels exposed to DCF were affected mostly during the first days 
showing later overall recovery responses. The antioxidant system was swiftly triggered 
particularly in gills and evidence of damage was observed in digestive glands. Likewise, 
DCF significantly induced a direct relationship between AChE activity and ALP levels 
in females . Finally, the enhancement of AChE does not give evidence to the breakdown 
of cholinergic neurotransmission functions but rather to potential estrogenic activity 
alteration or cell apoptosis, nevertheless further assessment concerning estradiol and 
prostaglandin content in mussel tissues would greatly clarify this outcome.   
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6 Effect of APIs mixtures in mussel M. galloprovincialis 
through a multibiomarker approach 
Abstract 
Active pharmaceutical ingredients (APIs) are considered environmental emergent 
contaminants. APIs occurrence in surface water has been widely reported resulting from 
incomplete waste water treatment plants (WWTPs) removal processes and improper 
disposal. The assessment of potential effects in non-target organisms is still very scarce. 
Mussels Mytilus galloprovincialis were exposed to single environmental relevant 
concentrations of 250 ng.L
-1 
ibuprofen (IBU), 250 ng.L
-1
 diclofenac (DCF) and 75 ng.L
-
1 
fluoxetine (FLX) and as mixtures without (MIX 1) and with 5 µg.L
-1 
copper (Cu) 
(MIX 2) during two weeks. A multibiomarker approach was applied to assess APIs-
derived responses in exposed mussels: i) condition index (CI); ii) superoxide dismutase 
(SOD), catalase (CAT), glutathione reductase (GR) and phase II biotransformation 
glutathione-S-transferase (GST) enzymatic activities and lipid peroxidation levels 
(LPO) associated to oxidative stress; iii) acetylcholinesterase (AChE) activity related to 
neurotoxic effect and iv) vitellogenin-like proteins by alkali-labile phosphate (ALP) 
method in sex-differentiated gonads linked to endocrine disruption. APIs mixtures 
induced transient antioxidant enzymes activity patterns (particularly MIX 1) which were 
not enough to prevent LPO damage particularly in MIX 2 exposed gills. Moreover, 
neither one of the mixtures altered AChE activity alterations, while both enhanced 
vitellogenin in females over first week. Finally, this study confirms variable tissue and 
time specific biomarkers susceptibility of M. galloprovincialis to single and APIs 
mixtures at environmental relevant concentrations and several interactions between each 
mixture component on each biomarker outcome.  
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6.1 Introduction 
All APIs’ therapeutic classes have been detected in surface waters (Kümmerer et al., 
2009; Santos et al., 2010) (see previous chapters, and particularly Chapter 2). In an 
ecotoxicological viewpoint it is essential to consider the interactions of multiple 
stressors and associated effects regarding biochemical responses alterations of exposed 
organisms since they may differ entirely from each contaminant singular mode of 
action. Therefore the assessment of APIs mixtures exposure effects is particularly 
relevant since APIs are biological active compounds. Multistressor ecotoxicity 
assessment is very complex relaying on the assumption of a concerted action between 
contaminants whether chemicals act on an independent non-interactive manner (“simple 
similar action”, “dose addition” or “independent action”) or in an interactive one 
producing combined effects which can be synergetic or antagonistic departed from the 
additivity between individual components (EPA, 2002; IPCS, 2009). Regardless of the 
increasing research effort focused on the assessment of potential effects of APIs 
exposure in non-target organisms in which most focus in single APIs exposure (see 
Kümmerer et al., 2009; Santos et al., 2011 – Chapter 3-5) to our knowledge there are 
very few studies addressing the effects of either binary or multiple pharmaceutical 
mixtures exposure in aquatic organisms (as single species or as microcosms studies) 
(Table 6.1).   
As mentioned previously, the selected NSAIDs IBU and DCF and SSRI FLX are 
amongst the most frequently detected in surface waters such reaching up to 2.4 µg.L
-1
, 
15 µg.L
-1
  and 0.6 µg.L
-1
 respectively (Jux et al., 2002; Pailler et al., 2009; Benotti and 
Brownawell, 2008) and are associated to several deleterious biological end-points in 
mussel species (see Chapters 3-5) regarding oxidative stress and DNA damage 
induction, physiological (e.g. growth, swimming/mobility, feeding and territorial 
behavior decrease), cytotoxicological (e.g. cell viability decrease) and reproductive 
fitness (e.g. vitellogenesis, embryonic development and spawning induction) alterations. 
Even though, it is absolutely unreal to mimic a true environmental scenario through 
laboratory conditions it is essential to address the potential exposure effects derived 
from different types of APIs mixtures using a species proven to be extremely vulnerable 
to APIs discharges such as mussel M. galloprovincialis testing possible synergistic or 
antagonistic interactions between APIs and between APIs with other commonly 
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detected aquatic contaminants such as metals and in particular copper (Cu) (Chapter 1). 
The latter despite of being an essential metal and naturally occurring in ranges between 
0.20 to 30 µg.L
-1
,
 
up to 200 mg.L
-1 
in surface waters adjacent to mining areas (EPA, 
2007), was reported to promote ROS-generation (mostly by its involvement in Fenton-
type redox reactions) with subsequent toxic effects induction in biomolecules, namely 
enzymatic activities alteration and LPO (Pipe et al., 1999; Dondero et al., 2006; 
Company et al., 2004; Funes et al., 2006; Maria and Bebianno, 2011).  
In this sense, the aim of this Chapter focuses on the effects of two mixtures of multiple 
stressors: one induced by a mixture od the APIS used on the previous chapters and the 
other using the same mixture od emerging contaminants (APIs) combined with a 
classical contaminant (Cu) and compare the effects on mussel M. galloprovincialis 
single APIs exposure (Gonzalez-Rey and Bebianno, 2011; 2012; 2013 – see preceding 
Chapters 3-5). Mussels were exposed to two mixtures consisting one of 250 ng.L
-1
 IBU 
+ 250 ng.L
-1
 DCF + 75 ng.L
-1
 FLX (mixture 1) and the other of 250 ng.L
-1
 IBU + 250 
ng.L
-1
 DCF + 75 ng.L
-1
 FLX + 5 µg.L
-1
 of Cu (mixture 2) for two weeks. The main goal 
was to compare the effects on biomarkers of susceptibility (antioxidant enzymes SOD, 
CAT, GR and GST), damage (LPO), neurotoxicity (AChE) and endocrine disruption in 
mussels’ gills, digestive gland and in sex-differentiated gonads and compared them with 
previously obtained from each selected APIs single exposure.  
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Table 6.1: Effects of APIs mixtures in aquatic organisms 
Species API mixture Concentration (µg.L
-1
) Test  Biological end-point Effect Reference 
Algae              
Desmodesmus 
subspicatus 
CLA, CAR, IBU-Na, DCF-Na, 
NAP-Na, CAP, METF, PRO 
and MET 
1 x 102, 0.32 x 103, 3.2 x 
103, 10 x 103, 32 x 103, 100 
x 103, 320 x 103 
acute and 
chronic  
3 – 7 days EC50 average growth rate   EC50: 5.8 mg.L
-1 (PRO) - 
320 mg.L-1 (MET and 
NAP) 
Cleuvers et 
al., 2003 
 DCF, IBU, NAP and ASA 1 x 103, 3.2 x 103, 1 x 104, 
32 x 103, 1 x 105, 3.2 x 105 
acute 24, 48 hours EC50 immobilization   EC50 (72 - 626 mg.L
-1) Cleuver et al., 
2004 
Dunaliella 
tertiolecta 
binary mixture: TRI with FLX 
and SIM with CLA 
1.6, 4.9, 14.8, 44, 133 
(TRI); 2.7, 8, 24, 72, 216 
(FLX); 1560, 6250, 25 x 
103, 1 x 105, 4 x 105 (SIM 
and CLA)  
acute 0, 24, 48, 72, 
96 hours 
EC50 cell density  cell density reduction and 
additive effect of mixtures 
De Lorenzo 
and 
Flemming, 
2008 
Plantae             
Lemna minor CLA, CAR, IBU-Na, DCF-Na, 
NAP-Na, CAP, METF, PRO 
and MET 
1 x 102, 0.32 x 103, 3.2 x 
103, 10 x 103, 32 x 103, 1x 
105, 3.2 x 105  
acute and 
chronic  
3 – 7 days EC50 average growth rate   EC50:  7.5 mg.L
-1 (DCF) - 
> 320 mg.L-1 (MET) 
Cleuvers et 
al., 2003 
Crustacean             
Daphnia magna CLA, CAR, IBU-Na, DCF-Na, 
NAP-Na, CAP, METF, PRO 
and MET 
0.1 x 103, 0.32 x 103, 3.2 x 
103, 10 x 103, 32 x 103, 1x 
105, 3.2 x 105 
acute and 
chronic  
48h EC50 immobilization   EC50 range: 7.5 mg.L
-1 
(PRO) - 174 mg.L-1 (NAP) 
Cleuvers et 
al., 2003 
  FLX and CLA 36 (FLX), 10 or 100 (CLA) acute and 
chronic  
6 – 30 days survival, growth and 
reproduction  
 
 mortality and 
malformations 
Flaherty and 
Dodson, 2005 
  DCF, CAR, MET and EE2  1 x 10-4,  0.36, 0.50, 1.2  chronic 
(multi-
gerational) 
 age of first reproduction, 
body length of females 
and neonates and number 
of offspring 
 age reduction of first 
reproduction and increased 
body length at ﬁrst 
reproduction. Impairments 
not predicted by the 
response to single 
substances 
 
Dietrich et 
al., 2010 
 DCF, IBU, NAP and ASA 1 x 103, 3.2 x 103, 10 x 103, 
32 x 103, 100 x 103, 320 x 
103  
acute  EC50 average growth rate   EC50 from 68 - 166 mg.L
-1 Cleuver et al., 
2004 
 
 
Hyalella azteca PAR, DCF, GEM, IBU, NAP, 
ASA and TRI  
1 x 10-4 each multi-
generational 
 survival, mating, body 
size or reproduction 
 sex ratio increase, 17% more 
males 
Borgmann 
et al., 2007 
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4
 nmol/animal 
5
 toxic units 
Table 6.1: (Continuation). 
Cnidaria        
Hydra attenuata BEZ, CAR, SULF, GEM, 
TRIM, SUL, NAP, NOV, 
OXY, IBU and CAF 
(mother solution: 7.5 x 10-3, 
0.033, 0.046, 0.059, 0.063, 
0.099, 0.217, 0.33, 0.44, 1.2, 
22.2 (respectively) exposed 
to serial dilutions 0.1, 1, 10, 
100, 1000, 10000x 
acute and 
chronic  
96 hours LC50 and EC50 
morphology, feeding, 
hydranth number and 
attachment 
 significant decrease in 
morphology at 0.1, 10 and 
100× and significant increase 
at 1000×. All parameters 
significantly reduced at 
10000× 
Quinn et 
al., 2009 
Bivalve             
Mytilus edulis 
trossulus 
binary mixtures: DCF and 
PRO 
100, 1000 of concentration 
ratios of PRO75/DCF25; 
PRO50/DCF50 and 
PRO25/DCF75 
chronic 14 and 19 
days 
 "scope for growth”  lower "scope for growth" for 
PRO25/DCF751000 and 
PRO50/DCF501000 
(synergetic effect) 
Ericson et 
al., 2010 
Mytilus 
galloprovincialis 
BEZ and GEM (molar ration 
1:1) 
0.01, 0.1, 14  acute  24 hours immune and digestive 
gland functions  
 concentration-dependent  
lysosomal membrane 
destabilization and 
extracellular lysozyme 
release similar to single 
exposure 
Canesi et 
al., 2007 
Fish             
Danio rerio 
(liver ZFL cells) 
ATE, BEZ, CAR, IBU, RAN, 
SAL, CYC, HYD, FUR, CIP, 
LIN, OFL, SUL 
environmental concentration 
levels 
acute 72 hours gene expression profiles   inhibition of cells 
proliferation in vitro; 
transcriptional repression and 
several genes up regulation  
Pomati et 
al., 2007 
Oncorhynchus 
mykiss (cell line 
RTL-W1) 
Similar mixtures between 
NSAIDS (IBU, NAP, KET, 
DCF); antidepressants (FLX, 
PAX, FLU); fibrates (FEN, 
CLA, BEZ and GEM) and 
dissimilar mixtures (DCF, 
BEZ, FLU and musk ketone 
and galaxolide)(less toxic); 
(IBU, CLA, FLX and musk 
xylene and celestolide) (more 
toxic) 
0.1, 0.5, 1, 2, 55  acute  EC50 cell viability  additive effect of mixture: 7 - 
50  µM (antidepressants), 
160-260 µM (NSAIDs), 20-
380  µM (lipid regulators); 
combined toxicity higher 
than additive in dissimilar 
mixtures 
Schnell et 
al., 2009 
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6
 µmol.L-1 
7
 nM 
Table 6.1: (Continuation). 
Pimephales 
promelas 
BUP, FLX, SER and VEN 2.2 x 10-3, 28 x 10-3 (FLX); 
1.3 x 10-3, 22 x 10-3 (SER); 
117 x 10-3, 798 x 10-3 
VEN); 50 x 10-3, 466 x 10-3 
(BUP)  
chronic  reproductive anatomy, 
physiology, and adult 
behavior 
 effects not carried over 
compared to single exposure 
nor become additive within 
antidepressant mixture. 
Schultz et 
al., 2011 
Microcosm 
experiment 
       
Lemna gibba 
and 
Myriophyllum 
sibiricum 
ATO, PAR, CAF, SUL, CAR, 
LEV, SER and TRIM 
0, 0.044, 0.608, 2.664, and 
24.5386   
acute and 
chronic  
35 days EC10, EC25, EC50 and 
phytoxicity 
 concentration-dependent 
response and phytotoxic 
injury  
Brain et 
al., 2004 
phytoplankton, 
zooplankton, 
macrophytes, 
bacteria species 
and fish Lepomis 
gibbosus 
IBU, FLX and CIP 6 x 103, 10 x 103 (low 
treatment); 6 x 104, 1 x 105 
(medium treatment);  6 x 
105, 1 x 106 (high treatment) 
acute and 
chronic  
35 days mortality, diversity, 
abundance, growth  
 mortality (Lepomis gibbosis); 
diversity decrease and 
abundance increase 
(phytoplancton and 
zooplancton), growth 
decrease (macrophytes), 
abundance change (bacteria) 
at HT and or/MT 
Richards et 
al., 2004 
Zooplancton: 
Rotifera, 
Cladocera, 
Copepoda 
FLX, FLU and SER 0, 91, 188, 424, 8727 acute and 
chronic  
4, 35 days abundance and species 
richness  
 abundance decrease (Rotifera 
and Copepoda); species 
richness (Copepoda) 
Laird et al., 
2007 
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6.2 Materials and Methods 
6.2.1 Chemicals 
All the applied chemicals were obtained as described: ibuprofen (2-(4-isobutylphenyl) 
propanoic acid) (I4883, ≥ 98% GC, CAS:15687-27-1); diclofenac sodium salt (D68990, 
CAS: 15307-79-6); R-(-) fluoxetine hydrochloride (F1678, > 98%, CAS: 114247-09-5); 
tetramethoxypropane (MDA) (108383, CAS: 102-52-3); 1-methyl-2-phenylindole 
(99%, CAS: 3558-24-5); 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) (D8130, ≥ 98% 
TLC, CAS: 69-78-3); acetyl thiocholine iodide (ATC) (A5751, ≥ 98% TLC, CAS: 
1866-15-5); bovine albumin serum (BSA) (A9418 > 98%, CAS: 9048-46-8); butylated 
hydroxytoluene (BHT) (B1378, ≥ 99.0% GC, CAS: 128-37-0); cytochrome c from 
equine heart (C7752, > 95%, CAS: 9007-43-6); diethylenetriaminepentaacetic acid 
dianhydride (DTPA) (D6148, CAS: 23911-26-4); ethylenediaminetetraacetic acid 
(EDTA) (ED, ≥ 99%, CAS: 60-00-4); Fiske and Subbarow Reducer (F5428); 
glutathione reductase (G3664, CAS: 9001-48-3); HEPES (H3375, > 99.5%, CAS: 7365-
43-9); hydrogen peroxide solution (H1009, 30% w/w, CAS: 7722-84-1); hypoxanthine 
(H9377, > 99%, CAS: 68-94-0); L-glutathione oxidized (GSSG) (G4501, > 98%, CAS: 
27025-41-8); L-glutathione reduced (GSH) (G4251, > 98%, CAS: 70-18-8); 
methanesulfonic acid (> 99.5%, CAS: 75-75-2); triton x-100 (X6878, CAS: 9002-93-1) 
xanthine oxidase from bovine milk (X1875, CAS: 9002-17-9); β-nicotinamide adenine 
dinucleotide reduced disodium salt hydrate (NADPH) (N8129, ≥ 97%, CAS: 606-68-8) 
were purchased from Sigma-Aldrich (Germany). Protein-assay dye reagent concentrate 
(phosphoric acid CAS: 7664-38-2 + methanol CAS: 67-56-1) was obtained from Bio-
Rad Laboratories, Inc. (USA). 1,4-dithiothreitol (DTT) (≥ 99%, CAS: 3483-12-3); 
acetonitrile (99.8%, CAS 75-05-8); methanol (99.9%, CAS 67-56-1); natriumazide 
(sodium azide) (106688, ≥ 99%, CAS: 26628-22-8); potassium chloride (KCl) (104936, 
99.5%, CAS: 7447-40-7); trichloroacetic acid (TCA) (100807, CAS: 76-03-9); TRIS-
(hydroxymethyl)-aminomethane (≥ 99%, CAS: 77-86-1) were acquired from Merck 
(Germany). 1-chloro-2,4,-dinitrobenzene (CDNB) (24440, ≥ 98.0% GC, CAS: 97-00-7) 
and molybdate reagent solution (puriss p.a.) and potassium dihydrogen phosphate 
(60218, 99.5%, CAS: 7778-77-0) acquired from Fluka.  D(+) saccharose extra pure 
(16104, 99%,  CAS: 57-50-1); sodium chloride (NaCl) (puriss p.a., CAS: 7647-14-5); 
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sodium hydroxide (NaOH) (purified, CAS: 1310-73-2) obtained from Riedel-de-Haën 
(Germany). 
6.2.2 APIs Mixtures Exposure Assay 
Mussels M. galloprovincialis (n = 300, average shell length size: 58 ± 4 mm, width: 33 
± 2 mm) were collected from Ria Formosa Lagoon (Portugal) and transported alive to 
the laboratory. Mussels were subjected to shell-cleaning and placed in aquaria 
acclimatizing during 7 days at a rate of 1 mussel.L
-1
. Aquaria were set for controls and 
for two-week exposure to either a mixture of: 250 ng.L
-1
 IBU + 250 ng.L
-1
 DCF + 75 
ng.L
-1
 FLX  (mixture 1) or a mixture of: 250 ng.L
-1
 IBU + 250 ng.L
-1
 DCF + 75 ng.L
-1
 
FLX + 5 µg.L
-1 
Cu (mixture 2). At every 48 hours natural seawater was changed and 
mixtures concentration re-established. All aquaria were kept at temperature (19.9ºC ± 
1.6), salinity (34.8 ± 0.2), pH (7.8 ± 0.1) and oxygen saturation (96.5% ± 4.3). 
After 0, 3, 7, and 15 days, mussels (n = 30) were collected from control and both 
mixtures exposure aquaria and subjected to individual shell biometric data measurement 
(length, width) preceding to tissue dissection (gills, digestive gland and gonads). Single 
tissue samples were immediately frozen in liquid nitrogen and stored at -80ºC prior to 
biomarker analysis.  
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For condition index (CI) assay, 15 mussels of each aquarium were individually 
weighted regarding the ratio:  
CI (%) =
                      
                                
     
6.2.3 Antioxidant Enzymes Analysis 
Single gills (n = 5) and digestive gland (n = 5) tissue samples were individually 
homogenized on ice with 20 mM TRIS buffer pH 7.6 (1 mM of EDTA + 0.5 M of 
saccharose + 0.15 M of KCl + 1 mM of DTT). Resulting homogenates were centrifuged 
at 500 × g for 15 minutes (4ºC) and supernatants recentrifuged at 12,000 × g for 45 
minutes (4ºC). Cytosolic fraction volumes were measured reserving a 100 µl aliquot of 
each sample for total protein quantification analysis (Bradford, 1976) and purified 
applying Sephadex
®
 G-25 gel columns to remove low molecular weight proteins. 
Each purified aliquot was analyzed in triplicate concerning the following 
spectrophometric assay:  
SOD activity was determined at 550 nm resulting from the 50% reduction of 
cytochrome c absorbance generated by xanthine oxidase/hypoxanthine system 
according to McCord and Fridovich (1969) and expressed as arbitrary units (U).mg
-1
 
total protein.min
-1
.  
CAT activity was assessed at 240 nm through the absorbance decrease resulting from 
hydrogen peroxide (H2O2) consumption according to Greenwald (1985) and expressed 
as µmol.mg
-1
 total protein.min
-1
.  
GR activity was determined at 340 nm as an outcome of the increase of co-factor 
NADPH oxidation using oxidized glutathione (GSSG) as substrate following an 
adaptation from Cribb et al. (1989) and expressed as µmol NADPH oxidized.mg
-1
 total 
protein.min
-1
. 
GST activity was assessed at 340 nm resulting from the conjugation of reduced 
glutathione (GSH) with 1-chloro-2,4- dinitrobenzene (CDNB)  following an adaptation 
from Habig et al. (1974) and expressed as µmol of CDNB conjugate formed.mg 
-1
 total 
protein.min
-1
.  
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6.2.4 LPO Analysis  
Gills (n = 10) and digestive gland (n = 10) tissue samples were homogenized separately 
on ice with 20 mM TRIS-HCl buffer (pH 8.6) and butylated hydroxytoluene (BHT) in a 
100:1 µl ratio. In order to precipitate cytosolic fraction homogenates were centrifuged 
for 45 minutes (4ºC) at 30,000 × g. An aliquot was reserved for total protein 
quantification according to Bradford (1976). The quantification of LPO levels was 
assessed in triplicate in each remaining cytosolic fractions following the formation of 
the by-products malondialdehyde (MDA) and (2E)-4-hydroxy-2-nonenal (HNE) at 586 
nm according to an adaptation from Erdelmeier et al. (1997) and expressed as µmol 
MDA.g
-1 
total protein. 
6.2.5 AChE Analysis 
Gills (n = 5) were homogenized separately on ice with 100 mM Tris-HCl buffer (pH 8.0) 
and 100:1 µl of Triton. Resulting homogenates were centrifuged for 30 minutes (4ºC) at 
12,000 ×g. An aliquot of the each supernant was saved for the analysis of total protein 
content (Bradford, 1976). The each remainder supernant was used in triplicate for AChE 
activity quantification by spectrophotometric analysis following the reaction of thiocholine 
(substrate) with DTNB on the increase of 5-mercapto-2-nitrobenzoate (yellow color) 
formation at 405 nm ( = 13.6 mM-1.cm-1) (Ellman et al., 1961) and  is expressed as 
nmol.mg
-1
 total protein.min
-1
. 
6.2.6 ALP Analysis 
Sex-differentiated gonads (n = 10) were homogenized separately on ice with 25 mM 
Hepes–NaOH buffer (pH 7.4) (125 mM NaCl + 1 mM DTT + 1 mM EDTA) and 
centrifuged for 30 minutes (2ºC) at 12,000 × g, resulting pellets were discarded. An 
aliquot of each supernant was collected to determine total protein content (Bradford, 1976) 
and another was adjusted with 35% acetone and later centrifuged for 5 minutes at 10,000 
× g. Resulting pellets were dissolved with 1 M NaOH and subjected for 30 minutes to a 
60ºC heating bath following an adaptation from Blaise et al. (1999). Phosphomolybdenum 
spectrophotometric method was applied in the measurement of inorganic phosphate 
(KH2PO4) concentration at 660 nm (Stanton, 1968) and ALP concentration expressed as μg 
[PO4].mg
-1
 total protein. 
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6.2.7 Statistical Analysis 
The present results are expressed as mean ± standard deviation at each set of time. Two-
way ANOVA was performed using SIGMAPLOT
®
 to test differences between 
treatments (controls and each mixture exposure) within each and between tissues at each 
set of time. Ad-hoc Holm-Sidak was used on each biomarker differences discrimination 
with time, within and when applicable between gills and digestive gland tissues. 
Pearson correlations were performed using XLSTAT
®
 2012 to verify each biomarker 
dependency between controls and each mixture treatment and between mixtures. PCAs 
were performed using XLSTAT
®
 2012 to assess the variability associated to each 
biomarker factorial weight (SOD, CAT, GR, GST, LPO and CI) at each set of time and 
treatment group (control, mixture 1 and 2) between and within tissues. Finally, a PCA 
was also applied on the overall comparison of biomarker responses (SOD, CAT, GST, 
LPO and CI) to single IBU, DCF and FLX exposure with MIX 1 and 2. Statistical 
significance was defined at p < 0.05 level. 
6.3 Results 
6.3.1 Condition Index 
No significant differences were found between controls and/or mixtures (p > 0.05) 
ranging between 14.2 ± 3.6 % to 15.8 ± 3.0 % in controls, 14.9 ± 3.7 % to 16.2 ± 2.5% 
in MIX 1 and 13.4 ± 2.5 % to 15.9 ± 6.1 % in MIX 2, respectively.  
6.3.2 Antioxidant Enzymes 
Generally the antioxidant response was more pronounced towards MIX 1 than MIX 2 in 
both tissues in which controls were mostly steady throughout time (Figure 6.1). 
In exposed gills (Figure 6.1A), SOD activity decreased in both mixtures during the first 
week compared to controls although not significantly (p > 0.05). After two weeks 
exposure SOD activity in MIX 1-exposed gills increased significantly (2-fold higher 
than on the 3
rd
 day) around 2-fold higher activities than controls and MIX 2-exposed 
gills respectively (p < 0.05). In exposed digestive gland (Figure 6.1B), no differences 
were found on the 3
rd
 day in SOD activity (p > 0.05). This was followed by a 4-fold 
increase towards the first week in MIX 1-exposed digestive gland which in turn was 4 
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and 3-fold higher than controls and MIX 2- respectively (p < 0.05). By the end of the 
experiment, SOD activity decreased to control levels in MIX 1 exposure digestive gland 
(3-fold lower than previously observed) while in MIX 2 SOD increased slightly but not 
significantly from controls and MIX 1 exposure. When comparing the effect of mixture 
exposure between tissues gills controls’ exhibited significantly higher SOD activity 
throughout time than digestive gland’, while in opposition SOD activity was 
significantly higher in MIX 1-exposed mussels’ digestive gland over the first week and 
in gills over the second week.  
CAT activity in gills (Figure 6.1C) followed the SOD profile and was quite stable over 
the first week regarding both mixtures, showing a slight increment by the second week 
in MIX 1-exposed gills (2-fold higher than on the 3
rd
 day) which even though 
significantly higher than MIX 2-exposure ones (p < 0.05) both were not different from 
controls (p > 0.05). In the digestive gland (Figure 6.1D) from the 3
rd
 day to the first 
week, CAT activity increased 2-fold within MIX 1 and decreased 2-fold in MIX 2-
exposed ones (p < 0.05). Over the 7
th
 day, CAT activity in MIX 1-exposed digestive 
gland was significantly higher than in controls and MIX 2-exposed ones (2 and 4-fold 
respectively) whereas over the second week CAT activity decreased 2-fold in MIX 1-
exposed digestive gland reaching controls and MIX 2-exposure levels. Finally, CAT 
activity was quite similar between tissues except for the significant enhancement in 
MIX 1-exposed digestive gland over the first week. 
Alike for SOD and CAT, in gills GR activity (Figure 6.1E) showed a similar evolution 
pattern, in which over the course of the first week no significant differences were 
observed between controls and mixtures, followed by a 3-fold increase in MIX 1-
exposed gills being at the same time 2-fold higher than controls and MIX 2-exposed 
gills (p < 0.05). In digestive gland (Figure 6.1F), GR activity varied significantly within 
controls, nonetheless after a slight inhibition tendency on the 3
rd
 day shown in both 
exposure mixtures (p > 0.05) GR activity increased significantly within both mixtures-
exposed digestive gland by the first week (approximately 3-fold) being also significant 
between them (higher after MIX 2) exposure. This was followed by a
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Figure 6.1: Antioxidant enzymes activities (mean ± standard deviation) in controls, mixtures 1 and 2 exposure of M. galloprovincialis tissues. SOD 
activity in gills (A) and digestive gland (B); CAT activity in gills (C) and digestive gland (D). Different letters express significant differences and bars 
signaled by an * express significant differences between females and males on respective day (p < 0.05). Note: Figure continues in the next page.  
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Figure 6.1 (Continuation): Antioxidant enzymes activities (mean ± standard deviation) in controls, mixtures 1 and 2 exposure of M. 
galloprovincialis tissues. GR activity in gills (E) and digestive gland (F); GST activity in gills (G) and digestive gland (H). Different letters express 
significant differences and bars signaled by an * express significant differences between females and males on respective day (p < 0.05). 
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significant 2-fold decrease of GR within each mixture, reaching controls activity by the 
end of the experiment. Regarding differences between tissues, in MIX 2-exposed gills 
GR activity was significantly lower than in digestive gland after one week, while over 
the second week MIX 1-exposed digestive gland exhibited significantly lower GR 
activity than MIX 1 exposed gills.  
In gills Phase II GST activity (Figure 6.1G) decreased significantly in controls over the 
second week compared to the first days. Nevertheless a different behavior was observed 
between mixtures exposed gills, in which from the 3
rd
 day to the first week MIX 1 GST 
activity enhanced over time (p > 0.05) while a significant 2-fold decrease occurred in 
MIX 2-exposed gills from the 3
rd
 to the remaining days (p < 0.05). Even though in 
opposing manner GST activity in exposed gills was 2-fold different between mixtures 
over the 3
rd
 and 7
th
 day (p < 0.05). Moreover, after two weeks only for MIX 1-exposed 
gills GST activity was 2-fold higher than controls (p < 0.05). In digestive gland (Figure 
6.1H) controls also decreased over time (p < 0.05). In this case, GST activity was steady 
in MIX 2-exposed digestive gland though higher than controls after the first week (p < 
0.05). Whereas for MIX 1-exposed digestive glands GST activity presented a 3-fold 
enhancement between the 3
rd
 and 7
th
 day which in turn was 4 and 2-fold higher than 
control and MIX 2-exposed digestive gland (p < 0.05), this was followed by a 
significant 2-fold decrease in GST activity after two weeks yet not different from 
controls. 
When comparing GST activity between tissues, exposed gills revealed significantly 
higher activities than digestive gland when exposed to MIX 1 over the 3
rd
 day and 
towards MIX 2 after two weeks. Additionally controls were not different between 
tissues except for the decreased GST activity on digestive gland control’ after the first 
week. Finally, SOD activity is directly related with CAT and GR activities in gills (r = 
0.925 and r = 0.895) and in the digestive glands SOD is directly related to both CAT 
and GST (r = 0.860 and 0.912) which in turn are directly related between them (r = 
0.680).  
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6.3.3 LPO  
In gills (Figure 6.2A) LPO levels were consistently higher towards MIX 2 comparing to 
controls (p < 0.05) and except for the 3
rd
 day to MIX 1-exposed ones. In MIX 1-
exposed gills LPO levels remained unchanged and higher than controls throughout the 
exposure time (p > 0.05) being only 2-fold significantly higher by the second week. 
Whereas in MIX 2-exposed gills LPO levels enhanced linearly (LPO (µmol MDA. g
−1 
protein) = 78.9 t (days) + 516.6, r = 1) being 2 and 3-fold higher than first and second 
week MIX 1-exposed gills and 2 to 7-fold higher than controls over time (p < 0.05). In 
the digestive gland (Figure 6.2B) LPO levels did not vary between controls and 
mixtures until the first week, showing an abrupt increase in MIX 2-exposed digestive 
glands (7-fold higher than control and MIX 1-exposed ones). Finally, when comparing 
LPO levels between tissues, exposed gills exhibited consistently higher LPO levels than 
digestive gland (except after the second week) being at the same time directly related 
between them (r = 0.863). 
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Figure 6.2: LPO (mean ± standard deviation) in mussel M. galloprovincialis controls, mixtures 1 and 2 exposure in gills (A) and digestive glands (B) over 15 days. 
Different letters are significantly different and bars signaled by an * express significant differences between tissues on respective day (p < 0.05). 
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6.3.4 AChE  
No significant differences of AChE activity (Figure 6.3) exist between controls and 
mixtures. Nevertheless both mixtures exhibited an enhancement tendency throughout 
time, particularly MIX 2-exposed gills (p > 0.05). Additionally, a direct relationship 
exists between AChE activity, LPO levels in gills (r = 0.806) and digestive gland (r = 
0.789).   
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Figure 6.3: AChE activity (mean ± standard deviation) in controls, mixtures 1 and 2 exposed M. 
galloprovincialis gills during 15 days. Different letters express significant differences (p < 0.05). 
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6.3.5 ALP  
ALP levels in female controls (Figure 6.4A) varied only after the second week being 
approximately 2-fold higher than remaining 3
rd
 and 7
th
 day ones, whereas male controls’ 
(Figure 6.4B) exhibited a 2-fold lower level over the 3
rd
 day than the ones after the 
following weeks (p < 0.05). Moreover the cross-comparison between genders only 
revealed a significantly lower ALP control level in males over the 3
rd
 day.  
Regarding exposed-females gonads while on the 3
rd
 and 7
th
 day MIX 1 showed 3-fold 
higher ALP levels than controls (p < 0.05), MIX 2-female gonads exhibited no 
differences over the 3
rd
 neither from MIX 1 nor control which was followed by 3-fold 
higher level than control over the first week. Finally, after the second week no 
differences exist between controls and exposed female gonads (p > 0.05).  
In males (Figure 6.4B), generally no significant differences exist found between 
mixtures and controls over the 3
rd
 day. Over the first week MIX 2-exposed males 
exhibited 2-fold lower ALP levels than MIX 1-exposed ones though not different from 
controls. Additionally, ALP levels were enhanced throughout time in male gonads 
exposed to MIX 1 and unaltered in the ones exposed to MIX 2. The comparison 
between genders revealed 2-fold higher ALP levels in females than males when exposed 
to MIX 1 and MIX 2 respectively after the 3
rd
 day and 7
th
 day (p < 0.05) being not 
significantly different by the end of the experience. Finally, a direct relationship exists 
between AChE and ALP in females (r = 0.695). 
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Figure 6.4: ALP levels (mean ± standard deviation) in controls, mixture 1 and mixture 2 exposed M. 
galloprovincialis sex-differentiated gonads (A – females, B – males) during 15 days. Different letters 
express significant differences and bars signaled by an * express significant differences between 
females and males on respective day (p < 0.05).  
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6.3.6 PCA in Gills and Digestive Gland 
PCA (Figure 6.5A) expresses 72% of total variance (Tvar) in gills highlighting 
primarily 1) a gills controls cluster due to lower biomarker activities associated to GST 
activity unchanged from remaining treatment groups, 2) the dispersal of day 15 MIX 1-
exposed gills was associated to the concomitant enhancement of the antioxidant 
enzymes SOD, CAT and GR activities, 3) day 3 and 7 in MIX 1-exposed gills unaltered 
biomarker responses and/or its inhibitory tendency when compared to controls and 4) 
MIX 2-exposed gills associated with the progressive enhancement of directly related 
LPO levels and AChE activity particularly over day 15. In digestive gland PCA (Figure 
6.5B) represents 78% of Tvar and expresses 1) day 7 MIX 1- exposed digestive gland 
dispersal due to the concomitant enhancement of directly related SOD, GST and CAT 
activities, 2) controls cluster with remaining MIX 1-exposed digestive glands due to the 
overall unaltered biomarker responses and 3) day 7 MIX 2-exposed digestive gland 
associated to unaltered SOD, GST activities with a higher GR activity opposing a lower 
CAT activity and 4) day 3 and 15 MIX 2-exposed digestive gland due to higher CI and 
LPO levels. The overall PCA (Figure 6.5C) using gills and digestive gland together 
represents 68% of Tvar and highlights mostly 1) the dispersal of biomarker responses 
between tissues in which gills showed higher biomarker responses than digestive gland 
except for day 3 MIX 1- exposed gills and day 7 MIX 1- exposed digestive gland, 2) the 
overlapping dispersal of MIX 1-exposed day 7 digestive glands and day 15 gills due to 
the enhancement of directly related SOD, CAT and GR activities, 2) day 15 MIX 2-
exposed tissues further influence by higher LPO levels opposing to an overall 
unchanged of biomarker responses, 3) day 3 MIX 2 and day 7 MIX 1-exposed gills due 
to higher GST activities and LPO levels enhancement concomitant with overall 
unaltered antioxidant responses, 4) gills controls cluster regarding lower SOD, GR, 
CAT activities responses, 5) MIX 1 and 2-exposed digestive glands showed no 
alterations of biomarker responses along with the ones given by controls. 
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Figure 6.5: PCA (A) represents 72% of total variance (TVar) of biomarkers (SOD, CAT, GR, 
GST, AChE, LPO and CI) integration in gills; PCA (B) represents 78% of TVar of biomarkers 
(SOD, CAT, GR, GST, LPO and CI) in digestive gland; PCA (C) represents 68 % of TVar of 
tissue-specific integration of biomarkers (SOD, CAT, GR, GST, LPO levels and CI) between 
controls and mixtures (1 and 2) exposed mussels M. galloprovincialis (○ - gills controls,  ● – MIX 
1-exposed gills,  ● - MIX 2-exposed gills; ◊ – digestive gland controls, ♦ - MIX 1-exposed 
digestive glands, ♦ - MIX 2 exposed digestive glands) during exposure time (days: 0, 3, 7 and 15). 
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6.4 Discussion 
Mussels possess an open circulatory system continually exposed to the fluctuation of 
multiple stressor concentrations (Pipe et al., 1999) which impact assessment data, 
particularly linking APIs, is extremely challenging and deficient. To our knowledge this 
is the first study addressing environmental realistic concentrations exposure to IBU, 
DCF and FLX (with and without Cu) mixtures effects in mussels M. galloprovincialis. 
The results showed that mixtures do not induce detriment on mussels’ CI although 
promoting differential antioxidant enzymatic responses, damage and endocrine 
disruption effects. 
Antioxidant enzymatic activities are universally applied as effective biomarkers of 
susceptibility to environmental contaminants due to their ability to counteract derived-
ROS increase through the upkeep between pro- and antioxidant agents balance essential 
for cellular homeostasis (Livingstone, 2001; Lau et al., 2004; Funes et al., 2006; 
Valavanidis et al., 2006).  
In gills, only in MIX 1 exposure, SOD, CAT and GR activity were upregulated by the 
end of the exposure while an inhibitory tendency or unchanged of these enzymes 
occurred in those exposed to MIX 2 throughout the time (Figure 6.1A, C and E and 
6.5A). Therefore Cu presence in MIX 2 led to an antagonistic effect by preventing, in 
particular, SOD activity conversion of superoxide anion to H202 and consequently to the 
depletion of CAT activity substrate and GR inability to enhance antioxidant GSH as an 
additional free-radical scavenger or antioxidant enzyme co-factor (Figure 6.1) (Regoli 
and Principato, 1995; Regoli et al., 2002; Geret et al., 2002; Maria and Bebianno, 
2011). Moreover, although Phase II GST activity was swiftly enhanced over the first 
days in MIX 2-exposed gills and only by the end of the experiment in MIX 1-exposed 
ones (Figure 6.1G), the conjugation reaction to convert these multi stressors into more 
excretable conjugates with free-GSH in the presence of Cu was also insufficient to 
prevent stronger damage evidences of LPO in this tissue (Figure 6.2A) (Regoli and 
Principato, 1995; Regoli et al., 2002; Manduzio et al., 2004). Contrarily with what was 
expected, in digestive gland the inducibility of antioxidant enzymes was swifter that in 
gills [since this organ is the first in contact with the contaminants presented in the 
water] (Figure 6.1). This is owed however, to the fact that most antioxidant enzymes 
appear to be inhibited in gills over the first week, triggering these enzymes to act 
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initially in the digestive gland on the detoxification of ROS. Either showing higher 
induction and direct relationship of SOD, CAT and GST activities after 7 days of 
exposure to MIX 1 (Figure 6.1B, D and H) or by higher inducibility of GR activity and 
CAT activity inhibition on exposed digestive gland after MIX 2 exposure (Figure 6.1B 
and F). Furthermore GST activity in MIX 2-exposed digestive gland was consistently 
enhanced after the first week (Figure 6.1 H) emphasizing Phase II conjugation reaction 
with GSH to enhance formed metabolites elimination. Though, the joint action of 
antioxidant enzymes in digestive gland prevented LPO during the exposure to both 
mixtures over the first week, over the following week the antioxidant system defense in 
digestive gland exposed to MIX 2 failed to counteract ROS derived from Cu presence 
through an abrupt enhancement of LPO in this tissue.  
In summary, compared to digestive gland, gills tissue revealed to be more affected by 
mixtures exposure showing higher damage throughout the time owing to either delayed 
antioxidant system responses after the exposure to MIX 1 or by its enzymatic activities 
inactivation after MIX 2. Nonetheless, the prolonged exposure to the latter showed Cu 
additional impact blocking the antioxidant system ability to prevent LPO induction. 
This in agreement to the fact that this metal is known to produce LPO in mussel species 
by converting harmless oxidants into toxic ROS through Fenton-type reactions (Figure 
1.9) (Viarengo et al., 1990; Lau et al., 2004; Maria and Bebianno, 2011). 
As mentioned before, ALP levels alteration are an endocrine disruption biomarker 
(Blaise et al., 1999; Porte et al., 2006; Ortiz-Zarragoitia and Cajaraville, 2006; Matozzo 
and Marin, 2008; Matozzo et al., 2008). ALP levels were enhanced by both mixtures in 
females (Figure 6.4A); at day 3 firstly onset by MIX 1, then over the first week 
inverting to a higher induction by MIX-2 pointing out to the increase of Vtg-like 
proteins synthesis in exposed gonads. In males (Figure 6.4B), the effect of mixtures is 
not so evident although MIX 1 yield to higher and continuously elevated ALP levels 
than MIX 2. Though control values variation with time rendered to unclear or masked 
results by the end of the exposure period, both mixtures clearly induced time-specific 
vitellogenin-like proteins in both sex-differentiated gonads, highlighting an effective 
endocrine disruptor effect of these contaminants at environmental realistic 
concentrations. 
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When comparing antioxidant system responses, mixtures of APIs exerted different 
tissue-specific enzymatic activities than single exposures (Chapters 3-5) further 
confirmed in Figures 6.6A and B
8
. 
In gills (Figure 6.6A), the integration of all data, reveals different time and API specific 
dispersal distribution in which for single exposure IBU the most distinct integrated 
effect happened after the first week of exposure related to higher SOD activity and LPO 
levels. The same could be stated (although to a lesser extent) for DCF single exposure 
(after 3 days) and MIX 2 (after two weeks) most related to LPO levels increase. 
Whereas, for FLX and MIX 1 exposures the integration revealed higher relevance of 
GST and CAT activities increase either after the first and second week respectively.  
In digestive gland (Figure 6.6B), the most distinct effects are related to higher LPO 
levels after both FLX and MIX 2 exposures after two weeks and to a much lesser extent 
after the first 3 days of DCF exposure, higher CAT activity for IBU single exposure 
clustering between the 3
rd
 and 7
th
 day, higher SOD and GST activities after the first 
week of exposure to MIX 1 and DCF. 
  
                                                 
8
 Note: GR activity was not included since no data exists for single FLX exposed mussel’ tissues 
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Figure 6.6: PCA (A and B) represents 70 and 80% of TVar of tissue-specific integration biomarkers 
(SOD, CAT, GST, LPO) in mixtures and single API exposed mussels M. galloprovincialis gills (A) and 
digestive gland (B) in relation to each time-control (● – IBU exposed gills, ● –DCF exposed gills  ● – 
FLX exposed gills, ● – MIX 1-exposed gills,  ● - MIX 2-exposed gills; ◊ – digestive gland controls, ♦ - 
IBU-exposed digestive glands, ♦ - DCF-exposed digestive glands, ♦ - FLX-exposed digestive glands ♦ - 
MIX 1 exposed digestive gland, ♦ - MIX 2 exposed digestive glands) during exposure time (0, 3, 7 and 
15 days). 
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6.4.1 Mixture components interactions  
Herein follow the proposed interactions between mixture components affecting each 
biomarker behavior. 
6.4.1.1 SOD activity 
SOD activity in MIX 1 exposed gills (Figure 6.1A and 6.6A) relates mostly to FLX 
activity down regulation (Figure 4.1A) which is antagonized by NSAIDs IBU and DCF 
up regulation (Figures 3.1A and 5.1A) resulting in an inhibitory tendency of this 
enzyme activity whereas, Cu in MIX 2 counteracts the effect of FLX and renders SOD 
activity to control levels. Over the next week, the noticeable increase of SOD after IBU 
single action is independent from both MIX 1 and 2 (inhibition tendency) antagonized 
by the synergism between the down regulation after DCF and FLX exposure and/or Cu 
as observed by Maria and Bebianno (2011) promoting, as at the beginning of the 
experiment, the inhibition tendency of SOD activity. By the end of the experiment, the 
enhancement of SOD in MIX 1-exposed gills is due to a potentiation of IBU 
independent action (up regulation tendency) antagonistic to FLX and DCF 
downregulation effects, while the presence of Cu cancels IBU independent action, 
rendering SOD to an activity slightly lower than controls.   
In MIX 1-exposed digestive glands (Figure 6.1B and 6.6B), over the first 3 days,  the 
NSAIDs SOD activity increase is antagonized by FLX single exposure SOD down 
regulation behavior which alike for exposed gills leads to a inhibitory tendency of SOD 
activity. Inversely, over the first week, the addition of NSAIDs single exposure SOD 
activity up regulation is potentiated, resulting on a significant increase of this enzyme 
activity in MIX 1-exposed digestive gland while FLX exposure down regulation (p > 
0.05) has no effect in the mixture. Finally by the end of the experiment, the addition of 
each single APIs exposure independent action results in the significant decrease of SOD 
activity to basal levels after MIX 1; whereas in MIX 2-exposed digestive glands, the 
presence of Cu induces a slight, although not significant, increase of SOD activity 
compared to APIs mixture after the 3
rd
 and 15
th
 day. Furthermore, the enhancement of 
SOD activity due to Cu was only observed in digestive gland exposed to 10 µg Cu.L
-1
 
single exposure over 15 days (Gomes et al., 2012), while the exposure to the same 
concentration (5 µg.L
-1
) over one week resulted in the inhibition of SOD in both tissues 
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(Maria and Bebianno, 2012). Therefore the presence of Cu in MIX 2 reveals different 
SOD activity behavior from single exposure essays confirming its antagonistic action in 
gills and synergistic action in digestive glands. 
6.4.2 CAT activity 
In mixtures-exposed gills (Figure 6.1C and 6.6A), over the first 3 days, the CAT 
activity inhibitory tendency results clearly from the addictive effect of the three APIs 
(Figure 3.4A, 4.1C and 5.1C). Over the next week the synergetic effect of NSAIDs 
CAT inhibition  is counteracted by FLX induced CAT activity) either with (MIX 1) or 
without Cu (MIX 2) rendering CAT activity to basal levels. The enhancement of CAT 
activity was also observed after 5 µg.L
-1 
Cu single exposure for 7 days (Maria and 
Bebianno, 2011). By the end of the experiment, the slight increment of CAT activity in 
MIX 1-exposed gills follows the FLX single exposure effect (inverse to previous days) 
cancelling the synergetic down regulation effect of NSAIDs. The opposite was observed 
after MIX 2 exposure with a significant CAT activity down regulation owed to Cu and 
NSAIDs inhibitory synergism counteracting FLX single exposure up regulation.   
In mixtures exposed-digestive gland (Figure 6.1D and 6.6B), over the 3
rd
 day an 
antagonistic behavior between all three single APIs exposure promotes CAT activity up 
regulation (Figure 3.4B, 4.1D, 5.1D) resulting in slight inhibitory tendency of this 
enzyme activity in both mixtures, in the MIX 2 case, Cu presence induced a slight 
increment of SOD rendering in a less pronounced CAT downregulation than MIX 1. 
While over the next week, the increase of CAT activity in MIX 1-exposed digestive 
gland results from the antagonism between DCF down regulation tendency (Figure 
5.1D) and the synergism between FLX and IBU CAT activity up regulation (Figure 
3.4B and 4.1D). On other hand in MIX 2-exposed digestive gland CAT activity 
decrease  results from the antagonistic effect of IBU and FLX upregulation against the 
potentiation of DCF downregulation by Cu. By the end of the exposure time, after MIX 
2 exposure, digestive glands show an addictive behavior between mixture components 
translated in a slight CAT decrease, while in MIX 1 exposed ones, the unchanged of 
CAT activity results from the antagonism between NSAIDs and FLX.    
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6.4.3 GR activity 
Since GR activity FLX single effect data is missing, it is very difficult to ascertain 
mixtures components behavior. Nevertheless, GR activity up regulation in MIX 1-
exposed gills (Figure 6.1E and 6.6A) by the end of the experiment was more similar 
with the one after the 3
rd
 day of DCF single exposure (2-fold higher in relation to basal 
levels) (Figure 5.1E) and antagonistic with IBU single exposure down regulation 
(Figure 3.1C) over time. In MIX 2-exposed gills, GR activity remained mostly 
unchanged throughout the experiment probably due to antagonistic effects between IBU 
exposure (GR activity downregulation) and remaining mixture components particularly 
due to Cu single exposure since it induced the up regulation of GR activity in this 
tissues (Maria and Bebianno, 2011). 
GR activity in both mixtures-exposed digestive gland in the first 3 days (Figure 6.1F 
and 6.6B) seem to follow IBU single exposure down regulation independent action 
(Figure 3.4C) which is antagonistic with that of DCF exposure (up regulation) (p < 
0.05) (Figure 5.1F) while Cu probably cancelled IBU downregulation effect. Over the 
first week, mixtures followed instead DCF single exposure up regulation effect 
antagonist to IBU single exposure. In the case of MIX 2, the increase of GR activity  
was stronger due to the presence of Cu however inverse with that observed in single Cu 
exposed-digestive glands, which showed the down regulation of GR activity after one 
week (Maria and Bebianno, 2011). By the end of the experiment, NSAIDs single 
exposure show an antagonistic effect  rendering GR activity to basal levels in MIX 1-
exposed digestive glands, while the presence of Cu induced its slight enhancement over 
APIs antagonistic effects.  
6.4.4 GST activity 
In MIX 1-exposed gills, over the 3
rd
 day GST activity (Figure 6.1G and 6.6B) follows 
the addictive effect between APIs components (Figure 3.1D, 4.1E, 5.1G) resulting in an 
slightly decrease of GST activity, whereas at the same time MIX 2-exposed gills GST 
activity is enhanced probably due to Cu synergism with both FLX and DCF single 
exposure (up regulation effect) antagonizing IBU downregulation effect. After one 
week, the GST activity up regulation tendency in MIX 1-exposed gills results from the 
antagonism between up regulation additive effect of FLX and DCF single exposures 
with single IBU exposure (GST activity down regulation) . Inversely in MIX 2-gills, the 
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addictive effect of APIs with Cu resulted in GST activity down regulation tendency. By 
the end of the exposure period, the GST up regulation activity in MIX 1-exposed gills 
results from the potentiation of DCF single exposure up regulation (unaltered neither by 
single IBU nor FLX exposure down regulation), whereas the presence of Cu in MIX 2 
blocks this interaction rendering GST activity recovery to basal levels.       
In mixtures-exposed digestive gland (Figure 6.1H and 6.6B), over the first 3 days the up 
regulation of single NSAIDs and FLX exposures (Figure 3.4D, 4.1H and 4.1F) did not 
change significantly GST activity, pointing out to antagonistic effects between mixture 
components. In the first week, both mixtures show enhanced GST activity due to a 
probable potentiation of NSAIDs exposures up regulation which was not significantly 
affected by FLX single exposure down regulation tendency. Nevertheless at this time, 
the effect of Cu in MIX 2 resulted in a less pronounced increment of GST activity. By 
the end of the exposure, MIX 1-exposed digestive gland showed GST activity up 
regulation tendency. This is due to the up regulation synergism between FLX and DCF 
which was not counteracted by IBU independent down regulation action. The same 
happens after MIX 2 exposure, where the significant GST activity up regulation is due 
to the addictive effect of Cu with FLX and DCF. 
6.4.5 LPO level 
LPO levels in both mixtures-exposed gills (Figure 6.2A and 6.6A) follow the addictive 
effect of single API exposure (Figure 3.2, 4.2A, 5.2A) resulting in the enhancement of 
LPO levels though only significant after MIX 2 exposure. Over the first week, MIX 1 
LPO levels are slightly enhanced  due to a counter effect between IBU and DCF single 
exposures (Figure 3.2 and 5.2A) and similar FLX independent action, whereas in MIX 2 
LPO level is increased by IBU and FLX synergism with Cu, as reported by single Cu 
exposure LPO increase effect (Maria and Bebianno, 2011). By the end of the exposure 
period, as observed for the first 3 days, both mixtures induce a significant LPO levels 
increase resulting from the addictive effect of APIs, this is most evident after MIX 2 by 
Cu ability to potentiate LPO levels.     
In mixture exposed-digestive glands (Figure 6.2B), LPO levels remain either slightly 
enhanced (MIX 1) or unchanged (MIX 2) not following the addictive effect of single 
APIs exposure LPO upregulation (Figure 3.5, 4.2B, 5.2B) i.e. neither IBU nor DCF 
LPO increase independent action had effect after MIX 1 and no addictive effect was 
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associated to a probable Cu LPO level increase after MIX 2 exposure. In the first week, 
LPO levels remain unchanged in both mixtures, nevertheless showing evidence of an 
antagonism between IBU and DCF single exposures (up and down regulation effects 
respectively) following instead, as observed in gills, a behavior similar to FLX single 
exposure independent action. Finally, by the end of the experiment while in MIX 1-
exposed digestive glands LPO levels remain unaltered due to the antagonistic effect 
between the three APIs, in MIX 2 exposure ones, Cu is antagonistic to IBU rendering 
LPO levels similar to the addictive effect between FLX and DCF LPO levels. 
6.4.6 AChE activity 
Although no significant alterations were found in AChE activity, both mixtures showed 
a progressive AChE enhancement. In fact, FLX and DCF single exposures
9
 seem to lead 
to an AChE activity induction particularly over the first 3 days (Figure 4.3 and 5.3). 
This highlights an alternative evidence of nerve impulse transmission interference 
diverging from the general reported AChE activity inhibition after mussels exposure to 
organochloride pesticides, PAHs (like, benzo[a]pyrene), detergents, other APIs such as 
propranolol and paracetamol and several metals such as Cu (both as nanoparticles or 
ionic form) (Najimi et al., 1997; Banni et al., 2010; Solé et al., 2010; Gomes et al., 
2011).  
Several possible explanations were given in Chapters 4 and 5 concerning single 
exposure to FLX and DCF namely: the evidence of AChE activity increase during cell 
apoptosis (Zhang et al., 2002); and particularly in the case of FLX single exposure both 
to a possible competition for ACh activation receptor after the increase of 5-HT 
concentration in cells and also an inverse relationship between AChE and estradiol 
levels (Tsuchiya et al., 2004) since ALP levels were severely downregulated (Figure 
4.4). Therefore, these results point out to an antagonistic effect between mixture 
components that prevented its enhancement in mussels as previously mentioned. 
Furthermore, in the case of MIX 2-exposed ones the evidence of single Cu exposure 
down regulation effect in these species due to its affinity to bind with AChE thiol 
residues (Najimi et al., 1997; Gomes et al., 2011) were particularly antagonized by 
APIs since AChE activity is slightly higher than in MIX 1 exposure (p > 0.05).  
                                                 
9
 no available data for IBU 
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6.4.7 Vitellogenin-like proteins (ALP levels)  
In MIX 1-exposed females (Figure 6.4A) the enhancement of ALP levels in the first 3 
days is owed to the potentiation of IBU and DCF single exposure up regulations (Table 
3.4
10
 and Figure 5.4) antagonizing FLX single exposure down regulation effect (Figure 
4.4). The same effect happens although to a lesser extent after MIX 2 exposure. After 
the first week, ALP levels are derived from the synergetic effect between NSAIDs 
which continue to antagonize FLX single exposure down regulation effect. In the case 
of MIX 2-exposed females, Cu presence potentiates the synergism between NSAIDs 
enhancing even more vitellogenesis. By the end of exposure period, the up regulation of 
ALP observed after single DCF exposure is antagonized by the addictive effect of single 
FLX (down regulation) and IBU (up regulation) leading to the decrease of ALP to basal 
levels in both mixtures, particularly evident after MIX 2.  
 
In MIX 1-exposed males, ALP levels enhancement results from an antagonistic effect of 
DCF (up regulation) and FLX (down regulation) with IBU single exposure  which 
diminish IBU ability to increment ALP levels over the 3
rd
 day of exposure. The 
presence of Cu, on other hand, potentiates the induction of ALP compared to MIX 1. 
Over the following week in MIX 1-exposed males ALP level is slight enhanced 
resulting from IBU up regulation effect antagonism with FLX and DCF down 
regulation effect, while after MIX 2 exposure an antagonism effect between the 
addictive effects of APIs in the presence of Cu is observed rendering ALP to slightly 
lower levels than controls. By the end of the experiment the addictive effect of APIs 
single exposure was somewhat potentiated in MIX 1-exposed males, while Cu presence 
antagonized this effect decreasing ALP levels to basal ones. 
Finally, the ALP levels derived from mixtures are only significant in females and 
mostly following the interactions between NSAIDS, nevertheless Cu presence also 
enhanced vitellogenesis after the first week in exposed-females. Therefore, both 
mixtures have the potential to cause endocrine disruption in mussels. 
                                                 
10
 Note: clearly lower basal levels exist in IBU single exposure than the other single exposure assays 
between exposed individuals and respective controls. 
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6.5 Conclusions 
APIs occur in the aquatic environment always as part of complex mixtures (see Chapter 
1 and 2). This study revealed that multiple APIs stressors induce distinct effects in M. 
galloprovincialis depending on the nature of the mixture. While MIX 2 led to an overall 
increment of LPO levels (especially in gills) along with lower ability to induce 
antioxidant defense system and/or producing the inactivation of some antioxidant 
enzymes, MIX 1 exerted, in overall, higher antioxidant enzyme responses.  
Additionally, while neither MIX 1 nor 2 induced AChE activity alterations, both 
mixtures induced vitellogenin in females during the first week.  Finally, even though, it 
was extremely hard to assess each individual component true contribution, several time 
and tissue-specific interactions were proposed for the overall biomarker alteration 
outcome. 
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7 General Discussion 
The application of APIs in medical practice is undoubtedly one of the greatest 
achievements for life quality improvement in modern societies (Roberts and Bersuder, 
2006). In Europe, more than 3000 types of APIs from of all therapeutic classes (e.g. 
analgesics, antiasthmatics, antibiotics, anticonvulsants/antiepileptics, antidepressants, 
antidiabetics, antihypertensive, anti-inflammatory drugs, antineoplastics, antipsychotics, 
antitumor agents, anti-ulcerants, beta-blockers, blood lipid lowering agents, lipid 
regulators, steroidal hormones, etc.) are daily applied in human and veterinary practice 
(Ternes et al., 2004; Fent et al., 2006). Novel and more efficient APIs are constantly 
being developed, and consumers demand has been growing in particular on the new 
emerging countries (such as China, Brazil and India) (IMS Health, 2010). Nevertheless 
worldwide, the use of APIs is at halfway of the desirable as more than 50% of the 
medicines are prescribed and taken incorrectly by the patients and half of the countries 
do not have suitable responsible rational use policies or if so, fail on its implementation 
(WHO, 2010; 2011).  
The problematic around APIs in the environment arises mostly from the fact that after 
therapeutic application, these compounds are excreted almost in their native form or as 
metabolites, entering by diffuse (through aquaculture or agricultural run-off) or point 
(through hospital and domestic untreated and/or WWTPs effluents) sources into the 
aquatic systems (Heberer, 2002; Kümmerer, 2004; Bound and Voulvoulis, 2007; 
Kümmerer, 2009). Until recently, the lack of proper instrumental techniques (able to 
infer APIs presence in the environment) resulted on the overlook of its fate, occurrence 
and impact over the ecosystems and therefore on their classification as emergent 
environmental contaminants (Fent et al., 2006). Subsequently, most WWTPs are ill-
prepared for APIs removal or even consider its contamination in their treatment 
processes aggravating their ubiquitous cycle in the aquatic environment. Although 
several methods (such as increasing sludge age, ultrafiltration and ozonization) could be 
adopted fairly easily to improve APIs removal from WWTP effluents also measures that 
involve the hospital wastewater and urine treatment separation should be considered to 
greatly diminish APIs load in WWTPs (Ternes et al., 2004).  
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Presently, almost two hundred APIs (from all therapeutic classes) have been screened 
worldwide in surface and ground waters as well as in public tap water at concentrations 
from ng.L
-1
 to μg.L-1 (Fent et al., 2006; Kümmerer, 2009; Daughton, 2010; Santos et al., 
2010). Yet, as mentioned and stressed out in Chapter 2, since APIs assessment by 
conventional water screening methods continues to be severely limited, the application 
of passive integrative samplers (like POCIS) is increasingly regarded as a suitable 
alternative to better respond to Water Framework Directive (WFD – 2000/60/EC) 
criteria and demands (Togola and Budzinski, 2007; Dévier et al., 2011). Most 
importantly, in an ecotoxicological perspective, APIs effects (particularly the chronic 
ones) assessment on non-target species is still rather unknown and far from readily 
predicted, since beside presenting multiple chemical structures, properties and modes of 
action, these contaminants are bioactive and occur as part of complex mixtures (Togola 
and Budzinski, 2007; Quinn et al., 2008; Kümmerer, 2009; Kasprzyk-Hordern, 2010; 
Santos et al., 2010). Accordingly, the main focus of this thesis, beside APIs 
quantification in Portuguese riverine water (Chapter 2), was to assess and provide new 
data concerning oxidative stress, neurotoxic and endocrine disruption effects applying a 
multibiomarker approach after the exposure of sentinel species Mytilus 
galloprovincialis to single and mixtures of three highly consumed APIs, NSAIDs 
ibuprofen and diclofenac and SSRI fluoxetine and the interaction with a traditional 
contaminant (Cu) at environmentally relevant concentrations (Chapters 3-6).  
7.1 Occurrence of APIs in the Aquatic System: Arade River (Portugal) 
In 2008, when this thesis first started, there was no information whatsoever concerning 
APIs in Portuguese surface waters, beside fluoroquinolone antibiotic in Mondego river 
(Coimbra, Portugal) (Pena et al., 2007). Meanwhile, only two articles were published 
targeting and validating the quantification of 7 APIs (of which only FLX, CAR, DIA 
were concurrent with this study) in Douro riverine water (Oporto, Portugal) using SPE-
LC–MS/MS method with ion trap detection (Madureira et al. 2009; 2010) and a very 
recent study focused only on NSAIDs IBU concentrations assessment in 12 rivers and 
Ria de Aveiro estuary located in the North of Portugal (max. concentration of 723 
ng.L
−1
 in Lima river) (Paíga et al., 2012). Since the analytical techniques commonly 
employed in this type of screening are extremely expensive and time-consuming it 
partially justifies the lack of information. Accordingly, it urged a further assessment of a 
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greater number of APIs from several different therapeutic classes in Portuguese waters. 
This motivated the intent to perform APIs quantification and presence profile in Arade 
river (one of the two major rivers in the South of Portugal) favoring the holistic TWA 
concentration assessment given by passive device samplers for polar compounds 
POCIS. Since there were no records to compare with, and POCIS handling and analysis 
methodology was still fairly recent (U.S. Patent #6,478,961 - by Petty et al., 2002) it 
was necessary to perform a first screening (on 2009) at 2 different sites in Arade river 
(Section 2.2.1, Figure 2.3) for POCIS’ preliminary validation using reference Rt pre-
calibrated APIs (described in Table 2.2 and 2.3 and section 2.3.3). After this one-month 
validation study, a more comprehensive study followed at the same sites accessing the 
impact of tourism across the summer months (from August to November in 2010) on 
APIs concentration variation due to the expected overload of WWTP discharges. 
First of all, analgesic ASP and antiasthmatic TER were not reconsidered in 2010 due to 
low recovery rates therefore the reference APIs list was reduced to 19 APIs (Table 2.2), 
from these neither antidepressants DOX and IMI, antiasthmatics CLE and SAL or 
NSAID KET were ever detected in Arade river. Moreover, antidepressant AMI was 
only identified in 2009 and anxiolytic BRO in 2010.  
The comparison between years revealed that the overall average of APIs concentrations 
increased remarkably from 2009 to 2010, particularly for stimulant CAF (~10-fold 
higher) and antiasthmatic THEO (~ 5-fold higher) (with the exception of BRO which 
concentration was below the limit of detection) (Figures 2.6, 2.7 and 2.9 - 2.11). 
Likewise, it was noticed that CAF and THEO concentrations were the highest in Arade 
river (~ 1 µg.L
-1
 and 200 ng.L
-1 
respectively), followed either by analgesic PAR (~ 20 to 
90 ng.L
-1
) or NSAID IBU (between ~ 5 to 30 ng.L
-1
) (Figure 2.6, 2.9 and 2.10). Also, 
while in 2009, anti-lipidemic GEM was alternatively the 4 or 5
th
 highest (~ 2.5 to 5 
ng.L
-1
) detected API depending on the site (Figure 2.6), in 2010 anticonvulsant CAR (~ 
10 to 30 ng.L
-1
) presence was generally more preponderant (less than 1 ng.L
-1 
in 2009) 
in both sites (Figure 2.10). NSAIDs NAP and DCF relative concentrations were similar 
within each year, though much higher in 2010 (from an average of less than 1 ng.L
-1 
to 
one over 10 ng.L
-1
) (Figures 2.7 and 2.10). Lastly, antidepressants and anxiolytics 
(BRO, NOR, FLX, AMI, DIA and ALP) were always detected at very low 
concentrations either below 1 or 3 ng.L
-1
 in 2009 and 2010 respectively (Figure 2.7 and 
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2.11). Although it was difficult to ascertain whether abiotic parameters and the evident 
alteration in the trends of medical products consumption between years (Table 1.6) may 
be influencing these concentrations differences, it was assumed that the main 
contributing factor was the alteration performed in the extraction methodology by using 
RapidVap vacuum evaporation system to concentrate the samples (Section 2.3.2).  
In terms of the impact of summer (Section 2.5.1), the results revealed to be quite 
inconclusive, with noticeable site and time-dependent individual APIs concentration 
differences. Some similarities between sites were noticeable though, namely a higher 
prevalence of psychoactive drugs in August (such as DIA), higher NSAID DCF in 
September and a concomitant highest presence of antiasthmatic THEO, analgesic PAR 
and anxiolytic ALP in October. All the other APIs concentrations were quite transient. 
It was highlighted that while at site 1 APIs monthly distribution was more 
heterogeneous (Figure 2.13), APIs concentrations were in overall higher at site 2 (with 
the exception of NSAID DCF and psychoactive drugs FLX and DIA). These differences 
between sites were explained as being due to the combination of a noticeable 
confinement of site 2 associated with a closer proximity to WWTP2 discharge and a 
higher dilution factor and hydrodynamics at the vicinity of site 1 which is at much 
greater distance of WWTP1 (Figure 2.2). Therefore the possible impact of summer was 
related to the continuous presence of APIs during the dry-season and especially by the 
highest concentrations of several APIs by the end of October which pointed out to 
uncontrolled discharges and possible overload of the two WWTPs since as suggested by 
Vystavna et al. (2012) the water run-off volume is expected to be low at that time of 
year. More so, due to the presence of high concentrations of CAF, which non-
conservative behavior, usually renders high WWTP removal rates (Togola and 
Budzinski, 2007; Vystavna et al., 2012).   
Finally, the results of APIs’ TWA concentrations were compared to similar works 
performed using POCIS or spot analysis in surface waters (Section 2.5.2 and 2.5.3 
respectively). Several APIs’ TWA concentration were found to be in agreement (Table 
2.4) with Jalle river (France) and lower than in Lopan river (Ukraine) namely FLX, 
AMI and CAR, while others such as CAF, PAR, IBU and GEM were greatly higher in 
Arade river than the ones found in those rivers. Interestingly and inversely to that 
observed in the Portuguese river, NSAID KET was expressively reported in both rivers 
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while the highest detected antiasthmatic THEO in Arade river and anxiolytics DIA and 
ALP were below detection limit (Vystavna et al., 2012). The concentrations of CAF, 
CAR and GEM in Arade river were also much higher than the ones reported by 
Munaron et al. (2012) in a coastal lagoon and semi-enclosed bay in French 
Mediterranean coast, which also identify the presence of KET and much lower 
concentrations of DIA and DCF. As the semi-enclosed bay is more confined and 
therefore subjected to longer water renewal times and more vulnerable to effluents 
discharge can explain the overall higher APIs TWA concentrations. Therefore, a similar 
situation might explain the differences in APIs concentration between Arade river’ sites. 
Additionally, Arade river presented much lower concentrations of DCF, CAR than Ouse 
river (United Kingdom) and FLX in Crabtree Creek (USA) (Zhang et al., 2008; 
Bringolf et al., 2010).  
Relatively to studies involving spot sampling (Table 2.5), concentrations of CAR and 
DIA and higher FLX concentrations in the Arade river were lower than that of Douro 
river (Madureira et al., 2009; 2010). Although it was suggested that the difference 
between concentrations was due to different sampling techniques, it was also noticed 
that Arade river is in the vicinity of a much lesser densely populated area (8-fold lower 
than Douro river metropolitan area) (INE, 2011) showing nevertheless higher 
concentrations of the antidepressant. The same could be said in relation to Arade river’ 
CAF and PAR concentrations being in agreement with Halifax watershed and Ebro 
river basin (Comeu et al., 2008; Gros et al., 2010) or as for several other Arade river 
APIs’ concentrations that were in agreement with other areas worldwide. Therefore it 
was argued that even though APIs presence in water is dependent on numerous social-
economic factors and cultural health practices that the ubiquity of these emergent 
compounds could be greatly diminished with the improvement of current WWTP 
works. Moreover, the results showed that POCIS clearly enabled the characterization of 
APIs concentrations in the Arade river (which was totally unknown), highlighting that 
the application of this passive sampler may become legible as the preferential sampling 
method to access these emergent compounds in the aquatic systems and should be 
further included in the WFD guidelines. Finally, as remarked by Madureira et al. (2010) 
even if the detected APIs concentrations are considered low to singularly cause acute 
effects this should not exclude the potential chronic effects caused by the continuous 
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exposure to APIs (either as single or mixture) on an economically and ecological 
relevant non-target species like mussels Mytilus galloprovincialis. 
7.2 Effects of selected pharmaceuticals in mussel M. galloprovincialis 
Present knowledge concerning APIs effects on non-target organisms is still severely 
limited, although considering the increasing interest given by the scientific community 
in the past decade (Kümmerer et al., 2009; Santos et al., 2010). It is expected that the 
ubiquitous presence of bioactive molecules like APIs in the aquatic ecosystems may 
have the potential to affect analogous pathways on aquatic organisms presenting similar 
target organs, tissues, cells or biomolecules as during humans and/or mammals 
therapeutic action (Fent et al., 2006a). As mentioned before, invertebrates also possess 
biomolecules that can be affected by the presence of the selected APIs NSAID IBU and 
DCF (i.e. PGs and COX activity) (Section 1.10.1) and SSRI FLX (i.e. 5-HT) (Section 
1.10.2) MoAs (Osada and Nomura, 1990; Fong, 1998; Gagné and Blaise 2003; Gagné et 
al., 2007; 2011). As sessile filter-feeders with a relatively long life-span, mussel M. 
galloprovincialis is extremely exposed to all sorts of contaminants (including APIs) 
present in their habitats’ surrounding waters. These features along with a wide 
geographic distribution render them the recognition as preferential environmental 
sentinel species (Cajaraville et al., 2000; Porte et al., 2006; Cravo et al., 2009) and 
consequently their selection in the present thesis as an optimal species for APIs 
exposure essays. Mostly regarding to acute effects bioassays, very few other studies 
have included long-term single and mixture APIs exposure assays using environmental 
realistic exposure concentrations on potential biochemical, metabolic and physiological 
response alterations in mussels’ species applying a multibiomarker approach, which 
greatly impairs the current knowledge for a more comprehensive ERA feasibility (Van 
der Oost, 2003). More so, if considering that APIs major therapeutic functions are based 
on its specific redox reactivity and oxidative stability (Harmon et al., 2006; Martín-Díaz 
et al., 2009a). Therefore, the present thesis included the assessment of antioxidant 
enzymes SOD, CAT, GR and Phase II GST activities and LPO levels (oxidative stress 
and related damage) (Section 1.7), AChE activity (neurotoxic effect) (Section 1.8) and 
ALP related to vitellogenin-like proteins (endocrine disruption effects) (Section 1.9) 
effects after two weeks single and mixture exposure to the aforementioned APIs and a 
classical contaminant Cu.  
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7.2.1 Effect of IBU exposure in M. galloprovincialis (Chapter 3) 
IBU is one of the most sold over-the-counter NSAIDs worldwide consequently being 
one of the highest detected and ubiquitous APIs in aquatic ecosystems (Parolini et al., 
2009; Santos et al., 2010). Moreover, IBU was also defined as a class IA “highest risk 
for the environment” compound (Besse and Garric, 2008). Based on the available 
literature for surface waters at the time of the exposure assay, it was decided to use an 
average IBU environmental realist concentration of 250 ng.L
-1
 to assess its effects on 
mussels M. galloprovincialis 
7.2.1.1 IBU and Oxidative stress 
The results (Sections 3.10.3 and 3.11.1) confirm a tissue and time-specific alterations of 
antioxidant enzyme activities in mussels exposed to IBU. In IBU-exposed gills (Figure 
3.1 and 3.3), it was particularly evident the increase of SOD activity during the first 
week followed by its recovery by the end of the exposure period. The activities of CAT, 
GR and GST activities concomitantly decreased particular after 15 days. Whereas for 
IBU-exposed digestive gland (Figure 3.4 and 3.6), all the enzymes (except GST) were 
significantly enhanced after the 3
rd
 (except SOD) and 7
th
 days recovering to basal levels 
by the end of the exposure. LPO levels were nevertheless elevated in both tissues, in 
which either directly related to SOD activity in gills or GR activity in digestive glands. 
However, the differential antioxidant activity responses were linked to specific tissue 
functions and its particular ability to respond to IBU-derived ROS increase. Therefore 
even though, exhibiting a strong SOD activity increase, gills response was not as 
effective to counteract the inhibitory effect exerted by IBU-derived ROS over all the 
other antioxidant enzymes than in digestive glands resulting on a much higher LPO 
damage (Figures 3.2 and 3.5) which justified this latter as the organ most important in 
ROS detoxification response and antioxidant system recovery. Moreover, the fact that 
GR activity decreased constantly during the exposure in gills, suggested that in this 
tissue, IBU seriously affects cells ability to maintain a homeostatic level between 
GSSG/GSH (Vernouillet et al., 2010). This is further supported by Phase II GST 
activity concomitant inhibition tendency due to a lesser presence of its substrate GSH 
(which acts as oxidative-radicals scavenger and enzymatic co-factor) (Regoli, 1998) 
compromising its detoxification conjugation reactions. Consequently only in digestive 
glands, there was enough free-GSH (to enhance GR activity) to further counteract IBU-
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induced ROS, which nevertheless was not totally effective to prevent the elevation of 
LPO levels. 
Generally, it was hypothesized that since AA accumulation is related to an increase of 
ROS formation (Cocco et al., 1999; Delaporte et al., 2006), that the blockage by 
NSAIDs of COX pathway, one of major metabolic pathways of AA, may be 
potentiating IBU derived ROS induction and consequently LPO damage in exposed 
mussels. Since there were no antioxidant activities concerning IBU exposure the data 
was compared to other APIs exposure essays in mussels’ species. Therefore, the 
transient SOD activity pattern was similar to that of zebra mussel Dreissena 
polymorpha whole body exposed to analgesic PAR (150 ng.L
−1
) on the first 24 hours 
and progressive decrease to control levels over 96 hours, whereas CAT activity 
induction is slower and less pronounced (Parolini et al., 2010) this was associated 
though to a possible faster size-dependent metabolism of this freshwater species.  
The results were also in agreement with the outline of LPO levels in gills after one 
week-exposure of M. galloprovincialis to 
 
anticonvulsant CAR (100 ng.L
−1
) and with 
LPO levels in digestive glands of the same species after exposed to 23 µg.L
−1
 of 
paracetamol) and of E. complanata exposed to 0.4, 2 and 10 mM carbamazepine 
(Martín-Díaz et al., 2009a, b; Solé et al., 2010) (Table 3.2). Also as observed in this 
study, although in M. galloprovincialis exposed to CAR showed no noticeable alteration 
of CAT activity in gills, this enzyme was significantly inducted in digestive glands 
(Martín-Díaz et al., 2009b) which also occurred after a 24 hours injection of BEZ and 
GEM (0.1 nmol/animal) (Canesi et al., 2007) and after 3 ng.L
−1
 of DL-propranolol 
(Franzellitti et al., 2011).  
It was concluded in this Chapter, that although the contribution of other factors 
subjacent to the experimental design should not be excluded (such as food absence 
during the experiment which might have influenced some basal enzymatic variations 
and CI% at the beginning and the end of the exposure period) that even at a low 
concentration NSAID IBU does exert transient oxidative stress in M. galloprovincialis 
tissues. This affected mostly gills through CAT and GR activities breakdown and higher 
membrane damage, notwithstanding digestive gland also showed the necessity of 
overall enhanced activities of selected enzymes. Finally, both tissues showed signs of 
recovery by the concomitant decrease of LPO levels to basal levels.  
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7.2.1.2 IBU and Endocrine Disruption 
Concurrently, considering endocrine disruption associated to IBU exposure, the results 
(Section 3.10.4 and 3.11.2) showed much more uniformity than evidences of oxidative 
stress, with significant increment of ALP levels in both males and females’ gonads, in 
particular by the 2-fold higher levels of Vtg-like proteins in exposed males after one 
week (Table 3.4). It was argued, that the induction of these proteins was an effective 
biomarker of feminization in mussel E. complanata exposed for 30 days to NSAIDs 
containing primary-treated municipal extract (including IBU at concentrations of 
µg.L
−1
) (Gagné et al., 2005). Even though, this author also confirmed alterations by the 
assessment of female/male ratio and the expression of a female-specific protein in 
males, the present results clearly indicate an effective IBU exposure impact causing 
endocrine disruption effects which potentially lead to mussels’ reproductive fitness 
impairment or ultimately its feminization. 
In summary, the exposure to IBU at an environment realistic concentration (250 ng.L
−1
) 
beside inducing significant transitory antioxidant defense responses and LPO 
particularly in gills, indicated a more severe and continuous impact of IBU as an 
endocrine disruptor, particularly in males, with consistently higher Vtg-like proteins 
induction throughout the exposure period. 
7.2.2 Effect of FLX exposure in mussel M. galloprovincialis (Chapter 4) 
FLX is the highest prescribed antidepressant in the world. Acting as a SSRI it regulates 
the increase of 5-HT neurotransmitter levels in neurons (Hiemke and Härtter, 2000; 
Fent et al., 2006). 5-HT is associated to the modulation of important functions in 
hormonal and neuronal mechanisms in both vertebrates and invertebrates (Fong, 2001; 
Fent et al., 2006; Stanley, 2007; Painter et al., 2009; Styrishave et al., 2011) but also to 
affect antioxidant system in mice (Djordjevic et al., 2011). Applying the same principle, 
FLX environmental realistic concentration was chosen after careful review of all 
literature relating its occurrence in surface waters (Table 4.1) and reported effects in 
non-target organisms (Table 4.2). 
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7.2.2.1 FLX and Oxidative Stress 
Results (Section 4.3.2) revealed a transient antioxidant status alteration in both mussels’ 
tissues after exposure to SSRI FLX (75 ng.L
-1
), although with totally different activity 
profiles than that observed after IBU exposure. In both tissues, SOD activity (Figure 
5.1A and B) was down regulated over time, although only significant in gills by the end 
of the exposure. Moreover in digestive gland SOD activity was inversely related to 
CAT activity. SOD activity down regulation in the tissue, was due to the elevation of 
ROS levels by FLX presence, particularly H202. This oxygen-radical is the substrate for 
CAT activity responsible for the its conversion to less toxic compounds such as H20 and 
02 (Regoli and Principato, 1995), therefore as aforementioned for IBU, the preferential 
role of digestive glands on general redox-cycling (Livingstone et al., 1992) justified 
CAT’s activity swift trigger over the first 3 days of exposure, fluctuating again to less 
elevated levels by the end of the exposure. Although no alterations of CAT were ever 
mentioned in other FLX exposure essays, this is though in agreement to the confirmed 
increase of ROS production in rainbow trout (Oncorhynchus mykiss) hepatocytes and 
SOD activity inhibition in mice exposed to 5 mg.kg
-1
 FLX body mass (Laville et al., 
2004; Djordjevic et al., 2011). Higher CAT activities were also reported in M. 
galloprovincialis digestive glands than in gills either after IBU (as referred in the 
previous section) or CAR exposure (Martín-Díaz et al., 2009b; Gonzalez-Rey and 
Bebianno, 2011; 2012). Moreover, the transitory outline of GST activity in both tissues 
(Figures 4.1E and F) which included some variations on the basal GST activities 
(pointing also to other variables affecting this enzyme activity outcome) showed a 
higher responsiveness of digestive gland and a direct relationship with CAT activity 
also observed after IBU, CAR, BEN and PRO exposures, relating to evidences of partial 
metabolization of FLX in this tissue (Canesi et al., 2007; Martín-Díaz et al., 2009b; 
Franzellitti et al., 2011; Gonzalez-Rey and Bebianno, 2012) (section 1.2.1.1). Again, 
but at to a lesser extent than that observed in IBU exposure, FLX-exposed gills were 
again more prone to LPO damage (4-fold lower than after the first week of IBU 
exposure) (Figure 4.2A and B) and antioxidant system breakdown than digestive gland 
as highlighted by SOD activity and LPO levels related dispersal distribution throughout 
time opposing to the one of exposed-digestive gland time groups (Figure 4.6). 
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7.2.2.2 FLX and Neurotoxic Effect 
It was hypothesized that since SSRI FLX MoA involves the increase of 5-HT 
concentration, as observed in E. complanata after injection with FLX (Gagné and 
Blaise, 2003), that AChE function over neurotransmitter ACh hydrolysis was also 
affected by FLX derived 5-HT induction. The results (Section 4.3.4 and 4.4.2) pointed 
out to an induction of AChE activity after the first three days only inhibited by the end 
of the exposure period. Usually, AChE activity is inhibited by APIs, as observed for M. 
galloprovincialis gills exposed to PAR (23 and 403 μg.L-1) and E. complanata visceral 
mass exposed to DIA (4, 20 and 100 nmol per mussel) (Solé et al., 2010; Gagné et al., 
2011). Since very few other studies showed AChE induction in invertebrates, like 
mussels E. complanata from an aeration lagoon (Gagné et al., 2010), it was rather 
difficult to ascertain this phenomenon. Since AChE induction implies the depletion of 
ACh by an increased hydrolysis of this neurotransmitter to choline and acetic acid 
(Tsuchiya et al., 2004), several hypotheses were given to explain AChE increase in 
mussels’ gills tissue over the first days, such as the possible depletion of ACh due to its 
competition with 5-HT at the receptor activation level resulting on necessity of AChE 
activity further upregulation; an association of AChE increase due to cell apoptosis (as 
described by Zhang et al., 2002) or a link between AChE activity induction and low 
levels of E2 (Tsuchiya et al., 2004).  
7.2.2.3 FLX and Endocrine Disruption 
Contrarily to what was observed after IBU exposure (showing the consistent 
upregulation of ALP levels particularly in males) (Chapter 3B - Gonzalez-Rey and 
Bebianno, 2012), ALP levels after FLX exposure were altered rather by a constant 
down regulation in both sex-differentiated gonads as in females over the first 3 days of 
exposure. Although inverse to the Vtg-like proteins induction expected after exposure to 
other endocrine disruptors (Porte et al., 2006; Gagnaire et al., 2009), these results also 
attest an actual FLX impact in mussel’ reproductive fitness. The evidence of ALP levels 
inhibition was in agreement with that observed in M. edulis females exposed to North 
Sea crude oil (NSO) which also presented decreased of gonads development (Ortiz-
Zarragoitia and Cajaraville, 2006). These authors assumed that ALP levels may be 
either indirectly associated with gonad development in this species or by a directly 
related antiestrogenic effect of PAHs and oils, and therefore 5-HT levels should be 
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taken in account since this neurotransmitter is known to control gonad development and 
reproduction (Gagné and Blaise, 2003).  
Furthermore, the ALP down regulation in both FLX-exposed female and male gonads 
may be associated to the inverse relationships between Vtg synthesis and 5-HT levels 
and/or 5-HT and E2 levels as well as the observed 5-HT increase during active 
spawning period observed in E. complanata and E2 requirement to initiate 
vitellogenesis (Gagné and Blaise, 2003; Matozzo et al., 2008) with the E2 levels 
decrease observed in mussel D. polymorpha after exposure to FLX (20 and 200 ng.L
-1
) 
between spawning and after-spawning phases (Lazzara et al., 2012). Therefore, even 
though the E2 levels were not measured, the aforementioned a link between AChE 
increase and low E2 levels can be hypothesized, considering the observed Vtg-like 
decrease in FLX-exposed gonads along with AChE induction. For this reason, a 
histological study of FLX-exposed gonads along with the assessment of E2, 5-HT and 
FLX concentrations in mussels’ tissues would complement the assumptions on 
reproduction fitness alteration given by ALP levels decrease.  
In summary, the exposure to an environmental realistic concentration of FLX although 
not producing alteration on mussels’ condition index, induced tissue and time-specific 
transient antioxidant enzyme activities and LPO in M. galloprovincialis (particularly 
affecting gills tissue). Yet these oxidative stress effects were not as evident as the 
overall ALP down regulation in gonadal tissues suggesting a higher influence of FLX as 
an endocrine disruption rather than an oxidative stress inducer. Additionally, the 
influence of FLX as a SSRI on 5-HT levels also clearly altered AChE activity possibly 
resulting on cholinergic neurotransmission functions breakdown linked to either a 
competition at the level of receptor activation between neurotransmitters or with the 
possibility of higher cell apoptosis. A link was also hypothesized for AChE activity 
increase with the concomitant Vtg-like proteins decrease (implicating lower E2 levels). 
Finally, even though FLX presence in the water induce ecotoxicological effects in 
mussel M. galloprovincialis particularly affecting its reproduction fitness, the 
mechanisms of 5-HT receptor activation in mussels are still unknown (Gagné and 
Blaise, 2003) and should be further assessed.  
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7.2.3 Effect of NSAID DCF exposure in M. galloprovincialis (Chapter 5) 
NSAID DCF is, along with IBU, one of the most frequently applied anti-inflammatory 
in human and veterinary practice. This APIs has been ubiquitously detected in surface 
waters worldwide (Table 5.1) being recently included in the list of priority substances 
under the European Commission (European Commission, 2012a, b). In a ecotoxicology 
perspective, DCF was one of the first APIs associated to cause serious impact in non-
target animals, after being linked to the poisoning and liver failure of Indian vultures 
(Gyps sp.) after scavenging DFC-treated livestock carcasses (Oaks et al., 2004; Saini et 
al., 2012). As for the other APIs, DCF environmental realistic concentration applied in 
the exposure assay (250 ng.L
-1
) was based on currently available literature reporting its 
occurrence in surface water. 
7.2.3.1 DCF and Oxidative Stress 
The results (Section 5.3.2 and 5.4.1) showed an overall higher basal antioxidant 
enzymes activity (except CAT) in gills than in digestive glands but also a clear cluster 
distribution of each tissue associated to these differences (Figure 5.6). The direct 
relationship of SOD and GR activities in gills with CAT activity and further LPO levels 
in digestive glands (Table 5.3) suggested different tissue function and transport on the 
counteraction of DCF-induced ROS increase. In this case, SOD and GR activity 
induction was firstly triggered in gills (and to a lesser extent in digestive glands) after 3 
days of DCF exposure, thus resulting in a CAT activity induction in digestive glands to 
convert H2O2 produced by SOD into H2O and O2 (Van der Oost et al., 2003; Viarengo 
et al., 1995), nevertheless the parallel increase of free oxygen-radical scavenger GSH 
due to GR activity increase was not enough to prevent LPO in DCF-exposed digestive 
gland. However, the significant inhibition of antioxidant system activities and LPO 
levels in the tissues showed an antioxidant system recovery after the first days of DFC-
induced oxidative stress effects by the end of the experiment. Moreover, even though 
GSH was available for the eventual phase II conjugation reaction by GST, this enzyme 
activity was not altered in exposed tissues showing a direct relationship with digestive 
gland-SOD rather than with GR or CAT activity (Figure 5.1G and H, Table 5.3). 
Therefore, these results showed that at this concentration DCF does not promote phase 
II detoxification contrasting with that showed by the concomitant induction of GST and 
LPO in D. polymorpha and Mytilus spp. exposed to 4-fold higher concentration of DCF 
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(Quinn et al., 2011; Schmidt et al., 2011). Therefore, even mussel tissues showed some 
significant alterations in antioxidant enzymes responses after the exposure to DCF, in 
terms of oxidative stress results were pertained as much more inconclusive and unclear 
than the ones observed in the previously exposure essays to IBU and FLX (Gonzalez-
Rey and Bebianno, 2012; 2013 - Chapter 3 and 4).  
7.2.3.2 DCF and Neurotoxic Effect   
Like, observed after FLX exposure, DCF clearly induced AChE activity. In this case the 
increase was lower in proportion to basal levels but longer, extending also to the first 
week (Gonzalez-Rey and Bebianno, 2013 - Chapter 4). As mentioned, AChE increase 
was not expected and contrasted to that observed in mussels exposed to PAR and DIA 
(Solé et al., 2010; Gagné et al., 2011). Therefore as observed after FLX exposure 
(except the competition between ACh and 5-HT receptor activation), even though it is 
extremely difficult to ascertain the reason why AChE increased in DCF presence it was 
also hypothesized that after DCF exposure the AChE activity increase may be related to 
either possible cell apoptosis as suggested by Zhan et al. (2002) or due to its inverse 
relationship with endogenous E2 levels (which in turn are related to vitellogenesis) 
(Tsuchiya et al., 2004; Matozzo et al., 2008).  
7.2.3.3 DCF and Endocrine disruption  
The results (Section 5.3.5 and 5.4.2) only showed the induction of ALP levels in DCF-
exposed females (after 3
rd
 and 7
th
 days) and in exposed-males (only after the 3
rd
 day) 
(Figure 5.4). It was argued that the concomitant ALP levels increase in non-exposed 
mussels, particularly males, possibly overshadowed a clearer proof of endocrine 
disruption after DCF exposure. Even though, vitellogenesis occurred at the beginning of 
DCF exposure, again the exposure to IBU and FLX induced much stronger evidences of 
these APIs impact as endocrine disruptors than DCF (Gonzalez-Rey and Bebianno, 
2012; 2013 – Chapter 3 and 4). These results are again in disagreement to that of the 
exposure to a 4-fold higher concentration of DCF, as no alterations of ALP levels exist 
in exposed-mussels D. polymorpha and Mytilus spp (Quinn et al., 2011; Schmidt et al., 
2011). Moreover, though its significance may be less obvious than the possible 
connection between AChE activity increase and cell apoptosis, the direct relationship 
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between ALP levels in females and AChE induction (Table 5.3) also give evidence to 
an unknown and possible DFC-derived interference with mussels’ estrogen receptors.  
In summary, the highest effects of DCF exposure were related to the first 3 days of 
exposure, showing overall recovery responses by the end of the exposure period. 
Although the antioxidant system seemed to be more affected and altered in gills, the 
LPO levels were slightly more evident in digestive glands. Moreover, even though 
DCF-exposed gonads showed some evidence of ALP levels induction over the first 
week, the highest impact of DCF was further related to the neurotoxic effect associated 
to the clear AChE activity enhancement by a potential estrogenic activity alteration or 
cell apoptosis. This statement, however, can only be confirmed through the concomitant 
quantification and interactions assessment of E2, PGs and COX activity in mussel 
tissues. 
7.2.4 Effect of APIs mixtures exposure in M. galloprovincialis (Chapter 6) 
APIs occur in the aquatic environment as complex mixtures, as clearly demonstrated in 
Chapter 1 and 2. If the information lacks for single exposure APIs effects assessment it 
is even more elusive concerning environmental realistic concentrations APIs mixtures 
(Table 6.1). Therefore, it is crucial to assess the possible effects derived from the 
interactions between multiple stressors especially since they may differ to those 
associated to single exposures. Although it is difficult to mimic a totally realistic 
scenario, it was intended to assess the possible interactions between the selected APIs 
(MIX 1), and those introducing a common environmental contaminant Cu (MIX 2). For 
this an equivalent experimental design was performed using the same APIs 
concentrations and an equivalent multibiomarker approach as that described above 
concerning single selected APIs.   
7.2.4.1 Mixtures and Oxidative Stress 
First of all, neither mixture induced alterations in mussels’ CI%. Nevertheless, the 
antioxidant enzyme activities and LPO levels were mixture, tissue and time-specific. 
While, on one hand Cu present in MIX 2 generally induced higher and more progressive 
LPO levels in gills by the concomitant inactivation or inhibition of SOD, CAT and GR 
activities than MIX 1. MIX 1 exposed-gills showed the same antioxidant enzymes as 
well as phase II GST enhancement by the end of the experiment rendering a more 
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effective protection against ROS induced LPO (Figure 6.2A). On the other hand, the 
fact that MIX 1- exposed digestive gland showed swifter antioxidant enzyme responses 
than gills counterparts consistently prevented this tissue from LPO damage, and 
confirmed this tissue as better ‘equipped’ to deal with this mixture ROS-induced 
detoxification. Again, Cu in MIX 2 promoted a general inactivation of most enzymes 
(except GR activity) in digestive glands. However the GR activity enhancement, freeing 
ROS-scavenger GSH in this tissue cells, was not enough to prevent the significant 
induction of LPO in this tissue by the end of the second week.  
7.2.4.2 Mixtures and Neurotoxic effect 
The results also showed (Figure 6.3) that neither one of the mixtures exerted significant 
changes in AChE activity. Although MIX 2-exposed gills showed generally higher 
AChE activity (p > 0.05), it was assumed that these mixtures do not promote neurotoxic 
effect in exposed mussels. 
7.2.4.3 Mixtures and Endocrine disruption 
Induction of ALP levels occurred in females exposed to both mixtures over the 3
rd
 day 
and first week (Figure 6.4A). Nevertheless after the second week the concomitant 
enhancement of the basal levels as well as differential responses toward mixtures 
rendered the ALP levels outcome rather unclear. In males (Figure 6.4B) MIX 1 exerted 
a continuously impact on ALP levels than MIX 2. As mentioned for DCF-exposure 
(section 7.2.3) the fact that the basal levels varied with time might have masked the 
results. Nevertheless, both sex-differentiated gonads showed at some point the induction 
of ALP levels, giving evidence of these mixtures ability (particularly MIX 1) to induce 
endocrine disruption in exposed mussels. 
7.2.4.4 Interaction between mixture components 
As it is evident, there were several noticeable differences between each mixture and 
single APIs exposure effects on oxidative stress responses (antioxidant enzymes 
activities and LPO levels), neurotoxic effect and endocrine disruption.  
The interaction between mixture components assessment for each biomarker is 
summarized in Table 7.1. 
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Table 7.1: Interaction between mixture components for each biomarker 
  
  
  
  
Biomarkers/Tissue 
Time  
(days) 
IBU FLX DCF Cua MIX 1 MIX 2 Possible Interactions 
Oxidative stress                  
SOD activity                 
gills 
3 *   nd  
 MIX 1:FLX antagonistic effect with NSAIDs 
MIX 2: Cu counteracts FLX to basal levels  
7 *     
 MIX 1 and 2: Synergism between FLX, DCF with or without Cu 
antagonist with IBU 
15   * nd  
 MIX 1: Potentiation of IBU against FLX and DCF 
MIX 2: Cu cancels IBU independent action 
digestive gland 
3    nd  
 MIX 1: FLX antagonic effect with NSAIDs 
MIX 2: Cu antagonist with FLX 
7 *  *   
 MIX 1: NSAIDs potentiated, FLX has no effect 
MIX 2: Cu inhibits SOD activity although its activity is still 
slightly enhanced 
15   = nd  
 MIX 1: Addictive effect APIs 
MIX 2: Synergetic effect between Cu and IBU potentiates 
slight increase  
CAT activity               
 
gills 
3    nd  
 MIX 1 and 2: Addictive effect between APIS with or without 
Cu 
7      
 MIX 1 and 2: Synergetic effect of NSAIDs antagonistic with FLX 
and/or Cu 
15    nd  
 MIX 1: FLX antagonistic effect with NSAIDS 
MIX 2:  Synergism between Cu and NSAIDs antagonist to FLX 
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Table 7.1: (Continuation). 
CAT activity          
digestive gland 
3 * *  nd   = 
 MIX 1: Antagonistic effect between the three APIs 
MIX 2: Effect of Cu resulted and less pronounced antagonism 
between APIs  
7 *   =  
 MIX 1: Antagonism of DCF with the synergism between FLX 
and IBU 
MIX 2:  Antagonistic effect of IBU and FLX against the 
potentiation of DCF effect by Cu  
15  *  nd  = 
 MIX 1: Antagonism between FLX and NSAIDs 
 MIX 2: Addictive behavior between APIs and Cu 
GR activity               
 
gills 
3 * nd  nd     MIX 1: Significant downregulation seemed to follow DCF 
effect (on the 3
rd
 day) antagonistic with IBU 
 MIX 2: Antagonistic effect between IBU and remaining 
mixture components 
7 * nd =  = 
15 * nd = nd   = 
digestive gland 
3 * nd  nd   
 MIX 1: Follow IBU effect antagonistic to DCF 
MIX 2: Cancelling of IBU effect by Cu 
7 * nd    
 MIX 1: Follow DCF effect antagonistic to IBU 
MIX 2: Cu potentiated DCF effect cancelling IBU effect  
15  nd  nd  = 
 MIX 1: Antagonism between NSAIDs 
 MIX 2: Cu induced slight enhancement over APIs antagonistic 
effect 
         
         
         
         
         
         
         
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Table 7.1.: Continuation). 
GST activity                 
gills 
3    nd   
 MIX 1: Addictive effect between APIS 
MIX 2: Cu synergism with FLX and DCF and antagonism with 
IBU 
7    =  
 MIX 1: Antagonism between addictive effect of FLX and DCF 
with IBU 
MIX 2: Addictive effect of APIs with Cu  
15 *   nd   
 MIX 1: DCF potentiation (unaltered by neither IBU nor FLX) 
MIX 2: Cu blocked DCF potentiation 
digestive gland 
3    nd   = 
 MIX 1 and 2: Antagonistic effects of mixture component, 
less pronounce by Cu 
7  = * =  
 MIX 1 and 2: Potentiation of NSAIDS effect, not affect by 
FLX, Cu had a slight antagonist effect ( lower enhancement  
of GST activity) 
15    nd   
 MIX 1: Synergism between FLX and DCF not antagonized by 
IBU 
MIX 2: Addictive effect of Cu with FLX and DCF 
Damage               
 
LPO levels               
 
gills 
3 =   nd     MIX 1 and 2: Addictive effect between mixture components  
7 * * * =  
 MIX 1: Antagonistic effect between NSAIDs following 
similar FLX effect 
MIX 2: Cu synergism with both IBU and FLX 
15    nd     MIX 1 and 2: Addictive effect between mixture components 
digestive gland 
3 * = * nd   
 MIX 1 and 2: Do not follow addictive effect of mixture 
effects or independent action 
7 * * *   
 MIX 1 and 2: Antagonism between NSAIDs  and either FLX 
or FLX and Cu 
15  *  nd  = 
 MIX 1: Antagonistic effect between APIs 
MIX 2: Cu is antagonistic to IBU, more similar to addictive 
effect between FLX and DCF 
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Table 7.1: (Continuation). 
Neurotoxic effect                 
AChE activity               
 
gills 
3 nd   nd    
 FLX and DCF single exposure effects seem to lead to AChE 
induction tendency   
7 nd =  nd    
15 nd = = nd    
Endocrine disruption               
Vitellogenin-like proteins levels               
female gonads 
3    nd   
 MIX 1 and 2: Potentiation of NSAIDs effects antagonized by 
FLX and Cu 
7    nd   
 MIX 1: Synergetic effect of NSAIDs antagonized by FLX 
MIX 2: Cu potentiates the synergism between NSAIDs 
15    nd   
 MIX 1 and 2: DCF effect is antagonized by addictive effect of 
FLX and IBU, more evident by the presence of Cu 
male gonads 
3    nd   
 MIX 1: Antagonistic effect of DFC and FLX with IBU 
MIX 2: Cu potentiated slightly the effect observed in MIX 1 
7    nd   
 MIX 1: Antagonism between IBU with FLX and DCF 
MIX 2: Antagonism between APIs addictive effects with Cu 
15    nd   
 MIX 1: Potentiation of APIs addictive effects 
MIX 2:Cu antagonized the effect observed for MIX 1   
* significantly different (p < 0.05); a - 
 
5 µg Cu.L
−1 
(Maria and Bebianno, 2011); nd – not determined 
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7.3 Conclusions 
These findings collectively proven that APIs are ubiquitous in all types of surface 
waters and promote relevant impact in species M. galloprovincialis. Therefore it 
becomes evident that to prevent further APIs environmental implications in wildlife it is 
absolutely necessary to review and update current WWTP processes, to follow a further 
implementation and abide of current EMEA and FDA environmental guidelines, but 
also to inform the general public, physicians and manufacturers about APIs problematic 
in the environment to assure an easier adoption of “Green Chemistry” strategies (FDA, 
1998; Daughton, 2003; EMEA, 2006; 2007; EEA, 2010). 
7.4 Future perspectives 
Taking in account all the results presented in this thesis, further research should be 
performed to clarify and complement several aspects, overcome some limitations and 
enable a better comprehension related to APIs exposure in Mytilus galloprovincialis:  
 Assessment of each API concentration in mussels’ tissues and surrounding 
water, its bioaccumulation factor and preferential accumulation target-organ, 
 Quantification of enzyme COX activity, phospholipid AA and eicosanoid PG 
concentration in mussels tissues to ascertain whether NSAIDs do promote the 
non-selective inhibition of COX 1 and 2 isoforms and associated metabolization 
pathways in mussels as they do in humans and mammals, 
 Assessment of 5-HT in mussels exposed to SSRI fluoxetine to confirm the 
connection between FLX exposure and 5-HT levels enhancement,  
 Histological study of sex-differentiated the gonads and E2 levels concentration 
assessment to further complement findings related to APIs-derived Vtg-like 
proteins levels alteration,  
 Target cell apoptosis related enzymes or perform techniques associated to 
lysosomal membrane stability and permeabilization to ascertain possible 
linkage with AChE activity induction,     
 Application of “exposomics” techniques (such as genomics, metabolomics, 
transcriptomics and proteomics) to ascertain each API metabolization pathways 
in invertebrates, alteration in proteins and gene profile expressions (proteome 
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and genome) due to APIs exposure and identification of more effective APIs 
exposure biomarkers. 
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